<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Polyunsaturated fatty acids (PUFA) for attention deficit hyperactivity disorder (ADHD) in children and adolescents - Gillies, D - 2023 | Cochrane Library</title> <meta content="Polyunsaturated fatty acids (PUFA) for attention deficit hyperactivity disorder (ADHD) in children and adolescents - Gillies, D - 2023 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007986.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Polyunsaturated fatty acids (PUFA) for attention deficit hyperactivity disorder (ADHD) in children and adolescents - Gillies, D - 2023 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007986.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD007986.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Polyunsaturated fatty acids (PUFA) for attention deficit hyperactivity disorder (ADHD) in children and adolescents" name="citation_title"/> <meta content="Donna Gillies" name="citation_author"/> <meta content="University of Sydney" name="citation_author_institution"/> <meta content="donna.gillies@ndiscommission.gov.au" name="citation_author_email"/> <meta content="Matthew J Leach" name="citation_author"/> <meta content="University of South Australia" name="citation_author_institution"/> <meta content="Guillermo Perez Algorta" name="citation_author"/> <meta content="Lancaster University" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="4" name="citation_issue"/> <meta content="10.1002/14651858.CD007986.pub3" name="citation_doi"/> <meta content="2023" name="citation_date"/> <meta content="2023/04/14" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007986.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007986.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007986.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Amphetamine [therapeutic use]; Atomoxetine Hydrochloride [therapeutic use]; *Attention Deficit Disorder with Hyperactivity [drug therapy]; *Fatty Acids, Omega-3 [therapeutic use]; Fatty Acids, Unsaturated [therapeutic use]; *Methylphenidate [therapeutic use]; Quality of Life" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007986.pub3&amp;doi=10.1002/14651858.CD007986.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007986.pub3&amp;doi=10.1002/14651858.CD007986.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007986.pub3&amp;doi=10.1002/14651858.CD007986.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007986.pub3&amp;doi=10.1002/14651858.CD007986.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007986.pub3&amp;doi=10.1002/14651858.CD007986.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007986.pub3&amp;doi=10.1002/14651858.CD007986.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007986.pub3&amp;doi=10.1002/14651858.CD007986.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007986.pub3&amp;doi=10.1002/14651858.CD007986.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007986.pub3&amp;doi=10.1002/14651858.CD007986.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007986.pub3&amp;doi=10.1002/14651858.CD007986.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007986.pub3&amp;doi=10.1002/14651858.CD007986.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007986.pub3&amp;doi=10.1002/14651858.CD007986.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007986.pub3&amp;doi=10.1002/14651858.CD007986.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007986.pub3&amp;doi=10.1002/14651858.CD007986.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007986.pub3&amp;doi=10.1002/14651858.CD007986.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007986.pub3&amp;doi=10.1002/14651858.CD007986.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007986.pub3&amp;doi=10.1002/14651858.CD007986.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007986.pub3&amp;doi=10.1002/14651858.CD007986.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007986.pub3&amp;doi=10.1002/14651858.CD007986.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007986.pub3&amp;doi=10.1002/14651858.CD007986.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007986.pub3&amp;doi=10.1002/14651858.CD007986.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007986.pub3&amp;doi=10.1002/14651858.CD007986.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007986.pub3&amp;doi=10.1002/14651858.CD007986.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="dLyXbLct";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD007986\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD007986\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007986\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007986\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","ru","ko","pt","ms","hr","fr","hu","zh_HANS","zh_HANT","th","ja","fa","pl"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD007986.pub3",title:"Polyunsaturated fatty acids (PUFA) for attention deficit hyperactivity disorder (ADHD) in children and adolescents",firstPublishedDate:"Apr 14, 2023 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Developmental, Psychosocial and Learning Problems Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=dLyXbLct&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007986.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD007986.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD007986.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD007986.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007986.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD007986.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD007986.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD007986.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD007986.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD007986.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;초록&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;บทคัดย่อ&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;hu&quot;,&quot;title&quot;:&quot;Összefoglalás közérthető nyelven&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;쉬운 말 요약&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo para leigos&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;ข้้อสรุปภาษาธรรมดา&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD007986.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD007986.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD007986.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD007986.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>7409 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD007986.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007986.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007986.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007986.pub3/full#CD007986-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007986.pub3/full#CD007986-sec-0097"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007986.pub3/full#CD007986-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007986.pub3/full#CD007986-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007986.pub3/full#CD007986-sec-0017"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007986.pub3/full#CD007986-sec-0018"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007986.pub3/full#CD007986-sec-0046"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007986.pub3/full#CD007986-sec-0091"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD007986.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007986.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007986.pub3/appendices#CD007986-sec-0102"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007986.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007986.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD007986.pub3/media/CDSR/CD007986/supinfo/CD007986StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD007986.pub3/media/CDSR/CD007986/supinfo/CD007986StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007986.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007986.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007986.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD007986.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD007986.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD007986.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2023 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD007986.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Polyunsaturated fatty acids (PUFA) for attention deficit hyperactivity disorder (ADHD) in children and adolescents </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007986.pub3/information#CD007986-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Donna Gillies</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007986.pub3/information#CD007986-cr-0005">Matthew J Leach</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007986.pub3/information#CD007986-cr-0006">Guillermo Perez Algorta</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD007986.pub3/information/en#CD007986-sec-0139">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 14 April 2023 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD007986.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD007986.pub3">https://doi.org/10.1002/14651858.CD007986.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD007986-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD007986-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD007986-abs-0013">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD007986-abs-0021">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD007986-abs-0010">Français</a> </li> <li class="section-language"> <a class="" href="full/ko#CD007986-abs-0004">한국어</a> </li> <li class="section-language"> <a class="" href="full/pt#CD007986-abs-0006">Português</a> </li> <li class="section-language"> <a class="" href="full/th#CD007986-abs-0018">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD007986-abs-0015">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD007986-abs-0001" lang="en"> <section id="CD007986-sec-0001"> <h3 class="title" id="CD007986-sec-0001">Background</h3> <p>Attention deficit hyperactivity disorder (ADHD) is a major problem in children and adolescents, characterised by age‐inappropriate levels of inattention, hyperactivity, and impulsivity, and is associated with long‐term social, academic, and mental health problems. The stimulant medications methylphenidate and amphetamine are the most frequently used treatments for ADHD, but these are not always effective and can be associated with side effects. Clinical and biochemical evidence suggests that deficiencies of polyunsaturated fatty acids (PUFA) could be related to ADHD. Research has shown that children and adolescents with ADHD have significantly lower plasma and blood concentrations of PUFA and, in particular, lower levels of omega‐3 PUFA. These findings suggest that PUFA supplementation may reduce the attention and behaviour problems associated with ADHD. This review is an update of a previously published Cochrane Review. Overall, there was little evidence that PUFA supplementation improved symptoms of ADHD in children and adolescents. </p> </section> <section id="CD007986-sec-0002"> <h3 class="title" id="CD007986-sec-0002">Objectives</h3> <p>To compare the efficacy of PUFA to other forms of treatment or placebo in treating the symptoms of ADHD in children and adolescents. </p> </section> <section id="CD007986-sec-0003"> <h3 class="title" id="CD007986-sec-0003">Search methods</h3> <p>We searched 13 databases and two trials registers up to October 2021. We also checked the reference lists of relevant studies and reviews for additional references. </p> </section> <section id="CD007986-sec-0004"> <h3 class="title" id="CD007986-sec-0004">Selection criteria</h3> <p>We included randomised and quasi‐randomised controlled trials that compared PUFA with placebo or PUFA plus alternative therapy (medication, behavioural therapy, or psychotherapy) with the same alternative therapy alone in children and adolescents (aged 18 years and under) diagnosed with ADHD. </p> </section> <section id="CD007986-sec-0005"> <h3 class="title" id="CD007986-sec-0005">Data collection and analysis</h3> <p>We used standard Cochrane methods. Our primary outcome was severity or improvement of ADHD symptoms. Our secondary outcomes were severity or incidence of behavioural problems; quality of life; severity or incidence of depressive symptoms; severity or incidence of anxiety symptoms; side effects; loss to follow‐up; and cost. We used GRADE to assess the certainty of evidence for each outcome. </p> </section> <section id="CD007986-sec-0006"> <h3 class="title" id="CD007986-sec-0006">Main results</h3> <p>We included 37 trials with more than 2374 participants, of which 24 trials were new to this update. Five trials (seven reports) used a cross‐over design, while the remaining 32 trials (52 reports) used a parallel design. Seven trials were conducted in Iran, four each in the USA and Israel, and two each in Australia, Canada, New Zealand, Sweden, and the UK. Single studies were conducted in Brazil, France, Germany, India, Italy, Japan, Mexico, the Netherlands, Singapore, Spain, Sri Lanka, and Taiwan. Of the 36 trials that compared a PUFA to placebo, 19 used an omega‐3 PUFA, six used a combined omega‐3/omega‐6 supplement, and two used an omega‐6 PUFA. The nine remaining trials were included in the comparison of PUFA to placebo, but also had the same co‐intervention in the PUFA and placebo groups. Of these, four trials compared a combination of omega‐3 PUFA plus methylphenidate to methylphenidate. One trial each compared omega‐3 PUFA plus atomoxetine to atomoxetine; omega‐3 PUFA plus physical training to physical training; and an omega‐3 or omega‐6 supplement plus methylphenidate to methylphenidate; and two trials compared omega‐3 PUFA plus dietary supplement to dietary supplement. Supplements were given for a period of between two weeks and six months. </p> <p>Although we found low‐certainty evidence that PUFA compared to placebo may improve ADHD symptoms in the medium term (risk ratio (RR) 1.95, 95% confidence interval (CI) 1.47 to 2.60; 3 studies, 191 participants), there was high‐certainty evidence that PUFA had no effect on parent‐rated total ADHD symptoms compared to placebo in the medium term (standardised mean difference (SMD) −0.08, 95% CI −0.24 to 0.07; 16 studies, 1166 participants). There was also high‐certainty evidence that parent‐rated inattention (medium‐term: SMD −0.01, 95% CI −0.20 to 0.17; 12 studies, 960 participants) and hyperactivity/impulsivity (medium‐term: SMD 0.09, 95% CI −0.04 to 0.23; 10 studies, 869 participants) scores were no different compared to placebo. </p> <p>There was moderate‐certainty evidence that overall side effects likely did not differ between PUFA and placebo groups (RR 1.02, 95% CI 0.69 to 1.52; 8 studies, 591 participants). There was also moderate‐certainty evidence that medium‐term loss to follow‐up was likely similar between groups (RR 1.03, 95% CI 0.77 to 1.37; 13 studies, 1121 participants). </p> </section> <section id="CD007986-sec-0007"> <h3 class="title" id="CD007986-sec-0007">Authors' conclusions</h3> <p>Although we found low‐certainty evidence that children and adolescents receiving PUFA may be more likely to improve compared to those receiving placebo, there was high‐certainty evidence that PUFA had no effect on total parent‐rated ADHD symptoms. There was also high‐certainty evidence that inattention and hyperactivity/impulsivity did not differ between PUFA and placebo groups. </p> <p>We found moderate‐certainty evidence that overall side effects likely did not differ between PUFA and placebo groups. There was also moderate‐certainty evidence that follow‐up was similar between groups. </p> <p>It is important that future research addresses the current weaknesses in this area, which include small sample sizes, variability of selection criteria, variability of the type and dosage of supplementation, and short follow‐up times. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD007986-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD007986-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD007986-abs-0014">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD007986-abs-0022">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD007986-abs-0011">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD007986-abs-0009">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/hu#CD007986-abs-0012">Magyar</a> </li> <li class="section-language"> <a class="" href="full/ja#CD007986-abs-0020">日本語</a> </li> <li class="section-language"> <a class="" href="full/ko#CD007986-abs-0005">한국어</a> </li> <li class="section-language"> <a class="" href="full/ms#CD007986-abs-0008">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD007986-abs-0023">Polski</a> </li> <li class="section-language"> <a class="" href="full/pt#CD007986-abs-0007">Português</a> </li> <li class="section-language"> <a class="" href="full/ru#CD007986-abs-0003">Русский</a> </li> <li class="section-language"> <a class="" href="full/th#CD007986-abs-0019">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD007986-abs-0016">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD007986-abs-0017">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD007986-abs-0002" lang="en"> <h3>Polyunsaturated fatty acids (PUFA) supplements for attention deficit hyperactivity disorder (ADHD) in children and adolescents </h3> <p><b>What is ADHD?</b> </p> <p>Attention deficit hyperactivity disorder (ADHD) is a common problem in children and adolescents. Those affected may struggle to concentrate, feel restless, or act on impulse. As a result of these difficulties, ADHD can cause long‐term social, academic, and mental health problems. Medicines are the most frequently used treatments for ADHD, but they are not always effective and can cause unwanted side effects. </p> <p><b>What are polyunsaturated fatty acids (PUFA)?</b> </p> <p>Polyunsaturated fatty acids (PUFA) are a type of fat. They are necessary for normal brain development and are found in foods such as fish (omega‐3 PUFA) and vegetable oils (omega‐6 PUFA). </p> <p><b>How could PUFA be useful in ADHD?</b> </p> <p>There is some evidence that ADHD could be related to low levels of PUFA, in particular omega‐3 PUFA. PUFA supplements may therefore improve ADHD symptoms, behavioural problems, and related mental health symptoms such as anxiety and depression. </p> <p><b>What did we want to find out?</b> </p> <p>We wanted to know whether PUFA supplements improve ADHD symptoms in children and adolescents with ADHD. </p> <p>Although there were some limited data in the original review that suggested PUFA improved symptoms of ADHD, there is currently little evidence that PUFA supplementation is beneficial. It was important to update the evidence to incorporate new studies that have been published since the original review. </p> <p><b>What did we do?</b> </p> <p>We searched for all trials that compared PUFA to placebo (dummy pill), medicines, or psychological or medical therapies in children or adolescents with ADHD. We searched 13 databases and two trials registers up to October 2021. </p> <p><b>What did we find?</b> </p> <p>We found 24 new studies in this update, bringing the total number of studies included in the review to 37, which involved more than 2374 children and adolescents with ADHD. Seven studies were conducted in Iran; four each in the USA and Israel; two each in Australia, Canada, New Zealand, Sweden, and the UK; and one each in Brazil, France, Germany, India, Italy, Japan, Mexico, the Netherlands, Singapore, Spain, Sri Lanka, and Taiwan. </p> <p>Thirty‐six studies compared PUFA to placebo. Treatment with PUFA lasted between two weeks and six months. </p> <p>Although there was some evidence that PUFA could improve ADHD symptoms in children and adolescents, most of the evidence indicated that PUFA did not improve ADHD symptoms such as inattention or hyperactivity‐impulsivity. PUFA probably makes little to no difference to overall side effects or whether a person drops out of a study (i.e. does not complete it).  </p> <p><b>How confident are we about what we found?</b> </p> <p>We are confident that PUFA has no effect on ADHD symptoms when compared to placebo. Although there was some evidence that ADHD symptoms may be more likely to improve in children and adolescents receiving PUFA compared to those receiving placebo, we have little confidence in this finding. </p> <p>We are fairly confident that there are no differences between PUFA and placebo groups in overall side effects or dropout. </p> <p>Limitations of the analyses included small sample sizes, variability of selection criteria, variability of the type and dosage of supplementation, and short follow‐up times. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD007986-sec-0097" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD007986-sec-0097"></div> <h3 class="title" id="CD007986-sec-0098">Implications for practice</h3> <section id="CD007986-sec-0098"> <p>Although there has been a substantial increase in the number of trials since our original review, we did not find evidence that attention deficit hyperactivity disorder (ADHD) symptoms are likely to improve in children and adolescents with ADHD receiving polyunsaturated fatty acids (PUFA) supplements. We found high‐certainty evidence that PUFA had no effect on total parent‐rated ADHD symptoms, inattention, or hyperactivity/impulsivity, with only low‐certainty evidence of improvement. Consequently, even with moderate‐certainty evidence that side effects and loss to follow‐up were not increased by PUFA, there is little evidence to recommend PUFA supplementation as a treatment for ADHD in children and adolescents.  </p> </section> <h3 class="title" id="CD007986-sec-0099">Implications for research</h3> <section id="CD007986-sec-0099"> <p>Despite the large increase in the number of trials, data are still inadequate to conclude whether PUFA supplementation in children and adolescents with ADHD is effective. Overall, there is moderate‐ to high‐certainty evidence that PUFA supplementation does not provide any benefit for the symptoms of ADHD in children and adolescents. </p> <p>It seems unlikely that future high‐quality research will identify any benefits of PUFA on ADHD symptoms without more consistent approaches to supplementation. Given the lack of consistency in PUFA types and dosages, future studies could focus on active PUFA supplements at dosages that have previously been shown to significantly increase circulating PUFA. In addition, given evidence indicating that the ratio of omega‐3 to omega‐6 PUFA may be more important than omega‐3 supplements alone, trials of omega‐3 and omega‐6 PUFA at optimal ratios may be more effective. Furthermore, because follow‐up in the included studies was short term, longer‐term trials of PUFA may be more able to identify beneficial effects. Future trials should also prevent potential biases that were identified in the included trials, such as inadequate sample sizes and follow‐up, valid and reliable selection criteria, and complete reporting of outcomes. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD007986-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD007986-sec-0008"></div> <div class="table" id="CD007986-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Summary of findings table ‐ PUFA compared to placebo for children and adolescents with ADHD</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>PUFA compared to placebo for children and adolescents with ADHD</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> children and adolescents with ADHD<br/><b>Setting:</b> All settings<br/><b>Intervention:</b> PUFA<br/><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with PUFA</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ADHD symptoms – improvement – medium term</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>319 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>621 per 1000</b><br/>(468 to 829) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.95</b><br/>(1.47 to 2.60) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>191<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a,</sup><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ADHD symptoms – total, parent‐rated – medium term</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>SMD <b>0.08 SD lower</b><br/>(0.24 lower to 0.07 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1166<br/>(16 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/>High </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ADHD symptoms – inattention, parent‐rated – medium term</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>SMD <b>0.01 lower</b><br/>(0.2 lower to 0.17 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>960<br/>(12 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/>High </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ADHD symptoms – hyperactivity/impulsivity, parent‐rated – medium term</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>SMD <b>0.09 higher</b><br/>(0.04 lower to 0.23 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>869<br/>(10 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/>High </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Side effects – overall</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>190 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>194 per 1000</b><br/>(131 to 289) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.02</b><br/>(0.69 to 1.52) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>591<br/>(8 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Loss to follow‐up – medium term</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>138 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>142 per 1000</b><br/>(106 to 189) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.03</b><br/>(0.77 to 1.37) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1121<br/>(13 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio; <b>SMD:</b> standardised mean difference </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>See interactive version of this table: <a href="https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_425001674858162955" target="_blank">https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_425001674858162955</a>. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Downgraded one level for risk of bias concerns: less than 50% of risk of bias domains across all studies were rated low risk.<br/><sup>b</sup> Downgraded one level for serious imprecision: data came from only three RCTs with 191 participants.<br/><sup>c</sup> Downgraded one level for serious imprecision: wide confidence interval. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD007986-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD007986-sec-0009"></div> <section id="CD007986-sec-0010"> <h3 class="title" id="CD007986-sec-0010">Description of the condition</h3> <p>According to the Diagnostic and Statistical Manual of Mental Disorders (DSM‐5; <a href="./references#CD007986-bbs2-0069" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th edition. Arlington (VA): American Psychiatric Association, 2013.">APA 2013</a>), people with attention deficit hyperactivity disorder (ADHD) show developmentally inappropriate levels of inattention or hyperactivity–impulsivity, or both, before 12 years of age, that persist for at least 6 months; negatively affect social, school, or work function; and are not explained by another mental disorder (<a href="./references#CD007986-bbs2-0069" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th edition. Arlington (VA): American Psychiatric Association, 2013.">APA 2013</a>). A diagnosis of ADHD requires six or more symptoms in children aged up to 16 years, and five or more symptoms in those aged 17 years or older (<a href="./references#CD007986-bbs2-0069" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th edition. Arlington (VA): American Psychiatric Association, 2013.">APA 2013</a>). </p> <p>According to the International Classification of Diseases (ICD‐11; <a href="./references#CD007986-bbs2-0152" title="World Health Organization. International Classification of Diseases for Mortality and Morbidity Statistics 11th Revision. icd.who.int/browse11/l-m/en.">WHO 2018</a>), ADHD is characterised by a persistent pattern (at least six months) of inattention and/or hyperactivity‐impulsivity that has a direct negative impact on academic, occupational, or social functioning. Additionally, there is evidence of significant inattention and/or hyperactivity‐impulsivity symptoms prior to age 12. The ICD‐11 definition of ADHD supersedes the ICD‐10 hyperkinetic disorders which similarly included developmentally inappropriate levels of inattention, hyperactivity, and impulsivity (<a href="./references#CD007986-bbs2-0151" title="World Health Organization. ICD-10: International Statistical Classification of Diseases and Related Health Problems 10th Revision. apps.who.int/classifications/icd10/browse/2010/en.">WHO 2010</a>). </p> <p>ADHD is a common neurodevelopmental disorder with a worldwide prevalence of approximately 5% to 7% in children and adolescents (<a href="./references#CD007986-bbs2-0126" title="PolanczykG , De LimaMS , HortaBL , BiedermanJ , RohdeLA . The worldwide prevalence of ADHD: a systematic review and metaregression analysis. American Journal of Psychiatry2007;164(6):942-8. [DOI: 10.1176/ajp.2007.164.6.942] [PMID: 17541055]">Polanczyk 2007</a>; <a href="./references#CD007986-bbs2-0127" title="PolanczykGV , WillcuttEG , SalumGA , KielingC , RohdeLA . ADHD prevalence estimates across three decades: an updated systematic review and meta-regression analysis. International Journal of Epidemiology2014;43(2):434-42. [DOI: 10.1093/ije/dyt261] [PMCID: PMC4817588] [PMID: 24464188]">Polanczyk 2014</a>; <a href="./references#CD007986-bbs2-0148" title="ThomasR , SandersS , DoustJ , BellerE , GlasziouP . Prevalence of attention-deficit/hyperactivity disorder: a systematic review and meta-analysis. Pediatrics2015;135(4):e994-1001. [DOI: 10.1542/peds.2014-3482] [PMID: 25733754]">Thomas 2015</a>; <a href="./references#CD007986-bbs2-0153" title="WillcuttEG . The prevalence of DSM-IV attention-deficit/hyperactivity disorder: a meta-analytic review. Neurotherapeutics2012;9(3):490–9. [DOI: 10.1007/s13311-012-0135-8] [PMCID: PMC3441936] [PMID: 22976615]">Willcutt 2012</a>). Boys are more commonly diagnosed than girls, with an approximate ratio of two boys to one girl (<a href="./references#CD007986-bbs2-0126" title="PolanczykG , De LimaMS , HortaBL , BiedermanJ , RohdeLA . The worldwide prevalence of ADHD: a systematic review and metaregression analysis. American Journal of Psychiatry2007;164(6):942-8. [DOI: 10.1176/ajp.2007.164.6.942] [PMID: 17541055]">Polanczyk 2007</a>; <a href="./references#CD007986-bbs2-0153" title="WillcuttEG . The prevalence of DSM-IV attention-deficit/hyperactivity disorder: a meta-analytic review. Neurotherapeutics2012;9(3):490–9. [DOI: 10.1007/s13311-012-0135-8] [PMCID: PMC3441936] [PMID: 22976615]">Willcutt 2012</a>). Approximately 50% to 75% of children with ADHD will continue to have symptoms into adulthood (<a href="./references#CD007986-bbs2-0146" title="TargumSD , AdlerLA . Our current understanding of adult ADHD. Innovations in Clinical Neuroscience2014;11(11-12):30-5. [PMID: 25621186]">Targum 2014</a>; <a href="./references#CD007986-bbs2-0153" title="WillcuttEG . The prevalence of DSM-IV attention-deficit/hyperactivity disorder: a meta-analytic review. Neurotherapeutics2012;9(3):490–9. [DOI: 10.1007/s13311-012-0135-8] [PMCID: PMC3441936] [PMID: 22976615]">Willcutt 2012</a>). </p> <p>Children and adolescents with ADHD can have academic impairments (<a href="./references#CD007986-bbs2-0070" title="ArnoldLE , HodgkinsP , KahleJ , MadhooM , KewleyG . Long-term outcomes of ADHD: academic achievement and performance. Journal of Attention Disorders2020;24(1):73-85. [DOI: 10.1177/1087054714566076] [PMID: 25583985]">Arnold 2020</a>; <a href="./references#CD007986-bbs2-0116" title="LoeIM , FeldmanHM . Academic and educational outcomes of children with ADHD. Ambulatory Pediatrics2007;7(Suppl 1):82-90. [DOI: 10.1016/j.ambp.2006.05.005] [PMID: 17261487]">Loe 2007</a>), social dysfunction (<a href="./references#CD007986-bbs2-0081" title="Carpenter RichE , LooSK , YangM , DangJ , SmalleySL . Social functioning difficulties in ADHD: association with PDD risk. Clinical Child Psychology and Psychiatry2009;14(3):329-44. [DOI: 10.1177/1359104508100890] [PMID: 19515751]">Carpenter Rich 2009</a>; <a href="./references#CD007986-bbs2-0123" title="NijmeijerJS , MinderaaRB , BuitelaarJK , MulliganA , HartmanCA , HoekstraPJ . Attention-deficit/hyperactivity disorder and social dysfunctioning. Clinical Psychology Review2008;28(4):692-708. [DOI: 10.1016/j.cpr.2007.10.003] [PMID: 18036711]">Nijmeijer 2008</a>), and poor self‐esteem (<a href="./references#CD007986-bbs2-0086" title="CooperRE , TyeC , KuntsiJ , VassosE , AshersonP . Omega-3 polyunsaturated fatty acid supplementation and cognition: a systematic review and meta-analysis. Journal of Psychopharmacology2015;29(7):753-63. [DOI: 10.1177/0269881115587958] [PMID: 26040902]">Cooper 2015</a>; <a href="./references#CD007986-bbs2-0087" title="CueliM , RodríguezC , CañameroLM , NúñezJC , González-CastroP . Self-concept and inattention or hyperactivity-impulsivity symptomatology: the role of anxiety. Brain Sciences2020;10(4):250. [DOI: 10.3390/brainsci10040250] [PMID: 32340167]">Cueli 2020</a>; <a href="./references#CD007986-bbs2-0103" title="HouckG , KendallJ , MillerA , MorrellP , WiebeG . Self-concept in children and adolescents with attention deficit hyperactivity disorder. Journal of Pediatric Nursing2011;26(3):239-47. [DOI: 10.1016/j.pedn.2010.02.004] [PMCID: PMC3101477] [PMID: 21601148]">Houck 2011</a>). ADHD is frequently comorbid with other mental health disorders, such as anxiety and depression (<a href="./references#CD007986-bbs2-0084" title="ChungW , JiangSF , PaksarianD , NikolaidisA , CastellanosFX , MerikangasKR , et al. Trends in the prevalence and incidence of attention-deficit/hyperactivity disorder among adults and children of different racial and ethnic groups. JAMA2019;2(11):e1914344. [DOI: 10.1001/jamanetworkopen.2019.14344] [PMCID: PMC6826640] [PMID: 31675080]">Chung 2019</a>; <a href="./references#CD007986-bbs2-0106" title="KatzmanMA , BilkeyTS , ChokkaPR , FalluA , KlassenLJ . Adult ADHD and comorbid disorders: clinical implications of a dimensional approach. BMC Psychiatry2017;17(1):302. [DOI: 10.1186/s12888-017-1463-3] [PMID: 28830387]">Katzman 2017</a>; <a href="./references#CD007986-bbs2-0134" title="RowlandAS , LesesneCA , AbramowitzAJ . The epidemiology of attention‐deficit/hyperactivity disorder (ADHD): a public health view. Mental Retardation and Developmental Disabilities Research Reviews2002;8(3):162-70. [DOI: 10.1002/mrdd.10036] [PMID: 12216060]">Rowland 2002</a>), and is associated with a higher risk of negative effects such as substance abuse (<a href="./references#CD007986-bbs2-0088" title="DaleyKC . Update on attention-deficit/hyperactivity disorder. Current Opinion in Pediatrics2004;16(2):217-26. [DOI: 10.1097/00008480-200404000-00020] [PMID: 15021207]">Daley 2004</a>; <a href="./references#CD007986-bbs2-0089" title="DavisC , CohenA , DavidsM , RabindranathA . Attention-deficit/hyperactivity disorder in relation to addictive behaviors: a moderated-mediation analysis of personality-risk factors and sex. Frontiers in Psychiatry2015;6:47. [DOI: 10.3389/fpsyt.2015.00047] [PMID: 25941494]">Davis 2015</a>; <a href="./references#CD007986-bbs2-0127" title="PolanczykGV , WillcuttEG , SalumGA , KielingC , RohdeLA . ADHD prevalence estimates across three decades: an updated systematic review and meta-regression analysis. International Journal of Epidemiology2014;43(2):434-42. [DOI: 10.1093/ije/dyt261] [PMCID: PMC4817588] [PMID: 24464188]">Polanczyk 2014</a>; <a href="./references#CD007986-bbs2-0134" title="RowlandAS , LesesneCA , AbramowitzAJ . The epidemiology of attention‐deficit/hyperactivity disorder (ADHD): a public health view. Mental Retardation and Developmental Disabilities Research Reviews2002;8(3):162-70. [DOI: 10.1002/mrdd.10036] [PMID: 12216060]">Rowland 2002</a>. </p> <section id="CD007986-sec-0011"> <h4 class="title">Aetiology</h4> <p>A range of factors may contribute to the onset and maintenance of ADHD symptoms, including genetic factors (<a href="./references#CD007986-bbs2-0144" title="SwansonJ , OosterlaanJ , MuriasM , SchuckS , FlodmanP , SpenceMA , et al. Attention deficit/hyperactivity disorder children with a 7‐repeat allele of the dopamine receptor D4 gene have extreme behaviour but normal performance on critical neuropsychology tests of attention. Proceedings of the National Academy of Sciences2000;97(9):4754-9. [PMCID: PMC18305 DOI: 10.1073/pnas.080070897] [PMID: 10.1073/pnas.080070897] [PMID: 10781080]">Swanson 2000</a>; <a href="./references#CD007986-bbs2-0145" title="SwansonJM , KinsbourneM , NiggJ , LanphearB , StefanatosGA , VolkowN , et al. Etiologic subtypes of attention‐deficit/hyperactivity disorder: brain imaging, molecular genetic and environmental factors and the dopamine hypothesis. Neuropsychology Review2007;17(1):39-59. [DOI: 10.1007/s11065-007-9019-9] [PMID: 17318414]">Swanson 2007</a>); neuroanatomical abnormalities (<a href="./references#CD007986-bbs2-0074" title="BiedermanJ . Attention‐deficit/hyperactivity disorder: a selective overview. Biological Psychiatry2005;57(11):1215‐20. [DOI: 10.1016/j.biopsych.2004.10.020] [PMID: 15949990]">Biederman 2005</a>); psychosocial factors (<a href="./references#CD007986-bbs2-0074" title="BiedermanJ . Attention‐deficit/hyperactivity disorder: a selective overview. Biological Psychiatry2005;57(11):1215‐20. [DOI: 10.1016/j.biopsych.2004.10.020] [PMID: 15949990]">Biederman 2005</a>; <a href="./references#CD007986-bbs2-0120" title="MorrellJ , MurrayL . Parenting and the development of conduct disorder and hyperactive symptoms in childhood: a prospective longitudinal study from 2 months to 8 years. Journal of Child Psychology and Psychiatry2003;44(4):489-508. [DOI: 10.1111/1469-7610.t01-1-00139] [PMID: 12751842]">Morrell 2003</a>); pregnancy and delivery complications (<a href="./references#CD007986-bbs2-0074" title="BiedermanJ . Attention‐deficit/hyperactivity disorder: a selective overview. Biological Psychiatry2005;57(11):1215‐20. [DOI: 10.1016/j.biopsych.2004.10.020] [PMID: 15949990]">Biederman 2005</a>; <a href="./references#CD007986-bbs2-0155" title="ZappitelliM , PintoT , GrizenkoN . Pre‐ peri‐ and postnatal trauma in subjects with attention‐deficit hyperactivity disorder. Canadian Journal of Psychiatry2001;46(6):542-8. [DOI: 10.1177/070674370104600609] [PMID: 11526811]">Zappitelli 2001</a>); and environmental factors, such as prenatal cigarettes or alcohol (<a href="./references#CD007986-bbs2-0115" title="LinnetKM , DalsgaardS , ObelC , WisborgK , HenriksenTB , RodriguezA , et al. Maternal lifestyle factors in pregnancy risk of attention deficit hyperactivity disorder and associated behaviors: review of the current evidence. American Journal of Psychiatry2003;160(6):1028-40. [DOI: 10.1176/appi.ajp.160.6.1028] [PMID: 12777257]">Linnet 2003</a>; <a href="./references#CD007986-bbs2-0112" title="LangleyK , RiceF , Van den BreeMB , ThaparA . Maternal smoking during pregnancy as an environmental risk factor for attention deficit hyperactivity disorder behaviour. A review. Minerva Pediatrica2005;57(6):359-71. [PMID: 16402008]">Langley 2005</a>), and artificial food colouring (<a href="./references#CD007986-bbs2-0135" title="SchabDW , TrinhNH . Do artificial food colors promote hyperactivity in children with hyperactive syndromes? A meta‐analysis of double‐blind placebo‐controlled trials. Journal of Developmental and Behavioral Pediatrics2004;25(6):423-34. [DOI: 10.1097/00004703-200412000-00007] [PMID: 15613992]">Schab 2004</a>). However, the most significant factor associated with ADHD is heritability, which contributes approximately 75% to the aetiology of ADHD (<a href="./references#CD007986-bbs2-0074" title="BiedermanJ . Attention‐deficit/hyperactivity disorder: a selective overview. Biological Psychiatry2005;57(11):1215‐20. [DOI: 10.1016/j.biopsych.2004.10.020] [PMID: 15949990]">Biederman 2005</a>; <a href="./references#CD007986-bbs2-0094" title="FroehlichTE , AnixtJS , LoeIM , ChirdkiatgumchaiV , KuanL , GilmanRC . Update on environmental risk factors for attention‐deficit/hyperactivity disorder. Current Psychiatry Reports2011;13(5):333-44. [DOI: 10.1007/s11920-011-0221-3] [PMCID: PMC3277258] [PMID: 21779823]">Froehlich 2011</a>). </p> <p>There is good evidence that the neurotransmitter dopamine may be implicated in the pathogenesis of ADHD. Stimulant drugs that are used in the management of ADHD symptoms increase the availability of dopamine in the brain (<a href="./references#CD007986-bbs2-0074" title="BiedermanJ . Attention‐deficit/hyperactivity disorder: a selective overview. Biological Psychiatry2005;57(11):1215‐20. [DOI: 10.1016/j.biopsych.2004.10.020] [PMID: 15949990]">Biederman 2005</a>), and a number of genes related to the dopamine pathway have been implicated in ADHD, in particular the dopamine D4 and D5 receptor, dopamine‐β‐hydroxylase and dopamine transporter genes (<a href="./references#CD007986-bbs2-0093" title="FaraoneSV . Genetics of childhood disorders: XX. ADHD Part 4: is ADHD genetically heterogeneous?Journal of the American Academy of Child and Adolescent Psychiatry2000;39(11):1455-7. [DOI: 10.1097/00004583-200011000-00022] [PMID: 11068903]">Faraone 2000</a>; <a href="./references#CD007986-bbs2-0114" title="LiD , ShamPC , OwenMJ , HeL . Meta‐analysis shows significant association between dopamine system genes and attention deficit hyperactivity disorder (ADHD). Human Molecular Genetics2006;15(14):2276-84. [DOI: 10.1093/hmg/ddl152] [PMID: 16774975]">Li 2006</a>). In addition, imaging studies have shown differences in the dopamine pathway in children and adults with ADHD (<a href="./references#CD007986-bbs2-0074" title="BiedermanJ . Attention‐deficit/hyperactivity disorder: a selective overview. Biological Psychiatry2005;57(11):1215‐20. [DOI: 10.1016/j.biopsych.2004.10.020] [PMID: 15949990]">Biederman 2005</a>; <a href="./references#CD007986-bbs2-0109" title="KrauseKH , DreselSH , KrauseJ , La FougereC , AckenheilM . The dopamine transporter and neuroimaging in attention deficit hyperactivity disorder. Neuroscience and Biobehavioral Reviews2003;27(7):605-13. [DOI: 10.1016/j.neubiorev.2003.08.012] [PMID: 14624805]">Krause 2003</a>; <a href="./references#CD007986-bbs2-0145" title="SwansonJM , KinsbourneM , NiggJ , LanphearB , StefanatosGA , VolkowN , et al. Etiologic subtypes of attention‐deficit/hyperactivity disorder: brain imaging, molecular genetic and environmental factors and the dopamine hypothesis. Neuropsychology Review2007;17(1):39-59. [DOI: 10.1007/s11065-007-9019-9] [PMID: 17318414]">Swanson 2007</a>). </p> </section> <section id="CD007986-sec-0012"> <h4 class="title">Diagnosis of ADHD</h4> <p>The diagnosis of ADHD in children and adolescents should be based on validated criteria, such as DSM‐5, <a href="./references#CD007986-bbs2-0069" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th edition. Arlington (VA): American Psychiatric Association, 2013.">APA 2013</a>, DSM‐IV, <a href="./references#CD007986-bbs2-0067" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th edition. Washington, DC: American Psychiatric Association, 1994.">APA 1994</a>, or DSM‐IV‐TR, <a href="./references#CD007986-bbs2-0068" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders - Text Revision. 4th edition. Washington, DC: American Psychiatric Association, 2000.">APA 2000</a>, for ADHD, or ICD‐11, <a href="./references#CD007986-bbs2-0152" title="World Health Organization. International Classification of Diseases for Mortality and Morbidity Statistics 11th Revision. icd.who.int/browse11/l-m/en.">WHO 2018</a>, or ICD‐10 for hyperkinetic disorder, <a href="./references#CD007986-bbs2-0151" title="World Health Organization. ICD-10: International Statistical Classification of Diseases and Related Health Problems 10th Revision. apps.who.int/classifications/icd10/browse/2010/en.">WHO 2010</a>. Assessment should be through diagnostic interviews and supported by behaviour rating scales, direct observations of behaviour, and clinic‐based testing (<a href="./references#CD007986-bbs2-0121" title="National Institute for Health and Care Excellence. NICE guideline [NG87]: Attention deficit hyperactivity disorder: diagnosis and management. www.nice.org.uk/guidance/ng87 (accessed prior to 20 January 2023).">NICE 2018</a>). </p> </section> <section id="CD007986-sec-0013"> <h4 class="title">Treatment for ADHD</h4> <p>The most frequently used treatment used for ADHD is the stimulant medication methylphenidate (<a href="./references#CD007986-bbs2-0073" title="Beau-LejdstromR , DouglasI , EvansSJ , SmeethL . Latest trends in ADHD drug prescribing patterns in children in the UK: prevalence, incidence and persistence. BMJ Open2016;6(6):e010508. [DOI: 10.1136/bmjopen-2015-010508] [PMID: 27297009]">Beau‐Lejdstrom 2016</a>); the stimulant dexamfetamine is also used (<a href="./references#CD007986-bbs2-0073" title="Beau-LejdstromR , DouglasI , EvansSJ , SmeethL . Latest trends in ADHD drug prescribing patterns in children in the UK: prevalence, incidence and persistence. BMJ Open2016;6(6):e010508. [DOI: 10.1136/bmjopen-2015-010508] [PMID: 27297009]">Beau‐Lejdstrom 2016</a>; <a href="./references#CD007986-bbs2-0128" title="PunjaS , ShamseerL , HartlingL , UrichukL , VandermeerB , NiklesJ , et al. Amphetamines for attention deficit hyperactivity disorder (ADHD) in children and adolescents. Cochrane Database of Systematic Reviews2016, Issue 2. Art. No: CD009996. [DOI: 10.1002/14651858.CD009996.pub2] [PMID: 26844979]">Punja 2016</a>). Meta‐analyses of stimulant medications have shown them to be effective in improving inattention and behavioural symptoms, although their effectiveness for improving cognition and achievement is more modest (<a href="./references#CD007986-bbs2-0128" title="PunjaS , ShamseerL , HartlingL , UrichukL , VandermeerB , NiklesJ , et al. Amphetamines for attention deficit hyperactivity disorder (ADHD) in children and adolescents. Cochrane Database of Systematic Reviews2016, Issue 2. Art. No: CD009996. [DOI: 10.1002/14651858.CD009996.pub2] [PMID: 26844979]">Punja 2016</a>; <a href="./references#CD007986-bbs2-0143" title="StorebøOJ , RamstadE , KroghHB , NilausenTD , SkoogM , HolmskovM , et al. Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD). Cochrane Database of Systematic Reviews2015, Issue 11. Art. No: CD009885. [DOI: 10.1002/14651858.CD009885.pub2] [PMCID: PMC8763351] [PMID: 26599576]">Storebø 2015</a>). However, as many as 30% of children do not respond to stimulants (<a href="./references#CD007986-bbs2-0072" title="BanaschewskiT , RoessnerV , DittmannRW , SantoshPJ , RothenbergerA . Non‐stimulant medications in the treatment of ADHD. European Child &amp; Adolescent Psychiatry2004;13(Suppl 1):i102-16. [DOI: 10.1007/s00787-004-1010-x] [PMID: 15322961]">Banaschewski 2004</a>). Stimulants may also be associated with a number of serious adverse events such as psychosis and arrhythmias (<a href="./references#CD007986-bbs2-0141" title="StorebøOJ , PedersenN , RamstadE , KielsholmML , NielsenSS , KroghHB , et al. Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents – assessment of adverse events in non‐randomised studies. Cochrane Database of Systematic Reviews2018, Issue 5. Art. No: CD012069. [DOI: 10.1002/14651858.CD012069.pub2] [PMCID: PMC6494554] [PMID: 29744873]">Storebø 2018</a>), as well as a range of non‐serious adverse events including decreased appetite, weight loss, insomnia, stomachache, headache, and irritability (<a href="./references#CD007986-bbs2-0128" title="PunjaS , ShamseerL , HartlingL , UrichukL , VandermeerB , NiklesJ , et al. Amphetamines for attention deficit hyperactivity disorder (ADHD) in children and adolescents. Cochrane Database of Systematic Reviews2016, Issue 2. Art. No: CD009996. [DOI: 10.1002/14651858.CD009996.pub2] [PMID: 26844979]">Punja 2016</a>; <a href="./references#CD007986-bbs2-0141" title="StorebøOJ , PedersenN , RamstadE , KielsholmML , NielsenSS , KroghHB , et al. Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents – assessment of adverse events in non‐randomised studies. Cochrane Database of Systematic Reviews2018, Issue 5. Art. No: CD012069. [DOI: 10.1002/14651858.CD012069.pub2] [PMCID: PMC6494554] [PMID: 29744873]">Storebø 2018</a>), and may also be associated with longer‐term adverse effects such as decreased growth (<a href="./references#CD007986-bbs2-0142" title="StorebøOJ , Elmose AndersenM , SkoogM , Joost HansenS , SimonsenE , PedersenN , et al. Social skills training for attention deficit hyperactivity disorder (ADHD) in children aged 5 to 18 years. Cochrane Database of Systematic Reviews2019, Issue 6. Art. No: CD008223. [DOI: 10.1002/14651858.CD008223.pub3] [PMCID: PMC6587063] [PMID: 31222721]">Storebø 2019</a>). </p> <p>The most commonly used non‐stimulant medications used for ADHD are atomoxetine (<a href="./references#CD007986-bbs2-0073" title="Beau-LejdstromR , DouglasI , EvansSJ , SmeethL . Latest trends in ADHD drug prescribing patterns in children in the UK: prevalence, incidence and persistence. BMJ Open2016;6(6):e010508. [DOI: 10.1136/bmjopen-2015-010508] [PMID: 27297009]">Beau‐Lejdstrom 2016</a>; <a href="./references#CD007986-bbs2-0100" title="HalesCM , KitBK , GuQ , OgdenCL . Trends in prescription medication use among children and adolescents - United States, 1999-2014. JAMA2018;319(19):2009-20. [DOI: 10.1001/jama.2018.5690] [PMID: 29800213]">Hales 2018</a>; <a href="./references#CD007986-bbs2-0130" title="RenouxC , ShinJY , Dell'AnielloS , FergussonE , SuissaS . Prescribing trends of attention-deficit hyperactivity disorder (ADHD) medications in UK primary care, 1995-2015. British Journal of Clinical Pharmacology2016;82(3):858-68. [DOI: 10.1111/bcp.13000] [PMCID: PMC5338115] [PMID: 27145886]">Renoux 2016</a>), clonidine, and guanfacine (<a href="./references#CD007986-bbs2-0100" title="HalesCM , KitBK , GuQ , OgdenCL . Trends in prescription medication use among children and adolescents - United States, 1999-2014. JAMA2018;319(19):2009-20. [DOI: 10.1001/jama.2018.5690] [PMID: 29800213]">Hales 2018</a>). Non‐stimulant medications may also be preferable to stimulants treatment of ADHD as stimulants can exacerbate comorbidities such as epilepsy, <a href="./references#CD007986-bbs2-0092" title="EatonC , YongK , WalterV , MbizvoGK , RhodesS , ChinRF . Stimulant and non-stimulant drug therapy for people with attention deficit hyperactivity disorder and epilepsy. Cochrane Database of Systematic Reviews2022, Issue 7. Art. No: CD013136. [DOI: 10.1002/14651858.CD013136.pub2] [PMCID: PMC9289704 (available on 13 July 2023)] [PMID: 35844168]">Eaton 2022</a>, and tics, <a href="./references#CD007986-bbs2-0124" title="OslandST , SteevesTD , PringsheimT . Pharmacological treatment for attention deficit hyperactivity disorder (ADHD) in children with comorbid tic disorders. Cochrane Database of Systematic Reviews2018, Issue 6. Art. No: CD007990. [DOI: 10.1002/14651858.CD007990.pub3] [PMCID: PMC6513283] [PMID: 29944175]">Osland 2018</a>. However, non‐stimulants may be less effective in treating the core symptoms of ADHD compared to stimulants (<a href="./references#CD007986-bbs2-0123" title="NijmeijerJS , MinderaaRB , BuitelaarJK , MulliganA , HartmanCA , HoekstraPJ . Attention-deficit/hyperactivity disorder and social dysfunctioning. Clinical Psychology Review2008;28(4):692-708. [DOI: 10.1016/j.cpr.2007.10.003] [PMID: 18036711]">Nijmeijer 2008</a>; <a href="./references#CD007986-bbs2-0150" title="VerbeeckW , BekkeringGE , Van den NoortgateW , KramersC . Bupropion for attention deficit hyperactivity disorder (ADHD) in adults. Cochrane Database of Systematic Reviews2017, Issue 10. Art. No: CD009504. [DOI: 10.1002/14651858.CD009504.pub2] [PMCID: PMC6485546] [PMID: 28965364]">Verbeeck 2017</a>). </p> <p>As alternatives to medication, there is some limited evidence that non‐pharmacological therapies may be effective in improving symptoms and associated behaviours in ADHD (<a href="./references#CD007986-bbs2-0117" title="LopezPL , TorrenteFM , CiapponiA , LischinskyAG , Cetkovich‐BakmasM , RojasJI , et al. Cognitive‐behavioural interventions for attention deficit hyperactivity disorder (ADHD) in adults. Cochrane Database of Systematic Reviews2018, Issue 3. Art. No: CD010840. [DOI: 10.1002/14651858.CD010840.pub2] [PMCID: PMC6494390] [PMID: 29566425]">Lopez 2018</a>; <a href="./references#CD007986-bbs2-0156" title="ZwiM , JonesH , ThorgaardC , YorkA , DennisJA . Parent training interventions for attention deficit hyperactivity disorder (ADHD) in children aged 5 to 18 years. Cochrane Database of Systematic Reviews2011, Issue 12. Art. No: CD003018. [DOI: 10.1002/14651858.CD003018.pub3] [PMCID: PMC6544776] [PMID: 22161373]">Zwi 2011</a>), while evidence for the effectiveness of other non‐pharmacological therapies is lacking (<a href="./references#CD007986-bbs2-0075" title="BjornstadGJ , MontgomeryP . Family therapy for attention‐deficit disorder or attention‐deficit/hyperactivity disorder in children and adolescents. Cochrane Database of Systematic Reviews2005, Issue 2. Art. No: CD005042. [DOI: 10.1002/14651858.CD005042.pub2] [PMID: 15846741]">Bjornstad 2005</a>; <a href="./references#CD007986-bbs2-0110" title="KrisanaprakornkitT , NgamjarusC , WitoonchartC , PiyavhatkulN . Meditation therapies for attention‐deficit/hyperactivity disorder (ADHD). Cochrane Database of Systematic Reviews2010, Issue 6. Art. No: CD006507. [DOI: 10.1002/14651858.CD006507.pub2] [PMCID: PMC6823216] [PMID: 20556767]">Krisanaprakornkit 2010</a>; <a href="./references#CD007986-bbs2-0142" title="StorebøOJ , Elmose AndersenM , SkoogM , Joost HansenS , SimonsenE , PedersenN , et al. Social skills training for attention deficit hyperactivity disorder (ADHD) in children aged 5 to 18 years. Cochrane Database of Systematic Reviews2019, Issue 6. Art. No: CD008223. [DOI: 10.1002/14651858.CD008223.pub3] [PMCID: PMC6587063] [PMID: 31222721]">Storebø 2019</a>). </p> <p>Because of the limitations associated with the available treatments for ADHD, particularly the stimulant medications, families often look for alternative treatments (<a href="./references#CD007986-bbs2-0122" title="National Institutes of Health Consensus Development Conference Statement: diagnosis and treatment of attention-deficit/hyperactivity disorder (ADHD). Journal of the American Academy of Child &amp; Adolescent Psychiatry2000;39(2):182-93. [DOI: 10.1097/00004583-200002000-00018] [PMID: 10673829]">NIH 2000</a>; <a href="./references#CD007986-bbs2-0088" title="DaleyKC . Update on attention-deficit/hyperactivity disorder. Current Opinion in Pediatrics2004;16(2):217-26. [DOI: 10.1097/00008480-200404000-00020] [PMID: 15021207]">Daley 2004</a>). The use of polyunsaturated fatty acids (PUFA) is one such potential alternative (<a href="./references#CD007986-bbs2-0009" title="BrueAW , OaklandTD , EvansRA . The use of a dietary supplement combination and an essential fatty acid as an alternative and complementary treatment for children with attention-deficit/hyperactivity disorder. Scientific Review of Alternative Medicine2001;5(4):187-94. [WEB PAGE: tinyurl.com/y56pdtxq]BrueAW . The Use of a Dietary Supplement Combination and an Essential Fatty Acid as an Alternative and Complementary Treatment for Children with Attention Deficit Hyperactivity Disorder (ADHD) [PhD thesis]. Gainesville (FL): University of Florida, 1999. ">Brue 2001</a>; <a href="./references#CD007986-bbs2-0088" title="DaleyKC . Update on attention-deficit/hyperactivity disorder. Current Opinion in Pediatrics2004;16(2):217-26. [DOI: 10.1097/00008480-200404000-00020] [PMID: 15021207]">Daley 2004</a>). </p> </section> </section> <section id="CD007986-sec-0014"> <h3 class="title" id="CD007986-sec-0014">Description of the intervention</h3> <p>Human infants require omega‐6 and omega‐3 PUFA for neural development and to maintain neural integrity and function (<a href="./references#CD007986-bbs2-0104" title="InnisSM . The role of dietary n‐6 and n‐3 fatty acids in the developing brain. Developmental Neuroscience2000;22(5‐6):474‐80. [DOI: 10.1159/000017478] [PMID: 11111165]">Innis 2000</a>; <a href="./references#CD007986-bbs2-0099" title="HaagM . Essential fatty acids and the brain. Canadian Journal of Psychiatry2003;48(3):195-203. [DOI: 10.1177/070674370304800308] [PMID: 12728744]">Haag 2003</a>). The omega‐3 PUFA, alpha‐linolenic acid (ALA) is found in green‐leaved plants, while eicosapentaenoic acid (EPA) and docosahexanoic acid (DHA) are found in high concentrations in fish oil; the omega‐6 PUFA precursor linoleic acid is found in vegetable oils (<a href="./references#CD007986-bbs2-0099" title="HaagM . Essential fatty acids and the brain. Canadian Journal of Psychiatry2003;48(3):195-203. [DOI: 10.1177/070674370304800308] [PMID: 12728744]">Haag 2003</a>; <a href="./references#CD007986-bbs2-0071" title="AssisiA , BanziR , BuonocoreC , CapassoF , Di MuzioV , MichelacciF , et al. Fish oil and mental health: the role of n‐3 long‐chain polyunsaturated fatty acids in cognitive development and neurological disorders. International Clinical Psychopharmacology2006;21(6):319-36. [DOI: 10.1097/01.yic.0000224790.98534.11] [PMID: 17012979]">Assisi 2006</a>). Omega‐3 PUFA, which include ALA, EPA, and DHA, are associated with brain development (<a href="./references#CD007986-bbs2-0104" title="InnisSM . The role of dietary n‐6 and n‐3 fatty acids in the developing brain. Developmental Neuroscience2000;22(5‐6):474‐80. [DOI: 10.1159/000017478] [PMID: 11111165]">Innis 2000</a>; <a href="./references#CD007986-bbs2-0132" title="RichardsonAJ , PuriBK . The potential role of fatty acids in attention-deficit/hyperactivity disorder. Prostaglandin, Leukotrienes and Essential Fatty Acids2000;63(1-2):79-87. [DOI: 10.1054/plef.2000.0196] [PMID: 10970718]">Richardson 2000</a>; <a href="./references#CD007986-bbs2-0099" title="HaagM . Essential fatty acids and the brain. Canadian Journal of Psychiatry2003;48(3):195-203. [DOI: 10.1177/070674370304800308] [PMID: 12728744]">Haag 2003</a>), and DHA is the major PUFA in the adult mammalian brain (<a href="./references#CD007986-bbs2-0104" title="InnisSM . The role of dietary n‐6 and n‐3 fatty acids in the developing brain. Developmental Neuroscience2000;22(5‐6):474‐80. [DOI: 10.1159/000017478] [PMID: 11111165]">Innis 2000</a>). Arachidonic acid is the most abundant omega‐6 PUFA in the human brain (<a href="./references#CD007986-bbs2-0064" title="AgostoniC . Role of long‐chain polyunsaturated fatty acids in the first year of life. Journal of Pediatric Gastroenterology and Nutrition2008;47(Suppl 2):S41-4. [DOI: 10.1097/01.mpg.0000338811.52062.b2] [PMID: 18931599]">Agostoni 2008</a>). The ratio of omega‐3 to omega‐6 PUFA is also considered important to normal development and function of the human brain (<a href="./references#CD007986-bbs2-0104" title="InnisSM . The role of dietary n‐6 and n‐3 fatty acids in the developing brain. Developmental Neuroscience2000;22(5‐6):474‐80. [DOI: 10.1159/000017478] [PMID: 11111165]">Innis 2000</a>; <a href="./references#CD007986-bbs2-0099" title="HaagM . Essential fatty acids and the brain. Canadian Journal of Psychiatry2003;48(3):195-203. [DOI: 10.1177/070674370304800308] [PMID: 12728744]">Haag 2003</a>), with a ratio of 1:4 considered optimal (<a href="./references#CD007986-bbs2-0071" title="AssisiA , BanziR , BuonocoreC , CapassoF , Di MuzioV , MichelacciF , et al. Fish oil and mental health: the role of n‐3 long‐chain polyunsaturated fatty acids in cognitive development and neurological disorders. International Clinical Psychopharmacology2006;21(6):319-36. [DOI: 10.1097/01.yic.0000224790.98534.11] [PMID: 17012979]">Assisi 2006</a>; <a href="./references#CD007986-bbs2-0078" title="BorsoneloEC , GaldurózJC . The role of polyunsaturated fatty acids (PUFAs) in development, aging and substance abuse disorders: review and propositions. Prostaglandins, Leukotrienes and Essential Fatty Acids2008;78(4-5):237-45. [DOI: 10.1016/j.plefa.2008.03.005] [PMID: 18502631]">Borsonelo 2008</a>). </p> </section> <section id="CD007986-sec-0015"> <h3 class="title" id="CD007986-sec-0015">How the intervention might work</h3> <p>Children and adults with ADHD have been shown to have significantly lower plasma and blood concentrations of PUFA (<a href="./references#CD007986-bbs2-0077" title="BonviciniC , FaraoneSV , ScassellatiC . Attention-deficit hyperactivity disorder in adults: a systematic review and meta-analysis of genetic, pharmacogenetic and biochemical studies. Molecular Psychiatry2016;21(7):872-84. Erratum in: Molecular Psychiatry. 2016 Nov;21(11):1643. DOI: 10.1038/mp.2016.128. [DOI: 10.1038/mp.2016.74] [PMCID: PMC5414093] [PMID: 27217152]">Bonvicini 2016</a>; <a href="./references#CD007986-bbs2-0082" title="ChangJP , SuKP , MondelliV , ParianteCM . Omega-3 polyunsaturated fatty acids in youths with attention deficit hyperactivity disorder: a systematic review and meta-analysis of clinical trials and biological studies. Neuropsychopharmacology2018;43(3):534-45. [DOI: 10.1038/npp.2017.160] [PMID: PMC5669464]">Chang 2018</a>; <a href="./references#CD007986-bbs2-0111" title="LangeKW , HauserJ , LangeKM , Makulska-GertrudaE , NakamuraY , ReissmannA , et al. The role of nutritional supplements in the treatment of ADHD: what the evidence says. Current Psychiatry Reports2017;19(2):8. [DOI: 10.1007/s11920-017-0762-1] [PMID: 28168597]">Lange 2017</a>; <a href="./references#CD007986-bbs2-0147" title="TeseiA , CrippaA , CeccarelliSB , MauriM , MolteniM , AgostoniC , et al. The potential relevance of docosahexaenoic acid and eicosapentaenoic acid to the etiopathogenesis of childhood neuropsychiatric disorders. European Child &amp; Adolescent Psychiatry2017;26(9):1011-30. [DOI: 10.1007/s00787-016-0932-4] [PMID: 27988864]">Tesei 2017</a>), and, in particular, lower levels of omega‐3 PUFA (<a href="./references#CD007986-bbs2-0079" title="BurgessJR , StevensL , ZhangW , Peck L. Long‐chain polyunsaturated fatty acids in children with attention‐deficit hyperactivity disorder. American Journal of Clinical Nutrition2000;71(Suppl 1):327S-30S. [DOI: 10.1093/ajcn/71.1.327S] [PMID: 10617991]">Burgess 2000</a>; <a href="./references#CD007986-bbs2-0083" title="ChenJR , HsuSF , HsuCD , HwangLH , YangSC . Dietary patterns and blood fatty acid composition in children with attention‐deficit hyperactivity disorder in Taiwan. Journal of Nutritional Biochemistry2004;15(8):467-72. [DOI: 10.1016/j.jnutbio.2004.01.008] [PMID: 15302081]">Chen 2004</a>; <a href="./references#CD007986-bbs2-0154" title="YonezawaK , NonakaS , IwakuraY , KusanoY , FunamotoY , KanchiN , et al. Investigation into the plasma concentration of ω3 polyunsaturated fatty acids in Japanese attention-deficit hyperactivity disorder patients. Journal of Neural Transmission2018;125(9):1395-400. [DOI: 10.1007/s00702-018-1895-z] [PMID: 29926268]">Yonezawa 2018</a>). There is also some evidence that PUFA supplementation can improve neurodevelopmental indicators in preterm infants (<a href="./references#CD007986-bbs2-0119" title="MoonK , RaoSC , SchulzkeSM , PatoleSK , SimmerK . Longchain polyunsaturated fatty acid supplementation in preterm infants. Cochrane Database of Systematic Reviews2016, Issue 12. Art. No: CD000375. [DOI: 10.1002/14651858.CD000375.pub5] [PMCID: PMC6463838] [PMID: 27995607]">Moon 2016</a>), but not full‐term infants (<a href="./references#CD007986-bbs2-0105" title="JasaniB , SimmerK , PatoleSK , RaoSC . Long chain polyunsaturated fatty acid supplementation in infants born at term. Cochrane Database of Systematic Reviews2017, Issue 3. Art. No: CD000376. [DOI: 10.1002/14651858.CD000376.pub4]">Jasani 2017</a>). Taken together, these findings suggest that PUFA supplementation may reduce the attention and behaviour problems associated with ADHD. </p> </section> <section id="CD007986-sec-0016"> <h3 class="title" id="CD007986-sec-0016">Why it is important to do this review</h3> <p>This review is an update of the original Cochrane Review of PUFA for ADHD in children and adolescents (<a href="./references#CD007986-bbs2-0158" title="GilliesD , SinnJKH , LadSS , LeachMJ , RossMJ . Polyunsaturated fatty acids (PUFA) for attention deficit hyperactivity disorder (ADHD) in children and adolescents. Cochrane Database of Systematic Reviews2012, Issue 7. Art. No: CD007986. [DOI: 10.1002/14651858.CD007986.pub2]">Gillies 2012</a>). In the original review, we found little evidence that PUFA supplementation improved ADHD symptoms in children and adolescents. However, our conclusions were limited by potential weaknesses such as small sample sizes in the included trials, variation in participants and in types of supplementation, and short follow‐up times. </p> <p>Since the original review was conducted there has been a steady increase of trials in this area, therefore it was important that this large body of data be integrated into a current Cochrane Review update. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD007986-sec-0017" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD007986-sec-0017"></div> <p>To compare the efficacy of polyunsaturated fatty acids (PUFA) to other forms of treatment or placebo in treating the symptoms of attention deficit hyperactivity disorder (ADHD) in children and adolescents. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD007986-sec-0018" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD007986-sec-0018"></div> <section id="CD007986-sec-0019"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD007986-sec-0020"> <h4 class="title">Types of studies</h4> <p>Randomised and quasi‐randomised controlled trials comparing PUFA with placebo or PUFA plus alternative therapy (medication, behavioural therapy, or psychotherapy) with the same alternative therapy alone in children and adolescents (up to and including 18 years of age) diagnosed with ADHD. </p> <p>Quasi‐randomised trials are trials that use allocation methods that are not truly random, for example allocation based on the last number of medical identifier numbers or last number of the date of birth. </p> </section> <section id="CD007986-sec-0021"> <h4 class="title">Types of participants</h4> <p>Children or adolescents (up to and including 18 years of age) diagnosed with ADHD using validated criteria, such as the ICD‐10, <a href="./references#CD007986-bbs2-0151" title="World Health Organization. ICD-10: International Statistical Classification of Diseases and Related Health Problems 10th Revision. apps.who.int/classifications/icd10/browse/2010/en.">WHO 2010</a>, or DSM‐5, <a href="./references#CD007986-bbs2-0069" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th edition. Arlington (VA): American Psychiatric Association, 2013.">APA 2013</a>, or scores on related scales with high sensitivity and specificity for a diagnosis of ADHD. We included children and adolescents with comorbidities. </p> </section> <section id="CD007986-sec-0022"> <h4 class="title">Types of interventions</h4> <p>We were interested in the following four comparisons.</p> <p> <ol id="CD007986-list-0001"> <li> <p>PUFA versus placebo</p> </li> <li> <p>PUFA versus medication, e.g. methylphenidate, amphetamine</p> </li> <li> <p>PUFA versus behavioural therapy*</p> </li> <li> <p>PUFA versus psychotherapy*</p> </li> </ol> </p> <p>*We included trials where participants continued with their usual medication as long as this was consistent in all groups. </p> </section> <section id="CD007986-sec-0023"> <h4 class="title">Types of outcome measures</h4> <section id="CD007986-sec-0024"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD007986-list-0002"> <li> <p>Severity or improvement of ADHD symptoms measured by validated scales such as the Child Behavior Checklist, <a href="./references#CD007986-bbs2-0063" title="AchenbachTM , EdelbrockCS . Manual for the Child Behavior Checklist and Revised Child Behavior Profile. Burlington (VT): University of Vermont, Department of Psychiatry, 1983.">Achenbach 1983</a>, or Conners Rating Scales, <a href="./references#CD007986-bbs2-0085" title="ConnersCK , SitareniosG , ParkerJD , EpsteinJN . Revision and restandardization of the Conners Teacher Rating Scale (CTRS-R): factor structure, reliability, and criterion validity. Journal of Abnormal Child Psychology1998;26(4):279-91. [DOI: 10.1023/a:1022606501530] [PMID: 9700520]">Conners 1998</a>. Severity was a continuous measure based on endpoint or change scores, while improvement was a dichotomous outcome based on author‐defined improvements in scores. </p> </li> </ol> </p> <p>N.B. We only included outcome data that were measured using a scale or questionnaire if the scale or questionnaire was reported to be valid and reliable in a peer‐reviewed journal. In addition, we only included improvement if the clinician making the judgement was blinded to the participant's treatment group, or if it was unclear whether they were blinded. </p> </section> <section id="CD007986-sec-0025"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD007986-list-0003"> <li> <p>Severity or incidence of behavioural problems, e.g. oppositional behaviour or conduct disorder (measured by scales such as the Child Behavior Checklist (<a href="./references#CD007986-bbs2-0063" title="AchenbachTM , EdelbrockCS . Manual for the Child Behavior Checklist and Revised Child Behavior Profile. Burlington (VT): University of Vermont, Department of Psychiatry, 1983.">Achenbach 1983</a>)). </p> </li> <li> <p>Quality of life (measured by, for example, Pediatric Quality of Life Inventory Version 4.0 (<a href="./references#CD007986-bbs2-0149" title="VarniJW , SeidM , KurtinPS . PedsQL™ 4.0: reliability and validity of the Pediatric Quality of Life Inventory™ version 4.0 generic core scales in healthy and patient populations. Medical Care2001;39(8):800-12. [DOI: 10.1097/00005650-200108000-00006] [PMID: 11468499]">Varni 2001</a>)). </p> </li> <li> <p>Severity or incidence of depressive symptoms (measured by, for example, Children's Depression Inventory (<a href="./references#CD007986-bbs2-0108" title="KovacsM . CDI: Children's Depression Inventory. A Measure of Depressive Symptoms in Young Persons. www.pearsonclinical.co.uk/Psychology/generic/ChildrensDepressionInventory(CDI)/Resources/Technical.pdf (accessed prior to 20 January 2023).">Kovacs 1992</a>)). </p> </li> <li> <p>Severity or incidence of anxiety symptoms (measured by, for example, State‐Trait Anxiety Inventory for Children (<a href="./references#CD007986-bbs2-0139" title="SpielbergerCD . Manual for the State-Trait Anxiety Inventory for Children. Palo Alto (CA): Consulting Psychologists Press, 1973.">Spielberger 1973</a>)). </p> </li> <li> <p>Side effects, such as gastrointestinal symptoms, allergies, changes in weight, changes in appetite or sleep pattern. </p> </li> <li> <p>Loss to follow‐up.</p> </li> <li> <p>Cost.</p> </li> </ol> </p> <p>We analysed data for parent, teacher, clinician, and self‐reported outcomes separately.</p> <p>We collected data for all time points. We subgrouped data as short term (up to three months of PUFA treatment), medium term (from three months up to one year of PUFA treatment), and long term (one year or more of PUFA treatment); see <a href="#CD007986-sec-0040">Data synthesis</a>. </p> </section> </section> </section> <section id="CD007986-sec-0026"> <h3 class="title">Search methods for identification of studies</h3> <p>For this update, the Information Specialist of Cochrane Developmental, Psychosocial and Learning Problems searched the following databases on 20 September 2016. Top‐up searches were run in November 2019, October 2020, and October 2021. We did not impose any date or language restrictions. The search strategies used for this update and the previous version of the review are listed in <a href="./appendices#CD007986-sec-0103">Appendix 1</a> and <a href="./appendices#CD007986-sec-0120">Appendix 2</a>, respectively. </p> <section id="CD007986-sec-0027"> <h4 class="title">Electronic searches</h4> <p>We searched the following databases.</p> <p> <ol id="CD007986-list-0004"> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL; 2021, Issue 10) in the Cochrane Library. Searched 6 October 2021. </p> </li> <li> <p>MEDLINE Ovid (1946 to 4 October 2021).</p> </li> <li> <p>MEDLINE E‐Pub Ovid (4 October 2021).</p> </li> <li> <p>MEDLINE In‐Process Ovid (1946 to 4 October 2021).</p> </li> <li> <p>Embase Ovid (1974 to 4 October 2021).</p> </li> <li> <p>APA PsycINFO Ovid (1806 to September Week 4 2021).</p> </li> <li> <p>CINAHL Plus EBSCOhost (Cumulative Index to Nursing and Allied Health Literature) (1937 to 6 October 2021). </p> </li> <li> <p>Web of Science Core Collection Clarivate (Science Citation Index; Social Science Citation Index; Conference Proceedings Citation Index ‐ Science; Conference Proceedings Citation Index ‐ Social Sciences &amp; Humanities; 1970 to 6 October 2021). </p> </li> <li> <p>Cochrane Database of Systematic Reviews (CDSR; 2021, Issue 10) in the Cochrane Library. Searched 6 October 2021. </p> </li> <li> <p>Epistemonikos (<a href="http://www.epistemonikos.org" target="_blank">www.epistemonikos.org</a>; searched 7 October 2021). </p> </li> <li> <p>ProQuest Dissertations &amp; Theses (all available years; searched 7 October 2021).</p> </li> <li> <p>TROVE (limited to theses; all available years, last searched 25 November 2019).</p> </li> <li> <p>WorldCat (limited to theses; all available years, last searched 25 November 2019).</p> </li> <li> <p>ClinicalTrials.gov (<a href="https://clinicaltrials.gov/" target="_blank">clinicaltrials.gov/</a>; searched 7 October 2021). </p> </li> <li> <p>World Health Organization International Clinical Trials Registry Platform (WHO ICTRP; <a href="http://apps.who.int/trialsearch/Default.aspx" target="_blank">who.int/trialsearch/Default.aspx</a>; searched 7 October 2021). </p> </li> </ol> </p> </section> <section id="CD007986-sec-0028"> <h4 class="title">Searching other resources</h4> <p>We checked the reference lists of relevant studies and reviews for additional references to potentially relevant studies. We included trials in languages other than English; where possible, these were translated by members of the author team; where this was not possible, we used translation software. </p> </section> </section> <section id="CD007986-sec-0029"> <h3 class="title" id="CD007986-sec-0029">Data collection and analysis</h3> <p>In the following sections, we describe the methods we undertook. Methods we had proposed to use in the protocol but could not undertake because of inadequate data are listed in <a href="./appendices#CD007986-sec-0133">Appendix 3</a>. </p> <section id="CD007986-sec-0030"> <h4 class="title">Selection of studies</h4> <p>Two review authors (DG, ML, GPA) independently assessed the records yielded by the searches for eligibility using a two‐step process. First, two review authors independently screened all titles and abstracts. Any records that appeared to meet the inclusion criteria were moved through to the second step where full texts were obtained and screened for inclusion. Any disagreements regarding the selection of studies were resolved through consensus or by consulting a third member of the review team if necessary. The study selection process is illustrated in a PRISMA diagram (<a href="./references#CD007986-bbs2-0118" title="MoherD , LiberatiA , TetzlaffJ , AltmanDG , PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ2009;339:b2535. [DOI: 10.1136/bmj.b2535] [PMCID: PMC2714657] [PMID: 19622551]">Moher 2009</a>). </p> </section> <section id="CD007986-sec-0031"> <h4 class="title">Data extraction and management</h4> <p>We developed and piloted a data extraction form for the original version of this review (<a href="./references#CD007986-bbs2-0158" title="GilliesD , SinnJKH , LadSS , LeachMJ , RossMJ . Polyunsaturated fatty acids (PUFA) for attention deficit hyperactivity disorder (ADHD) in children and adolescents. Cochrane Database of Systematic Reviews2012, Issue 7. Art. No: CD007986. [DOI: 10.1002/14651858.CD007986.pub2]">Gillies 2012</a>). Two review authors (DG, ML, GPA) independently extracted details of participants, setting, interventions, methodology, and outcome data from each trial. We then compared the data for any differences. If differences were identified, we resolved them by consensus or referral to a third member of the team, when necessary. Where further clarification or missing data from trial authors were needed, we made all reasonable attempts at contact. </p> </section> <section id="CD007986-sec-0032"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Using the Cochrane risk of bias tool as described in Chapter 8 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD007986-bbs2-0101" title="HigginsJPT , GreenS , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1/.">Higgins 2011</a>), two review authors (DG, ML, GPA) independently assessed trials based on the following risk of bias domains:  </p> <p> <ol id="CD007986-list-0005"> <li> <p>adequacy of sequence generation; </p> </li> <li> <p>allocation concealment; </p> </li> <li> <p>blinding of participants and personnel; </p> </li> <li> <p>blinding of outcome assessors; </p> </li> <li> <p>incomplete outcome data; and </p> </li> <li> <p>selective outcome reporting. </p> </li> </ol> </p> <p>We rated these criteria as at low, high, or unclear risk of bias (for further details, please see <a href="./appendices#CD007986-sec-0134">Appendix 4</a>). We also collected information on any other sources of bias (e.g. baseline imbalance, cross‐over design, differential loss to follow‐up, inappropriate administration of an intervention or co‐intervention, early stopping, and selective reporting of subgroups). </p> <p>We collected details on how each of these criteria were addressed from the trial reports. Any disagreements regarding risk of bias criteria were resolved by consensus or by referral to a third member of the review team. </p> </section> <section id="CD007986-sec-0033"> <h4 class="title">Measures of treatment effect</h4> <section id="CD007986-sec-0034"> <h5 class="title">Dichotomous data</h5> <p>For binary outcomes, we calculated the risk ratio (RR) and 95% confidence interval (CI) using a random‐effects model because of the significant clinical heterogeneity between studies. </p> </section> <section id="CD007986-sec-0035"> <h5 class="title">Continuous data</h5> <p>For continuous outcomes, we used endpoint data in preference to change data if both were available. We calculated the standardised mean difference (SMD) between groups and 95% CI using a random‐effects model because there was significant clinical heterogeneity between studies. We used SMDs because more than one scale was used for each of these continuous outcomes. </p> </section> </section> <section id="CD007986-sec-0036"> <h4 class="title">Unit of analysis issues</h4> <p>Because of the potential for carry‐over of effects in cross‐over trials (<a href="./references#CD007986-bbs2-0102" title="HigginsJP , EldridgeS , LiT , editor(s). Chapter 23: Including variants on randomized trials. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022. Available from www.training.cochrane.org/handbook.">Higgins 2022</a>, Section 23.3.2), we used first‐phase data were these were available. If first‐phase data were not available, we used data for both phases if reported and conducted sensitivity analysis for such trials. </p> </section> <section id="CD007986-sec-0037"> <h4 class="title">Dealing with missing data</h4> <p>We used intention‐to‐treat data where available, and collected information on how the intention‐to‐treat analysis was calculated, which we reported in <a href="./references#CD007986-sec-0151" title="">Characteristics of included studies</a>. Where the reporting of data appeared to be incomplete, we made all reasonable efforts to contact the trial authors to request the missing data. </p> <p>We reported loss to follow‐up and the reasons for missing data where this information was available. If outcome data were reported as a median or range, or as a mean without a variance, we reported them in Additional tables. </p> <p>We considered the potential impact of missing data on the results in the interpretation of the results of the review. </p> </section> <section id="CD007986-sec-0038"> <h4 class="title">Assessment of heterogeneity</h4> <p>We used a Tau<sup>2</sup> test and I<sup>2</sup> statistic to evaluate heterogeneity. We interpreted a P value of less than 0.10 for the Tau<sup>2</sup> test of heterogeneity or an I<sup>2</sup> value of greater than 50% (or both) as significant heterogeneity. </p> <p>A rough guide to interpretation in the context of meta‐analyses of randomised trials is as follows: </p> <p> <ol id="CD007986-list-0006"> <li> <p>0% to 40%: might not be important;*</p> </li> <li> <p>30% to 60%: may represent moderate heterogeneity;*</p> </li> <li> <p>50% to 90%: may represent substantial heterogeneity;*</p> </li> <li> <p>75% to 100%: considerable heterogeneity.*</p> </li> </ol> </p> <p>*(<a href="./references#CD007986-bbs2-0090" title="DeeksJJ , HigginsJP , AltmanDG , editor(s). Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022. Available from www.training.cochrane.org/handbook.">Deeks 2022</a>, Section 10.10.2) </p> </section> <section id="CD007986-sec-0039"> <h4 class="title">Assessment of reporting biases</h4> <p>Where data from at least 10 trials were available, we entered primary outcome data into a funnel plot to assess for asymmetry, which may indicate publication bias (<a href="./references#CD007986-bbs2-0125" title="PageMJ , HigginsJP , SterneJA . Chapter 13: Assessing risk of bias due to missing results in a synthesis. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022. Available from www.training.cochrane.org/handbook.">Page 2022</a>, Section 13.3.5.2). </p> </section> <section id="CD007986-sec-0040"> <h4 class="title">Data synthesis</h4> <p>In the case of sufficient data, we synthesised similar interventions and outcomes in a meta‐analysis. Where the same co‐interventions were used in both groups (e.g. methylphenidate), these trials were included in meta‐analysis. </p> <p>We created a summary of findings table using the primary outcome of ADHD symptoms ‐ improvement, parent rated, teacher rated, and clinician rated. </p> <section id="CD007986-sec-0041"> <h5 class="title">Data collection intervals</h5> <p>We collected data for all time points. All outcome data were subgrouped as short term (up to three months of PUFA treatment), medium term (from three months up to one year of PUFA treatment), and long term (one year or more of PUFA treatment). If a study reported data for more than one time point within any of these predefined intervals (e.g. data at three months and six months), then data for only one of these time points were used. The decision of which time point to use was based on the following criteria in order of priority: i) completeness of data; ii) loss to follow‐up; and iii) longer treatment intervals. </p> </section> <section id="CD007986-sec-0042"> <h5 class="title">Skewed data</h5> <p>As a meta‐analysis is based on assumptions of normality, we checked all continuous data for skew before inclusion. We considered data to be skewed if the standard deviation was greater than half the mean (<a href="./references#CD007986-bbs2-0066" title="AltmanDG , BlandJM . Detecting skewness from summary information. BMJ1996;313(7066):1200. [DOI: 10.1136/bmj.313.7066.1200] [PMCID: PMC2352469] [PMID: 8916759]">Altman 1996</a>). It was not possible to check change data, as these can include positive and negative values. We found no endpoint data to be skewed. </p> </section> </section> <section id="CD007986-sec-0043"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We aimed to undertake subgroup analyses for the type of PUFA supplement that was used, that is omega‐3 only, omega‐6 only, or a combination of omega‐3 and omega‐6. However, we were only able to compare omega‐3 with omega 3/omega‐6 PUFA, as there were inadequate data for omega‐6 PUFA. We used medium‐term total parent‐rated ADHD scores for this subgroup analysis. </p> </section> <section id="CD007986-sec-0044"> <h4 class="title">Sensitivity analysis</h4> <p>We used sensitivity analyses to compare studies that used a clinician diagnosis of ADHD as an inclusion criterion to those that included participants based on ADHD symptom scale scores. </p> <p>We also conducted sensitivity analyses for any cross‐over studies that were included but that did not report first‐phase data, and based on attrition bias. </p> <p>All sensitivity analyses were conducted for comparisons of PUFA versus placebo. We used the primary outcome of parent‐reported symptoms for all sensitivity analyses except for the sensitivity analysis for the one cross‐over trial for which first‐phase data was not available (<a href="./references#CD007986-bbs2-0001" title="AmanMG , MitchellEA , TurbottSH . The effects of essential fatty acid supplementation by efamol in hyperactive children. Journal of Abnormal Child Psychology1987;15(1):75-90. [DOI: 10.1007/BF00916467]">Aman 1987</a>), for which parent‐rated inattention as total scores were not available. </p> </section> <section id="CD007986-sec-0045"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We generated a summary of findings table employing GRADEpro GDT integrated with RevMan Web (<a href="./references#CD007986-bbs2-0098" title="GRADEpro GDT. Hamilton (ON): McMaster University (developed by Evidence Prime), accessed prior to 6 April 2023. Available at gradepro.org.">GRADEpro GDT</a>; <a href="./references#CD007986-bbs2-0131" title="Review Manager Web (RevMan Web). Version 4.12.0. The Cochrane Collaboration, 2022. Available at revman.cochrane.org.">RevMan Web 2022</a>; <a href="./references#CD007986-bbs2-0137" title="SchünemannHJ , HigginsJP , VistGE , GlasziouP , AklEA , SkoetzN , et al. Chapter 14: Completing ‘Summary of findings’ tables and grading the certainty of the evidence. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022. Available from www.training.cochrane.org/handbook.">Schünemann 2022</a>), using as the main comparison PUFA versus placebo for the medium‐term outcomes of improvement, parent‐rated total, inattention and hyperactivity‐impulsivity symptoms, overall side effects, and loss to follow‐up. </p> <p>The GRADE Working Group grades of evidence are as follows.</p> <p><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> <p>Using the GRADE approach, two review authors (DG, ML) independently rated the certainty of the evidence as high, moderate, low, or very low according to the presence of the following criteria: risk of bias, imprecision, inconsistency, indirectness, and publication bias. We downgraded the certainty of the evidence for risk of bias where only 50% of risk of bias domains were rated low risk. We downgraded the certainty of the evidence for serious imprecision when the evidence was based on few studies with few participants or resulted in a wide confidence interval. Any discrepancies between authors were resolved by discussion. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD007986-sec-0046" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD007986-sec-0046"></div> <section id="CD007986-sec-0047"> <h3 class="title">Description of studies</h3> <section id="CD007986-sec-0048"> <h4 class="title">Results of the search</h4> <p>We identified 2081 records in total in this update, of which 2073 records were retrieved by the electronic searches and 8 were records of studies that had been classified as ongoing studies in the previous version of the review. We discarded 751 duplicates before screening the titles and abstracts of the remaining 1330 records. We excluded 1259 irrelevant records and retrieved full text of the remaining 71 records for closer examination, from which we identified 24 new included studies (from 39 reports). We found 6 additional reports of studies included in the previous version of the review (<a href="./references#CD007986-bbs2-0007" title="BélangerSA , VanasseM , SpahisS , SylvestreMP , LippéS , L'HeureuxF , et al. Omega-3 fatty acid treatment of children with attention-deficit hyperactivity disorder: a randomized, double-blind, placebo-controlled study. Paediatrics and Child Health2009;14(2):89-98. [DOI: 10.1093/pch/14.2.89] [PMCID: PMC2661342] [PMID: 19436468]VanasseM , Ageranioti-BélangerS , L'HeureuxF , GhadirianP , LevyE , SpahisS , et al. A randomized, controlled trial of omega-3 and phospholipids supplementation in children with attention-deficit-hyperactivity disorder. Developmental Medicine &amp; Child Neurology2006;48(Suppl 107):48. [DOI: 10.1111/j.1469-8749.2006.tb12600.x]">Bélanger 2009</a>; <a href="./references#CD007986-bbs2-0009" title="BrueAW , OaklandTD , EvansRA . The use of a dietary supplement combination and an essential fatty acid as an alternative and complementary treatment for children with attention-deficit/hyperactivity disorder. Scientific Review of Alternative Medicine2001;5(4):187-94. [WEB PAGE: tinyurl.com/y56pdtxq]BrueAW . The Use of a Dietary Supplement Combination and an Essential Fatty Acid as an Alternative and Complementary Treatment for Children with Attention Deficit Hyperactivity Disorder (ADHD) [PhD thesis]. Gainesville (FL): University of Florida, 1999. ">Brue 2001</a>; <a href="./references#CD007986-bbs2-0016" title="EUCTR2004-003853-13-SE. Placebo controlled, randomised, double-blind, multicentre study of PlusEPA (a PUFA, polyunsaturated fatty acids, supplement) as treatment for ADHD (combined type) with co-morbidity in Swedish children ages 7-12. www.clinicaltrialsregister.eu/ctr-search/trial/2004-003853-13/SE (first received 16 November 2004). GustafssonPA , Birberg-ThornbergU , DuchénK , LandgrenM , MalmbergK , PellingH , et al. EPA supplementation improves teacher-rated behaviour and oppositional symptoms in children with ADHD. Acta Paediatrica2010;99(10):1540-9. [DOI: 10.1111/j.1651-2227.2010.01871.x] [PMID: 20491709]">Gustafsson 2010</a>; <a href="./references#CD007986-bbs2-0020" title="JohnsonM , OstlundS , FranssonG , KadesjöB , GillbergC . Omega-3/omega-6 fatty acids for attention deficit hyperactivity disorder: a randomized placebo-controlled trial in children and adolescents. Journal of Attention Disorders2009;12(5):394-401. [DOI: 10.1177/1087054708316261] [PMID: 18448859]NCT01219309. Omega-3/omega-6 fatty acids for attention-deficit/hyperactivity disorder (ADHD): a trial in children and adolescents. clinicaltrials.gov/show/NCT01219309. (first received 30 October 2010). ">Johnson 2009</a>; <a href="./references#CD007986-bbs2-0035" title="NCT00382616. Supplementation of phosphatidylserine (PS) and n-3 long chain fatty acids (EPA, DHA) in children with ADHD. clinicaltrials.gov/ct2/show/NCT00382616 (first received 29 September 2006). VaismanN , KaysarN , Zaruk-AdashaY , PelledD , BrichonG , ZwingelsteinG , et al. Correlation between changes in blood fatty acid composition and visual sustained attention performance in children with inattention: effect of dietary n-3 fatty acids containing phospholipids. American Journal of Clinical Nutrition2008;87(5):1170-80. [DOI: 10.1093/ajcn/87.5.1170] [PMID: 18469236]">Vaisman 2008</a>); identified 10 studies as awaiting classification (from 13 reports); and classified 1 report as an ongoing study. We also excluded 9 studies (from 12 reports). See <a href="#CD007986-fig-0001">Figure 1</a>. The review now has a total of 37 included studies (from 62 reports). </p> <div class="figure" id="CD007986-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram for review update." data-id="CD007986-fig-0001" src="/cdsr/doi/10.1002/14651858.CD007986.pub3/media/CDSR/CD007986/image_n/nCD007986-FIG-01.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram for review update.</p> </div> </div> </div> </section> <section id="CD007986-sec-0049"> <h4 class="title">Included studies</h4> <section id="CD007986-sec-0050"> <h5 class="title">Study design</h5> <p>Five trials (seven reports) had a cross‐over design (<a href="./references#CD007986-bbs2-0001" title="AmanMG , MitchellEA , TurbottSH . The effects of essential fatty acid supplementation by efamol in hyperactive children. Journal of Abnormal Child Psychology1987;15(1):75-90. [DOI: 10.1007/BF00916467]">Aman 1987</a>; <a href="./references#CD007986-bbs2-0003" title="ArnoldLE , KleykampD , VotolatoN , GibsonRA , HorrocksL . Potential link between dietary intake of fatty acids and behavior: pilot exploration of serum lipids in attention-deficit hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology1994;4(3):171-82. [DOI: 10.1089/cap.1994.4.171]ArnoldLE , KleykampD , VotolatoNA , TaylorWA , KontrasSB , TobinK . Gamma-linolenic acid for attention-deficit hyperactivity disorder: placebo-controlled comparison to D-amphetamine. Biological Psychiatry1989;25(2):222-8. [DOI: 10.1016/0006-3223(89)90167-4] [PMID: 2539203]ArnoldLE , PinkhamSM , VotolatoN . Does zinc moderate essential fatty acid and amphetamine treatment of attention-deficit/hyperactivity disorder?Journal of Child and Adolescent Psychopharmacology2000;10(2):111-7. [DOI: 10.1089/cap.2000.10.111] [PMID: 10933121]">Arnold 1989</a>; <a href="./references#CD007986-bbs2-0007" title="BélangerSA , VanasseM , SpahisS , SylvestreMP , LippéS , L'HeureuxF , et al. Omega-3 fatty acid treatment of children with attention-deficit hyperactivity disorder: a randomized, double-blind, placebo-controlled study. Paediatrics and Child Health2009;14(2):89-98. [DOI: 10.1093/pch/14.2.89] [PMCID: PMC2661342] [PMID: 19436468]VanasseM , Ageranioti-BélangerS , L'HeureuxF , GhadirianP , LevyE , SpahisS , et al. A randomized, controlled trial of omega-3 and phospholipids supplementation in children with attention-deficit-hyperactivity disorder. Developmental Medicine &amp; Child Neurology2006;48(Suppl 107):48. [DOI: 10.1111/j.1469-8749.2006.tb12600.x]">Bélanger 2009</a>; <a href="./references#CD007986-bbs2-0020" title="JohnsonM , OstlundS , FranssonG , KadesjöB , GillbergC . Omega-3/omega-6 fatty acids for attention deficit hyperactivity disorder: a randomized placebo-controlled trial in children and adolescents. Journal of Attention Disorders2009;12(5):394-401. [DOI: 10.1177/1087054708316261] [PMID: 18448859]NCT01219309. Omega-3/omega-6 fatty acids for attention-deficit/hyperactivity disorder (ADHD): a trial in children and adolescents. clinicaltrials.gov/show/NCT01219309. (first received 30 October 2010). ">Johnson 2009</a>; <a href="./references#CD007986-bbs2-0033" title="SinnN , BryanJ , WilsonC . Cognitive effects of polyunsaturated fatty acids in children with attention deficit hyperactivity disorder symptoms: a randomised controlled trial. Prostaglandins Leukotrienes and Essential Fatty Acids2008;78(4-5):311-26. [DOI: 10.1016/j.plefa.2008.04.004] [PMID: 18514501]SinnN , BryanJ . Effect of supplementation with polyunsaturated fatty acids and micronutrients on learning and behavior problems associated with child ADHD. Journal of Developmental and Behavioral Pediatrics2007;28(2):82-91. [DOI: 10.1097/01.DBP.0000267558.88457.a5] [PMID: 17435458]">Sinn 2007</a>). First‐phase data from cross‐over trials were integrated with data from parallel trials where first‐phase data were reported. Where first‐phase data were not reported separately (<a href="./references#CD007986-bbs2-0001" title="AmanMG , MitchellEA , TurbottSH . The effects of essential fatty acid supplementation by efamol in hyperactive children. Journal of Abnormal Child Psychology1987;15(1):75-90. [DOI: 10.1007/BF00916467]">Aman 1987</a>), data from cross‐over trials were included in the meta‐analysis but a sensitivity analysis was conducted. </p> <p>The 32 remaining trials (52 reports) all had a parallel‐group design. </p> <p>See <a href="./appendices#CD007986-sec-0135">Appendix 5</a>. </p> </section> <section id="CD007986-sec-0051"> <h5 class="title">Location/setting</h5> <p>Seven trials were conducted in Iran, four each in the USA and Israel, two each in Australia, Canada, New Zealand, Sweden, and the UK, and one each in Brazil, France, Germany, India, Italy, Japan, Mexico, the Netherlands, Singapore, Spain, Sri Lanka, and Taiwan. </p> </section> <section id="CD007986-sec-0052"> <h5 class="title">Participants</h5> <p>We included 37 studies with more than 2374 participants. It is not possible to be exact about the number of participants as this was not always clearly reported. The number of participants ranged from 17 to 160, and the age of participants was between six and 18 years, with a mean study age of 6 to 11 years. In most trials, the diagnosis of ADHD was made by a clinician, except for the studies by <a href="./references#CD007986-bbs2-0001" title="AmanMG , MitchellEA , TurbottSH . The effects of essential fatty acid supplementation by efamol in hyperactive children. Journal of Abnormal Child Psychology1987;15(1):75-90. [DOI: 10.1007/BF00916467]">Aman 1987</a>, <a href="./references#CD007986-bbs2-0003" title="ArnoldLE , KleykampD , VotolatoN , GibsonRA , HorrocksL . Potential link between dietary intake of fatty acids and behavior: pilot exploration of serum lipids in attention-deficit hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology1994;4(3):171-82. [DOI: 10.1089/cap.1994.4.171]ArnoldLE , KleykampD , VotolatoNA , TaylorWA , KontrasSB , TobinK . Gamma-linolenic acid for attention-deficit hyperactivity disorder: placebo-controlled comparison to D-amphetamine. Biological Psychiatry1989;25(2):222-8. [DOI: 10.1016/0006-3223(89)90167-4] [PMID: 2539203]ArnoldLE , PinkhamSM , VotolatoN . Does zinc moderate essential fatty acid and amphetamine treatment of attention-deficit/hyperactivity disorder?Journal of Child and Adolescent Psychopharmacology2000;10(2):111-7. [DOI: 10.1089/cap.2000.10.111] [PMID: 10933121]">Arnold 1989</a>, <a href="./references#CD007986-bbs2-0033" title="SinnN , BryanJ , WilsonC . Cognitive effects of polyunsaturated fatty acids in children with attention deficit hyperactivity disorder symptoms: a randomised controlled trial. Prostaglandins Leukotrienes and Essential Fatty Acids2008;78(4-5):311-26. [DOI: 10.1016/j.plefa.2008.04.004] [PMID: 18514501]SinnN , BryanJ . Effect of supplementation with polyunsaturated fatty acids and micronutrients on learning and behavior problems associated with child ADHD. Journal of Developmental and Behavioral Pediatrics2007;28(2):82-91. [DOI: 10.1097/01.DBP.0000267558.88457.a5] [PMID: 17435458]">Sinn 2007</a>, <a href="./references#CD007986-bbs2-0015" title="GowR . An Investigation Into Long-Chain Polyunsaturated Essential Fatty Acids, Event Related Potential Assessments of Brain Function and Behavioural Measures in Children and Adolescents With and Without Attention Deficit Hyperactivity Disorder [PhD thesis]. London, UK: King's College London, University of London, 2012. ">Gow 2012</a>, <a href="./references#CD007986-bbs2-0017" title="HaririM , DjazayeryA , DjalaliM , SaedisomeoliaA , RahimiA , AbdolahianE . Effect of n-3 supplementation on hyperactivity, oxidative stress and inflammatory mediators in children with attention-deficit-hyperactivity disorder. Malaysian Journal of Nutrition2012;18(3):329-52. [PMID: 24568073]">Hariri 2012</a>, <a href="./references#CD007986-bbs2-0013" title="DashtiN , HekmatH , SoltaniHR , RahimdelA , JavaherchianM . Comparison of therapeutic effects of omega-3 and methylphenidate (ritalin(®)) in treating children with attention deficit hyperactivity disorder. Iranian Journal of Psychiatry and Behavioral Sciences2014;8(4):7-11. [PMCID: PMC4364471] [PMID: 25798168]">Dashti 2014</a>, and <a href="./references#CD007986-bbs2-0026" title="IRCT2015092724209N2. Investigating the effectiveness of methylphenidate and multi chain polyunsaturated fatty acids in treatment of patients with attention deficit hyperactivity disorder (ADHD) in Zahedan City [Investigating the effectiveness of methylphenidate and multi chain polyunsaturated fatty acids in treatment of symptoms of attention deficit hyperactivity disorder (ADHD) among 6 to 12 children suffered from ADHD]. trialsearch.who.int/Trial2.aspx?TrialID=IRCT2015092724209N2 (first received 28 April 2016). MoghaddamMF , ShamekhiM , RakhshaniT . Effectiveness of methylphenidate and PUFA for the treatment of patients with ADHD: a double-blinded randomized clinical trial. Electronic Physician2017;9(5):4412-8. [DOI: 10.19082/4412] [PMCID: PMC5498708] [PMID: 28713515]">Moghaddam 2017</a>, which used scale cut‐offs with high sensitivity for a diagnosis of ADHD. Only one study used inclusion criteria that could be indicative of PUFA deficiency, that is thirst or skin symptoms (<a href="./references#CD007986-bbs2-0034" title="StevensL , ZhangW , PeckL , KuczekT , GrevstadN , MahonA , et al. EFA supplementation in children with inattention, hyperactivity, and other disruptive behaviors. Lipids2003;38(10):1007-21. [DOI: 10.1007/s11745-006-1155-0] [PMID: 14669965]">Stevens 2003</a>). </p> </section> <section id="CD007986-sec-0053"> <h5 class="title">Funding</h5> <p>Seven studies were funded by the company that produced PUFA supplements (<a href="./references#CD007986-bbs2-0001" title="AmanMG , MitchellEA , TurbottSH . The effects of essential fatty acid supplementation by efamol in hyperactive children. Journal of Abnormal Child Psychology1987;15(1):75-90. [DOI: 10.1007/BF00916467]">Aman 1987</a>; <a href="./references#CD007986-bbs2-0003" title="ArnoldLE , KleykampD , VotolatoN , GibsonRA , HorrocksL . Potential link between dietary intake of fatty acids and behavior: pilot exploration of serum lipids in attention-deficit hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology1994;4(3):171-82. [DOI: 10.1089/cap.1994.4.171]ArnoldLE , KleykampD , VotolatoNA , TaylorWA , KontrasSB , TobinK . Gamma-linolenic acid for attention-deficit hyperactivity disorder: placebo-controlled comparison to D-amphetamine. Biological Psychiatry1989;25(2):222-8. [DOI: 10.1016/0006-3223(89)90167-4] [PMID: 2539203]ArnoldLE , PinkhamSM , VotolatoN . Does zinc moderate essential fatty acid and amphetamine treatment of attention-deficit/hyperactivity disorder?Journal of Child and Adolescent Psychopharmacology2000;10(2):111-7. [DOI: 10.1089/cap.2000.10.111] [PMID: 10933121]">Arnold 1989</a>; <a href="./references#CD007986-bbs2-0005" title="BarragánE , BreuerD , DöpfnerM . Efficacy and safety of omega-3/6 fatty acids, methylphenidate, and a combined treatment in children with ADHD. Journal of Attention Disorders2017;21(5):433-41. [DOI: 10.1177/1087054713518239] [PMID: 24464327]">Barragán 2017</a>; <a href="./references#CD007986-bbs2-0012" title="CrippaA , AgostoniC , MauriM , MolteniM , NobileM . Polyunsaturated fatty acids are associated with behavior but not with cognition in children with and without ADHD: an Italian study. Journal of Attention Disorders2018;22(10):971-83. [DOI: 10.1177/1087054716629215]CrippaA , TeseiA , SangiorgioF , SalandiA , TrabattoniS , GrazioliS , et al. Behavioral and cognitive effects of docosahexaenoic acid in drug-naïve children with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled clinical trial. European Child &amp; Adolescent Psychiatry2019;28(4):571-83. [DOI: 10.1007/s00787-018-1223-z] [PMID: 30246216]NCT01796262. The effects of DHA on attention deficit and hyperactivity disorder (DADA) [The effects of DHA (docosahexaenoic acid) on attention deficit and hyperactivity disorder]. clinicaltrials.gov/show/nct01796262 (first received 12 February 2013). ">Crippa 2019</a>; <a href="./references#CD007986-bbs2-0020" title="JohnsonM , OstlundS , FranssonG , KadesjöB , GillbergC . Omega-3/omega-6 fatty acids for attention deficit hyperactivity disorder: a randomized placebo-controlled trial in children and adolescents. Journal of Attention Disorders2009;12(5):394-401. [DOI: 10.1177/1087054708316261] [PMID: 18448859]NCT01219309. Omega-3/omega-6 fatty acids for attention-deficit/hyperactivity disorder (ADHD): a trial in children and adolescents. clinicaltrials.gov/show/NCT01219309. (first received 30 October 2010). ">Johnson 2009</a>; <a href="./references#CD007986-bbs2-0023" title="ManorI , MagenA , KeidarD , RosenS , TaskerH , CohenT , et al. The effect of phosphatidylserine containing omega3 fatty-acids on attention-deficit hyperactivity disorder symptoms in children: a double-blind placebo-controlled trial, followed by an open-label extension. European Psychiatry2012;27(5):335-42. [DOI: 10.1016/j.eurpsy.2011.05.004] [PMID: 21807480]NCT00418184. The efficacy and safety of phosphatidylserine-omega3 in children with attention-deficit/hyperactivity disorder [A single-center, randomized, double-blind, placebo-controlled study of the efficacy and safety of phosphatidylserine-omega3 in children with attention-deficit/hyperactivity disorder]. clinicaltrials.gov/show/NCT00418184 (first received 4 January 2007). ">Manor 2012</a>; <a href="./references#CD007986-bbs2-0036" title="VoigtRG , LlorenteAM , JensenCL , FraleyJK , BerrettaMC , HeirdWC . A randomized, double-blind, placebo-controlled trial of docosahexaenoic acid supplementation in children with attention-deficit/hyperactivity disorder. Journal of Pediatrics2001;139(2):189-96. [DOI: 10.1067/mpd.2001.116050] [PMID: 11487742]">Voigt 2001</a>). Four appeared to be sponsored by a pharmaceutical company, but it was unclear whether the sponsor produced the PUFA used in the trial (<a href="./references#CD007986-bbs2-0008" title="BosD , Van BelleJ , WeustenJ , HoeksmaM , WisemanS , DurstonS . Effects of N-3 fatty acids (DHA and EPA) on cognitive control and associated brain activity in ADHD: a double-blind placebo controlled study. European Child &amp; Adolescent Psychiatry2010;19(Suppl 1):S69. [DOI: 10.1007/s00787-010-0117-5]BosD , Van BelleJ , WeustenJ , HoeksmaM , WisemanS , DurstonS . Effects of N-3 fatty acids (DHA and EPA) on cognitive control and associated brain activity in ADHD: a double-blind placebo controlled study. In: European Child and Adolescent Psychiatry, Conference: Eunethydis 1st International ADHD Conference: From Data to Best Clinical Practice; 2010 May 26–28; Amsterdam. 2010. BosDJ , OranjeB , VeerhoekES , Van DiepenRM , Weusten JMh, DemmelmairH , et al. Reduced symptoms of inattention after dietary omega-3 fatty acid supplementation in boys with and without attention deficit/hyperactivity disorder. Neuropsychopharmacology2015;40(10):2298–306. [DOI: 10.1038/npp.2015.73] [PMCID: PMC4538345] [PMID: 25790022]">Bos 2015</a>; <a href="./references#CD007986-bbs2-0011" title="CornuC , MercierC , GinhouxT , MassonS , MouchetJ , NonyP , et al. A double-blind placebo-controlled randomised trial of omega-3 supplementation in children with moderate ADHD symptoms. European Child &amp; Adolescent Psychiatry2018;27(3):377‐84. [DOI: 10.1007/s00787-017-1058-z] [PMID: 28993963]NCT00770627. Clinical trial to evaluate the efficacy and the tolerance of an omega 3 fatty acids supplementation in ADHD children [A randomized, controlled, double blind placebo trial to evaluate the efficacy and the tolerance of an omega 3 fatty acids supplementation in ADHD children]. clinicaltrials.gov/ct2/show/record/NCT00770627 (first received 9 October 2008). ">Cornu 2018</a>; <a href="./references#CD007986-bbs2-0021" title="KeanJD , SarrisJ , ScholeyA , SilbersteinR , DowneyLA , StoughC . Reduced inattention and hyperactivity and improved cognition after marine oil extract (PCSO-524®) supplementation in children and adolescents with clinical and subclinical symptoms of attention-deficit hyperactivity disorder (ADHD): a randomised, double-blind, placebo-controlled trial. Psychopharmacology2017;234(3):403-20. [DOI: 10.1007/s00213-016-4471-y] [PMCID: PMC5225177] [PMID: 27921139]">Kean 2017</a>; <a href="./references#CD007986-bbs2-0029" title="PereraH , JeewandaraKC , SeneviratneS , GurugeC . Combined ω3 and ω6 supplementation in children with attention-deficit hyperactivity disorder (ADHD) refractory to methylphenidate treatment: a double-blind, placebo-controlled study. Journal of Child Neurology2012;27(6):747‐53. [DOI: 10.1177/0883073811435243] [PMID: 22596014]SLCTR/2009/006. Effectiveness of omega-3 and omega-6 in childhood behaviour disorders [Effectiveness of omega-3 and omega-6 in children with neuro-developmental disorders: a double-blind placebo-controlled study]. slctr.lk/trials/slctr-2009-006 (first received 17 July 2009). ">Perera 2012</a>). Studies were funded by research grants from charitable institutions (<a href="./references#CD007986-bbs2-0024" title="EUCTR2005-005330-12-GB. Omega-3 fatty acids supplementation for adolescent boys with attention deficit hyperactivity disorder: a double-blind, randomized controlled trial - MAAFA. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2005-005330-12-GB (first received 10 April 2006). ISRCTN27741572. Omega-3 fatty acids supplementation for adolescent boys with attention deficit hyperactivity disorder: a double-blind, randomized controlled trial. tinyurl.com/jz99z7vd (first received 10 March 2006). [DOI: 10.1186/ISRCTN27741572]MatsudairaT , GowRV , KellyJ , MurphyC , PottsL , SumichA , et al. Biochemical and psychological effects of omega-3/6 supplements in male adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, clinical trial. Journal of Child &amp; Adolescent Psychopharmacology2015;25(10):775-82. [DOI: 10.1089/cap.2015.0052] [PMCID: PMC4691649] [PMID: 26682998]MatsudairaT . Omega-3 PUFA Fatty Acids and Attention-Deficit/Hyperactivity Disorder [PhD thesis]. London, UK: King's College London, University of London, 2011. ">Matsudaira 2015</a>), government (<a href="./references#CD007986-bbs2-0014" title="Dubnov-RazG , KhouryZ , WrightI , RazR , BergerI . The effect of alpha-linolenic acid supplementation on ADHD symptoms in children: a randomized controlled double-blind study. Frontiers in Human Neuroscience2014;8:780. [DOI: 10.3389/fnhum.2014.00780] [PMCID: PMC4188038] [PMID: 25339885]NCT00874536. Omega-3 supplementation and attention-deficit-hyperactivity disorder (ADHD) [The effect of omega-3 fatty acid supplementation on behavior of children with ADHD]. clinicaltrials.gov/show/nct00874536 (first received 1 April 2009). ">Dubnov‐Raz 2014</a>; <a href="./references#CD007986-bbs2-0025" title="ACTRN12607000332426. Omega-3 fatty acids for ADHD symptoms and learning difficulties in children [Randomised controlled trial investigating effect of supplementation with omega-3 fatty acids EPA and DHA versus omega-6 fatty acid LA on ADHD symptoms and learning difficulties in 7-12 year old children]. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=82104 (first received 19 June 2007). MilteCM , ParlettaN , BuckleyJD , CoatesAM , YoungRM , HowePR . Eicosapentaenoic and docosahexaenoic acids, cognition, and behavior in children with attention-deficit/hyperactivity disorder: a randomized controlled trial. Nutrition2012;28(6):670-7. [DOI: 10.1016/j.nut.2011.12.009] [PMID: 22541055]">Milte 2012</a>; <a href="./references#CD007986-bbs2-0033" title="SinnN , BryanJ , WilsonC . Cognitive effects of polyunsaturated fatty acids in children with attention deficit hyperactivity disorder symptoms: a randomised controlled trial. Prostaglandins Leukotrienes and Essential Fatty Acids2008;78(4-5):311-26. [DOI: 10.1016/j.plefa.2008.04.004] [PMID: 18514501]SinnN , BryanJ . Effect of supplementation with polyunsaturated fatty acids and micronutrients on learning and behavior problems associated with child ADHD. Journal of Developmental and Behavioral Pediatrics2007;28(2):82-91. [DOI: 10.1097/01.DBP.0000267558.88457.a5] [PMID: 17435458]">Sinn 2007</a>; <a href="./references#CD007986-bbs2-0037" title="Widenhorn-MüllerK , SchwandaS , ScholzE , SpitzerM , BodeH . Effect of supplementation with long-chain ω-3 polyunsaturated fatty acids on behavior and cognition in children with attention deficit/hyperactivity disorder (ADHD): a randomized placebo-controlled intervention trial. Prostaglandins Leukotrienes and Essential Fatty Acids2014;91(1-2):49-60. [DOI: 10.1016/j.plefa.2014.04.004] [PMID: 24958525]">Widenhorn‐Müller 2014</a>), and universities (<a href="./references#CD007986-bbs2-0004" title="AssarehM , Davari AshtianiR , KhademiM , JazayeriS , RaiA , NikooM . Efficacy of polyunsaturated fatty acids (PUFA) in the treatment of attention deficit hyperactivity disorder: a randomized, double-blind, placebo-controlled clinical trial. Journal of Attention Disorders2017;21(1):78-85. [DOI: 10.1177/1087054712463962] [PMID: 23160488]IRCT138803122000N1. Poly unsaturated fatty acid as a combination treatment in children with attention deficit hyperactivity disorder [Omega-3 in the treatment of attention deficit hyperactivity disorder]. en.irct.ir/trial/1598?revision=1598 (first received 21 May 2011). ">Assareh 2017</a>). Three studies received mixed funding from a government agency or university and pharmaceutical company (<a href="./references#CD007986-bbs2-0007" title="BélangerSA , VanasseM , SpahisS , SylvestreMP , LippéS , L'HeureuxF , et al. Omega-3 fatty acid treatment of children with attention-deficit hyperactivity disorder: a randomized, double-blind, placebo-controlled study. Paediatrics and Child Health2009;14(2):89-98. [DOI: 10.1093/pch/14.2.89] [PMCID: PMC2661342] [PMID: 19436468]VanasseM , Ageranioti-BélangerS , L'HeureuxF , GhadirianP , LevyE , SpahisS , et al. A randomized, controlled trial of omega-3 and phospholipids supplementation in children with attention-deficit-hyperactivity disorder. Developmental Medicine &amp; Child Neurology2006;48(Suppl 107):48. [DOI: 10.1111/j.1469-8749.2006.tb12600.x]">Bélanger 2009</a>; <a href="./references#CD007986-bbs2-0015" title="GowR . An Investigation Into Long-Chain Polyunsaturated Essential Fatty Acids, Event Related Potential Assessments of Brain Function and Behavioural Measures in Children and Adolescents With and Without Attention Deficit Hyperactivity Disorder [PhD thesis]. London, UK: King's College London, University of London, 2012. ">Gow 2012</a>; <a href="./references#CD007986-bbs2-0034" title="StevensL , ZhangW , PeckL , KuczekT , GrevstadN , MahonA , et al. EFA supplementation in children with inattention, hyperactivity, and other disruptive behaviors. Lipids2003;38(10):1007-21. [DOI: 10.1007/s11745-006-1155-0] [PMID: 14669965]">Stevens 2003</a>). The remaining studies provided no information on funding. </p> </section> <section id="CD007986-sec-0054"> <h5 class="title">Interventions and comparators</h5> <p>We aimed to include studies for the four main comparisons:</p> <p> <ol id="CD007986-list-0007"> <li> <p>PUFA versus placebo;</p> </li> <li> <p>PUFA versus medication, e.g. methylphenidate, amphetamine;</p> </li> <li> <p>PUFA versus behavioural therapy; and</p> </li> <li> <p>PUFA versus psychotherapy.</p> </li> </ol> </p> <p>However, data were only available for the following three comparisons:</p> <p> <ol id="CD007986-list-0008"> <li> <p>PUFA versus placebo;</p> </li> <li> <p>PUFA versus medication;</p> </li> <li> <p>omega‐3 versus omega‐6 PUFA. This comparison was a post hoc analysis, as it was not prespecified in the protocol (<a href="#CD007986-sec-0143">Differences between protocol and review</a>). </p> </li> </ol> </p> <p>Twenty‐seven studies compared PUFA alone to placebo alone. Of these, 19 compared an omega‐3 PUFA supplement to placebo (<a href="./references#CD007986-bbs2-0008" title="BosD , Van BelleJ , WeustenJ , HoeksmaM , WisemanS , DurstonS . Effects of N-3 fatty acids (DHA and EPA) on cognitive control and associated brain activity in ADHD: a double-blind placebo controlled study. European Child &amp; Adolescent Psychiatry2010;19(Suppl 1):S69. [DOI: 10.1007/s00787-010-0117-5]BosD , Van BelleJ , WeustenJ , HoeksmaM , WisemanS , DurstonS . Effects of N-3 fatty acids (DHA and EPA) on cognitive control and associated brain activity in ADHD: a double-blind placebo controlled study. In: European Child and Adolescent Psychiatry, Conference: Eunethydis 1st International ADHD Conference: From Data to Best Clinical Practice; 2010 May 26–28; Amsterdam. 2010. BosDJ , OranjeB , VeerhoekES , Van DiepenRM , Weusten JMh, DemmelmairH , et al. Reduced symptoms of inattention after dietary omega-3 fatty acid supplementation in boys with and without attention deficit/hyperactivity disorder. Neuropsychopharmacology2015;40(10):2298–306. [DOI: 10.1038/npp.2015.73] [PMCID: PMC4538345] [PMID: 25790022]">Bos 2015</a>; <a href="./references#CD007986-bbs2-0010" title="ChangJP , SuKP , MondelliV , SatyanarayananSK , YangHT , ChiangYJ , et al. High-dose eicosapentaenoic acid (EPA) improves attention and vigilance in children and adolescents with attention deficit hyperactivity disorder (ADHD) and low endogenous EPA levels. Translational Psychiatry2019;9(1):303. [DOI: 10.1038/s41398-019-0633-0] [PMCID: PMC6864068] [PMID: 31745072]NCT03542643. Omega-3 polyunsaturated fatty acids in youth with ADHD [A double-blind randomised controlled trial of N-3 PUFAs in children with attention deficit hyperactivity disorder]. clinicaltrials.gov/ct2/show/NCT03542643 (first received 20 May 2018). ">Chang 2019</a>; <a href="./references#CD007986-bbs2-0011" title="CornuC , MercierC , GinhouxT , MassonS , MouchetJ , NonyP , et al. A double-blind placebo-controlled randomised trial of omega-3 supplementation in children with moderate ADHD symptoms. European Child &amp; Adolescent Psychiatry2018;27(3):377‐84. [DOI: 10.1007/s00787-017-1058-z] [PMID: 28993963]NCT00770627. Clinical trial to evaluate the efficacy and the tolerance of an omega 3 fatty acids supplementation in ADHD children [A randomized, controlled, double blind placebo trial to evaluate the efficacy and the tolerance of an omega 3 fatty acids supplementation in ADHD children]. clinicaltrials.gov/ct2/show/record/NCT00770627 (first received 9 October 2008). ">Cornu 2018</a>; <a href="./references#CD007986-bbs2-0012" title="CrippaA , AgostoniC , MauriM , MolteniM , NobileM . Polyunsaturated fatty acids are associated with behavior but not with cognition in children with and without ADHD: an Italian study. Journal of Attention Disorders2018;22(10):971-83. [DOI: 10.1177/1087054716629215]CrippaA , TeseiA , SangiorgioF , SalandiA , TrabattoniS , GrazioliS , et al. Behavioral and cognitive effects of docosahexaenoic acid in drug-naïve children with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled clinical trial. European Child &amp; Adolescent Psychiatry2019;28(4):571-83. [DOI: 10.1007/s00787-018-1223-z] [PMID: 30246216]NCT01796262. The effects of DHA on attention deficit and hyperactivity disorder (DADA) [The effects of DHA (docosahexaenoic acid) on attention deficit and hyperactivity disorder]. clinicaltrials.gov/show/nct01796262 (first received 12 February 2013). ">Crippa 2019</a>; <a href="./references#CD007986-bbs2-0013" title="DashtiN , HekmatH , SoltaniHR , RahimdelA , JavaherchianM . Comparison of therapeutic effects of omega-3 and methylphenidate (ritalin(®)) in treating children with attention deficit hyperactivity disorder. Iranian Journal of Psychiatry and Behavioral Sciences2014;8(4):7-11. [PMCID: PMC4364471] [PMID: 25798168]">Dashti 2014</a>; <a href="./references#CD007986-bbs2-0015" title="GowR . An Investigation Into Long-Chain Polyunsaturated Essential Fatty Acids, Event Related Potential Assessments of Brain Function and Behavioural Measures in Children and Adolescents With and Without Attention Deficit Hyperactivity Disorder [PhD thesis]. London, UK: King's College London, University of London, 2012. ">Gow 2012</a>; <a href="./references#CD007986-bbs2-0016" title="EUCTR2004-003853-13-SE. Placebo controlled, randomised, double-blind, multicentre study of PlusEPA (a PUFA, polyunsaturated fatty acids, supplement) as treatment for ADHD (combined type) with co-morbidity in Swedish children ages 7-12. www.clinicaltrialsregister.eu/ctr-search/trial/2004-003853-13/SE (first received 16 November 2004). GustafssonPA , Birberg-ThornbergU , DuchénK , LandgrenM , MalmbergK , PellingH , et al. EPA supplementation improves teacher-rated behaviour and oppositional symptoms in children with ADHD. Acta Paediatrica2010;99(10):1540-9. [DOI: 10.1111/j.1651-2227.2010.01871.x] [PMID: 20491709]">Gustafsson 2010</a>; <a href="./references#CD007986-bbs2-0017" title="HaririM , DjazayeryA , DjalaliM , SaedisomeoliaA , RahimiA , AbdolahianE . Effect of n-3 supplementation on hyperactivity, oxidative stress and inflammatory mediators in children with attention-deficit-hyperactivity disorder. Malaysian Journal of Nutrition2012;18(3):329-52. [PMID: 24568073]">Hariri 2012</a>; <a href="./references#CD007986-bbs2-0018" title="HamazakiT , HirayamaS . The effect of docosahexaenoic acid-containing food administration on symptoms of attention-deficit/hyperactivity disorder - a placebo-controlled double-blind study. European Journal of Clinical Nutrition2004;58(5):838. [DOI: 10.1038/sj.ejcn.1601888] [PMID: 15116088]HirayamaS , HamazakiT , TerasawaK . Effect of docosahexaenoic acid-containing food administration on symptoms of attention-deficit/hyperactivity disorder - a placebo-controlled double-blind study. European Journal of Clinical Nutrition2004;58(3):467-73. [DOI: 10.1038/sj.ejcn.1601830] [PMID: 14985685]">Hirayama 2004</a>; <a href="./references#CD007986-bbs2-0019" title="IvityE . Supplementation with Docosahexaenoic Acid Ameliorates Paediatric AD/HD [PhD thesis]. Edmonton (AB): University of Alberta, 2015. ">Ivity 2015</a>; <a href="./references#CD007986-bbs2-0021" title="KeanJD , SarrisJ , ScholeyA , SilbersteinR , DowneyLA , StoughC . Reduced inattention and hyperactivity and improved cognition after marine oil extract (PCSO-524®) supplementation in children and adolescents with clinical and subclinical symptoms of attention-deficit hyperactivity disorder (ADHD): a randomised, double-blind, placebo-controlled trial. Psychopharmacology2017;234(3):403-20. [DOI: 10.1007/s00213-016-4471-y] [PMCID: PMC5225177] [PMID: 27921139]">Kean 2017</a>; <a href="./references#CD007986-bbs2-0022" title="Lim-AshworthN , OoiYP , WengSJ , LimCG , FungDSS , GlennA , et al. Preliminary findings on the effects of nutritional and social skills intervention among children with attention deficit hyperactivity disorder. Annals: the official journal of the Academy of Medicine, Singapore2013;42(Suppl 9):S162. [OP-CR-65] [WEB PAGE: www.annals.edu.sg/pdf/42VolNo9Sep2013/SHBC_2013_041013.pdf]">Lim‐Ashworth 2013</a>; <a href="./references#CD007986-bbs2-0023" title="ManorI , MagenA , KeidarD , RosenS , TaskerH , CohenT , et al. The effect of phosphatidylserine containing omega3 fatty-acids on attention-deficit hyperactivity disorder symptoms in children: a double-blind placebo-controlled trial, followed by an open-label extension. European Psychiatry2012;27(5):335-42. [DOI: 10.1016/j.eurpsy.2011.05.004] [PMID: 21807480]NCT00418184. The efficacy and safety of phosphatidylserine-omega3 in children with attention-deficit/hyperactivity disorder [A single-center, randomized, double-blind, placebo-controlled study of the efficacy and safety of phosphatidylserine-omega3 in children with attention-deficit/hyperactivity disorder]. clinicaltrials.gov/show/NCT00418184 (first received 4 January 2007). ">Manor 2012</a>; <a href="./references#CD007986-bbs2-0024" title="EUCTR2005-005330-12-GB. Omega-3 fatty acids supplementation for adolescent boys with attention deficit hyperactivity disorder: a double-blind, randomized controlled trial - MAAFA. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2005-005330-12-GB (first received 10 April 2006). ISRCTN27741572. Omega-3 fatty acids supplementation for adolescent boys with attention deficit hyperactivity disorder: a double-blind, randomized controlled trial. tinyurl.com/jz99z7vd (first received 10 March 2006). [DOI: 10.1186/ISRCTN27741572]MatsudairaT , GowRV , KellyJ , MurphyC , PottsL , SumichA , et al. Biochemical and psychological effects of omega-3/6 supplements in male adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, clinical trial. Journal of Child &amp; Adolescent Psychopharmacology2015;25(10):775-82. [DOI: 10.1089/cap.2015.0052] [PMCID: PMC4691649] [PMID: 26682998]MatsudairaT . Omega-3 PUFA Fatty Acids and Attention-Deficit/Hyperactivity Disorder [PhD thesis]. London, UK: King's College London, University of London, 2011. ">Matsudaira 2015</a>; <a href="./references#CD007986-bbs2-0025" title="ACTRN12607000332426. Omega-3 fatty acids for ADHD symptoms and learning difficulties in children [Randomised controlled trial investigating effect of supplementation with omega-3 fatty acids EPA and DHA versus omega-6 fatty acid LA on ADHD symptoms and learning difficulties in 7-12 year old children]. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=82104 (first received 19 June 2007). MilteCM , ParlettaN , BuckleyJD , CoatesAM , YoungRM , HowePR . Eicosapentaenoic and docosahexaenoic acids, cognition, and behavior in children with attention-deficit/hyperactivity disorder: a randomized controlled trial. Nutrition2012;28(6):670-7. [DOI: 10.1016/j.nut.2011.12.009] [PMID: 22541055]">Milte 2012</a>; <a href="./references#CD007986-bbs2-0031" title="RodríguezC , GarcíaT , ArecesD , FernándezE , García-NoriegaM , DomingoJC . Supplementation with high-content docosahexaenoic acid triglyceride in attention-deficit hyperactivity disorder: a randomized double-blind placebo-controlled trial. Neuropsychiatric Disease and Treatment2019;15:1193-209. [DOI: 10.2147/NDT.S206020] [PMID: 31190827] [PMID: PMC6514260]">Rodriguez 2019</a>; <a href="./references#CD007986-bbs2-0035" title="NCT00382616. Supplementation of phosphatidylserine (PS) and n-3 long chain fatty acids (EPA, DHA) in children with ADHD. clinicaltrials.gov/ct2/show/NCT00382616 (first received 29 September 2006). VaismanN , KaysarN , Zaruk-AdashaY , PelledD , BrichonG , ZwingelsteinG , et al. Correlation between changes in blood fatty acid composition and visual sustained attention performance in children with inattention: effect of dietary n-3 fatty acids containing phospholipids. American Journal of Clinical Nutrition2008;87(5):1170-80. [DOI: 10.1093/ajcn/87.5.1170] [PMID: 18469236]">Vaisman 2008</a>; <a href="./references#CD007986-bbs2-0036" title="VoigtRG , LlorenteAM , JensenCL , FraleyJK , BerrettaMC , HeirdWC . A randomized, double-blind, placebo-controlled trial of docosahexaenoic acid supplementation in children with attention-deficit/hyperactivity disorder. Journal of Pediatrics2001;139(2):189-96. [DOI: 10.1067/mpd.2001.116050] [PMID: 11487742]">Voigt 2001</a>; <a href="./references#CD007986-bbs2-0037" title="Widenhorn-MüllerK , SchwandaS , ScholzE , SpitzerM , BodeH . Effect of supplementation with long-chain ω-3 polyunsaturated fatty acids on behavior and cognition in children with attention deficit/hyperactivity disorder (ADHD): a randomized placebo-controlled intervention trial. Prostaglandins Leukotrienes and Essential Fatty Acids2014;91(1-2):49-60. [DOI: 10.1016/j.plefa.2014.04.004] [PMID: 24958525]">Widenhorn‐Müller 2014</a>); two compared an omega‐6 PUFA to placebo (<a href="./references#CD007986-bbs2-0001" title="AmanMG , MitchellEA , TurbottSH . The effects of essential fatty acid supplementation by efamol in hyperactive children. Journal of Abnormal Child Psychology1987;15(1):75-90. [DOI: 10.1007/BF00916467]">Aman 1987</a>; <a href="./references#CD007986-bbs2-0003" title="ArnoldLE , KleykampD , VotolatoN , GibsonRA , HorrocksL . Potential link between dietary intake of fatty acids and behavior: pilot exploration of serum lipids in attention-deficit hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology1994;4(3):171-82. [DOI: 10.1089/cap.1994.4.171]ArnoldLE , KleykampD , VotolatoNA , TaylorWA , KontrasSB , TobinK . Gamma-linolenic acid for attention-deficit hyperactivity disorder: placebo-controlled comparison to D-amphetamine. Biological Psychiatry1989;25(2):222-8. [DOI: 10.1016/0006-3223(89)90167-4] [PMID: 2539203]ArnoldLE , PinkhamSM , VotolatoN . Does zinc moderate essential fatty acid and amphetamine treatment of attention-deficit/hyperactivity disorder?Journal of Child and Adolescent Psychopharmacology2000;10(2):111-7. [DOI: 10.1089/cap.2000.10.111] [PMID: 10933121]">Arnold 1989</a>); and six compared a combined omega‐3 and omega‐6 supplement to placebo (<a href="./references#CD007986-bbs2-0004" title="AssarehM , Davari AshtianiR , KhademiM , JazayeriS , RaiA , NikooM . Efficacy of polyunsaturated fatty acids (PUFA) in the treatment of attention deficit hyperactivity disorder: a randomized, double-blind, placebo-controlled clinical trial. Journal of Attention Disorders2017;21(1):78-85. [DOI: 10.1177/1087054712463962] [PMID: 23160488]IRCT138803122000N1. Poly unsaturated fatty acid as a combination treatment in children with attention deficit hyperactivity disorder [Omega-3 in the treatment of attention deficit hyperactivity disorder]. en.irct.ir/trial/1598?revision=1598 (first received 21 May 2011). ">Assareh 2017</a>; <a href="./references#CD007986-bbs2-0014" title="Dubnov-RazG , KhouryZ , WrightI , RazR , BergerI . The effect of alpha-linolenic acid supplementation on ADHD symptoms in children: a randomized controlled double-blind study. Frontiers in Human Neuroscience2014;8:780. [DOI: 10.3389/fnhum.2014.00780] [PMCID: PMC4188038] [PMID: 25339885]NCT00874536. Omega-3 supplementation and attention-deficit-hyperactivity disorder (ADHD) [The effect of omega-3 fatty acid supplementation on behavior of children with ADHD]. clinicaltrials.gov/show/nct00874536 (first received 1 April 2009). ">Dubnov‐Raz 2014</a>; <a href="./references#CD007986-bbs2-0020" title="JohnsonM , OstlundS , FranssonG , KadesjöB , GillbergC . Omega-3/omega-6 fatty acids for attention deficit hyperactivity disorder: a randomized placebo-controlled trial in children and adolescents. Journal of Attention Disorders2009;12(5):394-401. [DOI: 10.1177/1087054708316261] [PMID: 18448859]NCT01219309. Omega-3/omega-6 fatty acids for attention-deficit/hyperactivity disorder (ADHD): a trial in children and adolescents. clinicaltrials.gov/show/NCT01219309. (first received 30 October 2010). ">Johnson 2009</a>; <a href="./references#CD007986-bbs2-0029" title="PereraH , JeewandaraKC , SeneviratneS , GurugeC . Combined ω3 and ω6 supplementation in children with attention-deficit hyperactivity disorder (ADHD) refractory to methylphenidate treatment: a double-blind, placebo-controlled study. Journal of Child Neurology2012;27(6):747‐53. [DOI: 10.1177/0883073811435243] [PMID: 22596014]SLCTR/2009/006. Effectiveness of omega-3 and omega-6 in childhood behaviour disorders [Effectiveness of omega-3 and omega-6 in children with neuro-developmental disorders: a double-blind placebo-controlled study]. slctr.lk/trials/slctr-2009-006 (first received 17 July 2009). ">Perera 2012</a>; <a href="./references#CD007986-bbs2-0030" title="RazR , CarassoRL , YehudaS . The influence of short-chain essential fatty acids on children with attention-deficit/hyperactivity disorder: a double-blind placebo-controlled study. Journal of Child and Adolescent Psychopharmacology2009;19(2):167-77. [DOI: 10.1089/cap.2008.070] [PMID: 19364294]">Raz 2009a</a>; <a href="./references#CD007986-bbs2-0034" title="StevensL , ZhangW , PeckL , KuczekT , GrevstadN , MahonA , et al. EFA supplementation in children with inattention, hyperactivity, and other disruptive behaviors. Lipids2003;38(10):1007-21. [DOI: 10.1007/s11745-006-1155-0] [PMID: 14669965]">Stevens 2003</a>).  </p> <p>Nine additional trials compared PUFA to placebo but also had the same co‐intervention in both the PUFA and placebo groups; these studies were included in comparison 1. Four studies compared omega‐3 PUFA plus methylphenidate to methylphenidate (<a href="./references#CD007986-bbs2-0006" title="BehdaniF , HebraniP , NaseraeeA , HaghighiMB , AkhavanrezayatA . Does omega-3 supplement enhance the therapeutic results of methylphenidate in attention deficit hyperactivity disorder patients?Journal of Research in Medical Sciences2013;18(8):653-8. [PMCID: PMC3872603] [PMID: 24379840]">Behdani 2013</a>; <a href="./references#CD007986-bbs2-0026" title="IRCT2015092724209N2. Investigating the effectiveness of methylphenidate and multi chain polyunsaturated fatty acids in treatment of patients with attention deficit hyperactivity disorder (ADHD) in Zahedan City [Investigating the effectiveness of methylphenidate and multi chain polyunsaturated fatty acids in treatment of symptoms of attention deficit hyperactivity disorder (ADHD) among 6 to 12 children suffered from ADHD]. trialsearch.who.int/Trial2.aspx?TrialID=IRCT2015092724209N2 (first received 28 April 2016). MoghaddamMF , ShamekhiM , RakhshaniT . Effectiveness of methylphenidate and PUFA for the treatment of patients with ADHD: a double-blinded randomized clinical trial. Electronic Physician2017;9(5):4412-8. [DOI: 10.19082/4412] [PMCID: PMC5498708] [PMID: 28713515]">Moghaddam 2017</a>; <a href="./references#CD007986-bbs2-0027" title="IRCT2016060128182N2. Omega-3 supplement in attention deficit hyperactivity disorder [The effectiveness of omega-3 supplement as an adjunctive therapy in children with attention deficit hyperactivity disorder]. www.irct.ir/trial/22914 (first received 23 January 2017). MohammadzadehS , BaghiN , YousefiF , YousefzamaniB . Effect of omega-3 plus methylphenidate as an alternative therapy to reduce attention deficit-hyperactivity disorder in children. Korean Journal of Pediatrics2019;62(9):360-6. [DOI: 10.3345/kjp.2018.06982] [PMCID: PMC6753311] [PMID: 31122010]">Mohammadzadeh 2019</a>; <a href="./references#CD007986-bbs2-0032" title="SalehiB , MohammadbeigiA , SheykholeslamH , MoshiriE , DorrehF . Omega-3 and zinc supplementation as complementary therapies in children with attention-deficit/hyperactivity disorder. Journal of Research in Pharmacy Practice2016;5(1):22-6. [DOI: 10.4103/2279-042X.176561] [PMCID: PMC4776543] [PMID: 26985432]">Salehi 2016</a>); two trials compared omega‐3 PUFA plus dietary supplement to dietary supplement (<a href="./references#CD007986-bbs2-0009" title="BrueAW , OaklandTD , EvansRA . The use of a dietary supplement combination and an essential fatty acid as an alternative and complementary treatment for children with attention-deficit/hyperactivity disorder. Scientific Review of Alternative Medicine2001;5(4):187-94. [WEB PAGE: tinyurl.com/y56pdtxq]BrueAW . The Use of a Dietary Supplement Combination and an Essential Fatty Acid as an Alternative and Complementary Treatment for Children with Attention Deficit Hyperactivity Disorder (ADHD) [PhD thesis]. Gainesville (FL): University of Florida, 1999. ">Brue 2001</a>; <a href="./references#CD007986-bbs2-0033" title="SinnN , BryanJ , WilsonC . Cognitive effects of polyunsaturated fatty acids in children with attention deficit hyperactivity disorder symptoms: a randomised controlled trial. Prostaglandins Leukotrienes and Essential Fatty Acids2008;78(4-5):311-26. [DOI: 10.1016/j.plefa.2008.04.004] [PMID: 18514501]SinnN , BryanJ . Effect of supplementation with polyunsaturated fatty acids and micronutrients on learning and behavior problems associated with child ADHD. Journal of Developmental and Behavioral Pediatrics2007;28(2):82-91. [DOI: 10.1097/01.DBP.0000267558.88457.a5] [PMID: 17435458]">Sinn 2007</a>); one trial each compared omega‐3 plus atomoxetine to atomoxetine (<a href="./references#CD007986-bbs2-0002" title="AnandP , SachdevaA . Effect of poly unsaturated fatty acids administration on children with attention deficit hyperactivity disorder: a randomized controlled trial. Journal of Clinical &amp; Diagnostic Research2016;10(9):OC01-5. [DOI: 10.7860/JCDR/2016/20423.8471] [PMCID: PMC5071983] [PMID: 27790483]">Anand 2016</a>); omega‐3 PUFA plus physical training to physical training (<a href="./references#CD007986-bbs2-0028" title="NCT01807299. The effect of physical training and the omega 3 consumption on attention deficit hyperactivity disorder in children (AOE) [The effect of physical training and the omega 3 consumption on attention deficit]. clinicaltrials.gov/ct2/show/NCT01807299 (first received 7 March 2013). ">NCT01807299</a>); and an omega‐3 or omega‐6 supplement plus methylphenidate to methylphenidate (<a href="./references#CD007986-bbs2-0005" title="BarragánE , BreuerD , DöpfnerM . Efficacy and safety of omega-3/6 fatty acids, methylphenidate, and a combined treatment in children with ADHD. Journal of Attention Disorders2017;21(5):433-41. [DOI: 10.1177/1087054713518239] [PMID: 24464327]">Barragán 2017</a>). </p> <p>Three studies compared PUFA to medication, in this case stimulants. One study compared omega‐3 to methylphenidate (<a href="./references#CD007986-bbs2-0013" title="DashtiN , HekmatH , SoltaniHR , RahimdelA , JavaherchianM . Comparison of therapeutic effects of omega-3 and methylphenidate (ritalin(®)) in treating children with attention deficit hyperactivity disorder. Iranian Journal of Psychiatry and Behavioral Sciences2014;8(4):7-11. [PMCID: PMC4364471] [PMID: 25798168]">Dashti 2014</a>); one study compared an omega‐3 or omega‐6 supplement to methylphenidate (<a href="./references#CD007986-bbs2-0005" title="BarragánE , BreuerD , DöpfnerM . Efficacy and safety of omega-3/6 fatty acids, methylphenidate, and a combined treatment in children with ADHD. Journal of Attention Disorders2017;21(5):433-41. [DOI: 10.1177/1087054713518239] [PMID: 24464327]">Barragán 2017</a>), and one study compared omega‐6 PUFA to dexamfetamine (<a href="./references#CD007986-bbs2-0003" title="ArnoldLE , KleykampD , VotolatoN , GibsonRA , HorrocksL . Potential link between dietary intake of fatty acids and behavior: pilot exploration of serum lipids in attention-deficit hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology1994;4(3):171-82. [DOI: 10.1089/cap.1994.4.171]ArnoldLE , KleykampD , VotolatoNA , TaylorWA , KontrasSB , TobinK . Gamma-linolenic acid for attention-deficit hyperactivity disorder: placebo-controlled comparison to D-amphetamine. Biological Psychiatry1989;25(2):222-8. [DOI: 10.1016/0006-3223(89)90167-4] [PMID: 2539203]ArnoldLE , PinkhamSM , VotolatoN . Does zinc moderate essential fatty acid and amphetamine treatment of attention-deficit/hyperactivity disorder?Journal of Child and Adolescent Psychopharmacology2000;10(2):111-7. [DOI: 10.1089/cap.2000.10.111] [PMID: 10933121]">Arnold 1989</a>). One study compared omega‐3 to omega‐6 PUFA (<a href="./references#CD007986-bbs2-0007" title="BélangerSA , VanasseM , SpahisS , SylvestreMP , LippéS , L'HeureuxF , et al. Omega-3 fatty acid treatment of children with attention-deficit hyperactivity disorder: a randomized, double-blind, placebo-controlled study. Paediatrics and Child Health2009;14(2):89-98. [DOI: 10.1093/pch/14.2.89] [PMCID: PMC2661342] [PMID: 19436468]VanasseM , Ageranioti-BélangerS , L'HeureuxF , GhadirianP , LevyE , SpahisS , et al. A randomized, controlled trial of omega-3 and phospholipids supplementation in children with attention-deficit-hyperactivity disorder. Developmental Medicine &amp; Child Neurology2006;48(Suppl 107):48. [DOI: 10.1111/j.1469-8749.2006.tb12600.x]">Bélanger 2009</a>). </p> <p>See <a href="./appendices#CD007986-sec-0135">Appendix 5</a>. </p> <p>The omega‐3 PUFA used in supplements was DHA (2.7 to 3600 mg/day, 22 studies), EPA (33 to 1039 mg/day, 22 studies), and ALA (60 to 1080 mg/day, 2 studies). The omega‐6 PUFA was arachidonic acid (40 to 60 mg/day, 2 studies), linoleic acid (240 to 360 mg/day, 5 studies), and gamma‐linoleic acid (6 to 345 mg/day, 8 studies). Supplements were given for a period of between two weeks and six months. </p> </section> <section id="CD007986-sec-0055"> <h5 class="title">Outcomes</h5> <section id="CD007986-sec-0056"> <h6 class="title">Improvement</h6> <p>Six studies reported improvement rated by parents (<a href="./references#CD007986-bbs2-0004" title="AssarehM , Davari AshtianiR , KhademiM , JazayeriS , RaiA , NikooM . Efficacy of polyunsaturated fatty acids (PUFA) in the treatment of attention deficit hyperactivity disorder: a randomized, double-blind, placebo-controlled clinical trial. Journal of Attention Disorders2017;21(1):78-85. [DOI: 10.1177/1087054712463962] [PMID: 23160488]IRCT138803122000N1. Poly unsaturated fatty acid as a combination treatment in children with attention deficit hyperactivity disorder [Omega-3 in the treatment of attention deficit hyperactivity disorder]. en.irct.ir/trial/1598?revision=1598 (first received 21 May 2011). ">Assareh 2017</a>; <a href="./references#CD007986-bbs2-0005" title="BarragánE , BreuerD , DöpfnerM . Efficacy and safety of omega-3/6 fatty acids, methylphenidate, and a combined treatment in children with ADHD. Journal of Attention Disorders2017;21(5):433-41. [DOI: 10.1177/1087054713518239] [PMID: 24464327]">Barragán 2017</a>; <a href="./references#CD007986-bbs2-0029" title="PereraH , JeewandaraKC , SeneviratneS , GurugeC . Combined ω3 and ω6 supplementation in children with attention-deficit hyperactivity disorder (ADHD) refractory to methylphenidate treatment: a double-blind, placebo-controlled study. Journal of Child Neurology2012;27(6):747‐53. [DOI: 10.1177/0883073811435243] [PMID: 22596014]SLCTR/2009/006. Effectiveness of omega-3 and omega-6 in childhood behaviour disorders [Effectiveness of omega-3 and omega-6 in children with neuro-developmental disorders: a double-blind placebo-controlled study]. slctr.lk/trials/slctr-2009-006 (first received 17 July 2009). ">Perera 2012</a>; <a href="./references#CD007986-bbs2-0034" title="StevensL , ZhangW , PeckL , KuczekT , GrevstadN , MahonA , et al. EFA supplementation in children with inattention, hyperactivity, and other disruptive behaviors. Lipids2003;38(10):1007-21. [DOI: 10.1007/s11745-006-1155-0] [PMID: 14669965]">Stevens 2003</a>), clinicians (<a href="./references#CD007986-bbs2-0020" title="JohnsonM , OstlundS , FranssonG , KadesjöB , GillbergC . Omega-3/omega-6 fatty acids for attention deficit hyperactivity disorder: a randomized placebo-controlled trial in children and adolescents. Journal of Attention Disorders2009;12(5):394-401. [DOI: 10.1177/1087054708316261] [PMID: 18448859]NCT01219309. Omega-3/omega-6 fatty acids for attention-deficit/hyperactivity disorder (ADHD): a trial in children and adolescents. clinicaltrials.gov/show/NCT01219309. (first received 30 October 2010). ">Johnson 2009</a>; <a href="./references#CD007986-bbs2-0026" title="IRCT2015092724209N2. Investigating the effectiveness of methylphenidate and multi chain polyunsaturated fatty acids in treatment of patients with attention deficit hyperactivity disorder (ADHD) in Zahedan City [Investigating the effectiveness of methylphenidate and multi chain polyunsaturated fatty acids in treatment of symptoms of attention deficit hyperactivity disorder (ADHD) among 6 to 12 children suffered from ADHD]. trialsearch.who.int/Trial2.aspx?TrialID=IRCT2015092724209N2 (first received 28 April 2016). MoghaddamMF , ShamekhiM , RakhshaniT . Effectiveness of methylphenidate and PUFA for the treatment of patients with ADHD: a double-blinded randomized clinical trial. Electronic Physician2017;9(5):4412-8. [DOI: 10.19082/4412] [PMCID: PMC5498708] [PMID: 28713515]">Moghaddam 2017</a>), and teachers (<a href="./references#CD007986-bbs2-0034" title="StevensL , ZhangW , PeckL , KuczekT , GrevstadN , MahonA , et al. EFA supplementation in children with inattention, hyperactivity, and other disruptive behaviors. Lipids2003;38(10):1007-21. [DOI: 10.1007/s11745-006-1155-0] [PMID: 14669965]">Stevens 2003</a>). All of these studies used the ADHD Rating Scale to measure improvement, except for <a href="./references#CD007986-bbs2-0026" title="IRCT2015092724209N2. Investigating the effectiveness of methylphenidate and multi chain polyunsaturated fatty acids in treatment of patients with attention deficit hyperactivity disorder (ADHD) in Zahedan City [Investigating the effectiveness of methylphenidate and multi chain polyunsaturated fatty acids in treatment of symptoms of attention deficit hyperactivity disorder (ADHD) among 6 to 12 children suffered from ADHD]. trialsearch.who.int/Trial2.aspx?TrialID=IRCT2015092724209N2 (first received 28 April 2016). MoghaddamMF , ShamekhiM , RakhshaniT . Effectiveness of methylphenidate and PUFA for the treatment of patients with ADHD: a double-blinded randomized clinical trial. Electronic Physician2017;9(5):4412-8. [DOI: 10.19082/4412] [PMCID: PMC5498708] [PMID: 28713515]">Moghaddam 2017</a>, who did not state which scale was used. </p> </section> <section id="CD007986-sec-0057"> <h6 class="title">ADHD symptoms</h6> <p>Twenty‐two studies reported parent‐rated total ADHD symptom scores (<a href="./references#CD007986-bbs2-0002" title="AnandP , SachdevaA . Effect of poly unsaturated fatty acids administration on children with attention deficit hyperactivity disorder: a randomized controlled trial. Journal of Clinical &amp; Diagnostic Research2016;10(9):OC01-5. [DOI: 10.7860/JCDR/2016/20423.8471] [PMCID: PMC5071983] [PMID: 27790483]">Anand 2016</a>; <a href="./references#CD007986-bbs2-0004" title="AssarehM , Davari AshtianiR , KhademiM , JazayeriS , RaiA , NikooM . Efficacy of polyunsaturated fatty acids (PUFA) in the treatment of attention deficit hyperactivity disorder: a randomized, double-blind, placebo-controlled clinical trial. Journal of Attention Disorders2017;21(1):78-85. [DOI: 10.1177/1087054712463962] [PMID: 23160488]IRCT138803122000N1. Poly unsaturated fatty acid as a combination treatment in children with attention deficit hyperactivity disorder [Omega-3 in the treatment of attention deficit hyperactivity disorder]. en.irct.ir/trial/1598?revision=1598 (first received 21 May 2011). ">Assareh 2017</a>; <a href="./references#CD007986-bbs2-0005" title="BarragánE , BreuerD , DöpfnerM . Efficacy and safety of omega-3/6 fatty acids, methylphenidate, and a combined treatment in children with ADHD. Journal of Attention Disorders2017;21(5):433-41. [DOI: 10.1177/1087054713518239] [PMID: 24464327]">Barragán 2017</a>; <a href="./references#CD007986-bbs2-0006" title="BehdaniF , HebraniP , NaseraeeA , HaghighiMB , AkhavanrezayatA . Does omega-3 supplement enhance the therapeutic results of methylphenidate in attention deficit hyperactivity disorder patients?Journal of Research in Medical Sciences2013;18(8):653-8. [PMCID: PMC3872603] [PMID: 24379840]">Behdani 2013</a>; <a href="./references#CD007986-bbs2-0007" title="BélangerSA , VanasseM , SpahisS , SylvestreMP , LippéS , L'HeureuxF , et al. Omega-3 fatty acid treatment of children with attention-deficit hyperactivity disorder: a randomized, double-blind, placebo-controlled study. Paediatrics and Child Health2009;14(2):89-98. [DOI: 10.1093/pch/14.2.89] [PMCID: PMC2661342] [PMID: 19436468]VanasseM , Ageranioti-BélangerS , L'HeureuxF , GhadirianP , LevyE , SpahisS , et al. A randomized, controlled trial of omega-3 and phospholipids supplementation in children with attention-deficit-hyperactivity disorder. Developmental Medicine &amp; Child Neurology2006;48(Suppl 107):48. [DOI: 10.1111/j.1469-8749.2006.tb12600.x]">Bélanger 2009</a>; <a href="./references#CD007986-bbs2-0008" title="BosD , Van BelleJ , WeustenJ , HoeksmaM , WisemanS , DurstonS . Effects of N-3 fatty acids (DHA and EPA) on cognitive control and associated brain activity in ADHD: a double-blind placebo controlled study. European Child &amp; Adolescent Psychiatry2010;19(Suppl 1):S69. [DOI: 10.1007/s00787-010-0117-5]BosD , Van BelleJ , WeustenJ , HoeksmaM , WisemanS , DurstonS . Effects of N-3 fatty acids (DHA and EPA) on cognitive control and associated brain activity in ADHD: a double-blind placebo controlled study. In: European Child and Adolescent Psychiatry, Conference: Eunethydis 1st International ADHD Conference: From Data to Best Clinical Practice; 2010 May 26–28; Amsterdam. 2010. BosDJ , OranjeB , VeerhoekES , Van DiepenRM , Weusten JMh, DemmelmairH , et al. Reduced symptoms of inattention after dietary omega-3 fatty acid supplementation in boys with and without attention deficit/hyperactivity disorder. Neuropsychopharmacology2015;40(10):2298–306. [DOI: 10.1038/npp.2015.73] [PMCID: PMC4538345] [PMID: 25790022]">Bos 2015</a>; <a href="./references#CD007986-bbs2-0010" title="ChangJP , SuKP , MondelliV , SatyanarayananSK , YangHT , ChiangYJ , et al. High-dose eicosapentaenoic acid (EPA) improves attention and vigilance in children and adolescents with attention deficit hyperactivity disorder (ADHD) and low endogenous EPA levels. Translational Psychiatry2019;9(1):303. [DOI: 10.1038/s41398-019-0633-0] [PMCID: PMC6864068] [PMID: 31745072]NCT03542643. Omega-3 polyunsaturated fatty acids in youth with ADHD [A double-blind randomised controlled trial of N-3 PUFAs in children with attention deficit hyperactivity disorder]. clinicaltrials.gov/ct2/show/NCT03542643 (first received 20 May 2018). ">Chang 2019</a>; <a href="./references#CD007986-bbs2-0011" title="CornuC , MercierC , GinhouxT , MassonS , MouchetJ , NonyP , et al. A double-blind placebo-controlled randomised trial of omega-3 supplementation in children with moderate ADHD symptoms. European Child &amp; Adolescent Psychiatry2018;27(3):377‐84. [DOI: 10.1007/s00787-017-1058-z] [PMID: 28993963]NCT00770627. Clinical trial to evaluate the efficacy and the tolerance of an omega 3 fatty acids supplementation in ADHD children [A randomized, controlled, double blind placebo trial to evaluate the efficacy and the tolerance of an omega 3 fatty acids supplementation in ADHD children]. clinicaltrials.gov/ct2/show/record/NCT00770627 (first received 9 October 2008). ">Cornu 2018</a>; <a href="./references#CD007986-bbs2-0012" title="CrippaA , AgostoniC , MauriM , MolteniM , NobileM . Polyunsaturated fatty acids are associated with behavior but not with cognition in children with and without ADHD: an Italian study. Journal of Attention Disorders2018;22(10):971-83. [DOI: 10.1177/1087054716629215]CrippaA , TeseiA , SangiorgioF , SalandiA , TrabattoniS , GrazioliS , et al. Behavioral and cognitive effects of docosahexaenoic acid in drug-naïve children with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled clinical trial. European Child &amp; Adolescent Psychiatry2019;28(4):571-83. [DOI: 10.1007/s00787-018-1223-z] [PMID: 30246216]NCT01796262. The effects of DHA on attention deficit and hyperactivity disorder (DADA) [The effects of DHA (docosahexaenoic acid) on attention deficit and hyperactivity disorder]. clinicaltrials.gov/show/nct01796262 (first received 12 February 2013). ">Crippa 2019</a>; <a href="./references#CD007986-bbs2-0013" title="DashtiN , HekmatH , SoltaniHR , RahimdelA , JavaherchianM . Comparison of therapeutic effects of omega-3 and methylphenidate (ritalin(®)) in treating children with attention deficit hyperactivity disorder. Iranian Journal of Psychiatry and Behavioral Sciences2014;8(4):7-11. [PMCID: PMC4364471] [PMID: 25798168]">Dashti 2014</a>; <a href="./references#CD007986-bbs2-0014" title="Dubnov-RazG , KhouryZ , WrightI , RazR , BergerI . The effect of alpha-linolenic acid supplementation on ADHD symptoms in children: a randomized controlled double-blind study. Frontiers in Human Neuroscience2014;8:780. [DOI: 10.3389/fnhum.2014.00780] [PMCID: PMC4188038] [PMID: 25339885]NCT00874536. Omega-3 supplementation and attention-deficit-hyperactivity disorder (ADHD) [The effect of omega-3 fatty acid supplementation on behavior of children with ADHD]. clinicaltrials.gov/show/nct00874536 (first received 1 April 2009). ">Dubnov‐Raz 2014</a>; <a href="./references#CD007986-bbs2-0016" title="EUCTR2004-003853-13-SE. Placebo controlled, randomised, double-blind, multicentre study of PlusEPA (a PUFA, polyunsaturated fatty acids, supplement) as treatment for ADHD (combined type) with co-morbidity in Swedish children ages 7-12. www.clinicaltrialsregister.eu/ctr-search/trial/2004-003853-13/SE (first received 16 November 2004). GustafssonPA , Birberg-ThornbergU , DuchénK , LandgrenM , MalmbergK , PellingH , et al. EPA supplementation improves teacher-rated behaviour and oppositional symptoms in children with ADHD. Acta Paediatrica2010;99(10):1540-9. [DOI: 10.1111/j.1651-2227.2010.01871.x] [PMID: 20491709]">Gustafsson 2010</a>; <a href="./references#CD007986-bbs2-0022" title="Lim-AshworthN , OoiYP , WengSJ , LimCG , FungDSS , GlennA , et al. Preliminary findings on the effects of nutritional and social skills intervention among children with attention deficit hyperactivity disorder. Annals: the official journal of the Academy of Medicine, Singapore2013;42(Suppl 9):S162. [OP-CR-65] [WEB PAGE: www.annals.edu.sg/pdf/42VolNo9Sep2013/SHBC_2013_041013.pdf]">Lim‐Ashworth 2013</a>; <a href="./references#CD007986-bbs2-0023" title="ManorI , MagenA , KeidarD , RosenS , TaskerH , CohenT , et al. The effect of phosphatidylserine containing omega3 fatty-acids on attention-deficit hyperactivity disorder symptoms in children: a double-blind placebo-controlled trial, followed by an open-label extension. European Psychiatry2012;27(5):335-42. [DOI: 10.1016/j.eurpsy.2011.05.004] [PMID: 21807480]NCT00418184. The efficacy and safety of phosphatidylserine-omega3 in children with attention-deficit/hyperactivity disorder [A single-center, randomized, double-blind, placebo-controlled study of the efficacy and safety of phosphatidylserine-omega3 in children with attention-deficit/hyperactivity disorder]. clinicaltrials.gov/show/NCT00418184 (first received 4 January 2007). ">Manor 2012</a>; <a href="./references#CD007986-bbs2-0024" title="EUCTR2005-005330-12-GB. Omega-3 fatty acids supplementation for adolescent boys with attention deficit hyperactivity disorder: a double-blind, randomized controlled trial - MAAFA. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2005-005330-12-GB (first received 10 April 2006). ISRCTN27741572. Omega-3 fatty acids supplementation for adolescent boys with attention deficit hyperactivity disorder: a double-blind, randomized controlled trial. tinyurl.com/jz99z7vd (first received 10 March 2006). [DOI: 10.1186/ISRCTN27741572]MatsudairaT , GowRV , KellyJ , MurphyC , PottsL , SumichA , et al. Biochemical and psychological effects of omega-3/6 supplements in male adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, clinical trial. Journal of Child &amp; Adolescent Psychopharmacology2015;25(10):775-82. [DOI: 10.1089/cap.2015.0052] [PMCID: PMC4691649] [PMID: 26682998]MatsudairaT . Omega-3 PUFA Fatty Acids and Attention-Deficit/Hyperactivity Disorder [PhD thesis]. London, UK: King's College London, University of London, 2011. ">Matsudaira 2015</a>; <a href="./references#CD007986-bbs2-0025" title="ACTRN12607000332426. Omega-3 fatty acids for ADHD symptoms and learning difficulties in children [Randomised controlled trial investigating effect of supplementation with omega-3 fatty acids EPA and DHA versus omega-6 fatty acid LA on ADHD symptoms and learning difficulties in 7-12 year old children]. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=82104 (first received 19 June 2007). MilteCM , ParlettaN , BuckleyJD , CoatesAM , YoungRM , HowePR . Eicosapentaenoic and docosahexaenoic acids, cognition, and behavior in children with attention-deficit/hyperactivity disorder: a randomized controlled trial. Nutrition2012;28(6):670-7. [DOI: 10.1016/j.nut.2011.12.009] [PMID: 22541055]">Milte 2012</a>; <a href="./references#CD007986-bbs2-0027" title="IRCT2016060128182N2. Omega-3 supplement in attention deficit hyperactivity disorder [The effectiveness of omega-3 supplement as an adjunctive therapy in children with attention deficit hyperactivity disorder]. www.irct.ir/trial/22914 (first received 23 January 2017). MohammadzadehS , BaghiN , YousefiF , YousefzamaniB . Effect of omega-3 plus methylphenidate as an alternative therapy to reduce attention deficit-hyperactivity disorder in children. Korean Journal of Pediatrics2019;62(9):360-6. [DOI: 10.3345/kjp.2018.06982] [PMCID: PMC6753311] [PMID: 31122010]">Mohammadzadeh 2019</a>; <a href="./references#CD007986-bbs2-0029" title="PereraH , JeewandaraKC , SeneviratneS , GurugeC . Combined ω3 and ω6 supplementation in children with attention-deficit hyperactivity disorder (ADHD) refractory to methylphenidate treatment: a double-blind, placebo-controlled study. Journal of Child Neurology2012;27(6):747‐53. [DOI: 10.1177/0883073811435243] [PMID: 22596014]SLCTR/2009/006. Effectiveness of omega-3 and omega-6 in childhood behaviour disorders [Effectiveness of omega-3 and omega-6 in children with neuro-developmental disorders: a double-blind placebo-controlled study]. slctr.lk/trials/slctr-2009-006 (first received 17 July 2009). ">Perera 2012</a>; <a href="./references#CD007986-bbs2-0032" title="SalehiB , MohammadbeigiA , SheykholeslamH , MoshiriE , DorrehF . Omega-3 and zinc supplementation as complementary therapies in children with attention-deficit/hyperactivity disorder. Journal of Research in Pharmacy Practice2016;5(1):22-6. [DOI: 10.4103/2279-042X.176561] [PMCID: PMC4776543] [PMID: 26985432]">Salehi 2016</a>; <a href="./references#CD007986-bbs2-0033" title="SinnN , BryanJ , WilsonC . Cognitive effects of polyunsaturated fatty acids in children with attention deficit hyperactivity disorder symptoms: a randomised controlled trial. Prostaglandins Leukotrienes and Essential Fatty Acids2008;78(4-5):311-26. [DOI: 10.1016/j.plefa.2008.04.004] [PMID: 18514501]SinnN , BryanJ . Effect of supplementation with polyunsaturated fatty acids and micronutrients on learning and behavior problems associated with child ADHD. Journal of Developmental and Behavioral Pediatrics2007;28(2):82-91. [DOI: 10.1097/01.DBP.0000267558.88457.a5] [PMID: 17435458]">Sinn 2007</a>; <a href="./references#CD007986-bbs2-0034" title="StevensL , ZhangW , PeckL , KuczekT , GrevstadN , MahonA , et al. EFA supplementation in children with inattention, hyperactivity, and other disruptive behaviors. Lipids2003;38(10):1007-21. [DOI: 10.1007/s11745-006-1155-0] [PMID: 14669965]">Stevens 2003</a>; <a href="./references#CD007986-bbs2-0037" title="Widenhorn-MüllerK , SchwandaS , ScholzE , SpitzerM , BodeH . Effect of supplementation with long-chain ω-3 polyunsaturated fatty acids on behavior and cognition in children with attention deficit/hyperactivity disorder (ADHD): a randomized placebo-controlled intervention trial. Prostaglandins Leukotrienes and Essential Fatty Acids2014;91(1-2):49-60. [DOI: 10.1016/j.plefa.2014.04.004] [PMID: 24958525]">Widenhorn‐Müller 2014</a>). Six studies used the ADHD Rating Scale (<a href="./references#CD007986-bbs2-0005" title="BarragánE , BreuerD , DöpfnerM . Efficacy and safety of omega-3/6 fatty acids, methylphenidate, and a combined treatment in children with ADHD. Journal of Attention Disorders2017;21(5):433-41. [DOI: 10.1177/1087054713518239] [PMID: 24464327]">Barragán 2017</a>; <a href="./references#CD007986-bbs2-0006" title="BehdaniF , HebraniP , NaseraeeA , HaghighiMB , AkhavanrezayatA . Does omega-3 supplement enhance the therapeutic results of methylphenidate in attention deficit hyperactivity disorder patients?Journal of Research in Medical Sciences2013;18(8):653-8. [PMCID: PMC3872603] [PMID: 24379840]">Behdani 2013</a>; <a href="./references#CD007986-bbs2-0011" title="CornuC , MercierC , GinhouxT , MassonS , MouchetJ , NonyP , et al. A double-blind placebo-controlled randomised trial of omega-3 supplementation in children with moderate ADHD symptoms. European Child &amp; Adolescent Psychiatry2018;27(3):377‐84. [DOI: 10.1007/s00787-017-1058-z] [PMID: 28993963]NCT00770627. Clinical trial to evaluate the efficacy and the tolerance of an omega 3 fatty acids supplementation in ADHD children [A randomized, controlled, double blind placebo trial to evaluate the efficacy and the tolerance of an omega 3 fatty acids supplementation in ADHD children]. clinicaltrials.gov/ct2/show/record/NCT00770627 (first received 9 October 2008). ">Cornu 2018</a>; <a href="./references#CD007986-bbs2-0012" title="CrippaA , AgostoniC , MauriM , MolteniM , NobileM . Polyunsaturated fatty acids are associated with behavior but not with cognition in children with and without ADHD: an Italian study. Journal of Attention Disorders2018;22(10):971-83. [DOI: 10.1177/1087054716629215]CrippaA , TeseiA , SangiorgioF , SalandiA , TrabattoniS , GrazioliS , et al. Behavioral and cognitive effects of docosahexaenoic acid in drug-naïve children with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled clinical trial. European Child &amp; Adolescent Psychiatry2019;28(4):571-83. [DOI: 10.1007/s00787-018-1223-z] [PMID: 30246216]NCT01796262. The effects of DHA on attention deficit and hyperactivity disorder (DADA) [The effects of DHA (docosahexaenoic acid) on attention deficit and hyperactivity disorder]. clinicaltrials.gov/show/nct01796262 (first received 12 February 2013). ">Crippa 2019</a>; <a href="./references#CD007986-bbs2-0027" title="IRCT2016060128182N2. Omega-3 supplement in attention deficit hyperactivity disorder [The effectiveness of omega-3 supplement as an adjunctive therapy in children with attention deficit hyperactivity disorder]. www.irct.ir/trial/22914 (first received 23 January 2017). MohammadzadehS , BaghiN , YousefiF , YousefzamaniB . Effect of omega-3 plus methylphenidate as an alternative therapy to reduce attention deficit-hyperactivity disorder in children. Korean Journal of Pediatrics2019;62(9):360-6. [DOI: 10.3345/kjp.2018.06982] [PMCID: PMC6753311] [PMID: 31122010]">Mohammadzadeh 2019</a>; <a href="./references#CD007986-bbs2-0029" title="PereraH , JeewandaraKC , SeneviratneS , GurugeC . Combined ω3 and ω6 supplementation in children with attention-deficit hyperactivity disorder (ADHD) refractory to methylphenidate treatment: a double-blind, placebo-controlled study. Journal of Child Neurology2012;27(6):747‐53. [DOI: 10.1177/0883073811435243] [PMID: 22596014]SLCTR/2009/006. Effectiveness of omega-3 and omega-6 in childhood behaviour disorders [Effectiveness of omega-3 and omega-6 in children with neuro-developmental disorders: a double-blind placebo-controlled study]. slctr.lk/trials/slctr-2009-006 (first received 17 July 2009). ">Perera 2012</a>); one used the Strengths and Weaknesses of ADHD symptoms and Normal behavior scale (SWAN) (<a href="./references#CD007986-bbs2-0008" title="BosD , Van BelleJ , WeustenJ , HoeksmaM , WisemanS , DurstonS . Effects of N-3 fatty acids (DHA and EPA) on cognitive control and associated brain activity in ADHD: a double-blind placebo controlled study. European Child &amp; Adolescent Psychiatry2010;19(Suppl 1):S69. [DOI: 10.1007/s00787-010-0117-5]BosD , Van BelleJ , WeustenJ , HoeksmaM , WisemanS , DurstonS . Effects of N-3 fatty acids (DHA and EPA) on cognitive control and associated brain activity in ADHD: a double-blind placebo controlled study. In: European Child and Adolescent Psychiatry, Conference: Eunethydis 1st International ADHD Conference: From Data to Best Clinical Practice; 2010 May 26–28; Amsterdam. 2010. BosDJ , OranjeB , VeerhoekES , Van DiepenRM , Weusten JMh, DemmelmairH , et al. Reduced symptoms of inattention after dietary omega-3 fatty acid supplementation in boys with and without attention deficit/hyperactivity disorder. Neuropsychopharmacology2015;40(10):2298–306. [DOI: 10.1038/npp.2015.73] [PMCID: PMC4538345] [PMID: 25790022]">Bos 2015</a>); one used the DISYPS‐II (<a href="./references#CD007986-bbs2-0037" title="Widenhorn-MüllerK , SchwandaS , ScholzE , SpitzerM , BodeH . Effect of supplementation with long-chain ω-3 polyunsaturated fatty acids on behavior and cognition in children with attention deficit/hyperactivity disorder (ADHD): a randomized placebo-controlled intervention trial. Prostaglandins Leukotrienes and Essential Fatty Acids2014;91(1-2):49-60. [DOI: 10.1016/j.plefa.2014.04.004] [PMID: 24958525]">Widenhorn‐Müller 2014</a>); one used the SNAP‐IV (<a href="./references#CD007986-bbs2-0010" title="ChangJP , SuKP , MondelliV , SatyanarayananSK , YangHT , ChiangYJ , et al. High-dose eicosapentaenoic acid (EPA) improves attention and vigilance in children and adolescents with attention deficit hyperactivity disorder (ADHD) and low endogenous EPA levels. Translational Psychiatry2019;9(1):303. [DOI: 10.1038/s41398-019-0633-0] [PMCID: PMC6864068] [PMID: 31745072]NCT03542643. Omega-3 polyunsaturated fatty acids in youth with ADHD [A double-blind randomised controlled trial of N-3 PUFAs in children with attention deficit hyperactivity disorder]. clinicaltrials.gov/ct2/show/NCT03542643 (first received 20 May 2018). ">Chang 2019</a>); and the remaining studies used the Conners Rating Scale. </p> <p>Three studies reported clinician‐rated total symptom scores. One study used the ADHD Rating Scale (<a href="./references#CD007986-bbs2-0020" title="JohnsonM , OstlundS , FranssonG , KadesjöB , GillbergC . Omega-3/omega-6 fatty acids for attention deficit hyperactivity disorder: a randomized placebo-controlled trial in children and adolescents. Journal of Attention Disorders2009;12(5):394-401. [DOI: 10.1177/1087054708316261] [PMID: 18448859]NCT01219309. Omega-3/omega-6 fatty acids for attention-deficit/hyperactivity disorder (ADHD): a trial in children and adolescents. clinicaltrials.gov/show/NCT01219309. (first received 30 October 2010). ">Johnson 2009</a>); one used the Conners Rating Scale (<a href="./references#CD007986-bbs2-0017" title="HaririM , DjazayeryA , DjalaliM , SaedisomeoliaA , RahimiA , AbdolahianE . Effect of n-3 supplementation on hyperactivity, oxidative stress and inflammatory mediators in children with attention-deficit-hyperactivity disorder. Malaysian Journal of Nutrition2012;18(3):329-52. [PMID: 24568073]">Hariri 2012</a>); and one did not state which measure was used (<a href="./references#CD007986-bbs2-0026" title="IRCT2015092724209N2. Investigating the effectiveness of methylphenidate and multi chain polyunsaturated fatty acids in treatment of patients with attention deficit hyperactivity disorder (ADHD) in Zahedan City [Investigating the effectiveness of methylphenidate and multi chain polyunsaturated fatty acids in treatment of symptoms of attention deficit hyperactivity disorder (ADHD) among 6 to 12 children suffered from ADHD]. trialsearch.who.int/Trial2.aspx?TrialID=IRCT2015092724209N2 (first received 28 April 2016). MoghaddamMF , ShamekhiM , RakhshaniT . Effectiveness of methylphenidate and PUFA for the treatment of patients with ADHD: a double-blinded randomized clinical trial. Electronic Physician2017;9(5):4412-8. [DOI: 10.19082/4412] [PMCID: PMC5498708] [PMID: 28713515]">Moghaddam 2017</a>). </p> <p>Nine studies reported teacher‐rated total symptoms. One study used the ADHD Rating Scale (<a href="./references#CD007986-bbs2-0006" title="BehdaniF , HebraniP , NaseraeeA , HaghighiMB , AkhavanrezayatA . Does omega-3 supplement enhance the therapeutic results of methylphenidate in attention deficit hyperactivity disorder patients?Journal of Research in Medical Sciences2013;18(8):653-8. [PMCID: PMC3872603] [PMID: 24379840]">Behdani 2013</a>); one used the DISYPS‐II (<a href="./references#CD007986-bbs2-0037" title="Widenhorn-MüllerK , SchwandaS , ScholzE , SpitzerM , BodeH . Effect of supplementation with long-chain ω-3 polyunsaturated fatty acids on behavior and cognition in children with attention deficit/hyperactivity disorder (ADHD): a randomized placebo-controlled intervention trial. Prostaglandins Leukotrienes and Essential Fatty Acids2014;91(1-2):49-60. [DOI: 10.1016/j.plefa.2014.04.004] [PMID: 24958525]">Widenhorn‐Müller 2014</a>); one used the SNAP‐IV (<a href="./references#CD007986-bbs2-0010" title="ChangJP , SuKP , MondelliV , SatyanarayananSK , YangHT , ChiangYJ , et al. High-dose eicosapentaenoic acid (EPA) improves attention and vigilance in children and adolescents with attention deficit hyperactivity disorder (ADHD) and low endogenous EPA levels. Translational Psychiatry2019;9(1):303. [DOI: 10.1038/s41398-019-0633-0] [PMCID: PMC6864068] [PMID: 31745072]NCT03542643. Omega-3 polyunsaturated fatty acids in youth with ADHD [A double-blind randomised controlled trial of N-3 PUFAs in children with attention deficit hyperactivity disorder]. clinicaltrials.gov/ct2/show/NCT03542643 (first received 20 May 2018). ">Chang 2019</a>); and the remaining studies used the Conners Rating Scale (<a href="./references#CD007986-bbs2-0014" title="Dubnov-RazG , KhouryZ , WrightI , RazR , BergerI . The effect of alpha-linolenic acid supplementation on ADHD symptoms in children: a randomized controlled double-blind study. Frontiers in Human Neuroscience2014;8:780. [DOI: 10.3389/fnhum.2014.00780] [PMCID: PMC4188038] [PMID: 25339885]NCT00874536. Omega-3 supplementation and attention-deficit-hyperactivity disorder (ADHD) [The effect of omega-3 fatty acid supplementation on behavior of children with ADHD]. clinicaltrials.gov/show/nct00874536 (first received 1 April 2009). ">Dubnov‐Raz 2014</a>; <a href="./references#CD007986-bbs2-0016" title="EUCTR2004-003853-13-SE. Placebo controlled, randomised, double-blind, multicentre study of PlusEPA (a PUFA, polyunsaturated fatty acids, supplement) as treatment for ADHD (combined type) with co-morbidity in Swedish children ages 7-12. www.clinicaltrialsregister.eu/ctr-search/trial/2004-003853-13/SE (first received 16 November 2004). GustafssonPA , Birberg-ThornbergU , DuchénK , LandgrenM , MalmbergK , PellingH , et al. EPA supplementation improves teacher-rated behaviour and oppositional symptoms in children with ADHD. Acta Paediatrica2010;99(10):1540-9. [DOI: 10.1111/j.1651-2227.2010.01871.x] [PMID: 20491709]">Gustafsson 2010</a>; <a href="./references#CD007986-bbs2-0023" title="ManorI , MagenA , KeidarD , RosenS , TaskerH , CohenT , et al. The effect of phosphatidylserine containing omega3 fatty-acids on attention-deficit hyperactivity disorder symptoms in children: a double-blind placebo-controlled trial, followed by an open-label extension. European Psychiatry2012;27(5):335-42. [DOI: 10.1016/j.eurpsy.2011.05.004] [PMID: 21807480]NCT00418184. The efficacy and safety of phosphatidylserine-omega3 in children with attention-deficit/hyperactivity disorder [A single-center, randomized, double-blind, placebo-controlled study of the efficacy and safety of phosphatidylserine-omega3 in children with attention-deficit/hyperactivity disorder]. clinicaltrials.gov/show/NCT00418184 (first received 4 January 2007). ">Manor 2012</a>; <a href="./references#CD007986-bbs2-0024" title="EUCTR2005-005330-12-GB. Omega-3 fatty acids supplementation for adolescent boys with attention deficit hyperactivity disorder: a double-blind, randomized controlled trial - MAAFA. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2005-005330-12-GB (first received 10 April 2006). ISRCTN27741572. Omega-3 fatty acids supplementation for adolescent boys with attention deficit hyperactivity disorder: a double-blind, randomized controlled trial. tinyurl.com/jz99z7vd (first received 10 March 2006). [DOI: 10.1186/ISRCTN27741572]MatsudairaT , GowRV , KellyJ , MurphyC , PottsL , SumichA , et al. Biochemical and psychological effects of omega-3/6 supplements in male adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, clinical trial. Journal of Child &amp; Adolescent Psychopharmacology2015;25(10):775-82. [DOI: 10.1089/cap.2015.0052] [PMCID: PMC4691649] [PMID: 26682998]MatsudairaT . Omega-3 PUFA Fatty Acids and Attention-Deficit/Hyperactivity Disorder [PhD thesis]. London, UK: King's College London, University of London, 2011. ">Matsudaira 2015</a>; <a href="./references#CD007986-bbs2-0030" title="RazR , CarassoRL , YehudaS . The influence of short-chain essential fatty acids on children with attention-deficit/hyperactivity disorder: a double-blind placebo-controlled study. Journal of Child and Adolescent Psychopharmacology2009;19(2):167-77. [DOI: 10.1089/cap.2008.070] [PMID: 19364294]">Raz 2009a</a>; <a href="./references#CD007986-bbs2-0034" title="StevensL , ZhangW , PeckL , KuczekT , GrevstadN , MahonA , et al. EFA supplementation in children with inattention, hyperactivity, and other disruptive behaviors. Lipids2003;38(10):1007-21. [DOI: 10.1007/s11745-006-1155-0] [PMID: 14669965]">Stevens 2003</a>). </p> <p>Seven studies reported hyperactivity/impulsivity or inattention (or both), which in all studies was rated by parents (<a href="./references#CD007986-bbs2-0001" title="AmanMG , MitchellEA , TurbottSH . The effects of essential fatty acid supplementation by efamol in hyperactive children. Journal of Abnormal Child Psychology1987;15(1):75-90. [DOI: 10.1007/BF00916467]">Aman 1987</a>; <a href="./references#CD007986-bbs2-0009" title="BrueAW , OaklandTD , EvansRA . The use of a dietary supplement combination and an essential fatty acid as an alternative and complementary treatment for children with attention-deficit/hyperactivity disorder. Scientific Review of Alternative Medicine2001;5(4):187-94. [WEB PAGE: tinyurl.com/y56pdtxq]BrueAW . The Use of a Dietary Supplement Combination and an Essential Fatty Acid as an Alternative and Complementary Treatment for Children with Attention Deficit Hyperactivity Disorder (ADHD) [PhD thesis]. Gainesville (FL): University of Florida, 1999. ">Brue 2001</a>; <a href="./references#CD007986-bbs2-0010" title="ChangJP , SuKP , MondelliV , SatyanarayananSK , YangHT , ChiangYJ , et al. High-dose eicosapentaenoic acid (EPA) improves attention and vigilance in children and adolescents with attention deficit hyperactivity disorder (ADHD) and low endogenous EPA levels. Translational Psychiatry2019;9(1):303. [DOI: 10.1038/s41398-019-0633-0] [PMCID: PMC6864068] [PMID: 31745072]NCT03542643. Omega-3 polyunsaturated fatty acids in youth with ADHD [A double-blind randomised controlled trial of N-3 PUFAs in children with attention deficit hyperactivity disorder]. clinicaltrials.gov/ct2/show/NCT03542643 (first received 20 May 2018). ">Chang 2019</a>; <a href="./references#CD007986-bbs2-0018" title="HamazakiT , HirayamaS . The effect of docosahexaenoic acid-containing food administration on symptoms of attention-deficit/hyperactivity disorder - a placebo-controlled double-blind study. European Journal of Clinical Nutrition2004;58(5):838. [DOI: 10.1038/sj.ejcn.1601888] [PMID: 15116088]HirayamaS , HamazakiT , TerasawaK . Effect of docosahexaenoic acid-containing food administration on symptoms of attention-deficit/hyperactivity disorder - a placebo-controlled double-blind study. European Journal of Clinical Nutrition2004;58(3):467-73. [DOI: 10.1038/sj.ejcn.1601830] [PMID: 14985685]">Hirayama 2004</a>; <a href="./references#CD007986-bbs2-0021" title="KeanJD , SarrisJ , ScholeyA , SilbersteinR , DowneyLA , StoughC . Reduced inattention and hyperactivity and improved cognition after marine oil extract (PCSO-524®) supplementation in children and adolescents with clinical and subclinical symptoms of attention-deficit hyperactivity disorder (ADHD): a randomised, double-blind, placebo-controlled trial. Psychopharmacology2017;234(3):403-20. [DOI: 10.1007/s00213-016-4471-y] [PMCID: PMC5225177] [PMID: 27921139]">Kean 2017</a>; <a href="./references#CD007986-bbs2-0035" title="NCT00382616. Supplementation of phosphatidylserine (PS) and n-3 long chain fatty acids (EPA, DHA) in children with ADHD. clinicaltrials.gov/ct2/show/NCT00382616 (first received 29 September 2006). VaismanN , KaysarN , Zaruk-AdashaY , PelledD , BrichonG , ZwingelsteinG , et al. Correlation between changes in blood fatty acid composition and visual sustained attention performance in children with inattention: effect of dietary n-3 fatty acids containing phospholipids. American Journal of Clinical Nutrition2008;87(5):1170-80. [DOI: 10.1093/ajcn/87.5.1170] [PMID: 18469236]">Vaisman 2008</a>; <a href="./references#CD007986-bbs2-0036" title="VoigtRG , LlorenteAM , JensenCL , FraleyJK , BerrettaMC , HeirdWC . A randomized, double-blind, placebo-controlled trial of docosahexaenoic acid supplementation in children with attention-deficit/hyperactivity disorder. Journal of Pediatrics2001;139(2):189-96. [DOI: 10.1067/mpd.2001.116050] [PMID: 11487742]">Voigt 2001</a>). Four of these studies also reported teacher‐rated symptoms (<a href="./references#CD007986-bbs2-0001" title="AmanMG , MitchellEA , TurbottSH . The effects of essential fatty acid supplementation by efamol in hyperactive children. Journal of Abnormal Child Psychology1987;15(1):75-90. [DOI: 10.1007/BF00916467]">Aman 1987</a>; <a href="./references#CD007986-bbs2-0009" title="BrueAW , OaklandTD , EvansRA . The use of a dietary supplement combination and an essential fatty acid as an alternative and complementary treatment for children with attention-deficit/hyperactivity disorder. Scientific Review of Alternative Medicine2001;5(4):187-94. [WEB PAGE: tinyurl.com/y56pdtxq]BrueAW . The Use of a Dietary Supplement Combination and an Essential Fatty Acid as an Alternative and Complementary Treatment for Children with Attention Deficit Hyperactivity Disorder (ADHD) [PhD thesis]. Gainesville (FL): University of Florida, 1999. ">Brue 2001</a>; <a href="./references#CD007986-bbs2-0010" title="ChangJP , SuKP , MondelliV , SatyanarayananSK , YangHT , ChiangYJ , et al. High-dose eicosapentaenoic acid (EPA) improves attention and vigilance in children and adolescents with attention deficit hyperactivity disorder (ADHD) and low endogenous EPA levels. Translational Psychiatry2019;9(1):303. [DOI: 10.1038/s41398-019-0633-0] [PMCID: PMC6864068] [PMID: 31745072]NCT03542643. Omega-3 polyunsaturated fatty acids in youth with ADHD [A double-blind randomised controlled trial of N-3 PUFAs in children with attention deficit hyperactivity disorder]. clinicaltrials.gov/ct2/show/NCT03542643 (first received 20 May 2018). ">Chang 2019</a>; <a href="./references#CD007986-bbs2-0018" title="HamazakiT , HirayamaS . The effect of docosahexaenoic acid-containing food administration on symptoms of attention-deficit/hyperactivity disorder - a placebo-controlled double-blind study. European Journal of Clinical Nutrition2004;58(5):838. [DOI: 10.1038/sj.ejcn.1601888] [PMID: 15116088]HirayamaS , HamazakiT , TerasawaK . Effect of docosahexaenoic acid-containing food administration on symptoms of attention-deficit/hyperactivity disorder - a placebo-controlled double-blind study. European Journal of Clinical Nutrition2004;58(3):467-73. [DOI: 10.1038/sj.ejcn.1601830] [PMID: 14985685]">Hirayama 2004</a>). All studies used the Conners Rating Scale, except for <a href="./references#CD007986-bbs2-0010" title="ChangJP , SuKP , MondelliV , SatyanarayananSK , YangHT , ChiangYJ , et al. High-dose eicosapentaenoic acid (EPA) improves attention and vigilance in children and adolescents with attention deficit hyperactivity disorder (ADHD) and low endogenous EPA levels. Translational Psychiatry2019;9(1):303. [DOI: 10.1038/s41398-019-0633-0] [PMCID: PMC6864068] [PMID: 31745072]NCT03542643. Omega-3 polyunsaturated fatty acids in youth with ADHD [A double-blind randomised controlled trial of N-3 PUFAs in children with attention deficit hyperactivity disorder]. clinicaltrials.gov/ct2/show/NCT03542643 (first received 20 May 2018). ">Chang 2019</a>, who used the SNAP‐IV; <a href="./references#CD007986-bbs2-0018" title="HamazakiT , HirayamaS . The effect of docosahexaenoic acid-containing food administration on symptoms of attention-deficit/hyperactivity disorder - a placebo-controlled double-blind study. European Journal of Clinical Nutrition2004;58(5):838. [DOI: 10.1038/sj.ejcn.1601888] [PMID: 15116088]HirayamaS , HamazakiT , TerasawaK . Effect of docosahexaenoic acid-containing food administration on symptoms of attention-deficit/hyperactivity disorder - a placebo-controlled double-blind study. European Journal of Clinical Nutrition2004;58(3):467-73. [DOI: 10.1038/sj.ejcn.1601830] [PMID: 14985685]">Hirayama 2004</a>, who reported the number of DSM‐IV‐symptoms; and <a href="./references#CD007986-bbs2-0036" title="VoigtRG , LlorenteAM , JensenCL , FraleyJK , BerrettaMC , HeirdWC . A randomized, double-blind, placebo-controlled trial of docosahexaenoic acid supplementation in children with attention-deficit/hyperactivity disorder. Journal of Pediatrics2001;139(2):189-96. [DOI: 10.1067/mpd.2001.116050] [PMID: 11487742]">Voigt 2001</a>, who reported the Child Behavior Checklist ‐ Attention. </p> </section> <section id="CD007986-sec-0058"> <h6 class="title">Behaviour</h6> <p>Four studies reported that aggression was measured (<a href="./references#CD007986-bbs2-0001" title="AmanMG , MitchellEA , TurbottSH . The effects of essential fatty acid supplementation by efamol in hyperactive children. Journal of Abnormal Child Psychology1987;15(1):75-90. [DOI: 10.1007/BF00916467]">Aman 1987</a>; <a href="./references#CD007986-bbs2-0008" title="BosD , Van BelleJ , WeustenJ , HoeksmaM , WisemanS , DurstonS . Effects of N-3 fatty acids (DHA and EPA) on cognitive control and associated brain activity in ADHD: a double-blind placebo controlled study. European Child &amp; Adolescent Psychiatry2010;19(Suppl 1):S69. [DOI: 10.1007/s00787-010-0117-5]BosD , Van BelleJ , WeustenJ , HoeksmaM , WisemanS , DurstonS . Effects of N-3 fatty acids (DHA and EPA) on cognitive control and associated brain activity in ADHD: a double-blind placebo controlled study. In: European Child and Adolescent Psychiatry, Conference: Eunethydis 1st International ADHD Conference: From Data to Best Clinical Practice; 2010 May 26–28; Amsterdam. 2010. BosDJ , OranjeB , VeerhoekES , Van DiepenRM , Weusten JMh, DemmelmairH , et al. Reduced symptoms of inattention after dietary omega-3 fatty acid supplementation in boys with and without attention deficit/hyperactivity disorder. Neuropsychopharmacology2015;40(10):2298–306. [DOI: 10.1038/npp.2015.73] [PMCID: PMC4538345] [PMID: 25790022]">Bos 2015</a>; <a href="./references#CD007986-bbs2-0018" title="HamazakiT , HirayamaS . The effect of docosahexaenoic acid-containing food administration on symptoms of attention-deficit/hyperactivity disorder - a placebo-controlled double-blind study. European Journal of Clinical Nutrition2004;58(5):838. [DOI: 10.1038/sj.ejcn.1601888] [PMID: 15116088]HirayamaS , HamazakiT , TerasawaK . Effect of docosahexaenoic acid-containing food administration on symptoms of attention-deficit/hyperactivity disorder - a placebo-controlled double-blind study. European Journal of Clinical Nutrition2004;58(3):467-73. [DOI: 10.1038/sj.ejcn.1601830] [PMID: 14985685]">Hirayama 2004</a>; <a href="./references#CD007986-bbs2-0029" title="PereraH , JeewandaraKC , SeneviratneS , GurugeC . Combined ω3 and ω6 supplementation in children with attention-deficit hyperactivity disorder (ADHD) refractory to methylphenidate treatment: a double-blind, placebo-controlled study. Journal of Child Neurology2012;27(6):747‐53. [DOI: 10.1177/0883073811435243] [PMID: 22596014]SLCTR/2009/006. Effectiveness of omega-3 and omega-6 in childhood behaviour disorders [Effectiveness of omega-3 and omega-6 in children with neuro-developmental disorders: a double-blind placebo-controlled study]. slctr.lk/trials/slctr-2009-006 (first received 17 July 2009). ">Perera 2012</a>); however, <a href="./references#CD007986-bbs2-0018" title="HamazakiT , HirayamaS . The effect of docosahexaenoic acid-containing food administration on symptoms of attention-deficit/hyperactivity disorder - a placebo-controlled double-blind study. European Journal of Clinical Nutrition2004;58(5):838. [DOI: 10.1038/sj.ejcn.1601888] [PMID: 15116088]HirayamaS , HamazakiT , TerasawaK . Effect of docosahexaenoic acid-containing food administration on symptoms of attention-deficit/hyperactivity disorder - a placebo-controlled double-blind study. European Journal of Clinical Nutrition2004;58(3):467-73. [DOI: 10.1038/sj.ejcn.1601830] [PMID: 14985685]">Hirayama 2004</a> and <a href="./references#CD007986-bbs2-0029" title="PereraH , JeewandaraKC , SeneviratneS , GurugeC . Combined ω3 and ω6 supplementation in children with attention-deficit hyperactivity disorder (ADHD) refractory to methylphenidate treatment: a double-blind, placebo-controlled study. Journal of Child Neurology2012;27(6):747‐53. [DOI: 10.1177/0883073811435243] [PMID: 22596014]SLCTR/2009/006. Effectiveness of omega-3 and omega-6 in childhood behaviour disorders [Effectiveness of omega-3 and omega-6 in children with neuro-developmental disorders: a double-blind placebo-controlled study]. slctr.lk/trials/slctr-2009-006 (first received 17 July 2009). ">Perera 2012</a> did not use a validated scale. <a href="./references#CD007986-bbs2-0001" title="AmanMG , MitchellEA , TurbottSH . The effects of essential fatty acid supplementation by efamol in hyperactive children. Journal of Abnormal Child Psychology1987;15(1):75-90. [DOI: 10.1007/BF00916467]">Aman 1987</a> used the parent‐rated Revised Behavior Problem Checklist subscales for conduct and aggression and teacher‐rated Conners subscale for conduct. <a href="./references#CD007986-bbs2-0008" title="BosD , Van BelleJ , WeustenJ , HoeksmaM , WisemanS , DurstonS . Effects of N-3 fatty acids (DHA and EPA) on cognitive control and associated brain activity in ADHD: a double-blind placebo controlled study. European Child &amp; Adolescent Psychiatry2010;19(Suppl 1):S69. [DOI: 10.1007/s00787-010-0117-5]BosD , Van BelleJ , WeustenJ , HoeksmaM , WisemanS , DurstonS . Effects of N-3 fatty acids (DHA and EPA) on cognitive control and associated brain activity in ADHD: a double-blind placebo controlled study. In: European Child and Adolescent Psychiatry, Conference: Eunethydis 1st International ADHD Conference: From Data to Best Clinical Practice; 2010 May 26–28; Amsterdam. 2010. BosDJ , OranjeB , VeerhoekES , Van DiepenRM , Weusten JMh, DemmelmairH , et al. Reduced symptoms of inattention after dietary omega-3 fatty acid supplementation in boys with and without attention deficit/hyperactivity disorder. Neuropsychopharmacology2015;40(10):2298–306. [DOI: 10.1038/npp.2015.73] [PMCID: PMC4538345] [PMID: 25790022]">Bos 2015</a> used the parent‐rated Child Behavior Checklist to measure aggression. </p> <p>In addition to <a href="./references#CD007986-bbs2-0001" title="AmanMG , MitchellEA , TurbottSH . The effects of essential fatty acid supplementation by efamol in hyperactive children. Journal of Abnormal Child Psychology1987;15(1):75-90. [DOI: 10.1007/BF00916467]">Aman 1987</a>, parent‐rated conduct problems were also reported by <a href="./references#CD007986-bbs2-0012" title="CrippaA , AgostoniC , MauriM , MolteniM , NobileM . Polyunsaturated fatty acids are associated with behavior but not with cognition in children with and without ADHD: an Italian study. Journal of Attention Disorders2018;22(10):971-83. [DOI: 10.1177/1087054716629215]CrippaA , TeseiA , SangiorgioF , SalandiA , TrabattoniS , GrazioliS , et al. Behavioral and cognitive effects of docosahexaenoic acid in drug-naïve children with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled clinical trial. European Child &amp; Adolescent Psychiatry2019;28(4):571-83. [DOI: 10.1007/s00787-018-1223-z] [PMID: 30246216]NCT01796262. The effects of DHA on attention deficit and hyperactivity disorder (DADA) [The effects of DHA (docosahexaenoic acid) on attention deficit and hyperactivity disorder]. clinicaltrials.gov/show/nct01796262 (first received 12 February 2013). ">Crippa 2019</a> and <a href="./references#CD007986-bbs2-0024" title="EUCTR2005-005330-12-GB. Omega-3 fatty acids supplementation for adolescent boys with attention deficit hyperactivity disorder: a double-blind, randomized controlled trial - MAAFA. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2005-005330-12-GB (first received 10 April 2006). ISRCTN27741572. Omega-3 fatty acids supplementation for adolescent boys with attention deficit hyperactivity disorder: a double-blind, randomized controlled trial. tinyurl.com/jz99z7vd (first received 10 March 2006). [DOI: 10.1186/ISRCTN27741572]MatsudairaT , GowRV , KellyJ , MurphyC , PottsL , SumichA , et al. Biochemical and psychological effects of omega-3/6 supplements in male adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, clinical trial. Journal of Child &amp; Adolescent Psychopharmacology2015;25(10):775-82. [DOI: 10.1089/cap.2015.0052] [PMCID: PMC4691649] [PMID: 26682998]MatsudairaT . Omega-3 PUFA Fatty Acids and Attention-Deficit/Hyperactivity Disorder [PhD thesis]. London, UK: King's College London, University of London, 2011. ">Matsudaira 2015</a>, both of whom used the Strengths and Difficulties Questionnaire. Parent‐ and teacher‐rated conduct problems were also reported by <a href="./references#CD007986-bbs2-0034" title="StevensL , ZhangW , PeckL , KuczekT , GrevstadN , MahonA , et al. EFA supplementation in children with inattention, hyperactivity, and other disruptive behaviors. Lipids2003;38(10):1007-21. [DOI: 10.1007/s11745-006-1155-0] [PMID: 14669965]">Stevens 2003</a>, using the Disrupted Behavior Disorders Rating Scale. </p> <p><a href="./references#CD007986-bbs2-0034" title="StevensL , ZhangW , PeckL , KuczekT , GrevstadN , MahonA , et al. EFA supplementation in children with inattention, hyperactivity, and other disruptive behaviors. Lipids2003;38(10):1007-21. [DOI: 10.1007/s11745-006-1155-0] [PMID: 14669965]">Stevens 2003</a> also used the Disrupted Behavior Disorders Rating Scale to report teacher‐rated oppositional behaviour. The Conners Rating Scale was used for teacher‐rated oppositional behaviour by <a href="./references#CD007986-bbs2-0016" title="EUCTR2004-003853-13-SE. Placebo controlled, randomised, double-blind, multicentre study of PlusEPA (a PUFA, polyunsaturated fatty acids, supplement) as treatment for ADHD (combined type) with co-morbidity in Swedish children ages 7-12. www.clinicaltrialsregister.eu/ctr-search/trial/2004-003853-13/SE (first received 16 November 2004). GustafssonPA , Birberg-ThornbergU , DuchénK , LandgrenM , MalmbergK , PellingH , et al. EPA supplementation improves teacher-rated behaviour and oppositional symptoms in children with ADHD. Acta Paediatrica2010;99(10):1540-9. [DOI: 10.1111/j.1651-2227.2010.01871.x] [PMID: 20491709]">Gustafsson 2010</a> and <a href="./references#CD007986-bbs2-0023" title="ManorI , MagenA , KeidarD , RosenS , TaskerH , CohenT , et al. The effect of phosphatidylserine containing omega3 fatty-acids on attention-deficit hyperactivity disorder symptoms in children: a double-blind placebo-controlled trial, followed by an open-label extension. European Psychiatry2012;27(5):335-42. [DOI: 10.1016/j.eurpsy.2011.05.004] [PMID: 21807480]NCT00418184. The efficacy and safety of phosphatidylserine-omega3 in children with attention-deficit/hyperactivity disorder [A single-center, randomized, double-blind, placebo-controlled study of the efficacy and safety of phosphatidylserine-omega3 in children with attention-deficit/hyperactivity disorder]. clinicaltrials.gov/show/NCT00418184 (first received 4 January 2007). ">Manor 2012</a>, and for parent‐rated oppositional behaviour by <a href="./references#CD007986-bbs2-0023" title="ManorI , MagenA , KeidarD , RosenS , TaskerH , CohenT , et al. The effect of phosphatidylserine containing omega3 fatty-acids on attention-deficit hyperactivity disorder symptoms in children: a double-blind placebo-controlled trial, followed by an open-label extension. European Psychiatry2012;27(5):335-42. [DOI: 10.1016/j.eurpsy.2011.05.004] [PMID: 21807480]NCT00418184. The efficacy and safety of phosphatidylserine-omega3 in children with attention-deficit/hyperactivity disorder [A single-center, randomized, double-blind, placebo-controlled study of the efficacy and safety of phosphatidylserine-omega3 in children with attention-deficit/hyperactivity disorder]. clinicaltrials.gov/show/NCT00418184 (first received 4 January 2007). ">Manor 2012</a>, <a href="./references#CD007986-bbs2-0025" title="ACTRN12607000332426. Omega-3 fatty acids for ADHD symptoms and learning difficulties in children [Randomised controlled trial investigating effect of supplementation with omega-3 fatty acids EPA and DHA versus omega-6 fatty acid LA on ADHD symptoms and learning difficulties in 7-12 year old children]. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=82104 (first received 19 June 2007). MilteCM , ParlettaN , BuckleyJD , CoatesAM , YoungRM , HowePR . Eicosapentaenoic and docosahexaenoic acids, cognition, and behavior in children with attention-deficit/hyperactivity disorder: a randomized controlled trial. Nutrition2012;28(6):670-7. [DOI: 10.1016/j.nut.2011.12.009] [PMID: 22541055]">Milte 2012</a>, and <a href="./references#CD007986-bbs2-0033" title="SinnN , BryanJ , WilsonC . Cognitive effects of polyunsaturated fatty acids in children with attention deficit hyperactivity disorder symptoms: a randomised controlled trial. Prostaglandins Leukotrienes and Essential Fatty Acids2008;78(4-5):311-26. [DOI: 10.1016/j.plefa.2008.04.004] [PMID: 18514501]SinnN , BryanJ . Effect of supplementation with polyunsaturated fatty acids and micronutrients on learning and behavior problems associated with child ADHD. Journal of Developmental and Behavioral Pediatrics2007;28(2):82-91. [DOI: 10.1097/01.DBP.0000267558.88457.a5] [PMID: 17435458]">Sinn 2007</a>. Parent‐ and teacher‐rated oppositional behaviour was also measured using the SNAP‐IV by <a href="./references#CD007986-bbs2-0010" title="ChangJP , SuKP , MondelliV , SatyanarayananSK , YangHT , ChiangYJ , et al. High-dose eicosapentaenoic acid (EPA) improves attention and vigilance in children and adolescents with attention deficit hyperactivity disorder (ADHD) and low endogenous EPA levels. Translational Psychiatry2019;9(1):303. [DOI: 10.1038/s41398-019-0633-0] [PMCID: PMC6864068] [PMID: 31745072]NCT03542643. Omega-3 polyunsaturated fatty acids in youth with ADHD [A double-blind randomised controlled trial of N-3 PUFAs in children with attention deficit hyperactivity disorder]. clinicaltrials.gov/ct2/show/NCT03542643 (first received 20 May 2018). ">Chang 2019</a>. </p> <p>Internalising and externalising behaviour was also reported by <a href="./references#CD007986-bbs2-0036" title="VoigtRG , LlorenteAM , JensenCL , FraleyJK , BerrettaMC , HeirdWC . A randomized, double-blind, placebo-controlled trial of docosahexaenoic acid supplementation in children with attention-deficit/hyperactivity disorder. Journal of Pediatrics2001;139(2):189-96. [DOI: 10.1067/mpd.2001.116050] [PMID: 11487742]">Voigt 2001</a> and <a href="./references#CD007986-bbs2-0037" title="Widenhorn-MüllerK , SchwandaS , ScholzE , SpitzerM , BodeH . Effect of supplementation with long-chain ω-3 polyunsaturated fatty acids on behavior and cognition in children with attention deficit/hyperactivity disorder (ADHD): a randomized placebo-controlled intervention trial. Prostaglandins Leukotrienes and Essential Fatty Acids2014;91(1-2):49-60. [DOI: 10.1016/j.plefa.2014.04.004] [PMID: 24958525]">Widenhorn‐Müller 2014</a>, both of whom used the parent‐rated Child Behavior Checklist. </p> <p>Higher scores are related to more severe or more frequent behavioural problems for all of these measures. </p> </section> <section id="CD007986-sec-0059"> <h6 class="title">Follow‐up</h6> <p>Fourteen studies only reported short‐term outcomes (<a href="./references#CD007986-bbs2-0001" title="AmanMG , MitchellEA , TurbottSH . The effects of essential fatty acid supplementation by efamol in hyperactive children. Journal of Abnormal Child Psychology1987;15(1):75-90. [DOI: 10.1007/BF00916467]">Aman 1987</a>; <a href="./references#CD007986-bbs2-0003" title="ArnoldLE , KleykampD , VotolatoN , GibsonRA , HorrocksL . Potential link between dietary intake of fatty acids and behavior: pilot exploration of serum lipids in attention-deficit hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology1994;4(3):171-82. [DOI: 10.1089/cap.1994.4.171]ArnoldLE , KleykampD , VotolatoNA , TaylorWA , KontrasSB , TobinK . Gamma-linolenic acid for attention-deficit hyperactivity disorder: placebo-controlled comparison to D-amphetamine. Biological Psychiatry1989;25(2):222-8. [DOI: 10.1016/0006-3223(89)90167-4] [PMID: 2539203]ArnoldLE , PinkhamSM , VotolatoN . Does zinc moderate essential fatty acid and amphetamine treatment of attention-deficit/hyperactivity disorder?Journal of Child and Adolescent Psychopharmacology2000;10(2):111-7. [DOI: 10.1089/cap.2000.10.111] [PMID: 10933121]">Arnold 1989</a>; <a href="./references#CD007986-bbs2-0004" title="AssarehM , Davari AshtianiR , KhademiM , JazayeriS , RaiA , NikooM . Efficacy of polyunsaturated fatty acids (PUFA) in the treatment of attention deficit hyperactivity disorder: a randomized, double-blind, placebo-controlled clinical trial. Journal of Attention Disorders2017;21(1):78-85. [DOI: 10.1177/1087054712463962] [PMID: 23160488]IRCT138803122000N1. Poly unsaturated fatty acid as a combination treatment in children with attention deficit hyperactivity disorder [Omega-3 in the treatment of attention deficit hyperactivity disorder]. en.irct.ir/trial/1598?revision=1598 (first received 21 May 2011). ">Assareh 2017</a>; <a href="./references#CD007986-bbs2-0006" title="BehdaniF , HebraniP , NaseraeeA , HaghighiMB , AkhavanrezayatA . Does omega-3 supplement enhance the therapeutic results of methylphenidate in attention deficit hyperactivity disorder patients?Journal of Research in Medical Sciences2013;18(8):653-8. [PMCID: PMC3872603] [PMID: 24379840]">Behdani 2013</a>; <a href="./references#CD007986-bbs2-0007" title="BélangerSA , VanasseM , SpahisS , SylvestreMP , LippéS , L'HeureuxF , et al. Omega-3 fatty acid treatment of children with attention-deficit hyperactivity disorder: a randomized, double-blind, placebo-controlled study. Paediatrics and Child Health2009;14(2):89-98. [DOI: 10.1093/pch/14.2.89] [PMCID: PMC2661342] [PMID: 19436468]VanasseM , Ageranioti-BélangerS , L'HeureuxF , GhadirianP , LevyE , SpahisS , et al. A randomized, controlled trial of omega-3 and phospholipids supplementation in children with attention-deficit-hyperactivity disorder. Developmental Medicine &amp; Child Neurology2006;48(Suppl 107):48. [DOI: 10.1111/j.1469-8749.2006.tb12600.x]">Bélanger 2009</a>; <a href="./references#CD007986-bbs2-0013" title="DashtiN , HekmatH , SoltaniHR , RahimdelA , JavaherchianM . Comparison of therapeutic effects of omega-3 and methylphenidate (ritalin(®)) in treating children with attention deficit hyperactivity disorder. Iranian Journal of Psychiatry and Behavioral Sciences2014;8(4):7-11. [PMCID: PMC4364471] [PMID: 25798168]">Dashti 2014</a>; <a href="./references#CD007986-bbs2-0014" title="Dubnov-RazG , KhouryZ , WrightI , RazR , BergerI . The effect of alpha-linolenic acid supplementation on ADHD symptoms in children: a randomized controlled double-blind study. Frontiers in Human Neuroscience2014;8:780. [DOI: 10.3389/fnhum.2014.00780] [PMCID: PMC4188038] [PMID: 25339885]NCT00874536. Omega-3 supplementation and attention-deficit-hyperactivity disorder (ADHD) [The effect of omega-3 fatty acid supplementation on behavior of children with ADHD]. clinicaltrials.gov/show/nct00874536 (first received 1 April 2009). ">Dubnov‐Raz 2014</a>; <a href="./references#CD007986-bbs2-0017" title="HaririM , DjazayeryA , DjalaliM , SaedisomeoliaA , RahimiA , AbdolahianE . Effect of n-3 supplementation on hyperactivity, oxidative stress and inflammatory mediators in children with attention-deficit-hyperactivity disorder. Malaysian Journal of Nutrition2012;18(3):329-52. [PMID: 24568073]">Hariri 2012</a>; <a href="./references#CD007986-bbs2-0018" title="HamazakiT , HirayamaS . The effect of docosahexaenoic acid-containing food administration on symptoms of attention-deficit/hyperactivity disorder - a placebo-controlled double-blind study. European Journal of Clinical Nutrition2004;58(5):838. [DOI: 10.1038/sj.ejcn.1601888] [PMID: 15116088]HirayamaS , HamazakiT , TerasawaK . Effect of docosahexaenoic acid-containing food administration on symptoms of attention-deficit/hyperactivity disorder - a placebo-controlled double-blind study. European Journal of Clinical Nutrition2004;58(3):467-73. [DOI: 10.1038/sj.ejcn.1601830] [PMID: 14985685]">Hirayama 2004</a>; <a href="./references#CD007986-bbs2-0019" title="IvityE . Supplementation with Docosahexaenoic Acid Ameliorates Paediatric AD/HD [PhD thesis]. Edmonton (AB): University of Alberta, 2015. ">Ivity 2015</a>; <a href="./references#CD007986-bbs2-0026" title="IRCT2015092724209N2. Investigating the effectiveness of methylphenidate and multi chain polyunsaturated fatty acids in treatment of patients with attention deficit hyperactivity disorder (ADHD) in Zahedan City [Investigating the effectiveness of methylphenidate and multi chain polyunsaturated fatty acids in treatment of symptoms of attention deficit hyperactivity disorder (ADHD) among 6 to 12 children suffered from ADHD]. trialsearch.who.int/Trial2.aspx?TrialID=IRCT2015092724209N2 (first received 28 April 2016). MoghaddamMF , ShamekhiM , RakhshaniT . Effectiveness of methylphenidate and PUFA for the treatment of patients with ADHD: a double-blinded randomized clinical trial. Electronic Physician2017;9(5):4412-8. [DOI: 10.19082/4412] [PMCID: PMC5498708] [PMID: 28713515]">Moghaddam 2017</a>; <a href="./references#CD007986-bbs2-0027" title="IRCT2016060128182N2. Omega-3 supplement in attention deficit hyperactivity disorder [The effectiveness of omega-3 supplement as an adjunctive therapy in children with attention deficit hyperactivity disorder]. www.irct.ir/trial/22914 (first received 23 January 2017). MohammadzadehS , BaghiN , YousefiF , YousefzamaniB . Effect of omega-3 plus methylphenidate as an alternative therapy to reduce attention deficit-hyperactivity disorder in children. Korean Journal of Pediatrics2019;62(9):360-6. [DOI: 10.3345/kjp.2018.06982] [PMCID: PMC6753311] [PMID: 31122010]">Mohammadzadeh 2019</a>; <a href="./references#CD007986-bbs2-0030" title="RazR , CarassoRL , YehudaS . The influence of short-chain essential fatty acids on children with attention-deficit/hyperactivity disorder: a double-blind placebo-controlled study. Journal of Child and Adolescent Psychopharmacology2009;19(2):167-77. [DOI: 10.1089/cap.2008.070] [PMID: 19364294]">Raz 2009a</a>; <a href="./references#CD007986-bbs2-0032" title="SalehiB , MohammadbeigiA , SheykholeslamH , MoshiriE , DorrehF . Omega-3 and zinc supplementation as complementary therapies in children with attention-deficit/hyperactivity disorder. Journal of Research in Pharmacy Practice2016;5(1):22-6. [DOI: 10.4103/2279-042X.176561] [PMCID: PMC4776543] [PMID: 26985432]">Salehi 2016</a>), with only one study reporting long‐term outcomes (<a href="./references#CD007986-bbs2-0005" title="BarragánE , BreuerD , DöpfnerM . Efficacy and safety of omega-3/6 fatty acids, methylphenidate, and a combined treatment in children with ADHD. Journal of Attention Disorders2017;21(5):433-41. [DOI: 10.1177/1087054713518239] [PMID: 24464327]">Barragán 2017</a>). The remaining 22 studies reported medium‐term outcomes. </p> </section> <section id="CD007986-sec-0060"> <h6 class="title">Data not used in meta‐analyses</h6> <p>Data from several studies could not be used in meta‐analyses. Outcome data were not reported in <a href="./references#CD007986-bbs2-0003" title="ArnoldLE , KleykampD , VotolatoN , GibsonRA , HorrocksL . Potential link between dietary intake of fatty acids and behavior: pilot exploration of serum lipids in attention-deficit hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology1994;4(3):171-82. [DOI: 10.1089/cap.1994.4.171]ArnoldLE , KleykampD , VotolatoNA , TaylorWA , KontrasSB , TobinK . Gamma-linolenic acid for attention-deficit hyperactivity disorder: placebo-controlled comparison to D-amphetamine. Biological Psychiatry1989;25(2):222-8. [DOI: 10.1016/0006-3223(89)90167-4] [PMID: 2539203]ArnoldLE , PinkhamSM , VotolatoN . Does zinc moderate essential fatty acid and amphetamine treatment of attention-deficit/hyperactivity disorder?Journal of Child and Adolescent Psychopharmacology2000;10(2):111-7. [DOI: 10.1089/cap.2000.10.111] [PMID: 10933121]">Arnold 1989</a>, <a href="./references#CD007986-bbs2-0015" title="GowR . An Investigation Into Long-Chain Polyunsaturated Essential Fatty Acids, Event Related Potential Assessments of Brain Function and Behavioural Measures in Children and Adolescents With and Without Attention Deficit Hyperactivity Disorder [PhD thesis]. London, UK: King's College London, University of London, 2012. ">Gow 2012</a>, and <a href="./references#CD007986-bbs2-0022" title="Lim-AshworthN , OoiYP , WengSJ , LimCG , FungDSS , GlennA , et al. Preliminary findings on the effects of nutritional and social skills intervention among children with attention deficit hyperactivity disorder. Annals: the official journal of the Academy of Medicine, Singapore2013;42(Suppl 9):S162. [OP-CR-65] [WEB PAGE: www.annals.edu.sg/pdf/42VolNo9Sep2013/SHBC_2013_041013.pdf]">Lim‐Ashworth 2013</a>, and only the median number of ADHD symptoms were reported in <a href="./references#CD007986-bbs2-0018" title="HamazakiT , HirayamaS . The effect of docosahexaenoic acid-containing food administration on symptoms of attention-deficit/hyperactivity disorder - a placebo-controlled double-blind study. European Journal of Clinical Nutrition2004;58(5):838. [DOI: 10.1038/sj.ejcn.1601888] [PMID: 15116088]HirayamaS , HamazakiT , TerasawaK . Effect of docosahexaenoic acid-containing food administration on symptoms of attention-deficit/hyperactivity disorder - a placebo-controlled double-blind study. European Journal of Clinical Nutrition2004;58(3):467-73. [DOI: 10.1038/sj.ejcn.1601830] [PMID: 14985685]">Hirayama 2004</a>. We could not include data for any outcome for <a href="./references#CD007986-bbs2-0009" title="BrueAW , OaklandTD , EvansRA . The use of a dietary supplement combination and an essential fatty acid as an alternative and complementary treatment for children with attention-deficit/hyperactivity disorder. Scientific Review of Alternative Medicine2001;5(4):187-94. [WEB PAGE: tinyurl.com/y56pdtxq]BrueAW . The Use of a Dietary Supplement Combination and an Essential Fatty Acid as an Alternative and Complementary Treatment for Children with Attention Deficit Hyperactivity Disorder (ADHD) [PhD thesis]. Gainesville (FL): University of Florida, 1999. ">Brue 2001</a> and <a href="./references#CD007986-bbs2-0007" title="BélangerSA , VanasseM , SpahisS , SylvestreMP , LippéS , L'HeureuxF , et al. Omega-3 fatty acid treatment of children with attention-deficit hyperactivity disorder: a randomized, double-blind, placebo-controlled study. Paediatrics and Child Health2009;14(2):89-98. [DOI: 10.1093/pch/14.2.89] [PMCID: PMC2661342] [PMID: 19436468]VanasseM , Ageranioti-BélangerS , L'HeureuxF , GhadirianP , LevyE , SpahisS , et al. A randomized, controlled trial of omega-3 and phospholipids supplementation in children with attention-deficit-hyperactivity disorder. Developmental Medicine &amp; Child Neurology2006;48(Suppl 107):48. [DOI: 10.1111/j.1469-8749.2006.tb12600.x]">Bélanger 2009</a> in meta‐analysis because variances were not reported. Data from <a href="./references#CD007986-bbs2-0025" title="ACTRN12607000332426. Omega-3 fatty acids for ADHD symptoms and learning difficulties in children [Randomised controlled trial investigating effect of supplementation with omega-3 fatty acids EPA and DHA versus omega-6 fatty acid LA on ADHD symptoms and learning difficulties in 7-12 year old children]. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=82104 (first received 19 June 2007). MilteCM , ParlettaN , BuckleyJD , CoatesAM , YoungRM , HowePR . Eicosapentaenoic and docosahexaenoic acids, cognition, and behavior in children with attention-deficit/hyperactivity disorder: a randomized controlled trial. Nutrition2012;28(6):670-7. [DOI: 10.1016/j.nut.2011.12.009] [PMID: 22541055]">Milte 2012</a> were only reported as correlations and effect difference. We have therefore reported data for ADHD symptoms in <a href="./references#CD007986-bbs2-0009" title="BrueAW , OaklandTD , EvansRA . The use of a dietary supplement combination and an essential fatty acid as an alternative and complementary treatment for children with attention-deficit/hyperactivity disorder. Scientific Review of Alternative Medicine2001;5(4):187-94. [WEB PAGE: tinyurl.com/y56pdtxq]BrueAW . The Use of a Dietary Supplement Combination and an Essential Fatty Acid as an Alternative and Complementary Treatment for Children with Attention Deficit Hyperactivity Disorder (ADHD) [PhD thesis]. Gainesville (FL): University of Florida, 1999. ">Brue 2001</a>, <a href="./references#CD007986-bbs2-0007" title="BélangerSA , VanasseM , SpahisS , SylvestreMP , LippéS , L'HeureuxF , et al. Omega-3 fatty acid treatment of children with attention-deficit hyperactivity disorder: a randomized, double-blind, placebo-controlled study. Paediatrics and Child Health2009;14(2):89-98. [DOI: 10.1093/pch/14.2.89] [PMCID: PMC2661342] [PMID: 19436468]VanasseM , Ageranioti-BélangerS , L'HeureuxF , GhadirianP , LevyE , SpahisS , et al. A randomized, controlled trial of omega-3 and phospholipids supplementation in children with attention-deficit-hyperactivity disorder. Developmental Medicine &amp; Child Neurology2006;48(Suppl 107):48. [DOI: 10.1111/j.1469-8749.2006.tb12600.x]">Bélanger 2009</a>, and <a href="./references#CD007986-bbs2-0025" title="ACTRN12607000332426. Omega-3 fatty acids for ADHD symptoms and learning difficulties in children [Randomised controlled trial investigating effect of supplementation with omega-3 fatty acids EPA and DHA versus omega-6 fatty acid LA on ADHD symptoms and learning difficulties in 7-12 year old children]. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=82104 (first received 19 June 2007). MilteCM , ParlettaN , BuckleyJD , CoatesAM , YoungRM , HowePR . Eicosapentaenoic and docosahexaenoic acids, cognition, and behavior in children with attention-deficit/hyperactivity disorder: a randomized controlled trial. Nutrition2012;28(6):670-7. [DOI: 10.1016/j.nut.2011.12.009] [PMID: 22541055]">Milte 2012</a> separately in <a href="#CD007986-tbl-0002">Table 1</a>. In addition, not all outcomes in <a href="./references#CD007986-bbs2-0033" title="SinnN , BryanJ , WilsonC . Cognitive effects of polyunsaturated fatty acids in children with attention deficit hyperactivity disorder symptoms: a randomised controlled trial. Prostaglandins Leukotrienes and Essential Fatty Acids2008;78(4-5):311-26. [DOI: 10.1016/j.plefa.2008.04.004] [PMID: 18514501]SinnN , BryanJ . Effect of supplementation with polyunsaturated fatty acids and micronutrients on learning and behavior problems associated with child ADHD. Journal of Developmental and Behavioral Pediatrics2007;28(2):82-91. [DOI: 10.1097/01.DBP.0000267558.88457.a5] [PMID: 17435458]">Sinn 2007</a> could be included in meta‐analyses as data for anxiety, oppositional behaviour, and social problems were skewed. </p> <div class="table" id="CD007986-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Other data</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Comparison</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>ADHD symptoms ‐ total</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>ADHD ‐ inattention</b><sup>a</sup> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>ADHD ‐ hyperactivity</b><sup>a</sup> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007986-bbs2-0007" title="BélangerSA , VanasseM , SpahisS , SylvestreMP , LippéS , L'HeureuxF , et al. Omega-3 fatty acid treatment of children with attention-deficit hyperactivity disorder: a randomized, double-blind, placebo-controlled study. Paediatrics and Child Health2009;14(2):89-98. [DOI: 10.1093/pch/14.2.89] [PMCID: PMC2661342] [PMID: 19436468]VanasseM , Ageranioti-BélangerS , L'HeureuxF , GhadirianP , LevyE , SpahisS , et al. A randomized, controlled trial of omega-3 and phospholipids supplementation in children with attention-deficit-hyperactivity disorder. Developmental Medicine &amp; Child Neurology2006;48(Suppl 107):48. [DOI: 10.1111/j.1469-8749.2006.tb12600.x]">Bélanger 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cross‐over trial of omega‐3 PUFA vs omega‐6 PUFA ‐ first phase</p> <p> </p> <p><i>SD not reported and could not be calculated.</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Conners Parent ‐ mean change</b> </p> <p>omega‐3: −8.8</p> <p>omega‐6: −5.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Conners Parent ‐ mean change</b> </p> <p>omega‐3: −9.1</p> <p>omega‐6: −7.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Conners Parent ‐ mean change</b> </p> <p>omega‐3: −7.2</p> <p>omega‐6: −3.1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><a href="./references#CD007986-bbs2-0009" title="BrueAW , OaklandTD , EvansRA . The use of a dietary supplement combination and an essential fatty acid as an alternative and complementary treatment for children with attention-deficit/hyperactivity disorder. Scientific Review of Alternative Medicine2001;5(4):187-94. [WEB PAGE: tinyurl.com/y56pdtxq]BrueAW . The Use of a Dietary Supplement Combination and an Essential Fatty Acid as an Alternative and Complementary Treatment for Children with Attention Deficit Hyperactivity Disorder (ADHD) [PhD thesis]. Gainesville (FL): University of Florida, 1999. ">Brue 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Parallel trial of omega‐3 PUFA vs dietary supplement</p> <p> </p> <p><i>SD not reported and could not be calculated.</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Conners Parent – non‐MPH (Ritalin)</b> </p> <p>omega‐3: 12.0</p> <p>supplement: 13.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Conners Parent – non‐MPH (Ritalin)</b> </p> <p>omega‐3: 9.4</p> <p>supplement: 13.1</p> <p>P = 0.03</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Conners Teacher – non‐MPH (Ritalin)</b> </p> <p>omega‐3: 19.1</p> <p>supplement: 15.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Conners Teacher – non‐MPH (Ritalin)</b> </p> <p>omega‐3: 17.9</p> <p>supplement: 13.4</p> <p>P = 0.04</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Conners Parent – MPH (Ritalin)</b> </p> <p>omega‐3: 15.6</p> <p>supplement: 14.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Conners Parent – MPH (Ritalin)</b> </p> <p>omega‐3: 13.7</p> <p>supplement: 13.5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Conners Teacher – MPH (Ritalin)</b> </p> <p>omega‐3: 16.3</p> <p>supplement: 12.2</p> <p>P = 0.04 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Conners Teacher – MPH (Ritalin)</b> </p> <p>omega‐3: 10.8</p> <p>supplement: 12.3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007986-bbs2-0025" title="ACTRN12607000332426. Omega-3 fatty acids for ADHD symptoms and learning difficulties in children [Randomised controlled trial investigating effect of supplementation with omega-3 fatty acids EPA and DHA versus omega-6 fatty acid LA on ADHD symptoms and learning difficulties in 7-12 year old children]. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=82104 (first received 19 June 2007). MilteCM , ParlettaN , BuckleyJD , CoatesAM , YoungRM , HowePR . Eicosapentaenoic and docosahexaenoic acids, cognition, and behavior in children with attention-deficit/hyperactivity disorder: a randomized controlled trial. Nutrition2012;28(6):670-7. [DOI: 10.1016/j.nut.2011.12.009] [PMID: 22541055]">Milte 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Parallel trial of EPA‐rich fish oil vs DHA‐rich fish oil vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Correlation of PUFA Conners Parent hyperactivity score vs placebo over 4 months (95% CI)</b> </p> <p>EPA: 0.98 (−1.27 to 3.23)</p> <p>DHA: 1.12 (−1.30 to 3.53)</p> <p> </p> <p><b>Correlation of PUFA Conners Parent ADHD index vs placebo over 4 months (95% CI)</b> </p> <p>EPA: 1.56 (−1.96 to 5.09)</p> <p>DHA: 1.64 (−2.15 to 5.43)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>ADHD:</b> attention deficit hyperactivity disorder; <b>CI:</b> confidence intervals; <b>EPA:</b> eicosapentanoic acid; <b>DHA:</b> docosahexanoic acid; <b>MPH:</b> methylphenidate; <b>PUFA:</b> polyunsaturated fatty acids; <b>SD:</b> standard deviation </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>a</sup>Where there were statistical differences between groups, P values are shown. </p> </div> </div> </section> </section> </section> <section id="CD007986-sec-0061"> <h4 class="title">Excluded studies</h4> <p>We excluded a total of 14 studies, five in the previous review and a further nine in this update. We excluded two studies because they were found to be literature reviews upon full‐text assessment (<a href="./references#CD007986-bbs2-0038" title="Omega-3/omega-6 fatty acids and ADHD. Brown University Child &amp; Adolescent Psychopharmacology Update2009;11(4):4-5. ">Anonymous 2009</a>; <a href="./references#CD007986-bbs2-0039" title="DoebelJK , KellerG , Zierau M-T. Dietary therapy for children with ADHD. Deutsche Apotheker Zeitung2005;145(24):54-7. ">Doebel 2005</a>); four studies that were not randomly allocated trials (<a href="./references#CD007986-bbs2-0042" title="HardingKL , JudahRD , GantC . Outcome-based comparison of ritalin versus food-supplement treated children with AD/HD. Alternative Medicine Review2003;8(3):319-30. [PMID: 12946241]">Harding 2003</a>; <a href="./references#CD007986-bbs2-0044" title="JoshiK , LadS , KaleM , PatwardhanB , MahadikSP , PatniB , et al. Supplementation with flax oil and vitamin C improves the outcome of attention deficit hyperactivity disorder (ADHD). Prostaglandins, Leukotrienes, and Essential Fatty Acids2006;74(1):17-21. [DOI: 10.1016/j.plefa.2005.10.001] [PMID: 16314082]">Joshi 2006</a>; <a href="./references#CD007986-bbs2-0045" title="EffatS , MohamedN , HusseinH , AzzamH , GoudaA , HassanH . ADHD symptoms: relation to omega 3 serum levels before and after supplementation. European Psychiatry2013;28(Suppl 1):1. [ABSTRACT NUMBER: 670] [DOI: 10.1016/S0924-9338(13)75914-5]MeguidN , EffatS , HussienH , AzzamH , GoudaAS , AnwarM , et al. Role of plasma fatty acids in Egyptian children with attention deficit hyperactivity disorder. International Journal of Pharmaceutical and Clinical Research2016;8(7):671-5. [WEB PAGE: impactfactor.org/PDF/IJPCR/8/IJPCR,Vol8,Issue7,Article6.pdf]">Meguid 2016</a>; <a href="./references#CD007986-bbs2-0049" title="NCT02999503. Attention deficit hyperactivity disorder: nutrition and environment [Nutritional and environmental conditions in attention deficit hyperactivity disorder]. clinicaltrials.gov/ct2/show/study/NCT02999503 (first received 1 December 2016). San Mauro MartinI , Sanz RojoS , González CosanoL , Conty de la CampaR , Garicano VilarE , Blumenfeld OlivaresJA . Impulsiveness in children with attention-deficit/hyperactivity disorder after an 8-week intervention with the Mediterranean diet and/or omega-3 fatty acids: a randomised clinical trial. Neurologia 2019 Dec 26 [Epub ahead of print]. [DOI: 10.1016/j.nrl.2019.09.007] [PMID: 31883771]">San Mauro Martin 2019</a>); and one study that was an open‐label trial (<a href="./references#CD007986-bbs2-0051" title="WilensTE , CarrellasNW , ZulaufC , YuleAM , UchidaM , SpencerA , et al. Pilot data supporting omega-3 fatty acids supplementation in medicated children with attention-deficit/hyperactivity disorder and deficits in emotional self-regulation. Journal of Child and Adolescent Psychopharmacology2017;27(8):755-6. [DOI: 10.1089/cap.2017.0080] [PMID: 28661708]">Wilens 2017</a>). We excluded three studies because participants did not have ADHD (<a href="./references#CD007986-bbs2-0040" title="DöpfnerM , DoseC , BreuerD , HeintzS , SchiffhauerS , BanaschewskiT . Efficacy of omega-3/omega-6 fatty acids in preschool children at risk of ADHD: a randomized placebo-controlled trial. Journal of Attention Disorders2021;25(8):1096-106. [DOI: 10.1177/1087054719883023] [PMID: 31680604]NCT01795040. Efficacy of omega-3/omega-6 fatty acids in pre-school children at risk for ADHD [Efficacy of a supplementary balanced diet with omega-3/omega-6 fatty acids among 3-6 year olds with symptoms of ADHD]. clinicaltrials.gov/ct2/show/NCT01795040 (first received 16 February 2013). ">Döpfner 2021</a>; <a href="./references#CD007986-bbs2-0041" title="GreeffJ . Effects of Iron and Omega–3 Fatty Acid Supplementation on Physical Activity of Iron Deficient Primary School Children Residing in KwaZulu–Natal (Master's thesis). Potchefstroom, South Africa: North-West University, 2011. [WEB PAGE: www.semanticscholar.org/paper/Effects-of-iron-and-omega%E2%80%933-fatty-acid-on-physical-Greeff/cec39452794706de5f20ee32a92903553bca1765]">Greeff 2011</a>; <a href="./references#CD007986-bbs2-0043" title="JohnsonM , FranssonG , ÖstlundS , AreskougB , GillbergC . Omega 3/6 fatty acids for reading in children: a randomized, double-blind, placebo-controlled trial in 9-year-old mainstream schoolchildren in Sweden. Journal of Child Psychology and Psychiatry2017;58(1):83-93. [DOI: 10.1111/jcpp.12614] [PMID: 27545509]">Johnson 2017</a>). Despite attempts to contact the authors of <a href="./references#CD007986-bbs2-0048" title="RichardsonAJ , PuriBK . A randomized double-blind, placebo-controlled study of the effects of supplementation with highly unsaturated fatty acids on ADHD-related symptoms in children with specific learning difficulties. Progress in Neuro-Psychopharmacology &amp; Biological Psychiatry2002;26(2):233-9. [DOI: 10.1016/s0278-5846(01)00254-8] [PMID: 11817499]">Richardson 2002</a>, we could not obtain further details on their inclusion criteria. <a href="./references#CD007986-bbs2-0050" title="TanX , LeeXY , LimCG , FungDSS . Effectiveness of omega-3 fatty acids supplementation on sleep in children and adolescents with attention deficit hyperactivity disorder. Annals: the official journal of the Academy of Medicine, Singapore2014;43(Suppl 9):S340. [ABSTRACT #: PP-CR-44] [WEB PAGE: www.annals.edu.sg/pdf/43VolNo9Sep2014/SHBC2014_Final.pdf]">Tan 2014</a> only reported data for a subgroup of participants with ADHD from a larger randomised controlled trial in children with disruptive behaviour disorders. Two trials were terminated before completion (<a href="./references#CD007986-bbs2-0046" title="NCT01777048. Omega-3 fatty acids supplementation in ADHD [Augmenting the effects of methylphenidate: a randomized, placebo-controlled trial of omega-3 fatty acids supplementation in children with attention deficit hyperactivity disorder]. clinicaltrials.gov/ct2/show/NCT01777048 (first received 16 January 2013). ">NCT01777048</a>; <a href="./references#CD007986-bbs2-0047" title="NCT01778647. Omega-3 fatty acids as an adjunctive therapy for stimulants in children with ADHD. clinicaltrials.gov/ct2/show/NCT01778647 (first received 30 September 2010). ">NCT01778647</a>). </p> </section> <section id="CD007986-sec-0062"> <h4 class="title">Studies awaiting classification</h4> <p>Ten studies (from 13 reports) are awaiting classification, as the results of these studies are not yet available, although the studies appear to have been completed. All are parallel, randomised trials, and one is a multicentre trial (<a href="./references#CD007986-bbs2-0052" title="CarucciS , RomanielloR , BaliaC , DemuruG , CuratoloP , MereuA , et al. Efficacy study of an omega-3/6 combination for mild- to moderate-inattentive ADHD: a randomized, double-blind, placebo-controlled trial in Italian children. Journal of the American Academy of Child &amp; Adolescent Psychiatry2019;58(Suppl 10):S285-6. [ABSTRACT NUMBER: 6.45] [DOI: 10.1016/j.jaac.2019.08.437]CarucciS , RomanielloR , MasiG , CuratoloP , GaglianoA , ZuddasA . A randomized, double blind, placebo-controlled, efficacy study of omega 3/6 in children with mild to moderate inattentive ADHD-preliminary results. European Neuropsychopharmacology2017;27(Suppl 4):S1109-10. [ABSTRACT NUMBER: P.7.d.007] [DOI: 10.1016/S0924-977X(17)31924-7]RomanielloR , CarucciS , SannaE , BaliaC , ZuddasA . Efficacy of an omega-3/6 combination on specific learning abilities in children with mild to moderate inattentive ADHD - preliminary results. European Neuropsychopharmacology2018;28(Suppl 1):79-80. [ABSTRACT NUMBER: P.3.023] [DOI: 10.1016/j.euroneuro.2017.12.113]SannaE , RomanielloR , BaliaC , CarucciS , ZuddasA . Plasma poly-unsatured fatty acids profile in children with inattentive ADHD - preliminary results of an efficacy Italian study with omega 3/6. European Neuropsychopharmacology2019;29(Suppl 1):S548‐9. [ABSTRACT NUMBER: P.798] [DOI: 10.1016/j.euroneuro.2018.11.809]">Carucci 2017</a>). Four studies compare omega‐3 to placebo (<a href="./references#CD007986-bbs2-0056" title="NCT00770627. Clinical trial to evaluate the efficacy and the tolerance of an omega 3 fatty acids supplementation in ADHD children [A randomized, controlled, double blind placebo trial to evaluate the efficacy and the tolerance of an omega 3 fatty acids supplementation in ADHD children]. clinicaltrials.gov/ct2/show/NCT00770627 (first received 9 October 2008). ">NCT00770627</a>; <a href="./references#CD007986-bbs2-0059" title="NCT02348073. Efficacy of phosphatidylserine enriched with n-3 PUFA supplementation on ADHD in children with epilepsy (AGPIn3) [Efficacy of phosphatidylserine enriched with polyunsaturated n-3 fatty acid supplementation on attention deficit disorders in children with epilepsy. A randomized double-blind placebo-controlled trial]. clinicaltrials.gov/ct2/show/NCT02348073 (first received 22 January 2015). ">NCT02348073</a>; <a href="./references#CD007986-bbs2-0060" title="NCT02986672. Intervention with omega-3 in children with attention deficit hyperactivity disorder (ADHD) [ADHD and nutrition: the influence of omega-3 on ADHD related symptoms]. clinicaltrials.gov/ct2/show/NCT02986672 (first received 8 January 2016). ">NCT02986672</a>; <a href="./references#CD007986-bbs2-0061" title="NCT03542643. Omega-3 polyunsaturated fatty acids in youth with ADHD [A double-blind randomised controlled trial of N-3 PUFAs in children with attention deficit hyperactivity disorder]. clinicaltrials.gov/ct2/show/NCT03542643 (first received 20 May 2018). ">NCT03542643</a>); three compare omega‐3/omega‐6 PUFA to placebo (<a href="./references#CD007986-bbs2-0052" title="CarucciS , RomanielloR , BaliaC , DemuruG , CuratoloP , MereuA , et al. Efficacy study of an omega-3/6 combination for mild- to moderate-inattentive ADHD: a randomized, double-blind, placebo-controlled trial in Italian children. Journal of the American Academy of Child &amp; Adolescent Psychiatry2019;58(Suppl 10):S285-6. [ABSTRACT NUMBER: 6.45] [DOI: 10.1016/j.jaac.2019.08.437]CarucciS , RomanielloR , MasiG , CuratoloP , GaglianoA , ZuddasA . A randomized, double blind, placebo-controlled, efficacy study of omega 3/6 in children with mild to moderate inattentive ADHD-preliminary results. European Neuropsychopharmacology2017;27(Suppl 4):S1109-10. [ABSTRACT NUMBER: P.7.d.007] [DOI: 10.1016/S0924-977X(17)31924-7]RomanielloR , CarucciS , SannaE , BaliaC , ZuddasA . Efficacy of an omega-3/6 combination on specific learning abilities in children with mild to moderate inattentive ADHD - preliminary results. European Neuropsychopharmacology2018;28(Suppl 1):79-80. [ABSTRACT NUMBER: P.3.023] [DOI: 10.1016/j.euroneuro.2017.12.113]SannaE , RomanielloR , BaliaC , CarucciS , ZuddasA . Plasma poly-unsatured fatty acids profile in children with inattentive ADHD - preliminary results of an efficacy Italian study with omega 3/6. European Neuropsychopharmacology2019;29(Suppl 1):S548‐9. [ABSTRACT NUMBER: P.798] [DOI: 10.1016/j.euroneuro.2018.11.809]">Carucci 2017</a>; <a href="./references#CD007986-bbs2-0057" title="NCT02114632. Supplementation of polyunsaturated fatty acids in children with attention deficit/hyperactivity disorder (ADHD) [A double blind, placebo controlled trial of effectiveness of omega-3 and omega-6 polyunsaturated fatty acids in treatment of children with attention deficit/hyperactivity disorder]. clinicaltrials.gov/ct2/show/results/NCT02114632 (first received 23 March 2014). ">NCT02114632</a>; <a href="./references#CD007986-bbs2-0058" title="NCT02248948. Superiority of omega-3 versus placebo on the improvement of ADHD in children (ECOMEGA) [Multicenter randomized controlled trial for the evaluation of superiority of a supplement with omega-3 fatty acids versus placebo for the improvement of attention deficit and hyperactivity disorder (ADHD) in children]. clinicaltrials.gov/ct2/show/NCT02248948 (first received 22 September 2014). ">NCT02248948</a>); and three compare omega‐3 plus stimulant to stimulant alone (<a href="./references#CD007986-bbs2-0053" title="IRCT201104166201N1. Effect of zinc and omega-3 supplements as adjuvant therapy in children with attention-deficit hyperactivity disorder [Effect of zinc and omega-3 supplements in children with attention-deficit hyperactivity disorder]. en.irct.ir/trial/6635 (first received 13 May 2011). ">IRCT201104166201N1</a>; <a href="./references#CD007986-bbs2-0054" title="IRCT201304035393N3. Omega-3 effects on patient with attention deficit hyperactivity disorder [Comparison of therapeutic effects of omega-3 and methylphenidate (ritalin) in treating patients with attention deficit hyperactivity disorder]. en.irct.ir/trial/5801?revision=5801 (first received 3 July 2013). ">IRCT201304035393N3</a>; <a href="./references#CD007986-bbs2-0055" title="IRCT2016050918927N2. Effect of omega-3 on treatment of hyperactive children [Effect of omega-3 supplements as complementary treatment with methylphenidate in children with attention-deficit/hyperactivity disorder]. en.irct.ir/trial/17040 (first received 6 July 2016). ">IRCT2016050918927N2</a>). All of these studies have listed ADHD symptoms as an outcome. </p> <section id="CD007986-sec-0063"> <h5 class="title">Ongoing studies</h5> <p>One ongoing cluster‐randomised trial, <a href="./references#CD007986-bbs2-0062" title="CTRI/2020/05/025267. Effect of omega-3 fatty acids in addition to methylphenidate in ADHD. trialsearch.who.int/?TrialID=CTRI/2020/05/025267 (first received 20 May 2020). ">CTRI/2020/05/025267</a>, is comparing omega‐3 PUFA plus methylphenidate therapy to methylphenidate alone in children aged 6 to 12 years who have ADHD and who have not previously received methylphenidate. </p> </section> </section> </section> <section id="CD007986-sec-0064"> <h3 class="title">Risk of bias in included studies</h3> <p>The risk of bias assessment based on the six risk of bias domains is provided below. See <a href="#CD007986-fig-0002">Figure 2</a> for the overall risk of bias, and <a href="#CD007986-fig-0003">Figure 3</a> for risk of bias ratings for each of the included studies. </p> <div class="figure" id="CD007986-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD007986-fig-0002" src="/cdsr/doi/10.1002/14651858.CD007986.pub3/media/CDSR/CD007986/image_n/nCD007986-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD007986-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD007986-fig-0003" src="/cdsr/doi/10.1002/14651858.CD007986.pub3/media/CDSR/CD007986/image_n/nCD007986-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD007986-sec-0065"> <h4 class="title">Allocation</h4> <section id="CD007986-sec-0066"> <h5 class="title">Random sequence generation</h5> <p>We assessed 19 trials as at low risk of bias for random sequence generation (<a href="./references#CD007986-bbs2-0002" title="AnandP , SachdevaA . Effect of poly unsaturated fatty acids administration on children with attention deficit hyperactivity disorder: a randomized controlled trial. Journal of Clinical &amp; Diagnostic Research2016;10(9):OC01-5. [DOI: 10.7860/JCDR/2016/20423.8471] [PMCID: PMC5071983] [PMID: 27790483]">Anand 2016</a>; <a href="./references#CD007986-bbs2-0005" title="BarragánE , BreuerD , DöpfnerM . Efficacy and safety of omega-3/6 fatty acids, methylphenidate, and a combined treatment in children with ADHD. Journal of Attention Disorders2017;21(5):433-41. [DOI: 10.1177/1087054713518239] [PMID: 24464327]">Barragán 2017</a>; <a href="./references#CD007986-bbs2-0006" title="BehdaniF , HebraniP , NaseraeeA , HaghighiMB , AkhavanrezayatA . Does omega-3 supplement enhance the therapeutic results of methylphenidate in attention deficit hyperactivity disorder patients?Journal of Research in Medical Sciences2013;18(8):653-8. [PMCID: PMC3872603] [PMID: 24379840]">Behdani 2013</a>; <a href="./references#CD007986-bbs2-0008" title="BosD , Van BelleJ , WeustenJ , HoeksmaM , WisemanS , DurstonS . Effects of N-3 fatty acids (DHA and EPA) on cognitive control and associated brain activity in ADHD: a double-blind placebo controlled study. European Child &amp; Adolescent Psychiatry2010;19(Suppl 1):S69. [DOI: 10.1007/s00787-010-0117-5]BosD , Van BelleJ , WeustenJ , HoeksmaM , WisemanS , DurstonS . Effects of N-3 fatty acids (DHA and EPA) on cognitive control and associated brain activity in ADHD: a double-blind placebo controlled study. In: European Child and Adolescent Psychiatry, Conference: Eunethydis 1st International ADHD Conference: From Data to Best Clinical Practice; 2010 May 26–28; Amsterdam. 2010. BosDJ , OranjeB , VeerhoekES , Van DiepenRM , Weusten JMh, DemmelmairH , et al. Reduced symptoms of inattention after dietary omega-3 fatty acid supplementation in boys with and without attention deficit/hyperactivity disorder. Neuropsychopharmacology2015;40(10):2298–306. [DOI: 10.1038/npp.2015.73] [PMCID: PMC4538345] [PMID: 25790022]">Bos 2015</a>; <a href="./references#CD007986-bbs2-0011" title="CornuC , MercierC , GinhouxT , MassonS , MouchetJ , NonyP , et al. A double-blind placebo-controlled randomised trial of omega-3 supplementation in children with moderate ADHD symptoms. European Child &amp; Adolescent Psychiatry2018;27(3):377‐84. [DOI: 10.1007/s00787-017-1058-z] [PMID: 28993963]NCT00770627. Clinical trial to evaluate the efficacy and the tolerance of an omega 3 fatty acids supplementation in ADHD children [A randomized, controlled, double blind placebo trial to evaluate the efficacy and the tolerance of an omega 3 fatty acids supplementation in ADHD children]. clinicaltrials.gov/ct2/show/record/NCT00770627 (first received 9 October 2008). ">Cornu 2018</a>; <a href="./references#CD007986-bbs2-0012" title="CrippaA , AgostoniC , MauriM , MolteniM , NobileM . Polyunsaturated fatty acids are associated with behavior but not with cognition in children with and without ADHD: an Italian study. Journal of Attention Disorders2018;22(10):971-83. [DOI: 10.1177/1087054716629215]CrippaA , TeseiA , SangiorgioF , SalandiA , TrabattoniS , GrazioliS , et al. Behavioral and cognitive effects of docosahexaenoic acid in drug-naïve children with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled clinical trial. European Child &amp; Adolescent Psychiatry2019;28(4):571-83. [DOI: 10.1007/s00787-018-1223-z] [PMID: 30246216]NCT01796262. The effects of DHA on attention deficit and hyperactivity disorder (DADA) [The effects of DHA (docosahexaenoic acid) on attention deficit and hyperactivity disorder]. clinicaltrials.gov/show/nct01796262 (first received 12 February 2013). ">Crippa 2019</a>; <a href="./references#CD007986-bbs2-0014" title="Dubnov-RazG , KhouryZ , WrightI , RazR , BergerI . The effect of alpha-linolenic acid supplementation on ADHD symptoms in children: a randomized controlled double-blind study. Frontiers in Human Neuroscience2014;8:780. [DOI: 10.3389/fnhum.2014.00780] [PMCID: PMC4188038] [PMID: 25339885]NCT00874536. Omega-3 supplementation and attention-deficit-hyperactivity disorder (ADHD) [The effect of omega-3 fatty acid supplementation on behavior of children with ADHD]. clinicaltrials.gov/show/nct00874536 (first received 1 April 2009). ">Dubnov‐Raz 2014</a>; <a href="./references#CD007986-bbs2-0015" title="GowR . An Investigation Into Long-Chain Polyunsaturated Essential Fatty Acids, Event Related Potential Assessments of Brain Function and Behavioural Measures in Children and Adolescents With and Without Attention Deficit Hyperactivity Disorder [PhD thesis]. London, UK: King's College London, University of London, 2012. ">Gow 2012</a>; <a href="./references#CD007986-bbs2-0016" title="EUCTR2004-003853-13-SE. Placebo controlled, randomised, double-blind, multicentre study of PlusEPA (a PUFA, polyunsaturated fatty acids, supplement) as treatment for ADHD (combined type) with co-morbidity in Swedish children ages 7-12. www.clinicaltrialsregister.eu/ctr-search/trial/2004-003853-13/SE (first received 16 November 2004). GustafssonPA , Birberg-ThornbergU , DuchénK , LandgrenM , MalmbergK , PellingH , et al. EPA supplementation improves teacher-rated behaviour and oppositional symptoms in children with ADHD. Acta Paediatrica2010;99(10):1540-9. [DOI: 10.1111/j.1651-2227.2010.01871.x] [PMID: 20491709]">Gustafsson 2010</a>; <a href="./references#CD007986-bbs2-0017" title="HaririM , DjazayeryA , DjalaliM , SaedisomeoliaA , RahimiA , AbdolahianE . Effect of n-3 supplementation on hyperactivity, oxidative stress and inflammatory mediators in children with attention-deficit-hyperactivity disorder. Malaysian Journal of Nutrition2012;18(3):329-52. [PMID: 24568073]">Hariri 2012</a>; <a href="./references#CD007986-bbs2-0018" title="HamazakiT , HirayamaS . The effect of docosahexaenoic acid-containing food administration on symptoms of attention-deficit/hyperactivity disorder - a placebo-controlled double-blind study. European Journal of Clinical Nutrition2004;58(5):838. [DOI: 10.1038/sj.ejcn.1601888] [PMID: 15116088]HirayamaS , HamazakiT , TerasawaK . Effect of docosahexaenoic acid-containing food administration on symptoms of attention-deficit/hyperactivity disorder - a placebo-controlled double-blind study. European Journal of Clinical Nutrition2004;58(3):467-73. [DOI: 10.1038/sj.ejcn.1601830] [PMID: 14985685]">Hirayama 2004</a>; <a href="./references#CD007986-bbs2-0021" title="KeanJD , SarrisJ , ScholeyA , SilbersteinR , DowneyLA , StoughC . Reduced inattention and hyperactivity and improved cognition after marine oil extract (PCSO-524®) supplementation in children and adolescents with clinical and subclinical symptoms of attention-deficit hyperactivity disorder (ADHD): a randomised, double-blind, placebo-controlled trial. Psychopharmacology2017;234(3):403-20. [DOI: 10.1007/s00213-016-4471-y] [PMCID: PMC5225177] [PMID: 27921139]">Kean 2017</a>; <a href="./references#CD007986-bbs2-0023" title="ManorI , MagenA , KeidarD , RosenS , TaskerH , CohenT , et al. The effect of phosphatidylserine containing omega3 fatty-acids on attention-deficit hyperactivity disorder symptoms in children: a double-blind placebo-controlled trial, followed by an open-label extension. European Psychiatry2012;27(5):335-42. [DOI: 10.1016/j.eurpsy.2011.05.004] [PMID: 21807480]NCT00418184. The efficacy and safety of phosphatidylserine-omega3 in children with attention-deficit/hyperactivity disorder [A single-center, randomized, double-blind, placebo-controlled study of the efficacy and safety of phosphatidylserine-omega3 in children with attention-deficit/hyperactivity disorder]. clinicaltrials.gov/show/NCT00418184 (first received 4 January 2007). ">Manor 2012</a>; <a href="./references#CD007986-bbs2-0024" title="EUCTR2005-005330-12-GB. Omega-3 fatty acids supplementation for adolescent boys with attention deficit hyperactivity disorder: a double-blind, randomized controlled trial - MAAFA. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2005-005330-12-GB (first received 10 April 2006). ISRCTN27741572. Omega-3 fatty acids supplementation for adolescent boys with attention deficit hyperactivity disorder: a double-blind, randomized controlled trial. tinyurl.com/jz99z7vd (first received 10 March 2006). [DOI: 10.1186/ISRCTN27741572]MatsudairaT , GowRV , KellyJ , MurphyC , PottsL , SumichA , et al. Biochemical and psychological effects of omega-3/6 supplements in male adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, clinical trial. Journal of Child &amp; Adolescent Psychopharmacology2015;25(10):775-82. [DOI: 10.1089/cap.2015.0052] [PMCID: PMC4691649] [PMID: 26682998]MatsudairaT . Omega-3 PUFA Fatty Acids and Attention-Deficit/Hyperactivity Disorder [PhD thesis]. London, UK: King's College London, University of London, 2011. ">Matsudaira 2015</a>; <a href="./references#CD007986-bbs2-0027" title="IRCT2016060128182N2. Omega-3 supplement in attention deficit hyperactivity disorder [The effectiveness of omega-3 supplement as an adjunctive therapy in children with attention deficit hyperactivity disorder]. www.irct.ir/trial/22914 (first received 23 January 2017). MohammadzadehS , BaghiN , YousefiF , YousefzamaniB . Effect of omega-3 plus methylphenidate as an alternative therapy to reduce attention deficit-hyperactivity disorder in children. Korean Journal of Pediatrics2019;62(9):360-6. [DOI: 10.3345/kjp.2018.06982] [PMCID: PMC6753311] [PMID: 31122010]">Mohammadzadeh 2019</a>; <a href="./references#CD007986-bbs2-0031" title="RodríguezC , GarcíaT , ArecesD , FernándezE , García-NoriegaM , DomingoJC . Supplementation with high-content docosahexaenoic acid triglyceride in attention-deficit hyperactivity disorder: a randomized double-blind placebo-controlled trial. Neuropsychiatric Disease and Treatment2019;15:1193-209. [DOI: 10.2147/NDT.S206020] [PMID: 31190827] [PMID: PMC6514260]">Rodriguez 2019</a>; <a href="./references#CD007986-bbs2-0035" title="NCT00382616. Supplementation of phosphatidylserine (PS) and n-3 long chain fatty acids (EPA, DHA) in children with ADHD. clinicaltrials.gov/ct2/show/NCT00382616 (first received 29 September 2006). VaismanN , KaysarN , Zaruk-AdashaY , PelledD , BrichonG , ZwingelsteinG , et al. Correlation between changes in blood fatty acid composition and visual sustained attention performance in children with inattention: effect of dietary n-3 fatty acids containing phospholipids. American Journal of Clinical Nutrition2008;87(5):1170-80. [DOI: 10.1093/ajcn/87.5.1170] [PMID: 18469236]">Vaisman 2008</a>; <a href="./references#CD007986-bbs2-0036" title="VoigtRG , LlorenteAM , JensenCL , FraleyJK , BerrettaMC , HeirdWC . A randomized, double-blind, placebo-controlled trial of docosahexaenoic acid supplementation in children with attention-deficit/hyperactivity disorder. Journal of Pediatrics2001;139(2):189-96. [DOI: 10.1067/mpd.2001.116050] [PMID: 11487742]">Voigt 2001</a>; <a href="./references#CD007986-bbs2-0037" title="Widenhorn-MüllerK , SchwandaS , ScholzE , SpitzerM , BodeH . Effect of supplementation with long-chain ω-3 polyunsaturated fatty acids on behavior and cognition in children with attention deficit/hyperactivity disorder (ADHD): a randomized placebo-controlled intervention trial. Prostaglandins Leukotrienes and Essential Fatty Acids2014;91(1-2):49-60. [DOI: 10.1016/j.plefa.2014.04.004] [PMID: 24958525]">Widenhorn‐Müller 2014</a>), and the remaining 18 trials as at unclear risk due to inadequate information. </p> </section> <section id="CD007986-sec-0067"> <h5 class="title">Allocation concealment</h5> <p>We assessed 13 trials as at low risk of bias for allocation concealment (<a href="./references#CD007986-bbs2-0002" title="AnandP , SachdevaA . Effect of poly unsaturated fatty acids administration on children with attention deficit hyperactivity disorder: a randomized controlled trial. Journal of Clinical &amp; Diagnostic Research2016;10(9):OC01-5. [DOI: 10.7860/JCDR/2016/20423.8471] [PMCID: PMC5071983] [PMID: 27790483]">Anand 2016</a>; <a href="./references#CD007986-bbs2-0011" title="CornuC , MercierC , GinhouxT , MassonS , MouchetJ , NonyP , et al. A double-blind placebo-controlled randomised trial of omega-3 supplementation in children with moderate ADHD symptoms. European Child &amp; Adolescent Psychiatry2018;27(3):377‐84. [DOI: 10.1007/s00787-017-1058-z] [PMID: 28993963]NCT00770627. Clinical trial to evaluate the efficacy and the tolerance of an omega 3 fatty acids supplementation in ADHD children [A randomized, controlled, double blind placebo trial to evaluate the efficacy and the tolerance of an omega 3 fatty acids supplementation in ADHD children]. clinicaltrials.gov/ct2/show/record/NCT00770627 (first received 9 October 2008). ">Cornu 2018</a>; <a href="./references#CD007986-bbs2-0012" title="CrippaA , AgostoniC , MauriM , MolteniM , NobileM . Polyunsaturated fatty acids are associated with behavior but not with cognition in children with and without ADHD: an Italian study. Journal of Attention Disorders2018;22(10):971-83. [DOI: 10.1177/1087054716629215]CrippaA , TeseiA , SangiorgioF , SalandiA , TrabattoniS , GrazioliS , et al. Behavioral and cognitive effects of docosahexaenoic acid in drug-naïve children with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled clinical trial. European Child &amp; Adolescent Psychiatry2019;28(4):571-83. [DOI: 10.1007/s00787-018-1223-z] [PMID: 30246216]NCT01796262. The effects of DHA on attention deficit and hyperactivity disorder (DADA) [The effects of DHA (docosahexaenoic acid) on attention deficit and hyperactivity disorder]. clinicaltrials.gov/show/nct01796262 (first received 12 February 2013). ">Crippa 2019</a>; <a href="./references#CD007986-bbs2-0014" title="Dubnov-RazG , KhouryZ , WrightI , RazR , BergerI . The effect of alpha-linolenic acid supplementation on ADHD symptoms in children: a randomized controlled double-blind study. Frontiers in Human Neuroscience2014;8:780. [DOI: 10.3389/fnhum.2014.00780] [PMCID: PMC4188038] [PMID: 25339885]NCT00874536. Omega-3 supplementation and attention-deficit-hyperactivity disorder (ADHD) [The effect of omega-3 fatty acid supplementation on behavior of children with ADHD]. clinicaltrials.gov/show/nct00874536 (first received 1 April 2009). ">Dubnov‐Raz 2014</a>; <a href="./references#CD007986-bbs2-0018" title="HamazakiT , HirayamaS . The effect of docosahexaenoic acid-containing food administration on symptoms of attention-deficit/hyperactivity disorder - a placebo-controlled double-blind study. European Journal of Clinical Nutrition2004;58(5):838. [DOI: 10.1038/sj.ejcn.1601888] [PMID: 15116088]HirayamaS , HamazakiT , TerasawaK . Effect of docosahexaenoic acid-containing food administration on symptoms of attention-deficit/hyperactivity disorder - a placebo-controlled double-blind study. European Journal of Clinical Nutrition2004;58(3):467-73. [DOI: 10.1038/sj.ejcn.1601830] [PMID: 14985685]">Hirayama 2004</a>; <a href="./references#CD007986-bbs2-0019" title="IvityE . Supplementation with Docosahexaenoic Acid Ameliorates Paediatric AD/HD [PhD thesis]. Edmonton (AB): University of Alberta, 2015. ">Ivity 2015</a>; <a href="./references#CD007986-bbs2-0020" title="JohnsonM , OstlundS , FranssonG , KadesjöB , GillbergC . Omega-3/omega-6 fatty acids for attention deficit hyperactivity disorder: a randomized placebo-controlled trial in children and adolescents. Journal of Attention Disorders2009;12(5):394-401. [DOI: 10.1177/1087054708316261] [PMID: 18448859]NCT01219309. Omega-3/omega-6 fatty acids for attention-deficit/hyperactivity disorder (ADHD): a trial in children and adolescents. clinicaltrials.gov/show/NCT01219309. (first received 30 October 2010). ">Johnson 2009</a>; <a href="./references#CD007986-bbs2-0021" title="KeanJD , SarrisJ , ScholeyA , SilbersteinR , DowneyLA , StoughC . Reduced inattention and hyperactivity and improved cognition after marine oil extract (PCSO-524®) supplementation in children and adolescents with clinical and subclinical symptoms of attention-deficit hyperactivity disorder (ADHD): a randomised, double-blind, placebo-controlled trial. Psychopharmacology2017;234(3):403-20. [DOI: 10.1007/s00213-016-4471-y] [PMCID: PMC5225177] [PMID: 27921139]">Kean 2017</a>; <a href="./references#CD007986-bbs2-0023" title="ManorI , MagenA , KeidarD , RosenS , TaskerH , CohenT , et al. The effect of phosphatidylserine containing omega3 fatty-acids on attention-deficit hyperactivity disorder symptoms in children: a double-blind placebo-controlled trial, followed by an open-label extension. European Psychiatry2012;27(5):335-42. [DOI: 10.1016/j.eurpsy.2011.05.004] [PMID: 21807480]NCT00418184. The efficacy and safety of phosphatidylserine-omega3 in children with attention-deficit/hyperactivity disorder [A single-center, randomized, double-blind, placebo-controlled study of the efficacy and safety of phosphatidylserine-omega3 in children with attention-deficit/hyperactivity disorder]. clinicaltrials.gov/show/NCT00418184 (first received 4 January 2007). ">Manor 2012</a>; <a href="./references#CD007986-bbs2-0024" title="EUCTR2005-005330-12-GB. Omega-3 fatty acids supplementation for adolescent boys with attention deficit hyperactivity disorder: a double-blind, randomized controlled trial - MAAFA. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2005-005330-12-GB (first received 10 April 2006). ISRCTN27741572. Omega-3 fatty acids supplementation for adolescent boys with attention deficit hyperactivity disorder: a double-blind, randomized controlled trial. tinyurl.com/jz99z7vd (first received 10 March 2006). [DOI: 10.1186/ISRCTN27741572]MatsudairaT , GowRV , KellyJ , MurphyC , PottsL , SumichA , et al. Biochemical and psychological effects of omega-3/6 supplements in male adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, clinical trial. Journal of Child &amp; Adolescent Psychopharmacology2015;25(10):775-82. [DOI: 10.1089/cap.2015.0052] [PMCID: PMC4691649] [PMID: 26682998]MatsudairaT . Omega-3 PUFA Fatty Acids and Attention-Deficit/Hyperactivity Disorder [PhD thesis]. London, UK: King's College London, University of London, 2011. ">Matsudaira 2015</a>; <a href="./references#CD007986-bbs2-0027" title="IRCT2016060128182N2. Omega-3 supplement in attention deficit hyperactivity disorder [The effectiveness of omega-3 supplement as an adjunctive therapy in children with attention deficit hyperactivity disorder]. www.irct.ir/trial/22914 (first received 23 January 2017). MohammadzadehS , BaghiN , YousefiF , YousefzamaniB . Effect of omega-3 plus methylphenidate as an alternative therapy to reduce attention deficit-hyperactivity disorder in children. Korean Journal of Pediatrics2019;62(9):360-6. [DOI: 10.3345/kjp.2018.06982] [PMCID: PMC6753311] [PMID: 31122010]">Mohammadzadeh 2019</a>; <a href="./references#CD007986-bbs2-0029" title="PereraH , JeewandaraKC , SeneviratneS , GurugeC . Combined ω3 and ω6 supplementation in children with attention-deficit hyperactivity disorder (ADHD) refractory to methylphenidate treatment: a double-blind, placebo-controlled study. Journal of Child Neurology2012;27(6):747‐53. [DOI: 10.1177/0883073811435243] [PMID: 22596014]SLCTR/2009/006. Effectiveness of omega-3 and omega-6 in childhood behaviour disorders [Effectiveness of omega-3 and omega-6 in children with neuro-developmental disorders: a double-blind placebo-controlled study]. slctr.lk/trials/slctr-2009-006 (first received 17 July 2009). ">Perera 2012</a>; <a href="./references#CD007986-bbs2-0033" title="SinnN , BryanJ , WilsonC . Cognitive effects of polyunsaturated fatty acids in children with attention deficit hyperactivity disorder symptoms: a randomised controlled trial. Prostaglandins Leukotrienes and Essential Fatty Acids2008;78(4-5):311-26. [DOI: 10.1016/j.plefa.2008.04.004] [PMID: 18514501]SinnN , BryanJ . Effect of supplementation with polyunsaturated fatty acids and micronutrients on learning and behavior problems associated with child ADHD. Journal of Developmental and Behavioral Pediatrics2007;28(2):82-91. [DOI: 10.1097/01.DBP.0000267558.88457.a5] [PMID: 17435458]">Sinn 2007</a>), one trial at high risk of bias (<a href="./references#CD007986-bbs2-0005" title="BarragánE , BreuerD , DöpfnerM . Efficacy and safety of omega-3/6 fatty acids, methylphenidate, and a combined treatment in children with ADHD. Journal of Attention Disorders2017;21(5):433-41. [DOI: 10.1177/1087054713518239] [PMID: 24464327]">Barragán 2017</a>), and the remaining trials at unclear risk of bias. </p> </section> </section> <section id="CD007986-sec-0068"> <h4 class="title">Blinding</h4> <section id="CD007986-sec-0069"> <h5 class="title">Participants and personnel</h5> <p>The majority (19) of the included trials described methods used to blind participants and personnel and were therefore assessed as at a low risk of performance bias. However, we rated 17 studies as at unclear risk of performance bias (<a href="./references#CD007986-bbs2-0002" title="AnandP , SachdevaA . Effect of poly unsaturated fatty acids administration on children with attention deficit hyperactivity disorder: a randomized controlled trial. Journal of Clinical &amp; Diagnostic Research2016;10(9):OC01-5. [DOI: 10.7860/JCDR/2016/20423.8471] [PMCID: PMC5071983] [PMID: 27790483]">Anand 2016</a>; <a href="./references#CD007986-bbs2-0003" title="ArnoldLE , KleykampD , VotolatoN , GibsonRA , HorrocksL . Potential link between dietary intake of fatty acids and behavior: pilot exploration of serum lipids in attention-deficit hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology1994;4(3):171-82. [DOI: 10.1089/cap.1994.4.171]ArnoldLE , KleykampD , VotolatoNA , TaylorWA , KontrasSB , TobinK . Gamma-linolenic acid for attention-deficit hyperactivity disorder: placebo-controlled comparison to D-amphetamine. Biological Psychiatry1989;25(2):222-8. [DOI: 10.1016/0006-3223(89)90167-4] [PMID: 2539203]ArnoldLE , PinkhamSM , VotolatoN . Does zinc moderate essential fatty acid and amphetamine treatment of attention-deficit/hyperactivity disorder?Journal of Child and Adolescent Psychopharmacology2000;10(2):111-7. [DOI: 10.1089/cap.2000.10.111] [PMID: 10933121]">Arnold 1989</a>; <a href="./references#CD007986-bbs2-0004" title="AssarehM , Davari AshtianiR , KhademiM , JazayeriS , RaiA , NikooM . Efficacy of polyunsaturated fatty acids (PUFA) in the treatment of attention deficit hyperactivity disorder: a randomized, double-blind, placebo-controlled clinical trial. Journal of Attention Disorders2017;21(1):78-85. [DOI: 10.1177/1087054712463962] [PMID: 23160488]IRCT138803122000N1. Poly unsaturated fatty acid as a combination treatment in children with attention deficit hyperactivity disorder [Omega-3 in the treatment of attention deficit hyperactivity disorder]. en.irct.ir/trial/1598?revision=1598 (first received 21 May 2011). ">Assareh 2017</a>; <a href="./references#CD007986-bbs2-0006" title="BehdaniF , HebraniP , NaseraeeA , HaghighiMB , AkhavanrezayatA . Does omega-3 supplement enhance the therapeutic results of methylphenidate in attention deficit hyperactivity disorder patients?Journal of Research in Medical Sciences2013;18(8):653-8. [PMCID: PMC3872603] [PMID: 24379840]">Behdani 2013</a>; <a href="./references#CD007986-bbs2-0007" title="BélangerSA , VanasseM , SpahisS , SylvestreMP , LippéS , L'HeureuxF , et al. Omega-3 fatty acid treatment of children with attention-deficit hyperactivity disorder: a randomized, double-blind, placebo-controlled study. Paediatrics and Child Health2009;14(2):89-98. [DOI: 10.1093/pch/14.2.89] [PMCID: PMC2661342] [PMID: 19436468]VanasseM , Ageranioti-BélangerS , L'HeureuxF , GhadirianP , LevyE , SpahisS , et al. A randomized, controlled trial of omega-3 and phospholipids supplementation in children with attention-deficit-hyperactivity disorder. Developmental Medicine &amp; Child Neurology2006;48(Suppl 107):48. [DOI: 10.1111/j.1469-8749.2006.tb12600.x]">Bélanger 2009</a>; <a href="./references#CD007986-bbs2-0010" title="ChangJP , SuKP , MondelliV , SatyanarayananSK , YangHT , ChiangYJ , et al. High-dose eicosapentaenoic acid (EPA) improves attention and vigilance in children and adolescents with attention deficit hyperactivity disorder (ADHD) and low endogenous EPA levels. Translational Psychiatry2019;9(1):303. [DOI: 10.1038/s41398-019-0633-0] [PMCID: PMC6864068] [PMID: 31745072]NCT03542643. Omega-3 polyunsaturated fatty acids in youth with ADHD [A double-blind randomised controlled trial of N-3 PUFAs in children with attention deficit hyperactivity disorder]. clinicaltrials.gov/ct2/show/NCT03542643 (first received 20 May 2018). ">Chang 2019</a>; <a href="./references#CD007986-bbs2-0013" title="DashtiN , HekmatH , SoltaniHR , RahimdelA , JavaherchianM . Comparison of therapeutic effects of omega-3 and methylphenidate (ritalin(®)) in treating children with attention deficit hyperactivity disorder. Iranian Journal of Psychiatry and Behavioral Sciences2014;8(4):7-11. [PMCID: PMC4364471] [PMID: 25798168]">Dashti 2014</a>; <a href="./references#CD007986-bbs2-0014" title="Dubnov-RazG , KhouryZ , WrightI , RazR , BergerI . The effect of alpha-linolenic acid supplementation on ADHD symptoms in children: a randomized controlled double-blind study. Frontiers in Human Neuroscience2014;8:780. [DOI: 10.3389/fnhum.2014.00780] [PMCID: PMC4188038] [PMID: 25339885]NCT00874536. Omega-3 supplementation and attention-deficit-hyperactivity disorder (ADHD) [The effect of omega-3 fatty acid supplementation on behavior of children with ADHD]. clinicaltrials.gov/show/nct00874536 (first received 1 April 2009). ">Dubnov‐Raz 2014</a>; <a href="./references#CD007986-bbs2-0015" title="GowR . An Investigation Into Long-Chain Polyunsaturated Essential Fatty Acids, Event Related Potential Assessments of Brain Function and Behavioural Measures in Children and Adolescents With and Without Attention Deficit Hyperactivity Disorder [PhD thesis]. London, UK: King's College London, University of London, 2012. ">Gow 2012</a>; <a href="./references#CD007986-bbs2-0017" title="HaririM , DjazayeryA , DjalaliM , SaedisomeoliaA , RahimiA , AbdolahianE . Effect of n-3 supplementation on hyperactivity, oxidative stress and inflammatory mediators in children with attention-deficit-hyperactivity disorder. Malaysian Journal of Nutrition2012;18(3):329-52. [PMID: 24568073]">Hariri 2012</a>; <a href="./references#CD007986-bbs2-0019" title="IvityE . Supplementation with Docosahexaenoic Acid Ameliorates Paediatric AD/HD [PhD thesis]. Edmonton (AB): University of Alberta, 2015. ">Ivity 2015</a>; <a href="./references#CD007986-bbs2-0022" title="Lim-AshworthN , OoiYP , WengSJ , LimCG , FungDSS , GlennA , et al. Preliminary findings on the effects of nutritional and social skills intervention among children with attention deficit hyperactivity disorder. Annals: the official journal of the Academy of Medicine, Singapore2013;42(Suppl 9):S162. [OP-CR-65] [WEB PAGE: www.annals.edu.sg/pdf/42VolNo9Sep2013/SHBC_2013_041013.pdf]">Lim‐Ashworth 2013</a>; <a href="./references#CD007986-bbs2-0024" title="EUCTR2005-005330-12-GB. Omega-3 fatty acids supplementation for adolescent boys with attention deficit hyperactivity disorder: a double-blind, randomized controlled trial - MAAFA. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2005-005330-12-GB (first received 10 April 2006). ISRCTN27741572. Omega-3 fatty acids supplementation for adolescent boys with attention deficit hyperactivity disorder: a double-blind, randomized controlled trial. tinyurl.com/jz99z7vd (first received 10 March 2006). [DOI: 10.1186/ISRCTN27741572]MatsudairaT , GowRV , KellyJ , MurphyC , PottsL , SumichA , et al. Biochemical and psychological effects of omega-3/6 supplements in male adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, clinical trial. Journal of Child &amp; Adolescent Psychopharmacology2015;25(10):775-82. [DOI: 10.1089/cap.2015.0052] [PMCID: PMC4691649] [PMID: 26682998]MatsudairaT . Omega-3 PUFA Fatty Acids and Attention-Deficit/Hyperactivity Disorder [PhD thesis]. London, UK: King's College London, University of London, 2011. ">Matsudaira 2015</a>; <a href="./references#CD007986-bbs2-0026" title="IRCT2015092724209N2. Investigating the effectiveness of methylphenidate and multi chain polyunsaturated fatty acids in treatment of patients with attention deficit hyperactivity disorder (ADHD) in Zahedan City [Investigating the effectiveness of methylphenidate and multi chain polyunsaturated fatty acids in treatment of symptoms of attention deficit hyperactivity disorder (ADHD) among 6 to 12 children suffered from ADHD]. trialsearch.who.int/Trial2.aspx?TrialID=IRCT2015092724209N2 (first received 28 April 2016). MoghaddamMF , ShamekhiM , RakhshaniT . Effectiveness of methylphenidate and PUFA for the treatment of patients with ADHD: a double-blinded randomized clinical trial. Electronic Physician2017;9(5):4412-8. [DOI: 10.19082/4412] [PMCID: PMC5498708] [PMID: 28713515]">Moghaddam 2017</a>; <a href="./references#CD007986-bbs2-0028" title="NCT01807299. The effect of physical training and the omega 3 consumption on attention deficit hyperactivity disorder in children (AOE) [The effect of physical training and the omega 3 consumption on attention deficit]. clinicaltrials.gov/ct2/show/NCT01807299 (first received 7 March 2013). ">NCT01807299</a>; <a href="./references#CD007986-bbs2-0030" title="RazR , CarassoRL , YehudaS . The influence of short-chain essential fatty acids on children with attention-deficit/hyperactivity disorder: a double-blind placebo-controlled study. Journal of Child and Adolescent Psychopharmacology2009;19(2):167-77. [DOI: 10.1089/cap.2008.070] [PMID: 19364294]">Raz 2009a</a>; <a href="./references#CD007986-bbs2-0032" title="SalehiB , MohammadbeigiA , SheykholeslamH , MoshiriE , DorrehF . Omega-3 and zinc supplementation as complementary therapies in children with attention-deficit/hyperactivity disorder. Journal of Research in Pharmacy Practice2016;5(1):22-6. [DOI: 10.4103/2279-042X.176561] [PMCID: PMC4776543] [PMID: 26985432]">Salehi 2016</a>), and one study at high risk (<a href="./references#CD007986-bbs2-0005" title="BarragánE , BreuerD , DöpfnerM . Efficacy and safety of omega-3/6 fatty acids, methylphenidate, and a combined treatment in children with ADHD. Journal of Attention Disorders2017;21(5):433-41. [DOI: 10.1177/1087054713518239] [PMID: 24464327]">Barragán 2017</a>). </p> </section> <section id="CD007986-sec-0070"> <h5 class="title">Outcome assessors</h5> <p>We considered the majority of trials (21) to be at low risk of detection bias because the intervention and placebo were described as identical, and because parent‐ or teacher‐rated measures (or both) were used (<a href="./references#CD007986-bbs2-0001" title="AmanMG , MitchellEA , TurbottSH . The effects of essential fatty acid supplementation by efamol in hyperactive children. Journal of Abnormal Child Psychology1987;15(1):75-90. [DOI: 10.1007/BF00916467]">Aman 1987</a>; <a href="./references#CD007986-bbs2-0003" title="ArnoldLE , KleykampD , VotolatoN , GibsonRA , HorrocksL . Potential link between dietary intake of fatty acids and behavior: pilot exploration of serum lipids in attention-deficit hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology1994;4(3):171-82. [DOI: 10.1089/cap.1994.4.171]ArnoldLE , KleykampD , VotolatoNA , TaylorWA , KontrasSB , TobinK . Gamma-linolenic acid for attention-deficit hyperactivity disorder: placebo-controlled comparison to D-amphetamine. Biological Psychiatry1989;25(2):222-8. [DOI: 10.1016/0006-3223(89)90167-4] [PMID: 2539203]ArnoldLE , PinkhamSM , VotolatoN . Does zinc moderate essential fatty acid and amphetamine treatment of attention-deficit/hyperactivity disorder?Journal of Child and Adolescent Psychopharmacology2000;10(2):111-7. [DOI: 10.1089/cap.2000.10.111] [PMID: 10933121]">Arnold 1989</a>; <a href="./references#CD007986-bbs2-0008" title="BosD , Van BelleJ , WeustenJ , HoeksmaM , WisemanS , DurstonS . Effects of N-3 fatty acids (DHA and EPA) on cognitive control and associated brain activity in ADHD: a double-blind placebo controlled study. European Child &amp; Adolescent Psychiatry2010;19(Suppl 1):S69. [DOI: 10.1007/s00787-010-0117-5]BosD , Van BelleJ , WeustenJ , HoeksmaM , WisemanS , DurstonS . Effects of N-3 fatty acids (DHA and EPA) on cognitive control and associated brain activity in ADHD: a double-blind placebo controlled study. In: European Child and Adolescent Psychiatry, Conference: Eunethydis 1st International ADHD Conference: From Data to Best Clinical Practice; 2010 May 26–28; Amsterdam. 2010. BosDJ , OranjeB , VeerhoekES , Van DiepenRM , Weusten JMh, DemmelmairH , et al. Reduced symptoms of inattention after dietary omega-3 fatty acid supplementation in boys with and without attention deficit/hyperactivity disorder. Neuropsychopharmacology2015;40(10):2298–306. [DOI: 10.1038/npp.2015.73] [PMCID: PMC4538345] [PMID: 25790022]">Bos 2015</a>; <a href="./references#CD007986-bbs2-0009" title="BrueAW , OaklandTD , EvansRA . The use of a dietary supplement combination and an essential fatty acid as an alternative and complementary treatment for children with attention-deficit/hyperactivity disorder. Scientific Review of Alternative Medicine2001;5(4):187-94. [WEB PAGE: tinyurl.com/y56pdtxq]BrueAW . The Use of a Dietary Supplement Combination and an Essential Fatty Acid as an Alternative and Complementary Treatment for Children with Attention Deficit Hyperactivity Disorder (ADHD) [PhD thesis]. Gainesville (FL): University of Florida, 1999. ">Brue 2001</a>; <a href="./references#CD007986-bbs2-0010" title="ChangJP , SuKP , MondelliV , SatyanarayananSK , YangHT , ChiangYJ , et al. High-dose eicosapentaenoic acid (EPA) improves attention and vigilance in children and adolescents with attention deficit hyperactivity disorder (ADHD) and low endogenous EPA levels. Translational Psychiatry2019;9(1):303. [DOI: 10.1038/s41398-019-0633-0] [PMCID: PMC6864068] [PMID: 31745072]NCT03542643. Omega-3 polyunsaturated fatty acids in youth with ADHD [A double-blind randomised controlled trial of N-3 PUFAs in children with attention deficit hyperactivity disorder]. clinicaltrials.gov/ct2/show/NCT03542643 (first received 20 May 2018). ">Chang 2019</a>; <a href="./references#CD007986-bbs2-0011" title="CornuC , MercierC , GinhouxT , MassonS , MouchetJ , NonyP , et al. A double-blind placebo-controlled randomised trial of omega-3 supplementation in children with moderate ADHD symptoms. European Child &amp; Adolescent Psychiatry2018;27(3):377‐84. [DOI: 10.1007/s00787-017-1058-z] [PMID: 28993963]NCT00770627. Clinical trial to evaluate the efficacy and the tolerance of an omega 3 fatty acids supplementation in ADHD children [A randomized, controlled, double blind placebo trial to evaluate the efficacy and the tolerance of an omega 3 fatty acids supplementation in ADHD children]. clinicaltrials.gov/ct2/show/record/NCT00770627 (first received 9 October 2008). ">Cornu 2018</a>; <a href="./references#CD007986-bbs2-0012" title="CrippaA , AgostoniC , MauriM , MolteniM , NobileM . Polyunsaturated fatty acids are associated with behavior but not with cognition in children with and without ADHD: an Italian study. Journal of Attention Disorders2018;22(10):971-83. [DOI: 10.1177/1087054716629215]CrippaA , TeseiA , SangiorgioF , SalandiA , TrabattoniS , GrazioliS , et al. Behavioral and cognitive effects of docosahexaenoic acid in drug-naïve children with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled clinical trial. European Child &amp; Adolescent Psychiatry2019;28(4):571-83. [DOI: 10.1007/s00787-018-1223-z] [PMID: 30246216]NCT01796262. The effects of DHA on attention deficit and hyperactivity disorder (DADA) [The effects of DHA (docosahexaenoic acid) on attention deficit and hyperactivity disorder]. clinicaltrials.gov/show/nct01796262 (first received 12 February 2013). ">Crippa 2019</a>; <a href="./references#CD007986-bbs2-0016" title="EUCTR2004-003853-13-SE. Placebo controlled, randomised, double-blind, multicentre study of PlusEPA (a PUFA, polyunsaturated fatty acids, supplement) as treatment for ADHD (combined type) with co-morbidity in Swedish children ages 7-12. www.clinicaltrialsregister.eu/ctr-search/trial/2004-003853-13/SE (first received 16 November 2004). GustafssonPA , Birberg-ThornbergU , DuchénK , LandgrenM , MalmbergK , PellingH , et al. EPA supplementation improves teacher-rated behaviour and oppositional symptoms in children with ADHD. Acta Paediatrica2010;99(10):1540-9. [DOI: 10.1111/j.1651-2227.2010.01871.x] [PMID: 20491709]">Gustafsson 2010</a>; <a href="./references#CD007986-bbs2-0018" title="HamazakiT , HirayamaS . The effect of docosahexaenoic acid-containing food administration on symptoms of attention-deficit/hyperactivity disorder - a placebo-controlled double-blind study. European Journal of Clinical Nutrition2004;58(5):838. [DOI: 10.1038/sj.ejcn.1601888] [PMID: 15116088]HirayamaS , HamazakiT , TerasawaK . Effect of docosahexaenoic acid-containing food administration on symptoms of attention-deficit/hyperactivity disorder - a placebo-controlled double-blind study. European Journal of Clinical Nutrition2004;58(3):467-73. [DOI: 10.1038/sj.ejcn.1601830] [PMID: 14985685]">Hirayama 2004</a>; <a href="./references#CD007986-bbs2-0021" title="KeanJD , SarrisJ , ScholeyA , SilbersteinR , DowneyLA , StoughC . Reduced inattention and hyperactivity and improved cognition after marine oil extract (PCSO-524®) supplementation in children and adolescents with clinical and subclinical symptoms of attention-deficit hyperactivity disorder (ADHD): a randomised, double-blind, placebo-controlled trial. Psychopharmacology2017;234(3):403-20. [DOI: 10.1007/s00213-016-4471-y] [PMCID: PMC5225177] [PMID: 27921139]">Kean 2017</a>; <a href="./references#CD007986-bbs2-0023" title="ManorI , MagenA , KeidarD , RosenS , TaskerH , CohenT , et al. The effect of phosphatidylserine containing omega3 fatty-acids on attention-deficit hyperactivity disorder symptoms in children: a double-blind placebo-controlled trial, followed by an open-label extension. European Psychiatry2012;27(5):335-42. [DOI: 10.1016/j.eurpsy.2011.05.004] [PMID: 21807480]NCT00418184. The efficacy and safety of phosphatidylserine-omega3 in children with attention-deficit/hyperactivity disorder [A single-center, randomized, double-blind, placebo-controlled study of the efficacy and safety of phosphatidylserine-omega3 in children with attention-deficit/hyperactivity disorder]. clinicaltrials.gov/show/NCT00418184 (first received 4 January 2007). ">Manor 2012</a>; <a href="./references#CD007986-bbs2-0025" title="ACTRN12607000332426. Omega-3 fatty acids for ADHD symptoms and learning difficulties in children [Randomised controlled trial investigating effect of supplementation with omega-3 fatty acids EPA and DHA versus omega-6 fatty acid LA on ADHD symptoms and learning difficulties in 7-12 year old children]. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=82104 (first received 19 June 2007). MilteCM , ParlettaN , BuckleyJD , CoatesAM , YoungRM , HowePR . Eicosapentaenoic and docosahexaenoic acids, cognition, and behavior in children with attention-deficit/hyperactivity disorder: a randomized controlled trial. Nutrition2012;28(6):670-7. [DOI: 10.1016/j.nut.2011.12.009] [PMID: 22541055]">Milte 2012</a>; <a href="./references#CD007986-bbs2-0027" title="IRCT2016060128182N2. Omega-3 supplement in attention deficit hyperactivity disorder [The effectiveness of omega-3 supplement as an adjunctive therapy in children with attention deficit hyperactivity disorder]. www.irct.ir/trial/22914 (first received 23 January 2017). MohammadzadehS , BaghiN , YousefiF , YousefzamaniB . Effect of omega-3 plus methylphenidate as an alternative therapy to reduce attention deficit-hyperactivity disorder in children. Korean Journal of Pediatrics2019;62(9):360-6. [DOI: 10.3345/kjp.2018.06982] [PMCID: PMC6753311] [PMID: 31122010]">Mohammadzadeh 2019</a>; <a href="./references#CD007986-bbs2-0029" title="PereraH , JeewandaraKC , SeneviratneS , GurugeC . Combined ω3 and ω6 supplementation in children with attention-deficit hyperactivity disorder (ADHD) refractory to methylphenidate treatment: a double-blind, placebo-controlled study. Journal of Child Neurology2012;27(6):747‐53. [DOI: 10.1177/0883073811435243] [PMID: 22596014]SLCTR/2009/006. Effectiveness of omega-3 and omega-6 in childhood behaviour disorders [Effectiveness of omega-3 and omega-6 in children with neuro-developmental disorders: a double-blind placebo-controlled study]. slctr.lk/trials/slctr-2009-006 (first received 17 July 2009). ">Perera 2012</a>; <a href="./references#CD007986-bbs2-0030" title="RazR , CarassoRL , YehudaS . The influence of short-chain essential fatty acids on children with attention-deficit/hyperactivity disorder: a double-blind placebo-controlled study. Journal of Child and Adolescent Psychopharmacology2009;19(2):167-77. [DOI: 10.1089/cap.2008.070] [PMID: 19364294]">Raz 2009a</a>; <a href="./references#CD007986-bbs2-0031" title="RodríguezC , GarcíaT , ArecesD , FernándezE , García-NoriegaM , DomingoJC . Supplementation with high-content docosahexaenoic acid triglyceride in attention-deficit hyperactivity disorder: a randomized double-blind placebo-controlled trial. Neuropsychiatric Disease and Treatment2019;15:1193-209. [DOI: 10.2147/NDT.S206020] [PMID: 31190827] [PMID: PMC6514260]">Rodriguez 2019</a>; <a href="./references#CD007986-bbs2-0033" title="SinnN , BryanJ , WilsonC . Cognitive effects of polyunsaturated fatty acids in children with attention deficit hyperactivity disorder symptoms: a randomised controlled trial. Prostaglandins Leukotrienes and Essential Fatty Acids2008;78(4-5):311-26. [DOI: 10.1016/j.plefa.2008.04.004] [PMID: 18514501]SinnN , BryanJ . Effect of supplementation with polyunsaturated fatty acids and micronutrients on learning and behavior problems associated with child ADHD. Journal of Developmental and Behavioral Pediatrics2007;28(2):82-91. [DOI: 10.1097/01.DBP.0000267558.88457.a5] [PMID: 17435458]">Sinn 2007</a>; <a href="./references#CD007986-bbs2-0034" title="StevensL , ZhangW , PeckL , KuczekT , GrevstadN , MahonA , et al. EFA supplementation in children with inattention, hyperactivity, and other disruptive behaviors. Lipids2003;38(10):1007-21. [DOI: 10.1007/s11745-006-1155-0] [PMID: 14669965]">Stevens 2003</a>; <a href="./references#CD007986-bbs2-0035" title="NCT00382616. Supplementation of phosphatidylserine (PS) and n-3 long chain fatty acids (EPA, DHA) in children with ADHD. clinicaltrials.gov/ct2/show/NCT00382616 (first received 29 September 2006). VaismanN , KaysarN , Zaruk-AdashaY , PelledD , BrichonG , ZwingelsteinG , et al. Correlation between changes in blood fatty acid composition and visual sustained attention performance in children with inattention: effect of dietary n-3 fatty acids containing phospholipids. American Journal of Clinical Nutrition2008;87(5):1170-80. [DOI: 10.1093/ajcn/87.5.1170] [PMID: 18469236]">Vaisman 2008</a>; <a href="./references#CD007986-bbs2-0036" title="VoigtRG , LlorenteAM , JensenCL , FraleyJK , BerrettaMC , HeirdWC . A randomized, double-blind, placebo-controlled trial of docosahexaenoic acid supplementation in children with attention-deficit/hyperactivity disorder. Journal of Pediatrics2001;139(2):189-96. [DOI: 10.1067/mpd.2001.116050] [PMID: 11487742]">Voigt 2001</a>; <a href="./references#CD007986-bbs2-0037" title="Widenhorn-MüllerK , SchwandaS , ScholzE , SpitzerM , BodeH . Effect of supplementation with long-chain ω-3 polyunsaturated fatty acids on behavior and cognition in children with attention deficit/hyperactivity disorder (ADHD): a randomized placebo-controlled intervention trial. Prostaglandins Leukotrienes and Essential Fatty Acids2014;91(1-2):49-60. [DOI: 10.1016/j.plefa.2014.04.004] [PMID: 24958525]">Widenhorn‐Müller 2014</a>). We rated <a href="./references#CD007986-bbs2-0005" title="BarragánE , BreuerD , DöpfnerM . Efficacy and safety of omega-3/6 fatty acids, methylphenidate, and a combined treatment in children with ADHD. Journal of Attention Disorders2017;21(5):433-41. [DOI: 10.1177/1087054713518239] [PMID: 24464327]">Barragán 2017</a> as at high risk of bias, and the remaining 15 studies as at unclear risk of detection bias because of insufficient information. </p> </section> </section> <section id="CD007986-sec-0071"> <h4 class="title">Incomplete outcome data</h4> <p>We considered only five studies to be at low risk of attrition bias (<a href="./references#CD007986-bbs2-0002" title="AnandP , SachdevaA . Effect of poly unsaturated fatty acids administration on children with attention deficit hyperactivity disorder: a randomized controlled trial. Journal of Clinical &amp; Diagnostic Research2016;10(9):OC01-5. [DOI: 10.7860/JCDR/2016/20423.8471] [PMCID: PMC5071983] [PMID: 27790483]">Anand 2016</a>; <a href="./references#CD007986-bbs2-0008" title="BosD , Van BelleJ , WeustenJ , HoeksmaM , WisemanS , DurstonS . Effects of N-3 fatty acids (DHA and EPA) on cognitive control and associated brain activity in ADHD: a double-blind placebo controlled study. European Child &amp; Adolescent Psychiatry2010;19(Suppl 1):S69. [DOI: 10.1007/s00787-010-0117-5]BosD , Van BelleJ , WeustenJ , HoeksmaM , WisemanS , DurstonS . Effects of N-3 fatty acids (DHA and EPA) on cognitive control and associated brain activity in ADHD: a double-blind placebo controlled study. In: European Child and Adolescent Psychiatry, Conference: Eunethydis 1st International ADHD Conference: From Data to Best Clinical Practice; 2010 May 26–28; Amsterdam. 2010. BosDJ , OranjeB , VeerhoekES , Van DiepenRM , Weusten JMh, DemmelmairH , et al. Reduced symptoms of inattention after dietary omega-3 fatty acid supplementation in boys with and without attention deficit/hyperactivity disorder. Neuropsychopharmacology2015;40(10):2298–306. [DOI: 10.1038/npp.2015.73] [PMCID: PMC4538345] [PMID: 25790022]">Bos 2015</a>; <a href="./references#CD007986-bbs2-0011" title="CornuC , MercierC , GinhouxT , MassonS , MouchetJ , NonyP , et al. A double-blind placebo-controlled randomised trial of omega-3 supplementation in children with moderate ADHD symptoms. European Child &amp; Adolescent Psychiatry2018;27(3):377‐84. [DOI: 10.1007/s00787-017-1058-z] [PMID: 28993963]NCT00770627. Clinical trial to evaluate the efficacy and the tolerance of an omega 3 fatty acids supplementation in ADHD children [A randomized, controlled, double blind placebo trial to evaluate the efficacy and the tolerance of an omega 3 fatty acids supplementation in ADHD children]. clinicaltrials.gov/ct2/show/record/NCT00770627 (first received 9 October 2008). ">Cornu 2018</a>; <a href="./references#CD007986-bbs2-0012" title="CrippaA , AgostoniC , MauriM , MolteniM , NobileM . Polyunsaturated fatty acids are associated with behavior but not with cognition in children with and without ADHD: an Italian study. Journal of Attention Disorders2018;22(10):971-83. [DOI: 10.1177/1087054716629215]CrippaA , TeseiA , SangiorgioF , SalandiA , TrabattoniS , GrazioliS , et al. Behavioral and cognitive effects of docosahexaenoic acid in drug-naïve children with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled clinical trial. European Child &amp; Adolescent Psychiatry2019;28(4):571-83. [DOI: 10.1007/s00787-018-1223-z] [PMID: 30246216]NCT01796262. The effects of DHA on attention deficit and hyperactivity disorder (DADA) [The effects of DHA (docosahexaenoic acid) on attention deficit and hyperactivity disorder]. clinicaltrials.gov/show/nct01796262 (first received 12 February 2013). ">Crippa 2019</a>; <a href="./references#CD007986-bbs2-0018" title="HamazakiT , HirayamaS . The effect of docosahexaenoic acid-containing food administration on symptoms of attention-deficit/hyperactivity disorder - a placebo-controlled double-blind study. European Journal of Clinical Nutrition2004;58(5):838. [DOI: 10.1038/sj.ejcn.1601888] [PMID: 15116088]HirayamaS , HamazakiT , TerasawaK . Effect of docosahexaenoic acid-containing food administration on symptoms of attention-deficit/hyperactivity disorder - a placebo-controlled double-blind study. European Journal of Clinical Nutrition2004;58(3):467-73. [DOI: 10.1038/sj.ejcn.1601830] [PMID: 14985685]">Hirayama 2004</a>). We assessed 12 trials as at high risk of attrition bias because data were only reported for participants who were not lost to follow‐up (<a href="./references#CD007986-bbs2-0007" title="BélangerSA , VanasseM , SpahisS , SylvestreMP , LippéS , L'HeureuxF , et al. Omega-3 fatty acid treatment of children with attention-deficit hyperactivity disorder: a randomized, double-blind, placebo-controlled study. Paediatrics and Child Health2009;14(2):89-98. [DOI: 10.1093/pch/14.2.89] [PMCID: PMC2661342] [PMID: 19436468]VanasseM , Ageranioti-BélangerS , L'HeureuxF , GhadirianP , LevyE , SpahisS , et al. A randomized, controlled trial of omega-3 and phospholipids supplementation in children with attention-deficit-hyperactivity disorder. Developmental Medicine &amp; Child Neurology2006;48(Suppl 107):48. [DOI: 10.1111/j.1469-8749.2006.tb12600.x]">Bélanger 2009</a>; <a href="./references#CD007986-bbs2-0009" title="BrueAW , OaklandTD , EvansRA . The use of a dietary supplement combination and an essential fatty acid as an alternative and complementary treatment for children with attention-deficit/hyperactivity disorder. Scientific Review of Alternative Medicine2001;5(4):187-94. [WEB PAGE: tinyurl.com/y56pdtxq]BrueAW . The Use of a Dietary Supplement Combination and an Essential Fatty Acid as an Alternative and Complementary Treatment for Children with Attention Deficit Hyperactivity Disorder (ADHD) [PhD thesis]. Gainesville (FL): University of Florida, 1999. ">Brue 2001</a>; <a href="./references#CD007986-bbs2-0014" title="Dubnov-RazG , KhouryZ , WrightI , RazR , BergerI . The effect of alpha-linolenic acid supplementation on ADHD symptoms in children: a randomized controlled double-blind study. Frontiers in Human Neuroscience2014;8:780. [DOI: 10.3389/fnhum.2014.00780] [PMCID: PMC4188038] [PMID: 25339885]NCT00874536. Omega-3 supplementation and attention-deficit-hyperactivity disorder (ADHD) [The effect of omega-3 fatty acid supplementation on behavior of children with ADHD]. clinicaltrials.gov/show/nct00874536 (first received 1 April 2009). ">Dubnov‐Raz 2014</a>; <a href="./references#CD007986-bbs2-0019" title="IvityE . Supplementation with Docosahexaenoic Acid Ameliorates Paediatric AD/HD [PhD thesis]. Edmonton (AB): University of Alberta, 2015. ">Ivity 2015</a>; <a href="./references#CD007986-bbs2-0021" title="KeanJD , SarrisJ , ScholeyA , SilbersteinR , DowneyLA , StoughC . Reduced inattention and hyperactivity and improved cognition after marine oil extract (PCSO-524®) supplementation in children and adolescents with clinical and subclinical symptoms of attention-deficit hyperactivity disorder (ADHD): a randomised, double-blind, placebo-controlled trial. Psychopharmacology2017;234(3):403-20. [DOI: 10.1007/s00213-016-4471-y] [PMCID: PMC5225177] [PMID: 27921139]">Kean 2017</a>; <a href="./references#CD007986-bbs2-0023" title="ManorI , MagenA , KeidarD , RosenS , TaskerH , CohenT , et al. The effect of phosphatidylserine containing omega3 fatty-acids on attention-deficit hyperactivity disorder symptoms in children: a double-blind placebo-controlled trial, followed by an open-label extension. European Psychiatry2012;27(5):335-42. [DOI: 10.1016/j.eurpsy.2011.05.004] [PMID: 21807480]NCT00418184. The efficacy and safety of phosphatidylserine-omega3 in children with attention-deficit/hyperactivity disorder [A single-center, randomized, double-blind, placebo-controlled study of the efficacy and safety of phosphatidylserine-omega3 in children with attention-deficit/hyperactivity disorder]. clinicaltrials.gov/show/NCT00418184 (first received 4 January 2007). ">Manor 2012</a>; <a href="./references#CD007986-bbs2-0030" title="RazR , CarassoRL , YehudaS . The influence of short-chain essential fatty acids on children with attention-deficit/hyperactivity disorder: a double-blind placebo-controlled study. Journal of Child and Adolescent Psychopharmacology2009;19(2):167-77. [DOI: 10.1089/cap.2008.070] [PMID: 19364294]">Raz 2009a</a>; <a href="./references#CD007986-bbs2-0031" title="RodríguezC , GarcíaT , ArecesD , FernándezE , García-NoriegaM , DomingoJC . Supplementation with high-content docosahexaenoic acid triglyceride in attention-deficit hyperactivity disorder: a randomized double-blind placebo-controlled trial. Neuropsychiatric Disease and Treatment2019;15:1193-209. [DOI: 10.2147/NDT.S206020] [PMID: 31190827] [PMID: PMC6514260]">Rodriguez 2019</a>; <a href="./references#CD007986-bbs2-0033" title="SinnN , BryanJ , WilsonC . Cognitive effects of polyunsaturated fatty acids in children with attention deficit hyperactivity disorder symptoms: a randomised controlled trial. Prostaglandins Leukotrienes and Essential Fatty Acids2008;78(4-5):311-26. [DOI: 10.1016/j.plefa.2008.04.004] [PMID: 18514501]SinnN , BryanJ . Effect of supplementation with polyunsaturated fatty acids and micronutrients on learning and behavior problems associated with child ADHD. Journal of Developmental and Behavioral Pediatrics2007;28(2):82-91. [DOI: 10.1097/01.DBP.0000267558.88457.a5] [PMID: 17435458]">Sinn 2007</a>; <a href="./references#CD007986-bbs2-0034" title="StevensL , ZhangW , PeckL , KuczekT , GrevstadN , MahonA , et al. EFA supplementation in children with inattention, hyperactivity, and other disruptive behaviors. Lipids2003;38(10):1007-21. [DOI: 10.1007/s11745-006-1155-0] [PMID: 14669965]">Stevens 2003</a>; <a href="./references#CD007986-bbs2-0035" title="NCT00382616. Supplementation of phosphatidylserine (PS) and n-3 long chain fatty acids (EPA, DHA) in children with ADHD. clinicaltrials.gov/ct2/show/NCT00382616 (first received 29 September 2006). VaismanN , KaysarN , Zaruk-AdashaY , PelledD , BrichonG , ZwingelsteinG , et al. Correlation between changes in blood fatty acid composition and visual sustained attention performance in children with inattention: effect of dietary n-3 fatty acids containing phospholipids. American Journal of Clinical Nutrition2008;87(5):1170-80. [DOI: 10.1093/ajcn/87.5.1170] [PMID: 18469236]">Vaisman 2008</a>; <a href="./references#CD007986-bbs2-0036" title="VoigtRG , LlorenteAM , JensenCL , FraleyJK , BerrettaMC , HeirdWC . A randomized, double-blind, placebo-controlled trial of docosahexaenoic acid supplementation in children with attention-deficit/hyperactivity disorder. Journal of Pediatrics2001;139(2):189-96. [DOI: 10.1067/mpd.2001.116050] [PMID: 11487742]">Voigt 2001</a>). We considered the remaining studies as at unclear risk of bias because of insufficient information. </p> </section> <section id="CD007986-sec-0072"> <h4 class="title">Selective reporting</h4> <p>We assessed 16 studies as at low risk of reporting bias as all outcomes appear to have been reported (<a href="./references#CD007986-bbs2-0001" title="AmanMG , MitchellEA , TurbottSH . The effects of essential fatty acid supplementation by efamol in hyperactive children. Journal of Abnormal Child Psychology1987;15(1):75-90. [DOI: 10.1007/BF00916467]">Aman 1987</a>; <a href="./references#CD007986-bbs2-0004" title="AssarehM , Davari AshtianiR , KhademiM , JazayeriS , RaiA , NikooM . Efficacy of polyunsaturated fatty acids (PUFA) in the treatment of attention deficit hyperactivity disorder: a randomized, double-blind, placebo-controlled clinical trial. Journal of Attention Disorders2017;21(1):78-85. [DOI: 10.1177/1087054712463962] [PMID: 23160488]IRCT138803122000N1. Poly unsaturated fatty acid as a combination treatment in children with attention deficit hyperactivity disorder [Omega-3 in the treatment of attention deficit hyperactivity disorder]. en.irct.ir/trial/1598?revision=1598 (first received 21 May 2011). ">Assareh 2017</a>; <a href="./references#CD007986-bbs2-0005" title="BarragánE , BreuerD , DöpfnerM . Efficacy and safety of omega-3/6 fatty acids, methylphenidate, and a combined treatment in children with ADHD. Journal of Attention Disorders2017;21(5):433-41. [DOI: 10.1177/1087054713518239] [PMID: 24464327]">Barragán 2017</a>; <a href="./references#CD007986-bbs2-0006" title="BehdaniF , HebraniP , NaseraeeA , HaghighiMB , AkhavanrezayatA . Does omega-3 supplement enhance the therapeutic results of methylphenidate in attention deficit hyperactivity disorder patients?Journal of Research in Medical Sciences2013;18(8):653-8. [PMCID: PMC3872603] [PMID: 24379840]">Behdani 2013</a>; <a href="./references#CD007986-bbs2-0009" title="BrueAW , OaklandTD , EvansRA . The use of a dietary supplement combination and an essential fatty acid as an alternative and complementary treatment for children with attention-deficit/hyperactivity disorder. Scientific Review of Alternative Medicine2001;5(4):187-94. [WEB PAGE: tinyurl.com/y56pdtxq]BrueAW . The Use of a Dietary Supplement Combination and an Essential Fatty Acid as an Alternative and Complementary Treatment for Children with Attention Deficit Hyperactivity Disorder (ADHD) [PhD thesis]. Gainesville (FL): University of Florida, 1999. ">Brue 2001</a>; <a href="./references#CD007986-bbs2-0014" title="Dubnov-RazG , KhouryZ , WrightI , RazR , BergerI . The effect of alpha-linolenic acid supplementation on ADHD symptoms in children: a randomized controlled double-blind study. Frontiers in Human Neuroscience2014;8:780. [DOI: 10.3389/fnhum.2014.00780] [PMCID: PMC4188038] [PMID: 25339885]NCT00874536. Omega-3 supplementation and attention-deficit-hyperactivity disorder (ADHD) [The effect of omega-3 fatty acid supplementation on behavior of children with ADHD]. clinicaltrials.gov/show/nct00874536 (first received 1 April 2009). ">Dubnov‐Raz 2014</a>; <a href="./references#CD007986-bbs2-0016" title="EUCTR2004-003853-13-SE. Placebo controlled, randomised, double-blind, multicentre study of PlusEPA (a PUFA, polyunsaturated fatty acids, supplement) as treatment for ADHD (combined type) with co-morbidity in Swedish children ages 7-12. www.clinicaltrialsregister.eu/ctr-search/trial/2004-003853-13/SE (first received 16 November 2004). GustafssonPA , Birberg-ThornbergU , DuchénK , LandgrenM , MalmbergK , PellingH , et al. EPA supplementation improves teacher-rated behaviour and oppositional symptoms in children with ADHD. Acta Paediatrica2010;99(10):1540-9. [DOI: 10.1111/j.1651-2227.2010.01871.x] [PMID: 20491709]">Gustafsson 2010</a>; <a href="./references#CD007986-bbs2-0017" title="HaririM , DjazayeryA , DjalaliM , SaedisomeoliaA , RahimiA , AbdolahianE . Effect of n-3 supplementation on hyperactivity, oxidative stress and inflammatory mediators in children with attention-deficit-hyperactivity disorder. Malaysian Journal of Nutrition2012;18(3):329-52. [PMID: 24568073]">Hariri 2012</a>; <a href="./references#CD007986-bbs2-0018" title="HamazakiT , HirayamaS . The effect of docosahexaenoic acid-containing food administration on symptoms of attention-deficit/hyperactivity disorder - a placebo-controlled double-blind study. European Journal of Clinical Nutrition2004;58(5):838. [DOI: 10.1038/sj.ejcn.1601888] [PMID: 15116088]HirayamaS , HamazakiT , TerasawaK . Effect of docosahexaenoic acid-containing food administration on symptoms of attention-deficit/hyperactivity disorder - a placebo-controlled double-blind study. European Journal of Clinical Nutrition2004;58(3):467-73. [DOI: 10.1038/sj.ejcn.1601830] [PMID: 14985685]">Hirayama 2004</a>; <a href="./references#CD007986-bbs2-0024" title="EUCTR2005-005330-12-GB. Omega-3 fatty acids supplementation for adolescent boys with attention deficit hyperactivity disorder: a double-blind, randomized controlled trial - MAAFA. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2005-005330-12-GB (first received 10 April 2006). ISRCTN27741572. Omega-3 fatty acids supplementation for adolescent boys with attention deficit hyperactivity disorder: a double-blind, randomized controlled trial. tinyurl.com/jz99z7vd (first received 10 March 2006). [DOI: 10.1186/ISRCTN27741572]MatsudairaT , GowRV , KellyJ , MurphyC , PottsL , SumichA , et al. Biochemical and psychological effects of omega-3/6 supplements in male adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, clinical trial. Journal of Child &amp; Adolescent Psychopharmacology2015;25(10):775-82. [DOI: 10.1089/cap.2015.0052] [PMCID: PMC4691649] [PMID: 26682998]MatsudairaT . Omega-3 PUFA Fatty Acids and Attention-Deficit/Hyperactivity Disorder [PhD thesis]. London, UK: King's College London, University of London, 2011. ">Matsudaira 2015</a>; <a href="./references#CD007986-bbs2-0028" title="NCT01807299. The effect of physical training and the omega 3 consumption on attention deficit hyperactivity disorder in children (AOE) [The effect of physical training and the omega 3 consumption on attention deficit]. clinicaltrials.gov/ct2/show/NCT01807299 (first received 7 March 2013). ">NCT01807299</a>; <a href="./references#CD007986-bbs2-0029" title="PereraH , JeewandaraKC , SeneviratneS , GurugeC . Combined ω3 and ω6 supplementation in children with attention-deficit hyperactivity disorder (ADHD) refractory to methylphenidate treatment: a double-blind, placebo-controlled study. Journal of Child Neurology2012;27(6):747‐53. [DOI: 10.1177/0883073811435243] [PMID: 22596014]SLCTR/2009/006. Effectiveness of omega-3 and omega-6 in childhood behaviour disorders [Effectiveness of omega-3 and omega-6 in children with neuro-developmental disorders: a double-blind placebo-controlled study]. slctr.lk/trials/slctr-2009-006 (first received 17 July 2009). ">Perera 2012</a>; <a href="./references#CD007986-bbs2-0031" title="RodríguezC , GarcíaT , ArecesD , FernándezE , García-NoriegaM , DomingoJC . Supplementation with high-content docosahexaenoic acid triglyceride in attention-deficit hyperactivity disorder: a randomized double-blind placebo-controlled trial. Neuropsychiatric Disease and Treatment2019;15:1193-209. [DOI: 10.2147/NDT.S206020] [PMID: 31190827] [PMID: PMC6514260]">Rodriguez 2019</a>; <a href="./references#CD007986-bbs2-0034" title="StevensL , ZhangW , PeckL , KuczekT , GrevstadN , MahonA , et al. EFA supplementation in children with inattention, hyperactivity, and other disruptive behaviors. Lipids2003;38(10):1007-21. [DOI: 10.1007/s11745-006-1155-0] [PMID: 14669965]">Stevens 2003</a>; <a href="./references#CD007986-bbs2-0035" title="NCT00382616. Supplementation of phosphatidylserine (PS) and n-3 long chain fatty acids (EPA, DHA) in children with ADHD. clinicaltrials.gov/ct2/show/NCT00382616 (first received 29 September 2006). VaismanN , KaysarN , Zaruk-AdashaY , PelledD , BrichonG , ZwingelsteinG , et al. Correlation between changes in blood fatty acid composition and visual sustained attention performance in children with inattention: effect of dietary n-3 fatty acids containing phospholipids. American Journal of Clinical Nutrition2008;87(5):1170-80. [DOI: 10.1093/ajcn/87.5.1170] [PMID: 18469236]">Vaisman 2008</a>; <a href="./references#CD007986-bbs2-0037" title="Widenhorn-MüllerK , SchwandaS , ScholzE , SpitzerM , BodeH . Effect of supplementation with long-chain ω-3 polyunsaturated fatty acids on behavior and cognition in children with attention deficit/hyperactivity disorder (ADHD): a randomized placebo-controlled intervention trial. Prostaglandins Leukotrienes and Essential Fatty Acids2014;91(1-2):49-60. [DOI: 10.1016/j.plefa.2014.04.004] [PMID: 24958525]">Widenhorn‐Müller 2014</a>). There was a high risk of reporting bias in seven trials because the result of at least one outcome was not reported (<a href="./references#CD007986-bbs2-0003" title="ArnoldLE , KleykampD , VotolatoN , GibsonRA , HorrocksL . Potential link between dietary intake of fatty acids and behavior: pilot exploration of serum lipids in attention-deficit hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology1994;4(3):171-82. [DOI: 10.1089/cap.1994.4.171]ArnoldLE , KleykampD , VotolatoNA , TaylorWA , KontrasSB , TobinK . Gamma-linolenic acid for attention-deficit hyperactivity disorder: placebo-controlled comparison to D-amphetamine. Biological Psychiatry1989;25(2):222-8. [DOI: 10.1016/0006-3223(89)90167-4] [PMID: 2539203]ArnoldLE , PinkhamSM , VotolatoN . Does zinc moderate essential fatty acid and amphetamine treatment of attention-deficit/hyperactivity disorder?Journal of Child and Adolescent Psychopharmacology2000;10(2):111-7. [DOI: 10.1089/cap.2000.10.111] [PMID: 10933121]">Arnold 1989</a>; <a href="./references#CD007986-bbs2-0007" title="BélangerSA , VanasseM , SpahisS , SylvestreMP , LippéS , L'HeureuxF , et al. Omega-3 fatty acid treatment of children with attention-deficit hyperactivity disorder: a randomized, double-blind, placebo-controlled study. Paediatrics and Child Health2009;14(2):89-98. [DOI: 10.1093/pch/14.2.89] [PMCID: PMC2661342] [PMID: 19436468]VanasseM , Ageranioti-BélangerS , L'HeureuxF , GhadirianP , LevyE , SpahisS , et al. A randomized, controlled trial of omega-3 and phospholipids supplementation in children with attention-deficit-hyperactivity disorder. Developmental Medicine &amp; Child Neurology2006;48(Suppl 107):48. [DOI: 10.1111/j.1469-8749.2006.tb12600.x]">Bélanger 2009</a>; <a href="./references#CD007986-bbs2-0023" title="ManorI , MagenA , KeidarD , RosenS , TaskerH , CohenT , et al. The effect of phosphatidylserine containing omega3 fatty-acids on attention-deficit hyperactivity disorder symptoms in children: a double-blind placebo-controlled trial, followed by an open-label extension. European Psychiatry2012;27(5):335-42. [DOI: 10.1016/j.eurpsy.2011.05.004] [PMID: 21807480]NCT00418184. The efficacy and safety of phosphatidylserine-omega3 in children with attention-deficit/hyperactivity disorder [A single-center, randomized, double-blind, placebo-controlled study of the efficacy and safety of phosphatidylserine-omega3 in children with attention-deficit/hyperactivity disorder]. clinicaltrials.gov/show/NCT00418184 (first received 4 January 2007). ">Manor 2012</a>; <a href="./references#CD007986-bbs2-0027" title="IRCT2016060128182N2. Omega-3 supplement in attention deficit hyperactivity disorder [The effectiveness of omega-3 supplement as an adjunctive therapy in children with attention deficit hyperactivity disorder]. www.irct.ir/trial/22914 (first received 23 January 2017). MohammadzadehS , BaghiN , YousefiF , YousefzamaniB . Effect of omega-3 plus methylphenidate as an alternative therapy to reduce attention deficit-hyperactivity disorder in children. Korean Journal of Pediatrics2019;62(9):360-6. [DOI: 10.3345/kjp.2018.06982] [PMCID: PMC6753311] [PMID: 31122010]">Mohammadzadeh 2019</a>; <a href="./references#CD007986-bbs2-0030" title="RazR , CarassoRL , YehudaS . The influence of short-chain essential fatty acids on children with attention-deficit/hyperactivity disorder: a double-blind placebo-controlled study. Journal of Child and Adolescent Psychopharmacology2009;19(2):167-77. [DOI: 10.1089/cap.2008.070] [PMID: 19364294]">Raz 2009a</a>; <a href="./references#CD007986-bbs2-0033" title="SinnN , BryanJ , WilsonC . Cognitive effects of polyunsaturated fatty acids in children with attention deficit hyperactivity disorder symptoms: a randomised controlled trial. Prostaglandins Leukotrienes and Essential Fatty Acids2008;78(4-5):311-26. [DOI: 10.1016/j.plefa.2008.04.004] [PMID: 18514501]SinnN , BryanJ . Effect of supplementation with polyunsaturated fatty acids and micronutrients on learning and behavior problems associated with child ADHD. Journal of Developmental and Behavioral Pediatrics2007;28(2):82-91. [DOI: 10.1097/01.DBP.0000267558.88457.a5] [PMID: 17435458]">Sinn 2007</a>; <a href="./references#CD007986-bbs2-0036" title="VoigtRG , LlorenteAM , JensenCL , FraleyJK , BerrettaMC , HeirdWC . A randomized, double-blind, placebo-controlled trial of docosahexaenoic acid supplementation in children with attention-deficit/hyperactivity disorder. Journal of Pediatrics2001;139(2):189-96. [DOI: 10.1067/mpd.2001.116050] [PMID: 11487742]">Voigt 2001</a>). We assessed the remaining studies as at unclear risk of bias. </p> </section> <section id="CD007986-sec-0073"> <h4 class="title">Other potential sources of bias</h4> <p>We considered 11 studies as at high risk of other bias as they were fully (<a href="./references#CD007986-bbs2-0001" title="AmanMG , MitchellEA , TurbottSH . The effects of essential fatty acid supplementation by efamol in hyperactive children. Journal of Abnormal Child Psychology1987;15(1):75-90. [DOI: 10.1007/BF00916467]">Aman 1987</a>; <a href="./references#CD007986-bbs2-0003" title="ArnoldLE , KleykampD , VotolatoN , GibsonRA , HorrocksL . Potential link between dietary intake of fatty acids and behavior: pilot exploration of serum lipids in attention-deficit hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology1994;4(3):171-82. [DOI: 10.1089/cap.1994.4.171]ArnoldLE , KleykampD , VotolatoNA , TaylorWA , KontrasSB , TobinK . Gamma-linolenic acid for attention-deficit hyperactivity disorder: placebo-controlled comparison to D-amphetamine. Biological Psychiatry1989;25(2):222-8. [DOI: 10.1016/0006-3223(89)90167-4] [PMID: 2539203]ArnoldLE , PinkhamSM , VotolatoN . Does zinc moderate essential fatty acid and amphetamine treatment of attention-deficit/hyperactivity disorder?Journal of Child and Adolescent Psychopharmacology2000;10(2):111-7. [DOI: 10.1089/cap.2000.10.111] [PMID: 10933121]">Arnold 1989</a>; <a href="./references#CD007986-bbs2-0005" title="BarragánE , BreuerD , DöpfnerM . Efficacy and safety of omega-3/6 fatty acids, methylphenidate, and a combined treatment in children with ADHD. Journal of Attention Disorders2017;21(5):433-41. [DOI: 10.1177/1087054713518239] [PMID: 24464327]">Barragán 2017</a>; <a href="./references#CD007986-bbs2-0008" title="BosD , Van BelleJ , WeustenJ , HoeksmaM , WisemanS , DurstonS . Effects of N-3 fatty acids (DHA and EPA) on cognitive control and associated brain activity in ADHD: a double-blind placebo controlled study. European Child &amp; Adolescent Psychiatry2010;19(Suppl 1):S69. [DOI: 10.1007/s00787-010-0117-5]BosD , Van BelleJ , WeustenJ , HoeksmaM , WisemanS , DurstonS . Effects of N-3 fatty acids (DHA and EPA) on cognitive control and associated brain activity in ADHD: a double-blind placebo controlled study. In: European Child and Adolescent Psychiatry, Conference: Eunethydis 1st International ADHD Conference: From Data to Best Clinical Practice; 2010 May 26–28; Amsterdam. 2010. BosDJ , OranjeB , VeerhoekES , Van DiepenRM , Weusten JMh, DemmelmairH , et al. Reduced symptoms of inattention after dietary omega-3 fatty acid supplementation in boys with and without attention deficit/hyperactivity disorder. Neuropsychopharmacology2015;40(10):2298–306. [DOI: 10.1038/npp.2015.73] [PMCID: PMC4538345] [PMID: 25790022]">Bos 2015</a>; <a href="./references#CD007986-bbs2-0011" title="CornuC , MercierC , GinhouxT , MassonS , MouchetJ , NonyP , et al. A double-blind placebo-controlled randomised trial of omega-3 supplementation in children with moderate ADHD symptoms. European Child &amp; Adolescent Psychiatry2018;27(3):377‐84. [DOI: 10.1007/s00787-017-1058-z] [PMID: 28993963]NCT00770627. Clinical trial to evaluate the efficacy and the tolerance of an omega 3 fatty acids supplementation in ADHD children [A randomized, controlled, double blind placebo trial to evaluate the efficacy and the tolerance of an omega 3 fatty acids supplementation in ADHD children]. clinicaltrials.gov/ct2/show/record/NCT00770627 (first received 9 October 2008). ">Cornu 2018</a>; <a href="./references#CD007986-bbs2-0012" title="CrippaA , AgostoniC , MauriM , MolteniM , NobileM . Polyunsaturated fatty acids are associated with behavior but not with cognition in children with and without ADHD: an Italian study. Journal of Attention Disorders2018;22(10):971-83. [DOI: 10.1177/1087054716629215]CrippaA , TeseiA , SangiorgioF , SalandiA , TrabattoniS , GrazioliS , et al. Behavioral and cognitive effects of docosahexaenoic acid in drug-naïve children with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled clinical trial. European Child &amp; Adolescent Psychiatry2019;28(4):571-83. [DOI: 10.1007/s00787-018-1223-z] [PMID: 30246216]NCT01796262. The effects of DHA on attention deficit and hyperactivity disorder (DADA) [The effects of DHA (docosahexaenoic acid) on attention deficit and hyperactivity disorder]. clinicaltrials.gov/show/nct01796262 (first received 12 February 2013). ">Crippa 2019</a>; <a href="./references#CD007986-bbs2-0020" title="JohnsonM , OstlundS , FranssonG , KadesjöB , GillbergC . Omega-3/omega-6 fatty acids for attention deficit hyperactivity disorder: a randomized placebo-controlled trial in children and adolescents. Journal of Attention Disorders2009;12(5):394-401. [DOI: 10.1177/1087054708316261] [PMID: 18448859]NCT01219309. Omega-3/omega-6 fatty acids for attention-deficit/hyperactivity disorder (ADHD): a trial in children and adolescents. clinicaltrials.gov/show/NCT01219309. (first received 30 October 2010). ">Johnson 2009</a>; <a href="./references#CD007986-bbs2-0021" title="KeanJD , SarrisJ , ScholeyA , SilbersteinR , DowneyLA , StoughC . Reduced inattention and hyperactivity and improved cognition after marine oil extract (PCSO-524®) supplementation in children and adolescents with clinical and subclinical symptoms of attention-deficit hyperactivity disorder (ADHD): a randomised, double-blind, placebo-controlled trial. Psychopharmacology2017;234(3):403-20. [DOI: 10.1007/s00213-016-4471-y] [PMCID: PMC5225177] [PMID: 27921139]">Kean 2017</a>; <a href="./references#CD007986-bbs2-0023" title="ManorI , MagenA , KeidarD , RosenS , TaskerH , CohenT , et al. The effect of phosphatidylserine containing omega3 fatty-acids on attention-deficit hyperactivity disorder symptoms in children: a double-blind placebo-controlled trial, followed by an open-label extension. European Psychiatry2012;27(5):335-42. [DOI: 10.1016/j.eurpsy.2011.05.004] [PMID: 21807480]NCT00418184. The efficacy and safety of phosphatidylserine-omega3 in children with attention-deficit/hyperactivity disorder [A single-center, randomized, double-blind, placebo-controlled study of the efficacy and safety of phosphatidylserine-omega3 in children with attention-deficit/hyperactivity disorder]. clinicaltrials.gov/show/NCT00418184 (first received 4 January 2007). ">Manor 2012</a>; <a href="./references#CD007986-bbs2-0029" title="PereraH , JeewandaraKC , SeneviratneS , GurugeC . Combined ω3 and ω6 supplementation in children with attention-deficit hyperactivity disorder (ADHD) refractory to methylphenidate treatment: a double-blind, placebo-controlled study. Journal of Child Neurology2012;27(6):747‐53. [DOI: 10.1177/0883073811435243] [PMID: 22596014]SLCTR/2009/006. Effectiveness of omega-3 and omega-6 in childhood behaviour disorders [Effectiveness of omega-3 and omega-6 in children with neuro-developmental disorders: a double-blind placebo-controlled study]. slctr.lk/trials/slctr-2009-006 (first received 17 July 2009). ">Perera 2012</a>; <a href="./references#CD007986-bbs2-0036" title="VoigtRG , LlorenteAM , JensenCL , FraleyJK , BerrettaMC , HeirdWC . A randomized, double-blind, placebo-controlled trial of docosahexaenoic acid supplementation in children with attention-deficit/hyperactivity disorder. Journal of Pediatrics2001;139(2):189-96. [DOI: 10.1067/mpd.2001.116050] [PMID: 11487742]">Voigt 2001</a>) or partly (<a href="./references#CD007986-bbs2-0007" title="BélangerSA , VanasseM , SpahisS , SylvestreMP , LippéS , L'HeureuxF , et al. Omega-3 fatty acid treatment of children with attention-deficit hyperactivity disorder: a randomized, double-blind, placebo-controlled study. Paediatrics and Child Health2009;14(2):89-98. [DOI: 10.1093/pch/14.2.89] [PMCID: PMC2661342] [PMID: 19436468]VanasseM , Ageranioti-BélangerS , L'HeureuxF , GhadirianP , LevyE , SpahisS , et al. A randomized, controlled trial of omega-3 and phospholipids supplementation in children with attention-deficit-hyperactivity disorder. Developmental Medicine &amp; Child Neurology2006;48(Suppl 107):48. [DOI: 10.1111/j.1469-8749.2006.tb12600.x]">Bélanger 2009</a>; <a href="./references#CD007986-bbs2-0015" title="GowR . An Investigation Into Long-Chain Polyunsaturated Essential Fatty Acids, Event Related Potential Assessments of Brain Function and Behavioural Measures in Children and Adolescents With and Without Attention Deficit Hyperactivity Disorder [PhD thesis]. London, UK: King's College London, University of London, 2012. ">Gow 2012</a>; <a href="./references#CD007986-bbs2-0034" title="StevensL , ZhangW , PeckL , KuczekT , GrevstadN , MahonA , et al. EFA supplementation in children with inattention, hyperactivity, and other disruptive behaviors. Lipids2003;38(10):1007-21. [DOI: 10.1007/s11745-006-1155-0] [PMID: 14669965]">Stevens 2003</a>) funded by a company that produced PUFA supplements. </p> <p>There were other potential confounding variables in five studies. In <a href="./references#CD007986-bbs2-0001" title="AmanMG , MitchellEA , TurbottSH . The effects of essential fatty acid supplementation by efamol in hyperactive children. Journal of Abnormal Child Psychology1987;15(1):75-90. [DOI: 10.1007/BF00916467]">Aman 1987</a>, it was not clear whether the additional five children included in the trial would have met the original inclusion criteria. The PUFA group in <a href="./references#CD007986-bbs2-0009" title="BrueAW , OaklandTD , EvansRA . The use of a dietary supplement combination and an essential fatty acid as an alternative and complementary treatment for children with attention-deficit/hyperactivity disorder. Scientific Review of Alternative Medicine2001;5(4):187-94. [WEB PAGE: tinyurl.com/y56pdtxq]BrueAW . The Use of a Dietary Supplement Combination and an Essential Fatty Acid as an Alternative and Complementary Treatment for Children with Attention Deficit Hyperactivity Disorder (ADHD) [PhD thesis]. Gainesville (FL): University of Florida, 1999. ">Brue 2001</a> had received an additional 12 weeks of dietary supplementation before the PUFA trial was started. In <a href="./references#CD007986-bbs2-0034" title="StevensL , ZhangW , PeckL , KuczekT , GrevstadN , MahonA , et al. EFA supplementation in children with inattention, hyperactivity, and other disruptive behaviors. Lipids2003;38(10):1007-21. [DOI: 10.1007/s11745-006-1155-0] [PMID: 14669965]">Stevens 2003</a>, although both groups were comparable over a large range of variables, the Conners Parent score and reaction time were significantly lower in the PUFA group. There were fewer children with Asperger's syndrome and more children with a learning disorder in the PUFA group in the trial reported by <a href="./references#CD007986-bbs2-0018" title="HamazakiT , HirayamaS . The effect of docosahexaenoic acid-containing food administration on symptoms of attention-deficit/hyperactivity disorder - a placebo-controlled double-blind study. European Journal of Clinical Nutrition2004;58(5):838. [DOI: 10.1038/sj.ejcn.1601888] [PMID: 15116088]HirayamaS , HamazakiT , TerasawaK . Effect of docosahexaenoic acid-containing food administration on symptoms of attention-deficit/hyperactivity disorder - a placebo-controlled double-blind study. European Journal of Clinical Nutrition2004;58(3):467-73. [DOI: 10.1038/sj.ejcn.1601830] [PMID: 14985685]">Hirayama 2004</a>, although this was not significant. More than half of the children in the PUFA group in <a href="./references#CD007986-bbs2-0033" title="SinnN , BryanJ , WilsonC . Cognitive effects of polyunsaturated fatty acids in children with attention deficit hyperactivity disorder symptoms: a randomised controlled trial. Prostaglandins Leukotrienes and Essential Fatty Acids2008;78(4-5):311-26. [DOI: 10.1016/j.plefa.2008.04.004] [PMID: 18514501]SinnN , BryanJ . Effect of supplementation with polyunsaturated fatty acids and micronutrients on learning and behavior problems associated with child ADHD. Journal of Developmental and Behavioral Pediatrics2007;28(2):82-91. [DOI: 10.1097/01.DBP.0000267558.88457.a5] [PMID: 17435458]">Sinn 2007</a> also received a multivitamin. <a href="./references#CD007986-bbs2-0033" title="SinnN , BryanJ , WilsonC . Cognitive effects of polyunsaturated fatty acids in children with attention deficit hyperactivity disorder symptoms: a randomised controlled trial. Prostaglandins Leukotrienes and Essential Fatty Acids2008;78(4-5):311-26. [DOI: 10.1016/j.plefa.2008.04.004] [PMID: 18514501]SinnN , BryanJ . Effect of supplementation with polyunsaturated fatty acids and micronutrients on learning and behavior problems associated with child ADHD. Journal of Developmental and Behavioral Pediatrics2007;28(2):82-91. [DOI: 10.1097/01.DBP.0000267558.88457.a5] [PMID: 17435458]">Sinn 2007</a> also reported that baseline scores for ADHD symptoms were significantly higher in the group lost to follow‐up. </p> <p>We considered six studies to be at low risk of other potential sources of bias as they reported that there were no apparent differences between groups in potentially confounding characteristics, and there were no other apparent sources of bias (<a href="./references#CD007986-bbs2-0013" title="DashtiN , HekmatH , SoltaniHR , RahimdelA , JavaherchianM . Comparison of therapeutic effects of omega-3 and methylphenidate (ritalin(®)) in treating children with attention deficit hyperactivity disorder. Iranian Journal of Psychiatry and Behavioral Sciences2014;8(4):7-11. [PMCID: PMC4364471] [PMID: 25798168]">Dashti 2014</a>; <a href="./references#CD007986-bbs2-0017" title="HaririM , DjazayeryA , DjalaliM , SaedisomeoliaA , RahimiA , AbdolahianE . Effect of n-3 supplementation on hyperactivity, oxidative stress and inflammatory mediators in children with attention-deficit-hyperactivity disorder. Malaysian Journal of Nutrition2012;18(3):329-52. [PMID: 24568073]">Hariri 2012</a>; <a href="./references#CD007986-bbs2-0024" title="EUCTR2005-005330-12-GB. Omega-3 fatty acids supplementation for adolescent boys with attention deficit hyperactivity disorder: a double-blind, randomized controlled trial - MAAFA. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2005-005330-12-GB (first received 10 April 2006). ISRCTN27741572. Omega-3 fatty acids supplementation for adolescent boys with attention deficit hyperactivity disorder: a double-blind, randomized controlled trial. tinyurl.com/jz99z7vd (first received 10 March 2006). [DOI: 10.1186/ISRCTN27741572]MatsudairaT , GowRV , KellyJ , MurphyC , PottsL , SumichA , et al. Biochemical and psychological effects of omega-3/6 supplements in male adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, clinical trial. Journal of Child &amp; Adolescent Psychopharmacology2015;25(10):775-82. [DOI: 10.1089/cap.2015.0052] [PMCID: PMC4691649] [PMID: 26682998]MatsudairaT . Omega-3 PUFA Fatty Acids and Attention-Deficit/Hyperactivity Disorder [PhD thesis]. London, UK: King's College London, University of London, 2011. ">Matsudaira 2015</a>; <a href="./references#CD007986-bbs2-0025" title="ACTRN12607000332426. Omega-3 fatty acids for ADHD symptoms and learning difficulties in children [Randomised controlled trial investigating effect of supplementation with omega-3 fatty acids EPA and DHA versus omega-6 fatty acid LA on ADHD symptoms and learning difficulties in 7-12 year old children]. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=82104 (first received 19 June 2007). MilteCM , ParlettaN , BuckleyJD , CoatesAM , YoungRM , HowePR . Eicosapentaenoic and docosahexaenoic acids, cognition, and behavior in children with attention-deficit/hyperactivity disorder: a randomized controlled trial. Nutrition2012;28(6):670-7. [DOI: 10.1016/j.nut.2011.12.009] [PMID: 22541055]">Milte 2012</a>; <a href="./references#CD007986-bbs2-0027" title="IRCT2016060128182N2. Omega-3 supplement in attention deficit hyperactivity disorder [The effectiveness of omega-3 supplement as an adjunctive therapy in children with attention deficit hyperactivity disorder]. www.irct.ir/trial/22914 (first received 23 January 2017). MohammadzadehS , BaghiN , YousefiF , YousefzamaniB . Effect of omega-3 plus methylphenidate as an alternative therapy to reduce attention deficit-hyperactivity disorder in children. Korean Journal of Pediatrics2019;62(9):360-6. [DOI: 10.3345/kjp.2018.06982] [PMCID: PMC6753311] [PMID: 31122010]">Mohammadzadeh 2019</a>; <a href="./references#CD007986-bbs2-0030" title="RazR , CarassoRL , YehudaS . The influence of short-chain essential fatty acids on children with attention-deficit/hyperactivity disorder: a double-blind placebo-controlled study. Journal of Child and Adolescent Psychopharmacology2009;19(2):167-77. [DOI: 10.1089/cap.2008.070] [PMID: 19364294]">Raz 2009a</a>). </p> </section> </section> <section id="CD007986-sec-0074"> <h3 class="title" id="CD007986-sec-0074">Effects of interventions</h3> <p>See: <a href="./full#CD007986-tbl-0001"><b>Summary of findings 1</b> Summary of findings table ‐ PUFA compared to placebo for children and adolescents with ADHD</a> </p> <section id="CD007986-sec-0075"> <h4 class="title">Comparison 1: PUFA versus placebo</h4> <section id="CD007986-sec-0076"> <h5 class="title">ADHD symptoms</h5> <p>There were seven data sets from six trials looking at ADHD symptoms. Improvement was more likely in the group receiving PUFA compared to placebo at short term: risk ratio (RR) 1.22, 95% confidence interval (CI) 0.85 to 1.76; 2 studies, 80 participants; Tau² = 0.04; Chi² = 2.68, df = 1 (P = 0.10); I² = 63%; medium term: RR 1.95, 95% CI 1.47 to 2.60; 3 studies, 191 participants; Tau² = 0.00; Chi² = 1.34, df = 2 (P = 0.51); I² = 0%; or in the long term: RR 1.67, 95% CI 0.70 to 3.95; 2 studies, 141 participants; Tau² = 0.36; Chi² = 15.41, df = 1 (P &lt; 0.001); I² = 94%; <a href="./references#CD007986-fig-0007" title="">Analysis 1.1</a>. We assessed the evidence that children and adolescents receiving PUFA were more likely to improve compared to those receiving placebo as of low certainty (<a href="./full#CD007986-tbl-0001">summary of findings Table 1</a>). </p> <p>There were no differences between groups in parent ratings of overall ADHD symptoms at any time point (short term: standardised mean difference (SMD) 0.17, 95% CI −0.25 to 0.59; 7 studies, 442 participants; Tau² = 0.27; Chi² = 30.80, df = 7 (P &lt; 0.001); I² = 77%; medium term: SMD −0.08, 95% CI −0.24 to 0.07; 16 studies, 1166 participants; Tau² = 0.04; Chi² = 24.62, df = 15 (P = 0.06); I² = 39%; long term: SMD −0.30, 95% CI −0.81 to 0.21; 1 study, 60 participants; Tau<sup>2</sup> = 0.04; I<sup>2</sup> = 0%; <a href="./references#CD007986-fig-0008" title="">Analysis 1.2</a>). Likewise, there were no differences for parent‐rated inattention (short term: SMD 0.01, 95% CI −0.31 to 0.33; 5 studies, 283 participants; Tau² = 0.06; Chi² = 7.57, df = 4 (P = 0.11); I² = 47%; medium term: SMD −0.01, 95% CI −0.20 to 0.17; 12 studies, 960 participants; Tau² = 0.04; Chi² = 17.16, df = 10 (P = 0.07); I² = 42%; long term: SMD −0.39, 95% CI −0.90 to 0.12; 1 study, 60 participants; I<sup>2</sup> = 0%; <a href="./references#CD007986-fig-0009" title="">Analysis 1.3</a>) and parent‐rated hyperactivity/impulsivity (short term: SMD 0.15, 95% CI −0.20 to 0.50; 5 studies, 283 participants; Tau² = 0.08; Chi² = 8.63, df = 4 (P = 0.07); I² = 54%; medium term: SMD 0.09, 95% CI −0.04 to 0.23; 10 studies, 869 participants; Tau² = 0.00; Chi² = 4.77, df = 9 (P = 0.85); I² = 0%; long term: SMD −0.21, 95% CI −0.72 to 0.29; 1 study, 60 participants; I<sup>2</sup> = 0%; <a href="./references#CD007986-fig-0010" title="">Analysis 1.4</a>). We assessed the evidence that PUFA had no effect on total ADHD symptoms, inattention, and hyperactivity/impulsivity as of high certainty (<a href="./full#CD007986-tbl-0001">summary of findings Table 1</a>). </p> <p>There were no clear differences in teacher ratings of overall ADHD symptoms in the short term: SMD 0.35, 95% CI −0.30 to 1.00; 4 studies, 185 participants; Tau² = 0.32; Chi² = 12.70, df = 3 (P = 0.005); I² = 76%; or the medium term: SMD 0.06, 95% CI −0.12 to 0.24; 5 studies, 598 participants; Tau² = 0.00; Chi² = 5.10, df = 5 (P = 0.40); I² = 2%; <a href="./references#CD007986-fig-0011" title="">Analysis 1.5</a>. There was also no difference in teacher‐rated inattention at any of the recorded time points (short term: SMD 0.02, 95% CI −0.40 to 0.44; 2 studies, 86 participants; Tau² = 0.00; Chi² = 0.04, df = 1 (P = 0.85); I² = 0%; medium term: SMD 0.17, 95% CI −0.14 to 0.49; 4 studies, 428 participants; Tau² = 0.07; Chi² = 9.67, df = 4 (P = 0.05); I² = 59%; <a href="./references#CD007986-fig-0012" title="">Analysis 1.6</a>) or in hyperactivity/impulsivity ratings in the short term: SMD 0.00, 95% CI −0.51 to 0.51; 1 study, 60 participants; I<sup>2</sup> = 0%; or medium term: SMD 00.15, 95% CI −0.03 to 0.34; 5 studies; 462 participants; Tau² = 0.00; Chi² = 4.30, df = 5 (P = 0.51); I² = 0%; <a href="./references#CD007986-fig-0013" title="">Analysis 1.7</a>. </p> <p>Three trials reported clinician ratings of overall ADHD symptoms. Total symptom scores rated by clinicians were lower in the PUFA group in the short term (SMD −0.74, 95% CI −1.08 to −0.40; 2 studies, 143 participants; I<sup>2</sup> = 0%) but not in the medium term (SMD −0.35, 95% CI −0.84 to 0.15; 1 study, 64 participants; Tau² = 0.00; Chi² = 0.01, df = 1 (P = 0.91); I² = 0%; <a href="./references#CD007986-fig-0014" title="">Analysis 1.8</a>). There were no differences between groups for clinician‐rated inattention (short term: SMD −0.05, 95% CI −1.00 to 0.90; 1 study, 17 participants; I<sup>2</sup> = 0%; medium term: SMD −0.29, 95% CI −0.65 to 0.07; 2 studies, 124 participants; Tau² = 0.00; Chi² = 0.01, df = 1 (P = 0.93); I² = 0%; <a href="./references#CD007986-fig-0015" title="">Analysis 1.9</a>) or for hyperactivity/impulsivity (short term: SMD 0.36, 95% CI −0.18 to 0.91; 2 studies, 53 participants; I<sup>2</sup> = 0%; medium term: SMD −0.28, 95% CI −0.77 to 0.21; 1 study, 64 participants; Tau² = 0.00; Chi² = 0.05, df = 1 (P = 0.82); I² = 0%; <a href="./references#CD007986-fig-0016" title="">Analysis 1.10</a>). </p> </section> <section id="CD007986-sec-0077"> <h5 class="title">Severity of behavioural problems</h5> <p>There were no differences between groups in parent‐rated internalising behaviour recorded at medium term (SMD 0.16, 95% CI −0.09 to 0.42; 3 studies, 237 participants; Tau² = 0.00; Chi² = 0.05, df = 1 (P = 0.82); I² = 0%; <a href="./references#CD007986-fig-0017" title="">Analysis 1.11</a>) or externalising behaviour in both the short term: SMD 0.02, 95% CI −0.49 to 0.52; 1 study, 60 participants; I<sup>2</sup> = 0%; and medium term: SMD 0.07, 95% CI −0.26 to 0.41; 5 studies, 340 participants; Tau² = 0.08; Chi² = 9.36, df = 4 (P = 0.05); I² = 57%; <a href="./references#CD007986-fig-0018" title="">Analysis 1.12</a>). Likewise, there were no clear differences in parent ratings of conduct in the short term: SMD −0.10, 95% CI −0.60 to 0.41; 1 study; 60 participants; I<sup>2</sup> = 0%; or medium term: SMD 0.16, 95% CI −0.05 to 0.38; 5 studies, 332 participants; Tau² = 0.00; Chi² = 1.14, df = 4 (P = 0.89); I² = 0%; <a href="./references#CD007986-fig-0019" title="">Analysis 1.13</a>. Similarly, there was no evidence of a difference in oppositional behaviour at medium term (SMD 0.02, 95% CI −0.17 to 0.21; 6 studies, 527 participants; Tau² = 0.01; Chi² = 5.69, df = 5 (P = 0.34); I² = 12%; <a href="./references#CD007986-fig-0020" title="">Analysis 1.14</a>) or socialisation behaviour also in the medium term (SMD 0.27, 95% CI −0.06 to 0.60; 2 studies, 145 participants; Tau² = 0.00; Chi² = 1.02, df = 1 (P = 0.31); I² = 2%; <a href="./references#CD007986-fig-0021" title="">Analysis 1.15</a>). </p> <p>There were no differences between groups in teacher ratings of conduct (short term: SMD −0.03, 95% CI −0.54 to 0.48; 1 study, 60 participants; I<sup>2</sup> = 0%; medium term: SMD −0.03, 95% CI −0.39 to 0.34; 2 studies, 118 participants; Tau² = 0.00; Chi² = 0.06, df = 1 (P = 0.80); I² = 0%; <a href="./references#CD007986-fig-0022" title="">Analysis 1.16</a>); oppositional behaviour (medium term: SMD 0.10, 95% CI −0.18 to 0.37; 2 studies, 224 participants; Tau² = 0.00; Chi² = 0.80, df = 1 (P = 0.37); I² = 0%; <a href="./references#CD007986-fig-0023" title="">Analysis 1.17</a>); or socialisation behaviour (medium term: SMD −0.16, 95% CI −0.58 to 0.27; 1 study, 85 participants; <a href="./references#CD007986-fig-0024" title="">Analysis 1.18</a>). </p> </section> <section id="CD007986-sec-0078"> <h5 class="title">Quality of life</h5> <p>There was no clear difference between omega‐3 PUFA and placebo groups in the medium term: SMD −0.01, 95% CI −0.37 to 0.35; 1 study, 138 participants; <a href="./references#CD007986-fig-0025" title="">Analysis 1.19</a>. </p> </section> <section id="CD007986-sec-0079"> <h5 class="title">Side effects</h5> <p>Side effects were reported at any time during the duration of the study.</p> <p>There was moderate‐certainty evidence that overall side effects did not differ between PUFA and placebo groups (RR 1.02, 95% CI 0.69 to 1.52; 8 studies, 591 participants; Tau² = 0.06; Chi² = 6.97, df = 5 (P = 0.22); I² = 28%; <a href="./full#CD007986-tbl-0001">summary of findings Table 1</a>). There was also no apparent difference between groups in appetite loss (RR 0.48, 95% CI 0.27 to 0.83; 1 study, 60 participants); anxiety (RR 0.38, 95% CI 0.11 to 1.28; 1 study, 60 participants); dermatitis (RR 1.43, 95% CI 0.06 to 34.36; 1 study, 147 participants); diarrhoea (RR 0.71, 95% CI 0.36 to 1.42; 3 studies, 207 participants; Tau² = 0.00; Chi² = 0.00, df = 1 (P = 0.96); I² = 0%); gastrointestinal discomfort (RR 0.73, 95% CI 0.24 to 2.23; 3 studies, 269 participants; Tau² = 0.00; Chi² = 0.02, df = 1 (P = 0.88); I² = 0%); headache (RR 0.54, 95% CI 0.30 to 0.97; 2 studies, 207 participants; Tau² = 0.00; Chi² = 0.65, df = 1 (P = 0.42); I² = 0%); hyperactivity (RR 1.43, 95% CI 0.06 to 34.36; 1 study, 147 participants); insomnia (RR 0.27, 95% CI 0.07 to 1.12; 2 studies, 122 participants; Tau² = 1.85; Chi² = 2.22, df = 1 (P = 0.14); I² = 55%); irritability (RR 0.07, 95% CI 0.00 to 1.12; 1 study, 60 participants); nausea (RR 1.00, 95% CI 0.43 to 2.33; 5 studies, 428 participants; Tau² = 0.00; Chi² = 1.33, df = 4 (P = 0.86); I² = 0%); nose bleed (RR 0.75, 95% CI 0.16 to 3.58; 2 studies, 158 participants; Tau² = 0.58; Chi² = 1.32, df = 1 (P = 0.25); I² = 24%); palpitations (RR 0.71, 95% CI 0.25 to 2.00; 1 study, 60 participants); tics (RR 0.46, 95% CI 0.07 to 3.27; 2 studies, 207 participants; Tau² = 0.00; Chi² = 0.78, df = 1 (P = 0.38); I² = 0%); or tremor (RR 0.33, 95% CI 0.01 to 7.87; 1 study, 60 participants). See <a href="./references#CD007986-fig-0026" title="">Analysis 1.20</a>. </p> </section> <section id="CD007986-sec-0080"> <h5 class="title">Loss to follow‐up</h5> <p>Loss to follow‐up likely did not differ between the PUFA and placebo groups (short term: RR 1.05, 95% CI 0.78 to 1.41; 10 studies, 785 participants; Tau² = 0.00; Chi² = 3.51, df = 7 (P = 0.83); I² = 0%; medium term: RR 1.03, 95% CI 0.77 to 1.37; 13 studies, 1121 participants; Tau² = 0.00; Chi² = 10.49, df = 11 (P = 0.49); I² = 0%; <a href="./references#CD007986-fig-0027" title="">Analysis 1.21</a>). We assessed the evidence that follow‐up was similar between groups as of moderate certainty (<a href="./full#CD007986-tbl-0001">summary of findings Table 1</a>). </p> <p>No studies provided data on depressive or anxiety symptoms or cost.</p> </section> </section> <section id="CD007986-sec-0081"> <h4 class="title">Comparison 2: PUFA versus medication (stimulants)</h4> <p>Two trials compared PUFA to medication, in this case stimulants. One trial each compared PUFA with dexamfetamine, <a href="./references#CD007986-bbs2-0003" title="ArnoldLE , KleykampD , VotolatoN , GibsonRA , HorrocksL . Potential link between dietary intake of fatty acids and behavior: pilot exploration of serum lipids in attention-deficit hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology1994;4(3):171-82. [DOI: 10.1089/cap.1994.4.171]ArnoldLE , KleykampD , VotolatoNA , TaylorWA , KontrasSB , TobinK . Gamma-linolenic acid for attention-deficit hyperactivity disorder: placebo-controlled comparison to D-amphetamine. Biological Psychiatry1989;25(2):222-8. [DOI: 10.1016/0006-3223(89)90167-4] [PMID: 2539203]ArnoldLE , PinkhamSM , VotolatoN . Does zinc moderate essential fatty acid and amphetamine treatment of attention-deficit/hyperactivity disorder?Journal of Child and Adolescent Psychopharmacology2000;10(2):111-7. [DOI: 10.1089/cap.2000.10.111] [PMID: 10933121]">Arnold 1989</a>, and with methylphenidate, <a href="./references#CD007986-bbs2-0005" title="BarragánE , BreuerD , DöpfnerM . Efficacy and safety of omega-3/6 fatty acids, methylphenidate, and a combined treatment in children with ADHD. Journal of Attention Disorders2017;21(5):433-41. [DOI: 10.1177/1087054713518239] [PMID: 24464327]">Barragán 2017</a>. </p> <section id="CD007986-sec-0082"> <h5 class="title">ADHD symptoms</h5> <p>In the short and medium term, total ADHD symptoms (short term: SMD 0.75, 95% CI 0.31 to 1.19; 2 studies, 96 participants; Tau² = 0.01; Chi² = 1.13, df = 1 (P = 0.29); I² = 11%; medium term: SMD 0.62, 95% CI 0.10 to 1.13; 1 study, 60 participants; <a href="./references#CD007986-fig-0028" title="">Analysis 2.1</a>); inattention (short term: SMD 0.88, 95% CI 0.35 to 1.41; 1 study, 60 participants; medium term: SMD 0.47, 95% CI −0.04 to 0.98; 1 study, 60 participants; <a href="./references#CD007986-fig-0029" title="">Analysis 2.2</a>); and hyperactivity‐impulsivity scores (short term: 0.66, 95% CI 0.25 to 1.07; 2 studies, 96 participants; Tau² = 0.00; Chi² = 0.38, df = 1 (P = 0.54); I² = 0%; medium term: SMD 0.58, 95% CI 0.07 to 1.10; 1 study, 60 participants; <a href="./references#CD007986-fig-0030" title="">Analysis 2.3</a>) were lower in the group receiving stimulants. However, there was no difference in the long term for total ADHD symptoms (SMD 0.30, 95% CI −0.21 to 0.81; 1 study, 60 participants; <a href="./references#CD007986-fig-0028" title="">Analysis 2.1</a>); inattention (SMD 0.06, 95% CI −0.45 to 0.57; 1 study, 60 participants; <a href="./references#CD007986-fig-0029" title="">Analysis 2.2</a>); or hyperactivity/impulsivity (not estimable; 1 study, 60 participants; <a href="./references#CD007986-fig-0030" title="">Analysis 2.3</a>). </p> <p>Neither study provided data on behavioural problems, quality of life, depressive or anxiety symptoms, side effects, loss to follow‐up, or cost. </p> </section> </section> <section id="CD007986-sec-0083"> <h4 class="title">Comparison 3: omega‐3 versus omega‐6 PUFA</h4> <section id="CD007986-sec-0084"> <h5 class="title">ADHD symptoms</h5> <p><a href="./references#CD007986-bbs2-0007" title="BélangerSA , VanasseM , SpahisS , SylvestreMP , LippéS , L'HeureuxF , et al. Omega-3 fatty acid treatment of children with attention-deficit hyperactivity disorder: a randomized, double-blind, placebo-controlled study. Paediatrics and Child Health2009;14(2):89-98. [DOI: 10.1093/pch/14.2.89] [PMCID: PMC2661342] [PMID: 19436468]VanasseM , Ageranioti-BélangerS , L'HeureuxF , GhadirianP , LevyE , SpahisS , et al. A randomized, controlled trial of omega-3 and phospholipids supplementation in children with attention-deficit-hyperactivity disorder. Developmental Medicine &amp; Child Neurology2006;48(Suppl 107):48. [DOI: 10.1111/j.1469-8749.2006.tb12600.x]">Bélanger 2009</a> reported a cross‐over trial of omega‐3 PUFA versus omega‐6 PUFA in 26 participants. Because variance was not reported and could not be calculated, mean data are presented in <a href="#CD007986-tbl-0002">Table 1</a>. The authors reported no clear differences between omega‐3 and omega‐6 PUFA groups in parent ratings of overall ADHD symptoms, inattention, or hyperactivity. </p> <p>No studies provided data on behavioural problems, quality of life, depressive or anxiety symptoms, side effects, loss to follow‐up, or cost. </p> </section> </section> <section id="CD007986-sec-0085"> <h4 class="title">Subgroup analyses</h4> <p>There was no difference between subgroups of studies that compared omega‐3 PUFA to placebo and those that compared combined omega‐3/omega‐6 supplements to placebo in total parent‐rated ADHD symptoms (Chi² = 1.23, df = 1, P = 0.27, I² = 18.8%; <a href="./references#CD007986-fig-0031" title="">Analysis 3.1</a>). </p> </section> <section id="CD007986-sec-0086"> <h4 class="title">Sensitivity analyses</h4> <p>We used the primary outcome of parent‐reported symptoms for the sensitivity analyses for bias and inclusion criteria. However, the primary outcome of symptoms could not be used to conduct sensitivity analysis for cross‐over trials that did not report first‐phase data, therefore the outcome of parent‐rated inattention was used. </p> <section id="CD007986-sec-0087"> <h5 class="title">Bias</h5> <p>We conducted a sensitivity analysis for attrition bias. There was no difference between PUFA and control groups in parent symptom ratings, regardless of whether attrition bias was low risk (SMD −0.19, 95% CI −0.63 to 0.24; 4 studies, 295 participants; I<sup>2</sup> = 66%); unclear risk (SMD 0.01, 95% CI −0.20 to 0.22; 12 studies, 789 participants; I<sup>2</sup> = 54%); or high risk (SMD 0.06, 95% CI −0.65 to 0.78; 4 studies, 278 participants; I<sup>2</sup> = 82%) (<a href="./references#CD007986-fig-0032" title="">Analysis 4.1</a>). </p> </section> <section id="CD007986-sec-0088"> <h5 class="title">Inclusion criteria</h5> <p>We also conducted a sensitivity analysis to evaluate whether there were any differences in findings in studies that used a clinician diagnosis of ADHD as an inclusion criterion compared to those that used scale cut‐offs. <a href="./references#CD007986-bbs2-0013" title="DashtiN , HekmatH , SoltaniHR , RahimdelA , JavaherchianM . Comparison of therapeutic effects of omega-3 and methylphenidate (ritalin(®)) in treating children with attention deficit hyperactivity disorder. Iranian Journal of Psychiatry and Behavioral Sciences2014;8(4):7-11. [PMCID: PMC4364471] [PMID: 25798168]">Dashti 2014</a>, <a href="./references#CD007986-bbs2-0033" title="SinnN , BryanJ , WilsonC . Cognitive effects of polyunsaturated fatty acids in children with attention deficit hyperactivity disorder symptoms: a randomised controlled trial. Prostaglandins Leukotrienes and Essential Fatty Acids2008;78(4-5):311-26. [DOI: 10.1016/j.plefa.2008.04.004] [PMID: 18514501]SinnN , BryanJ . Effect of supplementation with polyunsaturated fatty acids and micronutrients on learning and behavior problems associated with child ADHD. Journal of Developmental and Behavioral Pediatrics2007;28(2):82-91. [DOI: 10.1097/01.DBP.0000267558.88457.a5] [PMID: 17435458]">Sinn 2007</a>, and <a href="./references#CD007986-bbs2-0026" title="IRCT2015092724209N2. Investigating the effectiveness of methylphenidate and multi chain polyunsaturated fatty acids in treatment of patients with attention deficit hyperactivity disorder (ADHD) in Zahedan City [Investigating the effectiveness of methylphenidate and multi chain polyunsaturated fatty acids in treatment of symptoms of attention deficit hyperactivity disorder (ADHD) among 6 to 12 children suffered from ADHD]. trialsearch.who.int/Trial2.aspx?TrialID=IRCT2015092724209N2 (first received 28 April 2016). MoghaddamMF , ShamekhiM , RakhshaniT . Effectiveness of methylphenidate and PUFA for the treatment of patients with ADHD: a double-blinded randomized clinical trial. Electronic Physician2017;9(5):4412-8. [DOI: 10.19082/4412] [PMCID: PMC5498708] [PMID: 28713515]">Moghaddam 2017</a> used scale cut‐offs, but there was no difference in the effects of PUFA on ADHD total symptoms (SMD −0.59, 95% CI −0.90 to −0.27; 3 studies, 183 participants; I<sup>2</sup> = 0%) when these studies were compared to studies that only included participants with a clinician diagnosis of ADHD (SMD 0.04, 95% CI −0.15 to 0.23; 17 studies, 1179 participants; I<sup>2</sup> = 58%; <a href="./references#CD007986-fig-0033" title="">Analysis 4.2</a>). </p> </section> <section id="CD007986-sec-0089"> <h5 class="title">Cross‐over trials</h5> <p>There was no difference in short‐term parent‐rated inattention (<a href="./references#CD007986-fig-0009" title="">Analysis 1.3</a>) when sensitivity analyses were conducted without data from <a href="./references#CD007986-bbs2-0001" title="AmanMG , MitchellEA , TurbottSH . The effects of essential fatty acid supplementation by efamol in hyperactive children. Journal of Abnormal Child Psychology1987;15(1):75-90. [DOI: 10.1007/BF00916467]">Aman 1987</a>, the cross‐over study for which first‐phase data were unavailable (SMD 0.13, 95% CI −0.16 to 0.43; 5 studies, 223 participants), compared to parent‐rated inattention when data from <a href="./references#CD007986-bbs2-0001" title="AmanMG , MitchellEA , TurbottSH . The effects of essential fatty acid supplementation by efamol in hyperactive children. Journal of Abnormal Child Psychology1987;15(1):75-90. [DOI: 10.1007/BF00916467]">Aman 1987</a> were included (SMD 0.01, 95% CI −0.31 to 0.33; 5 studies, 283 participants). </p> </section> <section id="CD007986-sec-0090"> <h5 class="title">Funnel plots</h5> <p>We undertook funnel plots for the three primary outcomes: parent‐rated total ADHD symptoms (<a href="#CD007986-fig-0004">Figure 4</a>), inattention (<a href="#CD007986-fig-0005">Figure 5</a>), and hyperactivity/impulsivity (<a href="#CD007986-fig-0006">Figure 6</a>). However, there was no obvious asymmetry of these plots that may have indicated publication bias. </p> <div class="figure" id="CD007986-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Funnel plot for the comparison of PUFA versus placebo for ADHD symptoms ‐ total, parent rated.Footnotes ADHD: attention deficit hyperactivity disorder; PUFA: polyunsaturated fatty acids; SE: standard error; SMD: standardised mean difference." data-id="CD007986-fig-0004" src="/cdsr/doi/10.1002/14651858.CD007986.pub3/media/CDSR/CD007986/image_n/nCD007986-FIG-04.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot for the comparison of PUFA versus placebo for ADHD symptoms ‐ total, parent rated. </p> <p><i>Footnotes</i><br/>ADHD: attention deficit hyperactivity disorder; PUFA: polyunsaturated fatty acids; SE: standard error; SMD: standardised mean difference. </p> </div> </div> </div> <div class="figure" id="CD007986-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Funnel plot for the comparison of PUFA versus placebo for ADHD symptoms ‐ inattention, parent rated.Footnotes ADHD: attention deficit hyperactivity disorder; PUFA: polyunsaturated fatty acids; SE: standard error; SMD: standardised mean difference." data-id="CD007986-fig-0005" src="/cdsr/doi/10.1002/14651858.CD007986.pub3/media/CDSR/CD007986/image_n/nCD007986-FIG-05.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot for the comparison of PUFA versus placebo for ADHD symptoms ‐ inattention, parent rated. </p> <p><i>Footnotes</i><br/>ADHD: attention deficit hyperactivity disorder; PUFA: polyunsaturated fatty acids; SE: standard error; SMD: standardised mean difference. </p> </div> </div> </div> <div class="figure" id="CD007986-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Funnel plot for the comparison of PUFA versus placebo for ADHD symptoms ‐ hyperactivity/impulsivity, parent rated.Footnotes ADHD: attention deficit hyperactivity disorder; PUFA: polyunsaturated fatty acids; SE: standard error; SMD: standardised mean difference." data-id="CD007986-fig-0006" src="/cdsr/doi/10.1002/14651858.CD007986.pub3/media/CDSR/CD007986/image_n/nCD007986-FIG-06.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot for the comparison of PUFA versus placebo for ADHD symptoms ‐ hyperactivity/impulsivity, parent rated. </p> <p><i>Footnotes</i><br/>ADHD: attention deficit hyperactivity disorder; PUFA: polyunsaturated fatty acids; SE: standard error; SMD: standardised mean difference. </p> </div> </div> </div> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD007986-sec-0091" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD007986-sec-0091"></div> <section id="CD007986-sec-0092"> <h3 class="title" id="CD007986-sec-0092">Summary of main results</h3> <p>The number of trials of the effects of PUFA in children and adolescents with ADHD since our original review in 2012 has increased from 13 to 37 trials. Despite a nearly three‐fold increase in the number of included trials, there remains little evidence that PUFA supplementation provides any benefit for the symptoms of ADHD in children and adolescents compared to placebo. As with the original review, there was low‐certainty evidence that PUFA supplementation resulted in overall symptom improvement compared to placebo; however, there is now high‐certainty evidence that PUFA does not improve overall ADHD symptoms or the inattention or hyperactivity/impulsivity symptoms domains compared to placebo. </p> </section> <section id="CD007986-sec-0093"> <h3 class="title" id="CD007986-sec-0093">Overall completeness and applicability of evidence</h3> <p>Compared to the earlier version of this review (<a href="./references#CD007986-bbs2-0158" title="GilliesD , SinnJKH , LadSS , LeachMJ , RossMJ . Polyunsaturated fatty acids (PUFA) for attention deficit hyperactivity disorder (ADHD) in children and adolescents. Cochrane Database of Systematic Reviews2012, Issue 7. Art. No: CD007986. [DOI: 10.1002/14651858.CD007986.pub2]">Gillies 2012</a>), there has been a marked increase in the number of randomised controlled trials investigating the effectiveness of PUFA supplementation in children and adolescents with ADHD, although there are still very few that are of high quality. Most trials still have small sample sizes and highly variable selection criteria; use supplements that vary greatly in terms of dosage and constituents; do not address the use or non‐use of stimulant medications; and follow up participants for short periods. </p> <p>There was large variation in the constituents and dosages of PUFA supplements. Supplements used in the included trials included omega‐3 alone, omega‐6 alone, and combinations of omega‐3 and omega‐6 PUFA. The number of trials that investigated the effects of omega‐6 PUFA (in the absence of omega‐3 PUFA) was surprising given that the evidence for a role of PUFA in ADHD points to omega‐3 supplements rather than omega‐6 PUFA (<a href="./references#CD007986-bbs2-0129" title="RazR , GabisL . Essential fatty acids and attention-deficit-hyperactivity disorder: a systematic review. Developmental Medicine and Child Neurology2009;51(8):580-92. [DOI: 10.1111/j.1469-8749.2009.03351.x] [PMID: 19549202]">Raz 2009b</a>; <a href="./references#CD007986-bbs2-0132" title="RichardsonAJ , PuriBK . The potential role of fatty acids in attention-deficit/hyperactivity disorder. Prostaglandin, Leukotrienes and Essential Fatty Acids2000;63(1-2):79-87. [DOI: 10.1054/plef.2000.0196] [PMID: 10970718]">Richardson 2000</a>; <a href="./references#CD007986-bbs2-0133" title="RichardsonAJ . Omega-3 fatty acids in ADHD and related neurodevelopmental disorders. International Review of Psychiatry2006;18(2):155-72. [DOI: 10.1080/09540260600583031] [PMID: 16777670]">Richardson 2006</a>). In addition, pure PUFA supplements were not used in most studies, and non‐PUFA constituents were not replicated in the placebo. For example, PUFA supplements commonly include vitamin E as an antioxidant, but in most cases this was not included in the placebo. In future trials, more attention needs to be given to the constituents of PUFA supplements and placebos so that any beneficial effects, or lack thereof, may be more clearly attributed to PUFA supplementation. There also needs to be more consideration in the type and dosage of PUFA that is used. It may be most appropriate to base the type of supplement and dosages on supplements that have previously resulted in significant increases in plasma PUFA; for example, see <a href="./references#CD007986-bbs2-0036" title="VoigtRG , LlorenteAM , JensenCL , FraleyJK , BerrettaMC , HeirdWC . A randomized, double-blind, placebo-controlled trial of docosahexaenoic acid supplementation in children with attention-deficit/hyperactivity disorder. Journal of Pediatrics2001;139(2):189-96. [DOI: 10.1067/mpd.2001.116050] [PMID: 11487742]">Voigt 2001</a>, <a href="./references#CD007986-bbs2-0034" title="StevensL , ZhangW , PeckL , KuczekT , GrevstadN , MahonA , et al. EFA supplementation in children with inattention, hyperactivity, and other disruptive behaviors. Lipids2003;38(10):1007-21. [DOI: 10.1007/s11745-006-1155-0] [PMID: 14669965]">Stevens 2003</a>, and <a href="./references#CD007986-bbs2-0016" title="EUCTR2004-003853-13-SE. Placebo controlled, randomised, double-blind, multicentre study of PlusEPA (a PUFA, polyunsaturated fatty acids, supplement) as treatment for ADHD (combined type) with co-morbidity in Swedish children ages 7-12. www.clinicaltrialsregister.eu/ctr-search/trial/2004-003853-13/SE (first received 16 November 2004). GustafssonPA , Birberg-ThornbergU , DuchénK , LandgrenM , MalmbergK , PellingH , et al. EPA supplementation improves teacher-rated behaviour and oppositional symptoms in children with ADHD. Acta Paediatrica2010;99(10):1540-9. [DOI: 10.1111/j.1651-2227.2010.01871.x] [PMID: 20491709]">Gustafsson 2010</a>. </p> <p>A particular limitation was that follow‐up in all studies was very short, with most trials conducted for 16 weeks or less. Because it may take up to three months for the brain to recover from a chronic PUFA deficiency (<a href="./references#CD007986-bbs2-0132" title="RichardsonAJ , PuriBK . The potential role of fatty acids in attention-deficit/hyperactivity disorder. Prostaglandin, Leukotrienes and Essential Fatty Acids2000;63(1-2):79-87. [DOI: 10.1054/plef.2000.0196] [PMID: 10970718]">Richardson 2000</a>), most of these trials may have been too short to demonstrate a benefit. Future trials should therefore ensure that follow‐up extends beyond three months and preferably is considerably longer. </p> <p>Although the premise for the effectiveness of supplementation is a deficiency of PUFA in children and adolescents with ADHD, it is unclear how long‐lasting any effects of supplementation would be. Parallel‐design trials may therefore be more appropriate than cross‐over studies, which may be associated with carry‐over effects of PUFA. </p> <p>Compliance is also likely to be an issue in these trials because participants were commonly expected to take multiple capsules each day (up to eight), and loss to follow‐up was reported because participants could not swallow capsules. Although compliance was quite high in the five trials where it was reported (88% to 97% in the PUFA group and 86% to 100% in the placebo group, <a href="#CD007986-tbl-0003">Table 2</a>), in future trials it may be preferable to identify supplements that can deliver an appropriate dose in a smaller number of capsules. </p> <div class="table" id="CD007986-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Compliance with recommended dose of PUFA supplements</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Comparison</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>PUFA group</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Control group</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007986-bbs2-0023" title="ManorI , MagenA , KeidarD , RosenS , TaskerH , CohenT , et al. The effect of phosphatidylserine containing omega3 fatty-acids on attention-deficit hyperactivity disorder symptoms in children: a double-blind placebo-controlled trial, followed by an open-label extension. European Psychiatry2012;27(5):335-42. [DOI: 10.1016/j.eurpsy.2011.05.004] [PMID: 21807480]NCT00418184. The efficacy and safety of phosphatidylserine-omega3 in children with attention-deficit/hyperactivity disorder [A single-center, randomized, double-blind, placebo-controlled study of the efficacy and safety of phosphatidylserine-omega3 in children with attention-deficit/hyperactivity disorder]. clinicaltrials.gov/show/NCT00418184 (first received 4 January 2007). ">Manor 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Parallel trial of omega‐3 vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>92%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007986-bbs2-0030" title="RazR , CarassoRL , YehudaS . The influence of short-chain essential fatty acids on children with attention-deficit/hyperactivity disorder: a double-blind placebo-controlled study. Journal of Child and Adolescent Psychopharmacology2009;19(2):167-77. [DOI: 10.1089/cap.2008.070] [PMID: 19364294]">Raz 2009a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Parallel trial of omega‐3 or omega‐6 vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>92%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>86%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007986-bbs2-0048" title="RichardsonAJ , PuriBK . A randomized double-blind, placebo-controlled study of the effects of supplementation with highly unsaturated fatty acids on ADHD-related symptoms in children with specific learning difficulties. Progress in Neuro-Psychopharmacology &amp; Biological Psychiatry2002;26(2):233-9. [DOI: 10.1016/s0278-5846(01)00254-8] [PMID: 11817499]">Richardson 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Parallel trial of omega‐3 or omega‐6 vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>87%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007986-bbs2-0033" title="SinnN , BryanJ , WilsonC . Cognitive effects of polyunsaturated fatty acids in children with attention deficit hyperactivity disorder symptoms: a randomised controlled trial. Prostaglandins Leukotrienes and Essential Fatty Acids2008;78(4-5):311-26. [DOI: 10.1016/j.plefa.2008.04.004] [PMID: 18514501]SinnN , BryanJ . Effect of supplementation with polyunsaturated fatty acids and micronutrients on learning and behavior problems associated with child ADHD. Journal of Developmental and Behavioral Pediatrics2007;28(2):82-91. [DOI: 10.1097/01.DBP.0000267558.88457.a5] [PMID: 17435458]">Sinn 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Parallel trial of omega‐3 or omega‐6 vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>88% across all groups</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007986-bbs2-0036" title="VoigtRG , LlorenteAM , JensenCL , FraleyJK , BerrettaMC , HeirdWC . A randomized, double-blind, placebo-controlled trial of docosahexaenoic acid supplementation in children with attention-deficit/hyperactivity disorder. Journal of Pediatrics2001;139(2):189-96. [DOI: 10.1067/mpd.2001.116050] [PMID: 11487742]">Voigt 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Parallel trial of omega‐3 vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>97%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100%</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>PUFA: polyunsaturated fatty acids</p> </div> </div> <p>The importance of including learning‐related outcomes was identified by one of the editors during completion of this review. It is therefore important that such outcomes are included in future updates of this review. </p> </section> <section id="CD007986-sec-0094"> <h3 class="title" id="CD007986-sec-0094">Quality of the evidence</h3> <p>We assessed the evidence that children and adolescents receiving PUFA were more likely to improve compared to those receiving placebo to be of low certainty due to imprecision and overall risk of bias. We downgraded the certainty of evidence for improvement by two levels: one level for high risk of bias, as only 50% of risk of bias domains across all studies were rated low risk; and one level for serious imprecision, as data came from only three randomised controlled trials with 191 participants. However, there was high‐certainty evidence that PUFA had no effect on total ADHD symptoms. </p> <p>There was also high‐certainty evidence that inattention and hyperactivity/impulsivity did not differ between PUFA and placebo groups. There was moderate‐certainty evidence that overall side effects did not differ between PUFA and placebo groups. There was also moderate‐certainty evidence that follow‐up was similar between groups. We downgraded the certainty of evidence for both overall side effects and medium‐term loss to follow‐up by one level for serious imprecision, as meta‐analytic estimates had very wide confidence intervals. </p> <p>Ensuring adequate blinding may be crucially important in this area of research. Despite overall negative findings in a systematic review of essential fatty acids and ADHD (<a href="./references#CD007986-bbs2-0129" title="RazR , GabisL . Essential fatty acids and attention-deficit-hyperactivity disorder: a systematic review. Developmental Medicine and Child Neurology2009;51(8):580-92. [DOI: 10.1111/j.1469-8749.2009.03351.x] [PMID: 19549202]">Raz 2009b</a>), positive findings of PUFA supplementation were reported in all four open‐label trials. A major difficulty with omega‐3 PUFA supplementation is masking the distinctive smell and taste of fish oil (<a href="./references#CD007986-bbs2-0136" title="SchachterHM , KouradK , MeraliZ , LumbA , TranK , MiguelezM . Effects of Omega-3 Fatty Acids on Mental Health. Evidence Report/Technology Assessment No 116 (Report No 05-E022-2). Rockville (MD): Agency for Healthcare Research and Quality, 2005. [PMCID: PMC4781336] [PMID: 16111435]">Schachter 2005</a>). It is therefore likely that parents were aware when their children were receiving an omega‐3 supplement, which could explain why parent ratings were more much likely to show improvement than teacher ratings. </p> <p>The risk of attrition and reporting bias was high in the majority of included trials, which may have resulted in overestimates of benefits associated with PUFA supplementation. </p> <p>Systematic reviews of the literature have shown that industry‐funded research that identifies a beneficial effect of the industry product is more likely to be published (<a href="./references#CD007986-bbs2-0096" title="GolderS , LokeYK . Is there evidence for biased reporting of published adverse effects data in pharmaceutical industry-funded studies?British Journal of Clinical Pharmacology2008;66(6):767-73. [DOI: 10.1111/j.1365-2125.2008.03272.x] [PMCID: PMC2675760] [PMID: 18754841]">Golder 2008</a>; <a href="./references#CD007986-bbs2-0113" title="LexchinJ , BeroLA , DjulbegovicB , ClarkO . Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ2003;326(7400):1167-70. [DOI: 10.1136/bmj.326.7400.1167] [PMCID: PMC156458] [PMID: 12775614]">Lexchin 2003</a>). Because most of the included trials were funded by the suppliers of the supplement being tested, this may indicate a publication bias in the identified literature. </p> </section> <section id="CD007986-sec-0095"> <h3 class="title" id="CD007986-sec-0095">Potential biases in the review process</h3> <p>As fewer than half of the included trials contributed to any of the meta‐analyses in this review, there are substantial risks of reporting bias. A potential bias is the possibility that relevant studies may not have been identified, particularly studies that are not published in English. A major potential bias is the lack of available data from studies that have been identified from clinical trials registers but do not yet appear to have reported data or made data available. </p> </section> <section id="CD007986-sec-0096"> <h3 class="title" id="CD007986-sec-0096">Agreements and disagreements with other studies or reviews</h3> <p>In our original review, <a href="./references#CD007986-bbs2-0158" title="GilliesD , SinnJKH , LadSS , LeachMJ , RossMJ . Polyunsaturated fatty acids (PUFA) for attention deficit hyperactivity disorder (ADHD) in children and adolescents. Cochrane Database of Systematic Reviews2012, Issue 7. Art. No: CD007986. [DOI: 10.1002/14651858.CD007986.pub2]">Gillies 2012</a>, several narrative reviews of the effectiveness of PUFA in ADHD were identified (<a href="./references#CD007986-bbs2-0129" title="RazR , GabisL . Essential fatty acids and attention-deficit-hyperactivity disorder: a systematic review. Developmental Medicine and Child Neurology2009;51(8):580-92. [DOI: 10.1111/j.1469-8749.2009.03351.x] [PMID: 19549202]">Raz 2009b</a>; <a href="./references#CD007986-bbs2-0133" title="RichardsonAJ . Omega-3 fatty acids in ADHD and related neurodevelopmental disorders. International Review of Psychiatry2006;18(2):155-72. [DOI: 10.1080/09540260600583031] [PMID: 16777670]">Richardson 2006</a>; <a href="./references#CD007986-bbs2-0136" title="SchachterHM , KouradK , MeraliZ , LumbA , TranK , MiguelezM . Effects of Omega-3 Fatty Acids on Mental Health. Evidence Report/Technology Assessment No 116 (Report No 05-E022-2). Rockville (MD): Agency for Healthcare Research and Quality, 2005. [PMCID: PMC4781336] [PMID: 16111435]">Schachter 2005</a>). All of these reviews found no conclusive evidence of a beneficial role of omega‐3 or omega‐6 PUFA in people with ADHD. </p> <p>Since 2012, several additional systematic reviews and meta‐analyses covering this topic have been published. In addition to the meta‐analysis by <a href="./references#CD007986-bbs2-0076" title="BlochMH , QawasmiA . Omega-3 fatty acid supplementation for the treatment of children with attention-deficit/hyperactivity disorder symptomatology: systematic review and meta-analysis. Journal of the American Academy of Child &amp; Adolescent Psychiatry2011;50(10):991-1000. [DOI: 10.1016/j.jaac.2011.06.008] [PMCID: PMC3625948] [PMID: 21961774]">Bloch 2011</a>, which was published while we were completing our original review (<a href="./references#CD007986-bbs2-0158" title="GilliesD , SinnJKH , LadSS , LeachMJ , RossMJ . Polyunsaturated fatty acids (PUFA) for attention deficit hyperactivity disorder (ADHD) in children and adolescents. Cochrane Database of Systematic Reviews2012, Issue 7. Art. No: CD007986. [DOI: 10.1002/14651858.CD007986.pub2]">Gillies 2012</a>), seven further systematic reviews and meta‐analyses of the effects of omega‐3 supplementation have been published (<a href="./references#CD007986-bbs2-0065" title="AgostoniC , NobileM , CiappolinoV , DelvecchioG , TeseiA , TuroloS , et al. The role of omega-3 fatty acids in developmental psychopathology: a systematic review on early psychosis, autism, and ADHD. International Journal of Molecular Sciences2017;18(12):2608. [DOI: 10.3390/ijms18122608] [PMCID: PMC5751211] [PMID: 29207548]">Agostoni  2017</a>; <a href="./references#CD007986-bbs2-0080" title="Calderón-MooreA , Pizarro-CastellanosM , Rizzoli-CórdobaA . Systematic review of the efficacy and safety of omega 3 and omega 6 fatty acid supplementation in developmental neurological disorders. Boletín Médico del Hospital Infantil de México2012;69(4):265-70.">Calderón‐Moore 2012</a>; <a href="./references#CD007986-bbs2-0082" title="ChangJP , SuKP , MondelliV , ParianteCM . Omega-3 polyunsaturated fatty acids in youths with attention deficit hyperactivity disorder: a systematic review and meta-analysis of clinical trials and biological studies. Neuropsychopharmacology2018;43(3):534-45. [DOI: 10.1038/npp.2017.160] [PMID: PMC5669464]">Chang 2018</a>; <a href="./references#CD007986-bbs2-0086" title="CooperRE , TyeC , KuntsiJ , VassosE , AshersonP . Omega-3 polyunsaturated fatty acid supplementation and cognition: a systematic review and meta-analysis. Journal of Psychopharmacology2015;29(7):753-63. [DOI: 10.1177/0269881115587958] [PMID: 26040902]">Cooper 2015</a>; <a href="./references#CD007986-bbs2-0091" title="DerbyshireE . Do omega-3/6 fatty acids have a therapeutic role in children and young people with ADHD?Journal of Lipids2017;2017:6285218. [DOI: 10.1155/2017/6285218] [PMCID: PMC5603098] [PMID: 28951787]">Derbyshire 2017</a>; <a href="./references#CD007986-bbs2-0097" title="GoodeAP , CoeytauxRR , MaslowGR , DavisN , HillS , NamdariB , et al. Nonpharmacologic treatments for attention-deficit/hyperactivity disorder: a systematic review. Pediatrics2018;141(6):e20180094. [DOI: 10.1542/peds.2018-0094] [PMID: 29848556]">Goode 2018</a>; <a href="./references#CD007986-bbs2-0107" title="KemperAR , MaslowGR , HillS , NamdariB , La PointeNM , GoodeAP , et al. Attention Deficit Hyperactivity Disorder: Diagnosis and Treatment in Children and Adolescents. Comparative Effectiveness Reviews, No 203 (Report No.: 18-EHC005-EF). Rockville (MD): Agency for Healthcare Research and Quality, 2018. [BOOKSHELF ID: NBK487761] [PMID: 29558081]">Kemper 2018</a>). </p> <p>Four of these reviews found no evidence of an effect of supplementation. In a systematic review of omega‐3 and omega‐6 fatty acid supplementation in developmental neurological disorders in paediatric patients, <a href="./references#CD007986-bbs2-0080" title="Calderón-MooreA , Pizarro-CastellanosM , Rizzoli-CórdobaA . Systematic review of the efficacy and safety of omega 3 and omega 6 fatty acid supplementation in developmental neurological disorders. Boletín Médico del Hospital Infantil de México2012;69(4):265-70.">Calderón‐Moore 2012</a> found no significant difference in ADHD symptoms in the five identified trials. <a href="./references#CD007986-bbs2-0107" title="KemperAR , MaslowGR , HillS , NamdariB , La PointeNM , GoodeAP , et al. Attention Deficit Hyperactivity Disorder: Diagnosis and Treatment in Children and Adolescents. Comparative Effectiveness Reviews, No 203 (Report No.: 18-EHC005-EF). Rockville (MD): Agency for Healthcare Research and Quality, 2018. [BOOKSHELF ID: NBK487761] [PMID: 29558081]">Kemper 2018</a> reported that a meta‐analysis of seven identified trials comparing omega‐3 and omega‐6 PUFA to placebo showed no effect on ADHD symptoms in children and adolescents. <a href="./references#CD007986-bbs2-0086" title="CooperRE , TyeC , KuntsiJ , VassosE , AshersonP . Omega-3 polyunsaturated fatty acid supplementation and cognition: a systematic review and meta-analysis. Journal of Psychopharmacology2015;29(7):753-63. [DOI: 10.1177/0269881115587958] [PMID: 26040902]">Cooper 2015</a> identified 24 studies evaluating the effectiveness of omega‐3 PUFAs on cognitive outcomes in children and adults with and without ADHD but found no benefits of PUFA. In meta‐analyses of seven trials of children and adolescents, <a href="./references#CD007986-bbs2-0097" title="GoodeAP , CoeytauxRR , MaslowGR , DavisN , HillS , NamdariB , et al. Nonpharmacologic treatments for attention-deficit/hyperactivity disorder: a systematic review. Pediatrics2018;141(6):e20180094. [DOI: 10.1542/peds.2018-0094] [PMID: 29848556]">Goode 2018</a> also found no significant effects of omega‐3 or omega‐6 PUFA on parent‐ or teacher‐rated total ADHD symptoms. </p> <p>A beneficial effect of PUFA was reported in meta‐analyses by <a href="./references#CD007986-bbs2-0076" title="BlochMH , QawasmiA . Omega-3 fatty acid supplementation for the treatment of children with attention-deficit/hyperactivity disorder symptomatology: systematic review and meta-analysis. Journal of the American Academy of Child &amp; Adolescent Psychiatry2011;50(10):991-1000. [DOI: 10.1016/j.jaac.2011.06.008] [PMCID: PMC3625948] [PMID: 21961774]">Bloch 2011</a>, <a href="./references#CD007986-bbs2-0082" title="ChangJP , SuKP , MondelliV , ParianteCM . Omega-3 polyunsaturated fatty acids in youths with attention deficit hyperactivity disorder: a systematic review and meta-analysis of clinical trials and biological studies. Neuropsychopharmacology2018;43(3):534-45. [DOI: 10.1038/npp.2017.160] [PMID: PMC5669464]">Chang 2018</a>, and <a href="./references#CD007986-bbs2-0138" title="Sonuga-BarkeEJ , BrandeisD , CorteseS , DaleyD , FerrinM , HoltmannM , et al. Nonpharmacological interventions for ADHD: systematic review and meta-analyses of randomized controlled trials of dietary and psychological treatments. American Journal of Psychiatry2013;170(3):275-89. [DOI: 10.1176/appi.ajp.2012.12070991] [PMID: 23360949]">Sonuga‐Barke 2013</a>. <a href="./references#CD007986-bbs2-0076" title="BlochMH , QawasmiA . Omega-3 fatty acid supplementation for the treatment of children with attention-deficit/hyperactivity disorder symptomatology: systematic review and meta-analysis. Journal of the American Academy of Child &amp; Adolescent Psychiatry2011;50(10):991-1000. [DOI: 10.1016/j.jaac.2011.06.008] [PMCID: PMC3625948] [PMID: 21961774]">Bloch 2011</a> found a small improvement in ADHD symptoms in the group receiving omega‐3 supplementation (10 studies with 699 children). <a href="./references#CD007986-bbs2-0138" title="Sonuga-BarkeEJ , BrandeisD , CorteseS , DaleyD , FerrinM , HoltmannM , et al. Nonpharmacological interventions for ADHD: systematic review and meta-analyses of randomized controlled trials of dietary and psychological treatments. American Journal of Psychiatry2013;170(3):275-89. [DOI: 10.1176/appi.ajp.2012.12070991] [PMID: 23360949]">Sonuga‐Barke 2013</a> reported a beneficial effect of omega‐3 and omega‐6 PUFA across 11 studies of children and adolescents, and <a href="./references#CD007986-bbs2-0082" title="ChangJP , SuKP , MondelliV , ParianteCM . Omega-3 polyunsaturated fatty acids in youths with attention deficit hyperactivity disorder: a systematic review and meta-analysis of clinical trials and biological studies. Neuropsychopharmacology2018;43(3):534-45. [DOI: 10.1038/npp.2017.160] [PMID: PMC5669464]">Chang 2018</a> found that omega‐3 PUFAs decreased symptom scores in children and adolescents with ADHD (7 studies with 534 participants). Two other systematic reviews without meta‐analyses reported a notable proportion of studies that reported benefits of PUFA. These included <a href="./references#CD007986-bbs2-0091" title="DerbyshireE . Do omega-3/6 fatty acids have a therapeutic role in children and young people with ADHD?Journal of Lipids2017;2017:6285218. [DOI: 10.1155/2017/6285218] [PMCID: PMC5603098] [PMID: 28951787]">Derbyshire 2017</a>, who reported that, of 16 trials of omega‐3/6 fatty acids in children and adolescents, 13 reported favourable benefits on ADHD symptoms, and <a href="./references#CD007986-bbs2-0065" title="AgostoniC , NobileM , CiappolinoV , DelvecchioG , TeseiA , TuroloS , et al. The role of omega-3 fatty acids in developmental psychopathology: a systematic review on early psychosis, autism, and ADHD. International Journal of Molecular Sciences2017;18(12):2608. [DOI: 10.3390/ijms18122608] [PMCID: PMC5751211] [PMID: 29207548]">Agostoni  2017</a>, who reported that positive results were identified in nine of 25 trials of omega‐3 PUFA in all ages. </p> <p><a href="./references#CD007986-bbs2-0140" title="StevensonJ , BuitelaarJ , CorteseS , FerrinM , KonofalE , LecendreuxM , et al. Research review: the role of diet in the treatment of attention-deficit/hyperactivity disorder - an appraisal of the evidence on efficacy and recommendations on the design of future studies. Journal of Child Psychology and Psychiatry2014;55(5):416-27. [DOI: 10.1111/jcpp.12215. Epub 2014 Feb 19] [PMID: 24552603]">Stevenson 2014</a> compared our original meta‐analyses, <a href="./references#CD007986-bbs2-0158" title="GilliesD , SinnJKH , LadSS , LeachMJ , RossMJ . Polyunsaturated fatty acids (PUFA) for attention deficit hyperactivity disorder (ADHD) in children and adolescents. Cochrane Database of Systematic Reviews2012, Issue 7. Art. No: CD007986. [DOI: 10.1002/14651858.CD007986.pub2]">Gillies 2012</a>, with two other reviews by <a href="./references#CD007986-bbs2-0076" title="BlochMH , QawasmiA . Omega-3 fatty acid supplementation for the treatment of children with attention-deficit/hyperactivity disorder symptomatology: systematic review and meta-analysis. Journal of the American Academy of Child &amp; Adolescent Psychiatry2011;50(10):991-1000. [DOI: 10.1016/j.jaac.2011.06.008] [PMCID: PMC3625948] [PMID: 21961774]">Bloch 2011</a> and <a href="./references#CD007986-bbs2-0138" title="Sonuga-BarkeEJ , BrandeisD , CorteseS , DaleyD , FerrinM , HoltmannM , et al. Nonpharmacological interventions for ADHD: systematic review and meta-analyses of randomized controlled trials of dietary and psychological treatments. American Journal of Psychiatry2013;170(3):275-89. [DOI: 10.1176/appi.ajp.2012.12070991] [PMID: 23360949]">Sonuga‐Barke 2013</a>, which had found a significant effect of PUFA. <a href="./references#CD007986-bbs2-0140" title="StevensonJ , BuitelaarJ , CorteseS , FerrinM , KonofalE , LecendreuxM , et al. Research review: the role of diet in the treatment of attention-deficit/hyperactivity disorder - an appraisal of the evidence on efficacy and recommendations on the design of future studies. Journal of Child Psychology and Psychiatry2014;55(5):416-27. [DOI: 10.1111/jcpp.12215. Epub 2014 Feb 19] [PMID: 24552603]">Stevenson 2014</a> noted that the effect was not significant in our review because the number of trials included in our analysis was fewer than that reported by <a href="./references#CD007986-bbs2-0138" title="Sonuga-BarkeEJ , BrandeisD , CorteseS , DaleyD , FerrinM , HoltmannM , et al. Nonpharmacological interventions for ADHD: systematic review and meta-analyses of randomized controlled trials of dietary and psychological treatments. American Journal of Psychiatry2013;170(3):275-89. [DOI: 10.1176/appi.ajp.2012.12070991] [PMID: 23360949]">Sonuga‐Barke 2013</a>. However, we had included all 10 studies included by <a href="./references#CD007986-bbs2-0076" title="BlochMH , QawasmiA . Omega-3 fatty acid supplementation for the treatment of children with attention-deficit/hyperactivity disorder symptomatology: systematic review and meta-analysis. Journal of the American Academy of Child &amp; Adolescent Psychiatry2011;50(10):991-1000. [DOI: 10.1016/j.jaac.2011.06.008] [PMCID: PMC3625948] [PMID: 21961774]">Bloch 2011</a> and all 11 studies included by <a href="./references#CD007986-bbs2-0138" title="Sonuga-BarkeEJ , BrandeisD , CorteseS , DaleyD , FerrinM , HoltmannM , et al. Nonpharmacological interventions for ADHD: systematic review and meta-analyses of randomized controlled trials of dietary and psychological treatments. American Journal of Psychiatry2013;170(3):275-89. [DOI: 10.1176/appi.ajp.2012.12070991] [PMID: 23360949]">Sonuga‐Barke 2013</a>. Rather, the difference in effect was due to the fact that <a href="./references#CD007986-bbs2-0076" title="BlochMH , QawasmiA . Omega-3 fatty acid supplementation for the treatment of children with attention-deficit/hyperactivity disorder symptomatology: systematic review and meta-analysis. Journal of the American Academy of Child &amp; Adolescent Psychiatry2011;50(10):991-1000. [DOI: 10.1016/j.jaac.2011.06.008] [PMCID: PMC3625948] [PMID: 21961774]">Bloch 2011</a> had pooled measures of ADHD symptoms reported by different raters, and <a href="./references#CD007986-bbs2-0138" title="Sonuga-BarkeEJ , BrandeisD , CorteseS , DaleyD , FerrinM , HoltmannM , et al. Nonpharmacological interventions for ADHD: systematic review and meta-analyses of randomized controlled trials of dietary and psychological treatments. American Journal of Psychiatry2013;170(3):275-89. [DOI: 10.1176/appi.ajp.2012.12070991] [PMID: 23360949]">Sonuga‐Barke 2013</a> had synthesised data across raters and also used domain scores where total scores were not available. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD007986-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007986.pub3/media/CDSR/CD007986/urn:x-wiley:14651858:media:CD007986:CD007986-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram for review update." data-id="CD007986-fig-0001" src="/cdsr/doi/10.1002/14651858.CD007986.pub3/media/CDSR/CD007986/image_n/nCD007986-FIG-01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007986.pub3/media/CDSR/CD007986/image_t/tCD007986-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram for review update.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007986.pub3/full#CD007986-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007986.pub3/media/CDSR/CD007986/image_n/nCD007986-FIG-01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007986-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007986.pub3/media/CDSR/CD007986/urn:x-wiley:14651858:media:CD007986:CD007986-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD007986-fig-0002" src="/cdsr/doi/10.1002/14651858.CD007986.pub3/media/CDSR/CD007986/image_n/nCD007986-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007986.pub3/media/CDSR/CD007986/image_t/tCD007986-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007986.pub3/full#CD007986-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007986.pub3/media/CDSR/CD007986/image_n/nCD007986-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007986-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007986.pub3/media/CDSR/CD007986/urn:x-wiley:14651858:media:CD007986:CD007986-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD007986-fig-0003" src="/cdsr/doi/10.1002/14651858.CD007986.pub3/media/CDSR/CD007986/image_n/nCD007986-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007986.pub3/media/CDSR/CD007986/image_t/tCD007986-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007986.pub3/full#CD007986-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007986.pub3/media/CDSR/CD007986/image_n/nCD007986-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007986-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007986.pub3/media/CDSR/CD007986/urn:x-wiley:14651858:media:CD007986:CD007986-FIG-04" target="_blank"><b></b></a></p> </div><img alt="Funnel plot for the comparison of PUFA versus placebo for ADHD symptoms ‐ total, parent rated.Footnotes ADHD: attention deficit hyperactivity disorder; PUFA: polyunsaturated fatty acids; SE: standard error; SMD: standardised mean difference." data-id="CD007986-fig-0004" src="/cdsr/doi/10.1002/14651858.CD007986.pub3/media/CDSR/CD007986/image_n/nCD007986-FIG-04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007986.pub3/media/CDSR/CD007986/image_t/tCD007986-FIG-04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Funnel plot for the comparison of PUFA versus placebo for ADHD symptoms ‐ total, parent rated. </p> <p><i>Footnotes</i><br/>ADHD: attention deficit hyperactivity disorder; PUFA: polyunsaturated fatty acids; SE: standard error; SMD: standardised mean difference. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007986.pub3/full#CD007986-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007986.pub3/media/CDSR/CD007986/image_n/nCD007986-FIG-04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007986-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007986.pub3/media/CDSR/CD007986/urn:x-wiley:14651858:media:CD007986:CD007986-FIG-05" target="_blank"><b></b></a></p> </div><img alt="Funnel plot for the comparison of PUFA versus placebo for ADHD symptoms ‐ inattention, parent rated.Footnotes ADHD: attention deficit hyperactivity disorder; PUFA: polyunsaturated fatty acids; SE: standard error; SMD: standardised mean difference." data-id="CD007986-fig-0005" src="/cdsr/doi/10.1002/14651858.CD007986.pub3/media/CDSR/CD007986/image_n/nCD007986-FIG-05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007986.pub3/media/CDSR/CD007986/image_t/tCD007986-FIG-05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Funnel plot for the comparison of PUFA versus placebo for ADHD symptoms ‐ inattention, parent rated. </p> <p><i>Footnotes</i><br/>ADHD: attention deficit hyperactivity disorder; PUFA: polyunsaturated fatty acids; SE: standard error; SMD: standardised mean difference. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007986.pub3/full#CD007986-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007986.pub3/media/CDSR/CD007986/image_n/nCD007986-FIG-05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007986-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007986.pub3/media/CDSR/CD007986/urn:x-wiley:14651858:media:CD007986:CD007986-FIG-06" target="_blank"><b></b></a></p> </div><img alt="Funnel plot for the comparison of PUFA versus placebo for ADHD symptoms ‐ hyperactivity/impulsivity, parent rated.Footnotes ADHD: attention deficit hyperactivity disorder; PUFA: polyunsaturated fatty acids; SE: standard error; SMD: standardised mean difference." data-id="CD007986-fig-0006" src="/cdsr/doi/10.1002/14651858.CD007986.pub3/media/CDSR/CD007986/image_n/nCD007986-FIG-06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007986.pub3/media/CDSR/CD007986/image_t/tCD007986-FIG-06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Funnel plot for the comparison of PUFA versus placebo for ADHD symptoms ‐ hyperactivity/impulsivity, parent rated. </p> <p><i>Footnotes</i><br/>ADHD: attention deficit hyperactivity disorder; PUFA: polyunsaturated fatty acids; SE: standard error; SMD: standardised mean difference. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007986.pub3/full#CD007986-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007986.pub3/media/CDSR/CD007986/image_n/nCD007986-FIG-06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007986-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007986.pub3/media/CDSR/CD007986/urn:x-wiley:14651858:media:CD007986:CD007986-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: PUFA versus placebo, Outcome 1: ADHD symptoms ‐ improvement" data-id="CD007986-fig-0007" src="/cdsr/doi/10.1002/14651858.CD007986.pub3/media/CDSR/CD007986/image_n/nCD007986-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007986.pub3/media/CDSR/CD007986/image_t/tCD007986-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: PUFA versus placebo, Outcome 1: ADHD symptoms ‐ improvement</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007986.pub3/references#CD007986-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007986.pub3/media/CDSR/CD007986/image_n/nCD007986-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007986-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007986.pub3/media/CDSR/CD007986/urn:x-wiley:14651858:media:CD007986:CD007986-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: PUFA versus placebo, Outcome 2: ADHD symptoms ‐ total, parent rated" data-id="CD007986-fig-0008" src="/cdsr/doi/10.1002/14651858.CD007986.pub3/media/CDSR/CD007986/image_n/nCD007986-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007986.pub3/media/CDSR/CD007986/image_t/tCD007986-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: PUFA versus placebo, Outcome 2: ADHD symptoms ‐ total, parent rated</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007986.pub3/references#CD007986-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007986.pub3/media/CDSR/CD007986/image_n/nCD007986-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007986-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007986.pub3/media/CDSR/CD007986/urn:x-wiley:14651858:media:CD007986:CD007986-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: PUFA versus placebo, Outcome 3: ADHD symptoms ‐ inattention, parent rated" data-id="CD007986-fig-0009" src="/cdsr/doi/10.1002/14651858.CD007986.pub3/media/CDSR/CD007986/image_n/nCD007986-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007986.pub3/media/CDSR/CD007986/image_t/tCD007986-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: PUFA versus placebo, Outcome 3: ADHD symptoms ‐ inattention, parent rated </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007986.pub3/references#CD007986-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007986.pub3/media/CDSR/CD007986/image_n/nCD007986-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007986-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007986.pub3/media/CDSR/CD007986/urn:x-wiley:14651858:media:CD007986:CD007986-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: PUFA versus placebo, Outcome 4: ADHD symptoms ‐ hyperactivity/impulsivity, parent rated" data-id="CD007986-fig-0010" src="/cdsr/doi/10.1002/14651858.CD007986.pub3/media/CDSR/CD007986/image_n/nCD007986-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007986.pub3/media/CDSR/CD007986/image_t/tCD007986-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: PUFA versus placebo, Outcome 4: ADHD symptoms ‐ hyperactivity/impulsivity, parent rated </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007986.pub3/references#CD007986-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007986.pub3/media/CDSR/CD007986/image_n/nCD007986-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007986-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007986.pub3/media/CDSR/CD007986/urn:x-wiley:14651858:media:CD007986:CD007986-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: PUFA versus placebo, Outcome 5: ADHD symptoms ‐ total, teacher rated" data-id="CD007986-fig-0011" src="/cdsr/doi/10.1002/14651858.CD007986.pub3/media/CDSR/CD007986/image_n/nCD007986-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007986.pub3/media/CDSR/CD007986/image_t/tCD007986-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: PUFA versus placebo, Outcome 5: ADHD symptoms ‐ total, teacher rated</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007986.pub3/references#CD007986-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007986.pub3/media/CDSR/CD007986/image_n/nCD007986-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007986-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007986.pub3/media/CDSR/CD007986/urn:x-wiley:14651858:media:CD007986:CD007986-CMP-001.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: PUFA versus placebo, Outcome 6: ADHD symptoms ‐ inattention: teacher" data-id="CD007986-fig-0012" src="/cdsr/doi/10.1002/14651858.CD007986.pub3/media/CDSR/CD007986/image_n/nCD007986-CMP-001.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007986.pub3/media/CDSR/CD007986/image_t/tCD007986-CMP-001.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: PUFA versus placebo, Outcome 6: ADHD symptoms ‐ inattention: teacher</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007986.pub3/references#CD007986-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007986.pub3/media/CDSR/CD007986/image_n/nCD007986-CMP-001.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007986-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007986.pub3/media/CDSR/CD007986/urn:x-wiley:14651858:media:CD007986:CD007986-CMP-001.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: PUFA versus placebo, Outcome 7: ADHD symptoms ‐ hyperactivity/impulsivity, teacher rated" data-id="CD007986-fig-0013" src="/cdsr/doi/10.1002/14651858.CD007986.pub3/media/CDSR/CD007986/image_n/nCD007986-CMP-001.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007986.pub3/media/CDSR/CD007986/image_t/tCD007986-CMP-001.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1: PUFA versus placebo, Outcome 7: ADHD symptoms ‐ hyperactivity/impulsivity, teacher rated </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007986.pub3/references#CD007986-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007986.pub3/media/CDSR/CD007986/image_n/nCD007986-CMP-001.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007986-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007986.pub3/media/CDSR/CD007986/urn:x-wiley:14651858:media:CD007986:CD007986-CMP-001.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: PUFA versus placebo, Outcome 8: ADHD symptoms ‐ total, clinician rated" data-id="CD007986-fig-0014" src="/cdsr/doi/10.1002/14651858.CD007986.pub3/media/CDSR/CD007986/image_n/nCD007986-CMP-001.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007986.pub3/media/CDSR/CD007986/image_t/tCD007986-CMP-001.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1: PUFA versus placebo, Outcome 8: ADHD symptoms ‐ total, clinician rated</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007986.pub3/references#CD007986-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007986.pub3/media/CDSR/CD007986/image_n/nCD007986-CMP-001.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007986-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007986.pub3/media/CDSR/CD007986/urn:x-wiley:14651858:media:CD007986:CD007986-CMP-001.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: PUFA versus placebo, Outcome 9: ADHD symptoms ‐ inattention, clinician rated" data-id="CD007986-fig-0015" src="/cdsr/doi/10.1002/14651858.CD007986.pub3/media/CDSR/CD007986/image_n/nCD007986-CMP-001.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007986.pub3/media/CDSR/CD007986/image_t/tCD007986-CMP-001.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1: PUFA versus placebo, Outcome 9: ADHD symptoms ‐ inattention, clinician rated </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007986.pub3/references#CD007986-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007986.pub3/media/CDSR/CD007986/image_n/nCD007986-CMP-001.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007986-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007986.pub3/media/CDSR/CD007986/urn:x-wiley:14651858:media:CD007986:CD007986-CMP-001.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: PUFA versus placebo, Outcome 10: ADHD symptoms ‐ hyperactivity/impulsivity, clinician rated" data-id="CD007986-fig-0016" src="/cdsr/doi/10.1002/14651858.CD007986.pub3/media/CDSR/CD007986/image_n/nCD007986-CMP-001.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007986.pub3/media/CDSR/CD007986/image_t/tCD007986-CMP-001.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1: PUFA versus placebo, Outcome 10: ADHD symptoms ‐ hyperactivity/impulsivity, clinician rated </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007986.pub3/references#CD007986-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007986.pub3/media/CDSR/CD007986/image_n/nCD007986-CMP-001.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007986-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007986.pub3/media/CDSR/CD007986/urn:x-wiley:14651858:media:CD007986:CD007986-CMP-001.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: PUFA versus placebo, Outcome 11: Behaviour ‐ internalising, parent rated" data-id="CD007986-fig-0017" src="/cdsr/doi/10.1002/14651858.CD007986.pub3/media/CDSR/CD007986/image_n/nCD007986-CMP-001.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007986.pub3/media/CDSR/CD007986/image_t/tCD007986-CMP-001.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1: PUFA versus placebo, Outcome 11: Behaviour ‐ internalising, parent rated</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007986.pub3/references#CD007986-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007986.pub3/media/CDSR/CD007986/image_n/nCD007986-CMP-001.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007986-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007986.pub3/media/CDSR/CD007986/urn:x-wiley:14651858:media:CD007986:CD007986-CMP-001.12" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: PUFA versus placebo, Outcome 12: Behaviour ‐ externalising, parent rated" data-id="CD007986-fig-0018" src="/cdsr/doi/10.1002/14651858.CD007986.pub3/media/CDSR/CD007986/image_n/nCD007986-CMP-001.12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007986.pub3/media/CDSR/CD007986/image_t/tCD007986-CMP-001.12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1: PUFA versus placebo, Outcome 12: Behaviour ‐ externalising, parent rated</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007986.pub3/references#CD007986-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007986.pub3/media/CDSR/CD007986/image_n/nCD007986-CMP-001.12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007986-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007986.pub3/media/CDSR/CD007986/urn:x-wiley:14651858:media:CD007986:CD007986-CMP-001.13" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: PUFA versus placebo, Outcome 13: Behaviour ‐ conduct, parent rated" data-id="CD007986-fig-0019" src="/cdsr/doi/10.1002/14651858.CD007986.pub3/media/CDSR/CD007986/image_n/nCD007986-CMP-001.13.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007986.pub3/media/CDSR/CD007986/image_t/tCD007986-CMP-001.13.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1: PUFA versus placebo, Outcome 13: Behaviour ‐ conduct, parent rated</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007986.pub3/references#CD007986-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007986.pub3/media/CDSR/CD007986/image_n/nCD007986-CMP-001.13.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007986-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007986.pub3/media/CDSR/CD007986/urn:x-wiley:14651858:media:CD007986:CD007986-CMP-001.14" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: PUFA versus placebo, Outcome 14: Behaviour ‐ oppositional, parent rated" data-id="CD007986-fig-0020" src="/cdsr/doi/10.1002/14651858.CD007986.pub3/media/CDSR/CD007986/image_n/nCD007986-CMP-001.14.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007986.pub3/media/CDSR/CD007986/image_t/tCD007986-CMP-001.14.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.14</div> <div class="figure-caption"> <p>Comparison 1: PUFA versus placebo, Outcome 14: Behaviour ‐ oppositional, parent rated</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007986.pub3/references#CD007986-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007986.pub3/media/CDSR/CD007986/image_n/nCD007986-CMP-001.14.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007986-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007986.pub3/media/CDSR/CD007986/urn:x-wiley:14651858:media:CD007986:CD007986-CMP-001.15" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: PUFA versus placebo, Outcome 15: Behaviour ‐ socialisation, parent rated" data-id="CD007986-fig-0021" src="/cdsr/doi/10.1002/14651858.CD007986.pub3/media/CDSR/CD007986/image_n/nCD007986-CMP-001.15.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007986.pub3/media/CDSR/CD007986/image_t/tCD007986-CMP-001.15.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.15</div> <div class="figure-caption"> <p>Comparison 1: PUFA versus placebo, Outcome 15: Behaviour ‐ socialisation, parent rated</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007986.pub3/references#CD007986-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007986.pub3/media/CDSR/CD007986/image_n/nCD007986-CMP-001.15.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007986-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007986.pub3/media/CDSR/CD007986/urn:x-wiley:14651858:media:CD007986:CD007986-CMP-001.16" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: PUFA versus placebo, Outcome 16: Behaviour ‐ conduct, teacher rated" data-id="CD007986-fig-0022" src="/cdsr/doi/10.1002/14651858.CD007986.pub3/media/CDSR/CD007986/image_n/nCD007986-CMP-001.16.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007986.pub3/media/CDSR/CD007986/image_t/tCD007986-CMP-001.16.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.16</div> <div class="figure-caption"> <p>Comparison 1: PUFA versus placebo, Outcome 16: Behaviour ‐ conduct, teacher rated</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007986.pub3/references#CD007986-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007986.pub3/media/CDSR/CD007986/image_n/nCD007986-CMP-001.16.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007986-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007986.pub3/media/CDSR/CD007986/urn:x-wiley:14651858:media:CD007986:CD007986-CMP-001.17" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: PUFA versus placebo, Outcome 17: Behaviour ‐ oppositional, teacher rated" data-id="CD007986-fig-0023" src="/cdsr/doi/10.1002/14651858.CD007986.pub3/media/CDSR/CD007986/image_n/nCD007986-CMP-001.17.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007986.pub3/media/CDSR/CD007986/image_t/tCD007986-CMP-001.17.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.17</div> <div class="figure-caption"> <p>Comparison 1: PUFA versus placebo, Outcome 17: Behaviour ‐ oppositional, teacher rated</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007986.pub3/references#CD007986-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007986.pub3/media/CDSR/CD007986/image_n/nCD007986-CMP-001.17.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007986-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007986.pub3/media/CDSR/CD007986/urn:x-wiley:14651858:media:CD007986:CD007986-CMP-001.18" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: PUFA versus placebo, Outcome 18: Behaviour ‐ socialisation, teacher rated" data-id="CD007986-fig-0024" src="/cdsr/doi/10.1002/14651858.CD007986.pub3/media/CDSR/CD007986/image_n/nCD007986-CMP-001.18.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007986.pub3/media/CDSR/CD007986/image_t/tCD007986-CMP-001.18.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.18</div> <div class="figure-caption"> <p>Comparison 1: PUFA versus placebo, Outcome 18: Behaviour ‐ socialisation, teacher rated </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007986.pub3/references#CD007986-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007986.pub3/media/CDSR/CD007986/image_n/nCD007986-CMP-001.18.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007986-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007986.pub3/media/CDSR/CD007986/urn:x-wiley:14651858:media:CD007986:CD007986-CMP-001.19" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: PUFA versus placebo, Outcome 19: Quality of life: medium term" data-id="CD007986-fig-0025" src="/cdsr/doi/10.1002/14651858.CD007986.pub3/media/CDSR/CD007986/image_n/nCD007986-CMP-001.19.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007986.pub3/media/CDSR/CD007986/image_t/tCD007986-CMP-001.19.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.19</div> <div class="figure-caption"> <p>Comparison 1: PUFA versus placebo, Outcome 19: Quality of life: medium term</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007986.pub3/references#CD007986-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007986.pub3/media/CDSR/CD007986/image_n/nCD007986-CMP-001.19.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007986-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007986.pub3/media/CDSR/CD007986/urn:x-wiley:14651858:media:CD007986:CD007986-CMP-001.20" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: PUFA versus placebo, Outcome 20: Side effects" data-id="CD007986-fig-0026" src="/cdsr/doi/10.1002/14651858.CD007986.pub3/media/CDSR/CD007986/image_n/nCD007986-CMP-001.20.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007986.pub3/media/CDSR/CD007986/image_t/tCD007986-CMP-001.20.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.20</div> <div class="figure-caption"> <p>Comparison 1: PUFA versus placebo, Outcome 20: Side effects</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007986.pub3/references#CD007986-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007986.pub3/media/CDSR/CD007986/image_n/nCD007986-CMP-001.20.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007986-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007986.pub3/media/CDSR/CD007986/urn:x-wiley:14651858:media:CD007986:CD007986-CMP-001.21" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: PUFA versus placebo, Outcome 21: Loss to follow‐up" data-id="CD007986-fig-0027" src="/cdsr/doi/10.1002/14651858.CD007986.pub3/media/CDSR/CD007986/image_n/nCD007986-CMP-001.21.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007986.pub3/media/CDSR/CD007986/image_t/tCD007986-CMP-001.21.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.21</div> <div class="figure-caption"> <p>Comparison 1: PUFA versus placebo, Outcome 21: Loss to follow‐up</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007986.pub3/references#CD007986-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007986.pub3/media/CDSR/CD007986/image_n/nCD007986-CMP-001.21.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007986-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007986.pub3/media/CDSR/CD007986/urn:x-wiley:14651858:media:CD007986:CD007986-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: PUFA versus stimulants, Outcome 1: ADHD symptoms ‐ total" data-id="CD007986-fig-0028" src="/cdsr/doi/10.1002/14651858.CD007986.pub3/media/CDSR/CD007986/image_n/nCD007986-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007986.pub3/media/CDSR/CD007986/image_t/tCD007986-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: PUFA versus stimulants, Outcome 1: ADHD symptoms ‐ total</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007986.pub3/references#CD007986-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007986.pub3/media/CDSR/CD007986/image_n/nCD007986-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007986-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007986.pub3/media/CDSR/CD007986/urn:x-wiley:14651858:media:CD007986:CD007986-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: PUFA versus stimulants, Outcome 2: ADHD symptoms ‐ inattention" data-id="CD007986-fig-0029" src="/cdsr/doi/10.1002/14651858.CD007986.pub3/media/CDSR/CD007986/image_n/nCD007986-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007986.pub3/media/CDSR/CD007986/image_t/tCD007986-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: PUFA versus stimulants, Outcome 2: ADHD symptoms ‐ inattention</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007986.pub3/references#CD007986-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007986.pub3/media/CDSR/CD007986/image_n/nCD007986-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007986-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007986.pub3/media/CDSR/CD007986/urn:x-wiley:14651858:media:CD007986:CD007986-CMP-002.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: PUFA versus stimulants, Outcome 3: ADHD symptoms ‐ hyperactivity/impulsivity" data-id="CD007986-fig-0030" src="/cdsr/doi/10.1002/14651858.CD007986.pub3/media/CDSR/CD007986/image_n/nCD007986-CMP-002.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007986.pub3/media/CDSR/CD007986/image_t/tCD007986-CMP-002.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2: PUFA versus stimulants, Outcome 3: ADHD symptoms ‐ hyperactivity/impulsivity</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007986.pub3/references#CD007986-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007986.pub3/media/CDSR/CD007986/image_n/nCD007986-CMP-002.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007986-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007986.pub3/media/CDSR/CD007986/urn:x-wiley:14651858:media:CD007986:CD007986-CMP-003.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Subgroup analysis by PUFA, Outcome 1: ADHD symptoms ‐ total, parent rated" data-id="CD007986-fig-0031" src="/cdsr/doi/10.1002/14651858.CD007986.pub3/media/CDSR/CD007986/image_n/nCD007986-CMP-003.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007986.pub3/media/CDSR/CD007986/image_t/tCD007986-CMP-003.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3: Subgroup analysis by PUFA, Outcome 1: ADHD symptoms ‐ total, parent rated </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007986.pub3/references#CD007986-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007986.pub3/media/CDSR/CD007986/image_n/nCD007986-CMP-003.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007986-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007986.pub3/media/CDSR/CD007986/urn:x-wiley:14651858:media:CD007986:CD007986-CMP-004.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Sensitivity analyses, Outcome 1: Risk of attrition bias" data-id="CD007986-fig-0032" src="/cdsr/doi/10.1002/14651858.CD007986.pub3/media/CDSR/CD007986/image_n/nCD007986-CMP-004.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007986.pub3/media/CDSR/CD007986/image_t/tCD007986-CMP-004.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4: Sensitivity analyses, Outcome 1: Risk of attrition bias</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007986.pub3/references#CD007986-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007986.pub3/media/CDSR/CD007986/image_n/nCD007986-CMP-004.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007986-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007986.pub3/media/CDSR/CD007986/urn:x-wiley:14651858:media:CD007986:CD007986-CMP-004.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Sensitivity analyses, Outcome 2: Inclusion criteria" data-id="CD007986-fig-0033" src="/cdsr/doi/10.1002/14651858.CD007986.pub3/media/CDSR/CD007986/image_n/nCD007986-CMP-004.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007986.pub3/media/CDSR/CD007986/image_t/tCD007986-CMP-004.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4: Sensitivity analyses, Outcome 2: Inclusion criteria</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007986.pub3/references#CD007986-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007986.pub3/media/CDSR/CD007986/image_n/nCD007986-CMP-004.02.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD007986-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Summary of findings table ‐ PUFA compared to placebo for children and adolescents with ADHD</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>PUFA compared to placebo for children and adolescents with ADHD</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> children and adolescents with ADHD<br/><b>Setting:</b> All settings<br/><b>Intervention:</b> PUFA<br/><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with PUFA</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ADHD symptoms – improvement – medium term</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>319 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>621 per 1000</b><br/>(468 to 829) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.95</b><br/>(1.47 to 2.60) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>191<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a,</sup><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ADHD symptoms – total, parent‐rated – medium term</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>SMD <b>0.08 SD lower</b><br/>(0.24 lower to 0.07 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1166<br/>(16 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/>High </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ADHD symptoms – inattention, parent‐rated – medium term</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>SMD <b>0.01 lower</b><br/>(0.2 lower to 0.17 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>960<br/>(12 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/>High </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ADHD symptoms – hyperactivity/impulsivity, parent‐rated – medium term</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>SMD <b>0.09 higher</b><br/>(0.04 lower to 0.23 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>869<br/>(10 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/>High </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Side effects – overall</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>190 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>194 per 1000</b><br/>(131 to 289) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.02</b><br/>(0.69 to 1.52) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>591<br/>(8 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Loss to follow‐up – medium term</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>138 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>142 per 1000</b><br/>(106 to 189) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.03</b><br/>(0.77 to 1.37) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1121<br/>(13 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio; <b>SMD:</b> standardised mean difference </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>See interactive version of this table: <a href="https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_425001674858162955" target="_blank">https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_425001674858162955</a>. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Downgraded one level for risk of bias concerns: less than 50% of risk of bias domains across all studies were rated low risk.<br/><sup>b</sup> Downgraded one level for serious imprecision: data came from only three RCTs with 191 participants.<br/><sup>c</sup> Downgraded one level for serious imprecision: wide confidence interval. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Summary of findings table ‐ PUFA compared to placebo for children and adolescents with ADHD</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007986.pub3/full#CD007986-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD007986-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Other data</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Comparison</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>ADHD symptoms ‐ total</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>ADHD ‐ inattention</b><sup>a</sup> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>ADHD ‐ hyperactivity</b><sup>a</sup> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007986-bbs2-0007" title="BélangerSA , VanasseM , SpahisS , SylvestreMP , LippéS , L'HeureuxF , et al. Omega-3 fatty acid treatment of children with attention-deficit hyperactivity disorder: a randomized, double-blind, placebo-controlled study. Paediatrics and Child Health2009;14(2):89-98. [DOI: 10.1093/pch/14.2.89] [PMCID: PMC2661342] [PMID: 19436468]VanasseM , Ageranioti-BélangerS , L'HeureuxF , GhadirianP , LevyE , SpahisS , et al. A randomized, controlled trial of omega-3 and phospholipids supplementation in children with attention-deficit-hyperactivity disorder. Developmental Medicine &amp; Child Neurology2006;48(Suppl 107):48. [DOI: 10.1111/j.1469-8749.2006.tb12600.x]">Bélanger 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cross‐over trial of omega‐3 PUFA vs omega‐6 PUFA ‐ first phase</p> <p> </p> <p><i>SD not reported and could not be calculated.</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Conners Parent ‐ mean change</b> </p> <p>omega‐3: −8.8</p> <p>omega‐6: −5.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Conners Parent ‐ mean change</b> </p> <p>omega‐3: −9.1</p> <p>omega‐6: −7.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Conners Parent ‐ mean change</b> </p> <p>omega‐3: −7.2</p> <p>omega‐6: −3.1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><a href="./references#CD007986-bbs2-0009" title="BrueAW , OaklandTD , EvansRA . The use of a dietary supplement combination and an essential fatty acid as an alternative and complementary treatment for children with attention-deficit/hyperactivity disorder. Scientific Review of Alternative Medicine2001;5(4):187-94. [WEB PAGE: tinyurl.com/y56pdtxq]BrueAW . The Use of a Dietary Supplement Combination and an Essential Fatty Acid as an Alternative and Complementary Treatment for Children with Attention Deficit Hyperactivity Disorder (ADHD) [PhD thesis]. Gainesville (FL): University of Florida, 1999. ">Brue 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Parallel trial of omega‐3 PUFA vs dietary supplement</p> <p> </p> <p><i>SD not reported and could not be calculated.</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Conners Parent – non‐MPH (Ritalin)</b> </p> <p>omega‐3: 12.0</p> <p>supplement: 13.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Conners Parent – non‐MPH (Ritalin)</b> </p> <p>omega‐3: 9.4</p> <p>supplement: 13.1</p> <p>P = 0.03</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Conners Teacher – non‐MPH (Ritalin)</b> </p> <p>omega‐3: 19.1</p> <p>supplement: 15.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Conners Teacher – non‐MPH (Ritalin)</b> </p> <p>omega‐3: 17.9</p> <p>supplement: 13.4</p> <p>P = 0.04</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Conners Parent – MPH (Ritalin)</b> </p> <p>omega‐3: 15.6</p> <p>supplement: 14.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Conners Parent – MPH (Ritalin)</b> </p> <p>omega‐3: 13.7</p> <p>supplement: 13.5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Conners Teacher – MPH (Ritalin)</b> </p> <p>omega‐3: 16.3</p> <p>supplement: 12.2</p> <p>P = 0.04 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Conners Teacher – MPH (Ritalin)</b> </p> <p>omega‐3: 10.8</p> <p>supplement: 12.3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007986-bbs2-0025" title="ACTRN12607000332426. Omega-3 fatty acids for ADHD symptoms and learning difficulties in children [Randomised controlled trial investigating effect of supplementation with omega-3 fatty acids EPA and DHA versus omega-6 fatty acid LA on ADHD symptoms and learning difficulties in 7-12 year old children]. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=82104 (first received 19 June 2007). MilteCM , ParlettaN , BuckleyJD , CoatesAM , YoungRM , HowePR . Eicosapentaenoic and docosahexaenoic acids, cognition, and behavior in children with attention-deficit/hyperactivity disorder: a randomized controlled trial. Nutrition2012;28(6):670-7. [DOI: 10.1016/j.nut.2011.12.009] [PMID: 22541055]">Milte 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Parallel trial of EPA‐rich fish oil vs DHA‐rich fish oil vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Correlation of PUFA Conners Parent hyperactivity score vs placebo over 4 months (95% CI)</b> </p> <p>EPA: 0.98 (−1.27 to 3.23)</p> <p>DHA: 1.12 (−1.30 to 3.53)</p> <p> </p> <p><b>Correlation of PUFA Conners Parent ADHD index vs placebo over 4 months (95% CI)</b> </p> <p>EPA: 1.56 (−1.96 to 5.09)</p> <p>DHA: 1.64 (−2.15 to 5.43)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>ADHD:</b> attention deficit hyperactivity disorder; <b>CI:</b> confidence intervals; <b>EPA:</b> eicosapentanoic acid; <b>DHA:</b> docosahexanoic acid; <b>MPH:</b> methylphenidate; <b>PUFA:</b> polyunsaturated fatty acids; <b>SD:</b> standard deviation </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p><sup>a</sup>Where there were statistical differences between groups, P values are shown. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Other data</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007986.pub3/full#CD007986-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD007986-tbl-0003"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Compliance with recommended dose of PUFA supplements</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Comparison</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>PUFA group</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Control group</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007986-bbs2-0023" title="ManorI , MagenA , KeidarD , RosenS , TaskerH , CohenT , et al. The effect of phosphatidylserine containing omega3 fatty-acids on attention-deficit hyperactivity disorder symptoms in children: a double-blind placebo-controlled trial, followed by an open-label extension. European Psychiatry2012;27(5):335-42. [DOI: 10.1016/j.eurpsy.2011.05.004] [PMID: 21807480]NCT00418184. The efficacy and safety of phosphatidylserine-omega3 in children with attention-deficit/hyperactivity disorder [A single-center, randomized, double-blind, placebo-controlled study of the efficacy and safety of phosphatidylserine-omega3 in children with attention-deficit/hyperactivity disorder]. clinicaltrials.gov/show/NCT00418184 (first received 4 January 2007). ">Manor 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Parallel trial of omega‐3 vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>92%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007986-bbs2-0030" title="RazR , CarassoRL , YehudaS . The influence of short-chain essential fatty acids on children with attention-deficit/hyperactivity disorder: a double-blind placebo-controlled study. Journal of Child and Adolescent Psychopharmacology2009;19(2):167-77. [DOI: 10.1089/cap.2008.070] [PMID: 19364294]">Raz 2009a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Parallel trial of omega‐3 or omega‐6 vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>92%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>86%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007986-bbs2-0048" title="RichardsonAJ , PuriBK . A randomized double-blind, placebo-controlled study of the effects of supplementation with highly unsaturated fatty acids on ADHD-related symptoms in children with specific learning difficulties. Progress in Neuro-Psychopharmacology &amp; Biological Psychiatry2002;26(2):233-9. [DOI: 10.1016/s0278-5846(01)00254-8] [PMID: 11817499]">Richardson 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Parallel trial of omega‐3 or omega‐6 vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>87%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007986-bbs2-0033" title="SinnN , BryanJ , WilsonC . Cognitive effects of polyunsaturated fatty acids in children with attention deficit hyperactivity disorder symptoms: a randomised controlled trial. Prostaglandins Leukotrienes and Essential Fatty Acids2008;78(4-5):311-26. [DOI: 10.1016/j.plefa.2008.04.004] [PMID: 18514501]SinnN , BryanJ . Effect of supplementation with polyunsaturated fatty acids and micronutrients on learning and behavior problems associated with child ADHD. Journal of Developmental and Behavioral Pediatrics2007;28(2):82-91. [DOI: 10.1097/01.DBP.0000267558.88457.a5] [PMID: 17435458]">Sinn 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Parallel trial of omega‐3 or omega‐6 vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>88% across all groups</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007986-bbs2-0036" title="VoigtRG , LlorenteAM , JensenCL , FraleyJK , BerrettaMC , HeirdWC . A randomized, double-blind, placebo-controlled trial of docosahexaenoic acid supplementation in children with attention-deficit/hyperactivity disorder. Journal of Pediatrics2001;139(2):189-96. [DOI: 10.1067/mpd.2001.116050] [PMID: 11487742]">Voigt 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Parallel trial of omega‐3 vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>97%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100%</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="4"> <div class="table-footnote"> <p>PUFA: polyunsaturated fatty acids</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Compliance with recommended dose of PUFA supplements</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007986.pub3/full#CD007986-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD007986-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">PUFA versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 ADHD symptoms ‐ improvement <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.1 Short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.22 [0.85, 1.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.2 Medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>191</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.95 [1.47, 2.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.3 Long term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>141</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.67 [0.70, 3.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 ADHD symptoms ‐ total, parent rated <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.1 Short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>442</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.17 [‐0.25, 0.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.2 Medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1166</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.08 [‐0.24, 0.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.3 Long term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.30 [‐0.81, 0.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 ADHD symptoms ‐ inattention, parent rated <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.1 Short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>283</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.01 [‐0.31, 0.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.2 Medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>960</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.01 [‐0.20, 0.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.3 Long term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.39 [‐0.90, 0.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 ADHD symptoms ‐ hyperactivity/impulsivity, parent rated <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.1 Short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>283</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.15 [‐0.20, 0.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.2 Medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>869</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.09 [‐0.04, 0.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.3 Long term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.21 [‐0.72, 0.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 ADHD symptoms ‐ total, teacher rated <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.1 Short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>185</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.35 [‐0.30, 1.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.2 Medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>498</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.06 [‐0.12, 0.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 ADHD symptoms ‐ inattention: teacher <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.1 Short‐term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.02 [‐0.40, 0.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.2 Medium‐term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>428</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.17 [‐0.14, 0.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.7 ADHD symptoms ‐ hyperactivity/impulsivity, teacher rated <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.1 Short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.00 [‐0.51, 0.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.2 Medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>462</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.15 [‐0.03, 0.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.8 ADHD symptoms ‐ total, clinician rated <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.1 Short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>143</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.74 [‐1.08, ‐0.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.2 Medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.35 [‐0.84, 0.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.9 ADHD symptoms ‐ inattention, clinician rated <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9.1 Short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.05 [‐1.00, 0.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9.2 Medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>124</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.29 [‐0.65, 0.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.10 ADHD symptoms ‐ hyperactivity/impulsivity, clinician rated <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.10.1 Short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.36 [‐0.18, 0.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.10.2 Medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.28 [‐0.77, 0.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.11 Behaviour ‐ internalising, parent rated <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.11.1 Medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>237</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.16 [‐0.09, 0.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.12 Behaviour ‐ externalising, parent rated <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.12.1 Short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.02 [‐0.49, 0.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.12.2 Medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>340</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.07 [‐0.26, 0.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.13 Behaviour ‐ conduct, parent rated <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.13.1 Short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.10 [‐0.60, 0.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.13.2 Medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>332</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.16 [‐0.05, 0.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.14 Behaviour ‐ oppositional, parent rated <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.14.1 Medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>527</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.02 [‐0.17, 0.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.15 Behaviour ‐ socialisation, parent rated <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.15.1 Medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>145</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.27 [‐0.06, 0.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.16 Behaviour ‐ conduct, teacher rated <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.16.1 Short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.03 [‐0.54, 0.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.16.2 Medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>118</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.03 [‐0.39, 0.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.17 Behaviour ‐ oppositional, teacher rated <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.17.1 Medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>224</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.10 [‐0.18, 0.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.18 Behaviour ‐ socialisation, teacher rated <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.18.1 Medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.16 [‐0.58, 0.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.19 Quality of life: medium term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.20 Side effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.20.1 Overall</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>591</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.69, 1.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.20.2 Appetite loss</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.48 [0.27, 0.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.20.3 Anxiety</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.38 [0.11, 1.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.20.4 Dermatitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>147</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.43 [0.06, 34.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.20.5 Diarrhoea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>207</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.36, 1.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.20.6 Gastrointestinal discomfort</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>269</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.24, 2.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.20.7 Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>207</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.56 [0.31, 1.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.20.8 Hyperactivity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>147</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.43 [0.06, 34.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.20.9 Insomnia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>122</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.32 [0.03, 3.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.20.10 Irritability</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.07 [0.00, 1.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.20.11 Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>428</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.41, 2.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.20.12 Nose bleed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>158</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.09, 6.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.20.13 Palpitations</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.25, 2.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.20.14 Tics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>207</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [0.06, 4.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.20.15 Tremor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.01, 7.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.21 Loss to follow‐up <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.21.1 Short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>785</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.78, 1.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.21.2 Medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1121</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.77, 1.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.21.3 Long term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.30 [0.09, 0.98]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">PUFA versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007986.pub3/references#CD007986-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD007986-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">PUFA versus stimulants</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 ADHD symptoms ‐ total <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.1 Short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>96</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.31, 1.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.2 Medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.62 [0.10, 1.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.3 Long term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.30 [‐0.21, 0.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 ADHD symptoms ‐ inattention <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.1 Short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.35, 1.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.2 Medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.47 [‐0.04, 0.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.3 Long term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.06 [‐0.45, 0.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.3 ADHD symptoms ‐ hyperactivity/impulsivity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.1 Short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>96</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.25, 1.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.2 Medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.58 [0.07, 1.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.3 Long term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">PUFA versus stimulants</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007986.pub3/references#CD007986-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD007986-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Subgroup analysis by PUFA</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.1 ADHD symptoms ‐ total, parent rated <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.1 Omega‐3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1039</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.06 [‐0.23, 0.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.2 Omega‐3 / omega‐6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>127</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.28 [‐0.63, 0.07]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Subgroup analysis by PUFA</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007986.pub3/references#CD007986-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD007986-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Sensitivity analyses</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.1 Risk of attrition bias <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1.1 High risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>278</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.06 [‐0.65, 0.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1.2 Unclear risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>789</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.01 [‐0.20, 0.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1.3 Low risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>295</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.19 [‐0.63, 0.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.2 Inclusion criteria <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2.1 Clinician diagnosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1179</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.04 [‐0.15, 0.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2.2 ADHD symptom score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>183</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.59 [‐0.90, ‐0.27]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Sensitivity analyses</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007986.pub3/references#CD007986-tbl-0007">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD007986.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD007986-note-0015">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD007986-note-0020">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD007986-note-0013">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD007986-note-0012">Hrvatski</a> </li> <li class="section-language"> <a class="" href="hu#CD007986-note-0014">Magyar</a> </li> <li class="section-language"> <a class="" href="ja#CD007986-note-0019">日本語</a> </li> <li class="section-language"> <a class="" href="ko#CD007986-note-0009">한국어</a> </li> <li class="section-language"> <a class="" href="ms#CD007986-note-0011">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD007986-note-0021">Polski</a> </li> <li class="section-language"> <a class="" href="pt#CD007986-note-0010">Português</a> </li> <li class="section-language"> <a class="" href="ru#CD007986-note-0008">Русский</a> </li> <li class="section-language"> <a class="" href="th#CD007986-note-0018">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD007986-note-0016">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD007986-note-0017">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007986\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007986\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007986\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007986\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007986\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007986\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007986\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007986\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007986\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007986\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007986\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007986\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007986\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007986\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007986\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007986\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007986\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007986\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=dLyXbLct&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007986.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD007986.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD007986.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD007986.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007986.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740718639134"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD007986.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740718639137"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD007986.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918dd5305b12f47a',t:'MTc0MDcxODYzOS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 